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Abstract 
Osteogenesis Imperfecta (OI) is a hereditary disorder effecting approximately 1 in 20,000 
births.  Symptoms include; low bone mass, recurrent fractures, varying degrees of short 
stature and deformity.  There is currently no disease specific quality of life (QoL) measure 
for children with OI.  This study uses a mixed methods approach to develop a QoL 
measure for the paediatric OI population.  Patient reported outcome measure 
development is an iterative process, moving back and forth between concept elicitation, 
questionnaire development, pre-testing and psychometric analysis. 
In order to encourage a balance between good content validity, alongside promoting a 
robust, reliable and responsive measure, the methods chosen involved several stages: 
 Literature review to ensure no suitable QoL measure already existed and to begin 
eliciting themes. 
 Interview and focus groups with the target population to uncover relevant 
concepts, develop a conceptual framework and subsequently validate themes. 
 Questionnaire development; transforming themes into items, using the children’s’ 
language to ensure high content validity and acceptability. 
 Pre-testing the instrument alongside a sample of the OI population, making 
revisions as required. 
 Psychometric evaluation to assess validity, reliability and responsiveness of the 
questionnaire, informing potential item elimination and revision of the measure. 
Interviews and focus groups with the target population uncovered six main themes when 
describing QoL in children with OI; being safe and careful, reduced function, pain, fear, 
independence and isolation.  These themes and related sub themes informed the 
development of the conceptual framework, which alongside the children’s own thematic 
based quotes, was used to develop the OIQoL.     
Pre-testing of the OIQoL highlighted logistical issues and understanding, which lead to 
revisions of the initial version.  The final version underwent field testing; concerns around 
construct validity and internal consistency reliability highlighted the need to undertake 
further psychometric techniques on a larger cohort prior to item elimination. 
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Chapter 1  
Introduction  
Osteogenesis Imperfecta (OI) is a hereditary condition affecting approximately 1 in 
20,000 births with eleven recognized types of OI (Glorieux, 2008; Forlino et al, 2011).  
Children with OI have low bone mass, leading to recurrent fractures, varying degrees of 
short stature and deformity. 
The overall aim of this thesis was to develop a paediatric OI specific quality of life 
(QoL) questionnaire for self completion by children aged 6-18 years. 
Patient reported outcome measure (PROM) development is an iterative process, 
moving back and forth between concept elicitation, questionnaire development, pre-
testing and psychometric analysis. 
Specific secondary objectives were to: 
1) Review the literature to ensure no suitable QoL measure already existed and to 
begin eliciting themes. 
2) Interviews and focus groups with the target population to uncover relevant 
concepts, develop a conceptual framework and subsequently validate themes. 
3) Questionnaire development; transforming themes into items, using the 
children’s’ language to ensure high content validity and acceptability. 
4) Pre-testing the instrument alongside a sample of the OI population, making 
revisions as required. 
5) Psychometric evaluation to assess validity, reliability and responsiveness of the 
questionnaire, informing potential item elimination and revision of the measure. 
 
The overall research question was “Can we develop a condition/disease specific 
paediatric OI specific quality of life (QoL) questionnaire for self-completion by children 
aged 6-18 years?” 
The following study uses a mixed methods approach to the development of a disease 
specific QoL measure for the paediatric OI population.  Patient reported outcome measure 
development is an iterative process which involves moving back and forth between 
concepts and theme elicitation, questionnaire development and psychometric testing.  
This approach encourages a balance between ensuring good content validity, alongside 
promoting a robust, reliable and responsive instrument. 
This chapter will introduce the reader to the different stages of questionnaire 
development, as evidence is gathered from both the literature and personal experience 
(primary researcher, experts – children, parents, health professionals) with the disease 
to inform the developmental process.  The first sections of this thesis involve qualitative 
methods; eliciting concepts, validating themes and developing the questionnaire.  The 
latter half integrates the qualitative and quantitative methods within chapters, which are 
written to document the process of patient reported outcome measure development 
sequentially, as the stages were undertaken, rather than describe the methodologies 
separately. 
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The initial stages involved reviewing the current and historical literature to ensure that 
there was no other previously developed QoL instrument (generic or appropriate 
disease specific questionnaire) suitable for children and adolescents with OI, which 
would negate the need to develop a new questionnaire.  This literature review was then 
used alongside expert opinion, interviews and focus groups to inform the development 
of a conceptual framework portraying how OI can effect  QoL in individuals with OI and 
how the nature of OI, its management and treatment effects a child’s QoL. 
The term QoL will be used to encompass both QoL and health related quality of life 
(HRQoL) throughout this thesis.  The terms child, adolescent and young person may 
be used interchangeably when describing the paediatric OI population (0-18 years), but 
the QoL questionnaire will be developed for the 6-18 years age group to enable self 
completion. 
Phenomenology was the qualitative method chosen to enable meaning and 
appreciation of the disease process, its management and the effect this has on the life 
and experience of children and their families with OI.  Phenomenology involves close 
analysis of an individuals’ lived experience to gain understanding of their thought 
processes related to their disease.  Gaining access to this life experience, knowledge 
and meaning enables the researcher to understand common features of the population 
and draw out concepts and themes relevant to the research topic. 
As the process of instrument development is an iterative one, the conceptual 
framework undergoes change and revision as further information and understanding is 
uncovered.  This final framework is then used to develop the initial version of the 
questionnaire, with the concepts/themes used to inform the dimensional headings.  
Transparency of the processes used to develop the conceptual framework and the 
resultant questionnaire is vitally important.  How the themes were uncovered, validated 
and finally turned into questions or items within the instrument needs to be clear.  
Preliminary testing of the questionnaire for acceptability, ease of completion and 
understanding is a necessity; changes are then made to the initial instrument following 
feedback from the target population to ensure the development of an acceptable and 
relevant questionnaire with high content validity.   
Finally, after revision and improvement, psychometric testing of the newly developed 
questionnaire is required.  This encourages the development of a robust, reliable, valid 
and responsive instrument, highlighting areas which although deemed important to the 
target population may not be statistically sound.  At this stage the primary researcher 
should acknowledge the need to balance the content validity, as informed by the 
qualitative processes, against the requirement for a statistically robust instrument.   
The local research ethics committee reviewed and approved the study protocol 
(Appendix 1). 
 
Background (Chapter 2)   
The first half of this chapter reports on the background literature relevant to paediatric 
Osteogenesis Imperfecta (OI).  It provides an overview of the incidence, symptoms and 
phenotype, alongside the medical, genetic, surgical and therapy management of 
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children with OI.  The latter half provides an overview of quality of life (QoL) in children 
and the best methods available to measure it.  It considers proxy or self reporting of 
quality of life, and sets the scene for the following development chapter.   
Development of New Quality of Life Measures (Chapter 3) 
This chapter details best practice in patient reported outcome (PRO) measure 
development based on the FDA guidelines (2009) and the subsequent articles by 
Patrick et al (2011a & b).  The background literature is reviewed surrounding QoL 
questionnaire development, concept elicitation and the methods used to achieve this, 
content validation, pilot or pre-testing and finally the methodology used to assess the 
psychometric properties of the newly developed questionnaire. 
Systematically reviewing the literature (Chapter 4) 
This chapter searches for the answers to several questions; what would an appropriate 
QoL questionnaire for the paediatric OI population look like? What aspects of QoL 
would it include?  Is there a suitable QoL questionnaire already in existence which will 
meet the needs of the paediatric OI population? 
The chapter repeats a systematic review of the literature previously undertaken by 
Eiser and Morse(2001), McCabe (2003) and Stevens (2008).  It examines the literature 
related to generic QoL measures for children, and any suitable disease specific 
instrument which might also meet the needs of the paediatric OI population.  The lack 
of a suitable alternative QoL instrument highlighted the need to develop an OI specific 
QoL questionnaire. 
Item generation and the conceptual framework – Interviews (Chapter 5) 
This chapter describes the methods undertaken to elicit themes for inclusion in the OI 
specific QoL questionnaire.  At the start of this chapter the primary researcher provides 
the reader with a reflective statement describing their experience with the paediatric OI 
population, alongside their thoughts and feelings with regards to QoL and OI.  The 
need for transparency and reflexivity during qualitative methodologies is the motivation 
for this approach to the chapter.  An initial experience based conceptual framework is 
also documented.  
This chapter then discusses the semi structured interviews undertaken with children, 
parents and health professionals with experience in the management of children with 
OI.  Interviews were transcribed verbatim, undergoing thematic analysis and themes 
were extracted.  An exhaustive list of uncovered themes/items is included within the 
appendix (Appendix 2).  A second conceptual framework is documented to highlight 
themes elicited following the interviews. 
Item validation and the revised conceptual framework - Focus groups (Chapter 6) 
This chapter documents the methods undertaken to validate the themes uncovered 
following the semi structured interviews, and ensure that no potential themes have 
been missed.  Two focus groups were undertaken; previously elicited themes were 
discussed, and potentially missed themes were uncovered.  The latter group was also 
encouraged to discuss the potential format of the questionnaire, the Likert scale and 
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suitable recall period.  Revisions were made to the conceptual framework and this is 
documented towards the end of this chapter. 
Questionnaire and item development (Chapter 7) 
This chapter describes the process of instrument development; the terminology used 
by the children and adolescents during item elicitation (Chapter 5) was used to design 
the items.  Expertise was sought from primary school teachers and children to examine 
reading age and understanding.  A copy of the 39-item OIQoL questionnaire (version 1) 
is included at the end of this chapter. 
Pilot or pre-testing of the initial questionnaire (Chapter 8) 
Pre-testing of a newly developed questionnaire to ensure acceptability, comfort and 
understanding is a necessity.  This chapter documents the process of pre-testing the 
newly developed OIQoL on the paediatric OI population (on a sample of 25 children) 
and the results of post completion interviews.  Changes to the instrument as a 
consequence of pre-testing are noted, and a copy of the OIQoL (version 2) is included 
at the end of this chapter. 
Psychometric evaluation – reliability, validity, responsiveness, item reduction 
(Chapter 9) 
This penultimate chapter examines the preliminary psychometric properties of the 
newly developed OIQoL on a sample of n=95 children with OI measured at baseline, 1 
and 12 weeks.  Traditional statistical methods were used to investigate validity, 
reliability and responsiveness of the questionnaire at time points, baseline, one week 
and three months.  The process of potential item elimination is discussed, alongside 
the reasons behind the statistical methods chosen.  Plans for future research are 
acknowledged.   
Conclusions (Chapter 10) 
This chapter describes the overall outcome of the research, highlighting the strengths 
and limitations of the methodologies used.  Plans for future research are described. 
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Figure 1.1  Overall flow chart of the planned methodology 
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 Themes elicited from patients and 
experts used to inform dimensions 
and items. 
 Patients own words/quotes used to 
inform structure of items. 
 Expert review of format, reading age, 
questionnaire items and overall 
development. 
Pilot or Pre-testing  
Chapter 8 
 Post completion interviews with a 
purposive sample from target 
population 
 Assess acceptability - Identify poor 
understanding, discomfort, poorly 
worded items. 
 Revise instrument/questionnaire. 
Initial psychometric 
analysis 
Chapter 9 
 Assessment of acceptability, 
reliability, test-retest, validity, 
responsiveness. 
 Highlight potential concerns, item 
elimination 
 Need for further research. 
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Chapter 2    
Background Literature 
2.1 Osteogenesis Imperfecta 
Osteogenesis Imperfecta (OI) is a disease with varying severity affecting the physical, 
social and emotional well-being of the child and their family (Hill, 2014).  It is a 
hereditary condition affecting approximately 1 in 20,000 births with eleven recognised 
phenotypes (Glorieux, 2008; Forlino, 2011) and 15 genetically different types 
documented (Shapiro, 2014).  Children with OI have low bone mass, recurrent 
fractures, often with minimal trauma, varying degrees of short stature and long bone 
deformity, scoliosis, kyphosis, pain, some hearing loss, and respiratory failure in the 
severest types which can be lethal. 
The initial classification of OI (Sillence, 1979) was based on skeletal features alone.  
Smith et al (1983) describes the classification as being dependent on the age at which 
the diagnosis was made.  Those individuals who had fractures at birth were considered 
to have OI congenital, those who were diagnosed later and exhibited fractures after 
birth were described as OI tarda, (gravis if fractures occurred in the first year, levis if 
fractures occurred later).  Sillence classification (1979) described 4 types of OI.  Type I 
included most of the tarda levis, milder presentation, with minimal skeletal deformity 
(Shapiro, 2014).  Type II described patients with lethal OI, severe deformity, multiple 
fractures and death due to respiratory insufficiency.  OI type III described patients with 
a progressively deforming variation, with scoliosis, short stature, bowing of long bones 
and white sclera.  OI type IV describes a moderately affected individual with white 
sclera, moderate short stature and deformity.  
Over time the above ‘Sillence’ classification began to appear over simplified.  
Individuals previously diagnosed as type IV OI began to behave unexpectedly.  Some 
patients were noted to develop hypertrophic callus following fracture and were later 
described as type V (Glorieux et al, 2000). Others who had unusual histological 
changes when examined under polarised light were later denoted as type VI (Glorieux 
et al, 2002). 
Mutations within the genes COL1A1 or COL1A2 which encode type I collagen, are 
thought to be responsible for 98% of cases of OI.  More recently groups have 
uncovered recessive genes, which explain some of the variation seen within the more 
severe forms of OI (Barnes et al, 2010; Barnes et al, 2012; Kelley et al, 2011; Laine et 
al, 2013).  Marini et al (2013) describe mutations in CRTAP and LEPRE1 which lead to 
a very severe phenotype with white sclera, broad long bones, thin ribs without beading 
and smaller head circumference.  The table below details the OI type, phenotype and 
genetic back ground to the most up-to-date published information, although this 
continues to expand as new genes are uncovered. 
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Table 2.1  Current Classification of OI Types 
This table presents current classification of OI phenotypes and the associated mutations. 
OI type Phenotype Inheritance Genetic analysis 
I Mild, non-deforming 
Short or normal stature , 
blue sclera, mild joint laxity, 
no DI 
AD 
Null mutation due to 
premature stop 
codon COL1A1 : normal 
collagen but 
½ normal amount 
II Perinatal lethal 
Beaded ribs broad or 
narrow long bones, thin 
calvarium, Rhizomelia, 
severe pulmonary 
insufficiency 
AD 
AR++ 
COL1A1 and COL1A2 
structural 
alterations in type I 
collagen. 
CRTAP, LEPRE1 , PPIB 
III Severe, deforming 
White or blue sclera, DI, 
short stature, severe 
scoliosis, 
wheel chair dependent 
New mutation, AD 
Structural alteration in 
type I collagen: 
COL1A1, COL1A2 
CRTAP, LEPRE1, PPIB 
IV Moderately 
deforming 
Moderate skeletal 
deformity, frequent use of 
aids to 
ambulation, blue sclera 
early that tend to lighten 
with 
age, scoliosis, DI 
AR++ 
COL1A1 and COL1A2 
mutations 
V Mild to moderately 
deforming 
Variable phenotype, mild to 
severe, white sclera, 
dislocation radial head, 
interosseous membrane 
calcification, hyperplastic 
callus, no DI. The defining 
feature of OI type V is the 
mesh type lamellation 
pattern on bone histology 
AD IFITM5 
VI Hyperosteoidosis 
Moderate/severe, 
white/blue sclerae. Early 
onset 
fractures, osteomalacia on 
bone biopsy 
AD SERPINF1 
VII Moderately 
deforming 
First Nations Quebec 
families, recessive 
inheritance, 
moderate to severe, 
rhizomelia, no DI 
AR CRTAP, LEPRE1 
VIII Severe, lethal 
South African black 
population, lethal or severe, 
bone 
deformity 
AR CRTAP, LEPRE1 
IX 
Moderate to severe 
phenotype AR PPIB 
X 
Moderate to severe 
phenotype AR SERPINH1 
XI 
Moderate to severe 
phenotype AR FBK10 
XII 
Moderate to severe 
phenotype AR SP7/Osterix 
XIII 
Moderate to severe 
phenotype AR BMP1 
XIV 
Moderate to severe 
phenotype AR TMEM38B 
XV 
Moderate to severe 
phenotype AR Wnt1 
 
“In this table mutations associated with recessive disease are listed with OI Type II and 
type III categories because of the phenotype overlap. AD: Autosomal dominant 
inheritance; AR: Autosomal recessive inheritance; DI: Dentinogenesis imperfecta.” 
(Shapiro, 2014, pp16) 
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Osteogenesis Imperfecta (OI) cannot be cured currently, so the disease is managed 
rather than healed (Rauch, 2014).  Treatment for children with OI is best placed within 
a multidisciplinary team, where medical, surgical and therapy/rehabilitation can be 
offered.  Treatment aims to provide pain relief; reduce fractures; prevent deformity; 
improve mobility and facilitate independent function (Hill, 2014). 
The current standard treatment for children with OI is Bisphosphonate therapy (Zeitlan 
et al, 2003), and this has been used for over fifteen years (Rauch, 2014).  The initial 
hypothesis for using bisphosphonates was that the reduced osteoclastic activity, or 
bone reabsorption might strengthen the bone (Cheung and Glorieux, 2008).  Their use 
within the treatment of OI increased and became better known following a publication 
by the Montreal group in 1998 (Glorieux et al), who presented a case series of children 
with OI who were treated with intravenous Pamidronate.  This reduction in osteoclastic 
activity however did not improve the quality of the bone, it produced more of the same 
‘brittle bone’, but the mechanical strength was improved by the additional increased 
bone volume.  Bisphosphonates can be given both orally and intravenously; the latter 
necessitates a two to three day hospital stay in the case of Pamidronate therapy or a 
one day stay if Zoledronate is used.  
Glorieux et al (1998) reported reduced fracture rate, when compared to historical 
controls.  A process of healing of vertebral crush fractures has also been documented 
(Land et al, 2006; Letocha et al, 2005), when Bisphosphonates are given during 
growth.  Moreover, other literature reports reduction in bone pain and an increased 
feeling of well-being (Lowing et al, 2007; Kok et al, 2007). 
Non surgical management of children with OI aims to prevent and treat fractures; 
enhance motor development; muscle strength; range of movement; reduce 
contractures and deformity; improve functional ability and ambulation (Monti et al, 
2010).  From a skeletal and orthopaedic perspective children and adolescents with OI 
suffer numerous complications due to their disease.  The moderately and severely 
affected can be born with long bone deformities, or these may develop over time, due 
to recurrent fractures and/or poor positioning.  Deformities of the spine such as, 
kyphosis, scoliosis, spondylolithesis and spondylolysis can be observed, as can 
problems at the base of the skull (Platybasia, basilar invagination, basilar impression).  
These latter complications may lead to neurological dysfunction; the patient may 
complain of headaches, ataxia, dysphagia, hearing problems and signs related to 
hydrocephalus (Sawin and Menezes, 1997).  Variation is seen in the literature in the 
reporting of scoliosis in OI.  Incidences range from 26% in children under five years of 
age up to 82% in older children have been documented (Benson et al, 1978; Ishikawa 
et al, 1996), with agreement that increased age is associated with increased risk. 
Many children undergo orthopaedic surgery to improve deformity and alignment or to 
stabilise fractures.  The instrumentation used can take the form of fixed intermedullary 
rods or more often growing rods.  Shapiro (2014) states the goal of orthopaedic surgery 
is to help the bone grow straight, reduce fracture rate and in the event of fracture, 
prevent bone displacement.  Telescopic or growing rods were initially developed by 
Baily and Dubow (1963), but have since undergone development by Bell and 
colleagues (Stockley et al, 1989) who was instrumental in developing the Sheffield rod 
and Fassier-Duval (2001).  These rods prevent the need for recurrent surgery to 
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replace intermedullary rods as the child grows, as they are fixed both proximally and 
distally and elongate with growth.  However, complications can arise, such as; non 
telescoping; rod migration; disengagement of the male and female components 
(proximal and distal sections) and growth disturbance (Fassier and Gdalvitch, 2014). 
Therapy intervention for children with OI is best placed within a multidisciplinary team 
including; clinical nurse specialist; occupational therapist; physiotherapist; psychologist; 
social worker; dietician and speech and language specialist, but this is not essential.  
Early treatment involves educating the parents and carers in handling, positioning and 
caring for their new born.  Prevention of increased deformity and facilitation of normal 
development is an important management approach from the onset.  The motor 
development and functional ability of children with OI can be delayed and this is often 
related to the severity of the disease (Engelbert et al, 2004).  Children with severe 
disease may be encouraged to remain reclined within the first year of life, with gradual 
progression into supported vertical sitting.  This is done to prevent increased crush 
fractured vertebrae and poor spinal alignment. 
Many children with mild and moderate OI achieve independent walking with or without 
equipment; some may use wheelchairs for longer distances.  Some severely affected 
children may achieve household walking or therapeutic walking (Bleck, 1981).  
However fatigue, reduced exercise capacity and exercise intolerance is frequently 
reported to limit their activities of daily living (Van Brussel et al, 2008).  Takken et al 
(2004) studied cardio-respiratory function in children with OI.  They reported that 
exercise capacity and muscle strength were significantly reduced compared to their 
unaffected peers; fatigue was related to proximal muscle weakness and reduced peak 
oxygen consumption.  They concluded intervention to increase exercise capacity and 
muscle strength may be beneficial. 
2.1.1 QoL Outcomes in Ostoegenesis Imperfecta 
Perceived competence in relation to impairment and disability in OI was discussed by 
Engelbert et al (2001).  The group examined; joint range of movement; muscle 
strength; functional skills, using the Pediatric Evaluation of Disability Inventory (PEDI); 
mobility, using the Bleck; and perceived competence, using the Harter Self-Perception 
Profile.  They found range of movement, muscle strength, functional skills and mobility 
differed significantly between the different severities of OI.  They stated that overall 
perceived competence in children with OI was fairly to strongly positive, without any 
significant differences between the different types.  Perceived athletic competence in 
mildly affected children was below average, whereas this was not a finding in those 
severely affected children, who, it was suggested, may not compare themselves so 
readily to unaffected children, or their use of powered mobility may promote perceived 
competence.  Social acceptance correlated moderately with physical appearance, 
which in turn correlated highly with global self-worth.  
Hill et al (2014) states previous attempts at measuring quality of life in OI have used 
several generic instruments including; PEDI; WeeFim; visual analogue scale (VAS); 
Bleck score; Health Utilities Index III (HUI III) and the Self Perception Profile for 
Children (SPPC).  Seikaly et al (2005) examined the impact of Alendronate on QoL in 
children with OI.  The group used the PEDI to measure mobility, the WeeFim to 
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document self care and well-being, and pain was measured on a VAS.  They reported 
significant improvement in well-being and reduction in pain in those children treated 
with Alendronate, but failed to identify any improvement in QoL or function.  No insight 
is given with regards to this lack of identified improvement; could poor measurement or 
the choice to use a battery of outcome measures in an attempt to quantify QoL be a 
contributing factor?  They also demonstrate confusion around the difference between 
function and QoL, often using the terms interchangeably. 
Van Brussel et al (2008) examined the physical training of 34 children with mild-
moderate OI, who were randomised to two treatment groups (twelve week exercise 
intervention and control).  They used hand held dynamometers to measure muscle 
strength, the self report questionnaire checklist individual strength-20 (CIS-20) to 
examine fatigue, the self perception profile for children to measure perceived 
competence and the child health questionnaire parent-form 50 (CHQ) to measure 
HRQoL.  They found that exercise capacity and muscle strength significantly increased 
in the intervention group.  Subjective fatigue levels, perceived competence and HRQoL 
showed some improvement, but lacked significance.  The authors comment on the 
possible reasons for this lack of significant improvement in fatigue, perceived 
competence and HRQoL, with comparisons found in healthy children, but no 
suggestion of a more disease specific outcome measure is noted.  Normative data 
within the healthy population is available on the CHQ, but there is no available 
normative data for children with OI and we have no evidence to suggest that the CHQ 
measures themes or items which are relevant to the OI population, therefore content 
validity may be low. 
In 2009, Casillo et al conducted a systematic review into the effects of 
Bisphosphonates in children with OI.  They concluded that although Seikaly et al 
(2005) had demonstrated positive impacts on self care and well-being, other studies 
were not able to replicate these findings.  They do make note that several studies 
attempted to evaluate impacts made on mobility, ambulatory and functional status, but 
that no statistically significant change in the outcome was found. 
Generic QoL measures such as the HUI III and the SPPC can be used to assess and 
compare a range of different disease states and healthy individuals, but they may not 
be responsive enough to detect the small changes in QoL experienced by a child with a 
particular disease (Hill, 2014).  As a result clinically important aspects of a child’s life 
related to their disease may be overlooked (Juniper, 1997).  Due to the lack of a readily 
available disease specific QoL or functional measures for children with OI, several 
authors (Kok et al, 2007; Seikaly et al, 2005) have attempted to group together, in a 
battery approach, whole or parts of generic measures in an attempt to gain a suitable 
outcome measure for the paediatric OI population. 
2.2 Quality of Life 
Quality of life is an important part in assessing children with chronic conditions; as 
survival rates have increased, it has become necessary to measure outcomes in 
relation to how that child has adjusted to or is coping with his or her disease and 
possible treatments (Harding, 2001) 
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Within the background for this research it is important to state that functional 
status/ability and QoL/HRQoL are not one and the same.  Early models on QoL were 
largely concerned with function (Harding, 2001).  Eiser (1996) defined these attempts 
as ‘deficit centred models’, as they assumed individuals with chronic conditions would 
necessarily show poorer functioning compared to their healthy peers, and that this 
potentially reduced functioning would automatically be reflected in a poorer QoL.   
In some of the previous studies mentioned, within the OI population (Kok et al, 2007: 
Seikaly et al, 2005; Van Brussel et al, 2008; Engelbert et al, 2001) authors have stated 
their aim is to measure or observe change in QoL following a specific therapy or 
medical intervention.  They then describe methodology that measures and documents 
their participants’ function, level of activity or their ability to complete function activities 
of daily living.  Although functional ability can be considered to contribute towards an 
individual’s QoL, it shouldn’t be used as a measure of their QoL.  Care should therefore 
be taken when critiquing studies or previous research, that a relevant and valid 
questionnaire or instrument has been used to measure QoL. 
Quality of life is described in differing ways by different authors.  Bond (1996) considers 
there to be many elements that make up QoL including subjective elements; 
satisfaction with life; presence of social; emotional; physical and mental health; 
cognitive ability to evaluate life; happiness; psychological well-being and objective 
elements such as; socioeconomic status; functional status and housing. 
Objective and subjective components to QoL are also discussed by Eiser and Morse 
(2001), who felt objective assessment focuses on what an individual can do, and what 
this ability means to the individual is the more subjective element.  How different 
individuals appraise their objective ability can account for the different subjective QoL 
described by two individuals with the same objective health. 
Fayers and Machin (2007) state that QoL means different things to different people, but 
agree that although aspects vary between studies; they can include; general health; 
physical functioning; physical symptoms and toxicity; emotional functioning; cognitive 
functioning; role functioning; social well-being; social functioning and existential issues. 
Connolly and Johnson (1999) have a much more simplified outlook on QoL, and define 
it as physical, social and emotional aspects of a patients well-being that are relevant 
and important to the individual.  They go on to state that HRQoL includes those 
aspects of QoL which can be influenced by health interventions.  Difficulties arise when 
the aim of an intervention is to improve an individual’s QoL, as this includes several 
components of QoL that are related to the environment and social setting of an 
individual, which are not often affected or influenced by healthcare or medical 
intervention (Eiser and Varni, 2013).  As a result of this Eiser and Varni (2013) describe 
HRQoL as the patient’s perception of the impact of an illness and its treatment.  The 
key to measuring QoL appears to be the idea that all individuals have their own 
perspective on QoL.  It is dependent on their current life style, past experience, hopes, 
dreams and ambition for the future (Eiser and Morse, 2001).   
QoL or HRQoL measures can be generic or disease specific.  Generic measures can 
be used to assess a whole range of different disease states and healthy individuals, 
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allowing comparison between cohorts and individuals to be made.  Disease specific 
measures are more sensitive to one disease state; they are able to detect smaller, but 
potentially important changes in the patients’ condition, allowing comparison of different 
interventions or treatments (Eiser, 1997; Connolly and Johnson, 1999).  Generic 
instruments can be described as either health profiles, where several items, grouped 
into different domains are used to assess QoL or well-being; or preference based index 
measures.  The latter provide a single overall score which is assigned to the health 
state of the individual. 
Measuring QoL in children has added difficulties.  Children see things differently to their 
parents, carers or health professionals.  Children don’t often share the same views as 
their parents about the impact of their illness and their ability to use rating scales and 
understand language varies with age (Eiser and Morse, 2001) and educational ability.  
Parent and carers can therefore be used as a proxy respondent when children are too 
young or too ill to self report.  This however has its limitations and these are well 
reported within the literature (Eiser and Morse, 2001; Eiser and Varni, 2013; Connolly 
and Johnson, 1999).  Parents and children can disagree on the child’s reported QoL 
and their symptoms, yet there is no correct answer as to who is the most accurate 
reporter.  Although Eiser and Varini (2013) do conclude that it is ultimately the child 
who knows best, with regards to their internal states such as; feelings of pain, 
emotional distress, fatigue or gastrointestinal symptoms.  Evidence has shown that it is 
feasible, reliable and valid for children as young as 5 years of age to self report (Varni 
et al, 2007), particularly on concrete concepts such as pain or medication (Connolly 
and Johnson, 1999).  However it is suggested that for subjective concepts such as 
behaviour or self esteem, a child of 9-10 years may be more reliable (Landgraf et al, 
1996). 
Upton et al (2008) states that within healthy children, parents often rate their child’s 
HRQoL better than the child themselves; alternatively within children with chronic 
health conditions, parents typically describe their child’s HRQoL worse than their child’s 
self report.  Parents and children are often more in agreement when describing 
objective physical domains such as physical function, but less so when emotional or 
social function, or pain and fatigue are rated (Eiser and Varni, 2013).  Parental 
experience and psychological well-being also have an effect on how they report their 
child’s QoL.  Parents, who report higher levels of depressive symptoms and emotional 
distress, are more negative in their perception of their child’s HRQoL (Janicke et al, 
2007; Eiser and Varni, 2013).  This relationship is stronger for mothers than fathers 
(Davis et al, 2008). 
The relationship between child self report and proxy report (parent/carer) is a multi 
focal and complex one.  Young children spend more time with their parents and may 
therefore report closer agreement in their QoL with their parents/carers, than an 
adolescent who has more independence (Eiser and Varni, 2013). 
The ability to report QoL will vary with age, developmental level, comprehension and 
cognition.  Moreover, children’s cognitive and emotional development will affect the 
reliability of self reported health outcomes.  For this reason, several QoL measures 
have different age ranges for completion (e.g. PedsQL), in an attempt to make the 
items more relevant and to aid understanding of the questionnaire as a whole.  This 
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would initially appear straightforward, but difficulties arise if the child’s age does not 
correspond to or reflect their educational ability, understanding or emotional maturity.  
A very mature eleven year old may find herself completing a questionnaire deemed 
valid for 6-11 year olds, when she may be more suited to completing the older child’s 
version.  Complications can also arise if the different age versions differ too greatly, or 
the item content differs between the child self report and the proxy version (Eiser and 
Varni, 2013).  For these reasons a single questionnaire, allowing self completion by the 
child, over a wide age range may be more useful, allowing reliable monitoring of the 
child as they develop and transition into adult care.  Moreover, Erling (1999) states that 
if the aim is to monitor health or QoL within a longitudinal study, a potential solution 
would be to use items which are not overly age-related, which would therefore allow 
children of all ages to complete the same instrument. 
The following chapter goes into more detail about the development of new QoL 
instruments and the methods available to undertake this task. 
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Chapter 3   
Development of Quality of Life measures 
3.1 Background 
Quality of Life (QoL) questionnaires and the items included within can be developed in 
several ways.  Historically QoL instruments for children were developed from adult 
measures that were adjusted to suit the younger population.  Landgraf (2005) states 
that adapting adult items by rewording them is not sufficient as the item should be 
relevant at both the concept and item level.  Concepts uncovered from the adult 
population are often not suitable and relevant to children; their priorities, expectations 
and understanding are very different.  It is well known that children are not just small 
adults.  Kozinetz et al (1999) state that as the goal of adult functioning is to be self-
sufficient and economically productive, as a result, adult-based measures of 
functioning or QoL are not suitable for adaptation and use within the paediatric 
population.   
3.1.1 Developmental methods of patient reported outcome measures 
Questionnaire development more recently has followed a different path, attempting to 
produce QoL instruments which have improved content validity, ensuring that newly 
developed instruments are suitable for the paediatric population.  In the case of 
disease specific measures; that the items and dimensions are measuring what the 
target population feel is important and relevant to them.  Schmidt et al (2001), state that 
an instrument is more likely to be acceptable to the population group, if it measures 
what they consider to be important to their QoL.  This can be achieved if the specific 
population are involved in the uncovering and generating of the items and dimensions.   
3.1.2 Generating themes and uncovering concepts 
Themes or items for a new QoL questionnaire can be developed via a top down or 
bottom up approach.  The first involves pulling items from the literature, previous well 
known QoL instruments or from expert opinion; the latter approach involves canvassing 
the patient population, using qualitative research methodology to elicit potential themes 
or items, and the development/production of a conceptual framework. 
Some researchers describe the review of the literature as synonymous with the 
development of the conceptual framework (Maxwell, 1996).  This is of course not the 
case; a conceptual framework based on theoretical publications would not necessarily 
ensure good content validity for a particular population, as they had not been involved 
in the generation of concepts, which may later prove to be irrelevant.  Within the 
literature there is often a lack of transparency during questionnaire development 
surrounding the conceptual framework.  Some authors use only top down methods to 
develop QoL instruments (Bevans et al, 2010; Starfield et al, 1995, instigating item pool 
generation from literature or expert opinion, followed by factor analysis to define the 
scales, statistical analysis and subsequent modification of the scale.  This can lead to a 
scale with clinically curious item content and poor content validity.  Other developers 
use bottom up methodology (Landgraf, 1996; Sandeberg et al, 2010), but offer little 
information about the experience of the research team/authors, or the process 
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undertaken, alongside the relevant population, to develop the conceptual framework 
and any revisions that may have taken place. 
This bottom up approach of concept gathering from the participant population 
encourages good content validity and the boundaries of these concepts can be 
examined by triangulating them alongside expert opinion and literature review (Magasi, 
2012). 
The risk of a ‘top down approach’ is that it does not take into account the thoughts and 
opinions of the patients and how their underlying condition affects their QoL (Gorecki et 
al, 2010).  This lack of patient perspective can lead to issues surrounding content 
validity and responsiveness to change, as it may not be relevant to the target 
population (Guyatt and Cook, 1994).  The US Food and Drug Administration (FDA) 
guidance for industry (2009) detailed the process that should be undertaken when 
developing a patient reported outcome measure.  This stimulated debate around 
content validity and exposed the limitations of some ‘top down’ methodologies (Hobart, 
2013).  Basch et al (2011) reports that some measures which were developed for 
clinician reporting, are now used as a patient reported outcome measures (i.e. McGill 
Pain Questionnaire).  As the present pain intensity item of the McGill Pain 
Questionnaire was not developed with a patient-centred approach, it’s validity as an 
assessment of the patient experience associated with disease and treatment is 
questionable.  Basch et al (2011) go on to state that patient-centred PRO measures 
need to be understandable to patients from varied backgrounds, and therefore need 
direct patient involvement during development. 
3.2 Content validity and the conceptual framework 
The FDA guidance (2009) stresses the importance of content validity within instrument 
development, and alongside Patrick et al (2011a), encourage the development of a 
conceptual framework, informed by the themes uncovered from the patient population.  
This conceptual framework allows the manifestations of the disease, its treatments and 
how they affect the patient population to unfold and be explored. Interviews and focus 
groups are suggested qualitative methodologies through which to uncover these 
themes.  Hobart (2011) describes the FDA guidelines as a line drawn in the sand, and 
a move away from a top down approach to patient reported outcome (PRO) 
development.   
As a result of this FDA guidance, the importance of content validity within scale 
development to ensure good research practice, was raised and discussed further by 
the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
within their two task force reports (Patrick et al, 2011a & b).   
“content validity is defined by the empirical evidence that demonstrates the 
items and domains of an instrument are appropriate and comprehensive 
relative to it’s intended measurement concept, population and use.” 
 (FDA, 2009 in Patrick et al, 2011a, pp968) 
The overall aim of the conceptual framework is to organise the process of concept 
elicitation and pictorially document the information uncovered from the literature and 
expert opinion (patient, family and health professional).  This expert opinion can be 
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sought from several sources; one-to-one interviews, focus groups and postal/telephone 
questionnaire (Lasch et al, 2010). Consideration should be made to ensure that there is 
a representative sample of patients used to elicit the concepts, allowing the variation in 
severity and experience across the disease population to be represented and all views 
heard.  On the basis of the final comprehensive conceptual framework, these initial 
concepts, the dimension headings and items within the proposed 
questionnaire/measure can be constructed.   
3.2.1 Interviews. 
There are three main types of qualitative interview; structured, semi structured and in-
depth (Britten, 1995).  Structured interviews are administered in a standardised 
manner, and questions are closed requiring a fixed answer (yes/no/sometimes/always).   
Those which are less standardised are referred to as semi structured.  They consist of 
an interview schedule with ideas for open-ended questions outlining the subject to be 
explored (Britten, 1995).  These semi structured interviews explore participants’ 
experiences of a particular subject matter and the meaning behind them (Tong et al, 
2007).  Each interview within the study may take a different structure, the interviewer 
may re-order the questions as the participants’ experience and viewpoints are 
explored.  Interviewers have some latitude to ask further questions in response to what 
are seen as significant replies (Bryman, 2004).  The interviewer will try to use the 
participants own vocabulary to enhance the interview process and encourage the 
disclosure of more sensitive information.   
In depth interviews may cover a limited number of topics, but in great detail.  The 
interview follows the direction of the interviewee; further questions are based on what 
the interviewee said throughout the interview (Britten, 1995). 
Interviews can be face-to-face or over the telephone.  Structured interviews are easy to 
conduct in both settings; those with less structure are more suited to face to face 
situations.  Telephone interviews are cheaper and the respondents’ replies are not 
affected by the characteristics of the interviewer, but participants who have hearing 
deficit will find this form of interview more difficult.  It is therefore not suitable for the OI 
population, who can suffer from some deafness (57.9% in Kuurila (2002).  Face-to-face 
interviews would therefore be a suitable method for the OI population, as it would allow 
participants the freedom to discuss their thoughts and opinions, suggesting new topics 
as they arose; enabling the researcher to delve deeper into topics where appropriate.  
The researcher would also be aware if the interviewee had misheard or not understood 
the question posed. 
Patton (1987) suggests that interviews should start with simple questions then proceed 
to those of a more sensitive nature. Further questions may be introduced as the study 
progresses, and more interviews take place.  The researcher becomes more in-tune 
with the study topic and may start to develop further areas of increasing interest.  All 
stages of qualitative research are open to interpretation and influencing by the 
researcher.  Therefore for this reason it is important to reflect the patient narrative 
accurately.  The development of a clear interview guide avoids undue influence of the 
researcher (Patrick et al, 2011), and will discourage digression from the subject matter. 
 
 
23 
 
Various methods are discussed in the literature of how to record interviews.  These 
may be as simple as contemporaneous notes, those documented afterwards or audio 
taping.  Britten (1995) suggests that notes written at the time can interfere with the 
interview process, and those written after the event may miss vital details.  It is often 
more appropriate to tape record the interview and transcribe later, but with an 
awareness that each hour of interview is thought to take 6-7 hours to transcribe.  
Maintaining a good auditing approach which includes complete records of all phases of 
interviews and/or focus groups; problem formulation, selection of participants, field 
work notes, interview transcripts, and data analysis decisions will increase the overall 
dependability of the study and enhance transparency of the process (Bryman, 2004; 
Clift et al, 2007, Tong et al, 2007).  This latter technique is intrinsic to the transparency 
of the questionnaire development process, and should therefore be undertaken by the 
interviewer or the principle researcher, following each interview. 
Qualitative research aims to reflect a diverse population, rather than simply 
representative (Mays and Pope, 1995a & b).  Purposive or theoretical sampling allows 
the researcher a degree of control (Barbour, 2001).  The investigator can identify the 
outliers within a population, allowing their views to be sort and discussed, as they may 
offer differing or varied thought processes.  It is noteworthy at this stage to state that 
when purposeful sampling has been adopted, it is necessary to discuss its effects 
within the discussion section of the study, examining what, if any the differences were 
between the outliers in the group.  Within this study it will be pertinent to examine the 
population differences and similarities between the views of families affected by severe 
and mild forms of OI.  Unlike quantitative research, sample size calculations are not 
required for qualitative research.  The uncovering of themes takes place in an iterative 
way, and the research process (interviews, focus groups or questionnaires) continues 
until no new themes are identified.  This is called saturation of data, and occurs when 
no new information is heard or uncovered from the ongoing interviews (Hill et al, 2014).  
Once transcribed the interviews are examined in detail to search out themes.  
Significant statements are identified and extracted from the transcripts and then 
organised into categories which become research themes (Parahoo, 1997).  It is 
reported to be useful (Barbour, 2001) at this stage within the study to have another 
person to look over segments of the data to examine emergent themes.  This may take 
place during supervision sessions or at research team meetings.  Hummelinek and 
Pollock (2006) discuss the process of sequential analysis, where emerging themes and 
hypotheses are continually checked against the data.  These themes are then refined 
and the coding frame work developed.  Other findings are then mapped and used to 
seek associations between the themes and generate explanations for the findings.   
3.2.2 Focus groups. 
Kruegar (1994) described focus groups as a planned discussion, which attempts to 
gain the perceptions of a group on a defined area of interest in a permissive, non 
threatening environment.  They involve a purposive sample from a specific population, 
but are not necessarily representative.  The aim is to elicit a discussion enabling the 
researcher to see the world from the participants’ perspective, and exploring the 
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rationale behind people’s thoughts and behaviours.  Until the 1980s focus groups had 
been used with adults only, until Heinmann-Ratain et al (1985) used this method to 
explore health in children. Heary and Hennessy (2002) state that children often 
respond in ways that they believe the researcher desires, and this has often been the 
threat to the validity of one-to-one interview situations.  Focus groups remove this 
adult-child relationship, acknowledging the children as experts and therefore can have 
greater face validity.  Fayers and Machin (2007) describes controversy when assessing 
the advantages of focus groups over one-to-one interviews, stating that both require 
the facilitator/interviewer to have good communication skills and an open-minded 
outlook.  They feel one-to-one interviews allow greater expression from some 
individuals and more deviant cases, conversely focus groups are less likely to reach 
extreme conclusions and the results are therefore less polarised. 
Focus groups in children can have their faults too.  Children may be intimidated, 
choosing to adopt themes previously raised by other children, rather than offer new 
opinions of their own (Lewis, 1992).  Fern (1982) found that some individuals reported 
greater anonymity when interviewed compared with participating within a focus group, 
and this may be a reason for non-participation in some children.  McEwan et al (2004) 
described using techniques such as; writing down any issues that participants felt were 
too sensitive or personal to discuss to further improve anonyminity.     
Several researchers’ state group size is an important consideration when undertaking 
focus groups with children.  The optimum size is smaller than that of an adult focus 
group, often with 4-5 individuals to ensure three ‘talkers’ (Hoppe et al, 1995).  Other 
groups recommend 4-6 participants (Greenbaum, 1988; Vaughn et al, 1996), stating 
that larger groups are often difficult to control.  Larger groups can often lead to 
frustration as not all participants get chance to have their say, allowing larger 
personalities to be more dominant and therefore only a small proportion of the group 
are included within the discussion (Bloor et al, 2001).  Larger groups are also more 
difficult to transcribe and correctly attribute the interaction taking place to the specific 
participant.  Conversely smaller groups may result in limited discussion and are at risk 
of cancellation if only one or two participants fail to turn up, or could result in a small 
group interview rather than a group discussion due to lack of momentum (Green and 
Hart, 1999).  A concern for focus groups that include people, who use wheelchairs or 
walking frames, is often space.  Quine & Cameron (1995) advocated small groups with 
disabled elderly people, due to the space required for their mobility equipment.  
Overall, focus groups need to be large enough to avoid cancellation, but small enough 
to control, allowing all participants to feel satisfied they have had opportunity to speak 
and be heard.  Bloor et al (2001) also makes a valid point when they state that focus 
groups are labour intensive in their recruitment, transcription and analysis, and for this 
reason it can be best to keep numbers to a bare minimum. 
Bloor et al (2001) states the facilitator should attempt to facilitate a group and not 
control it; the interaction of some groups can be distorted by too much external control.  
The facilitator must encourage participation from all group members, and try not to 
allow some strong personalities to dominate the group.  They go on to say that if one 
member makes a suggestion, but no other participants make any spontaneous 
murmurs of agreement, then the facilitator should check that the suggestion does in 
fact fit with the other views.   
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Focus groups involving children should be well moderated by someone who is familiar 
with the cognitive and social abilities of children of different ages (Heary and Hennessy, 
2002).  Those undertaken for health services research should be moderated by 
someone who is aware of the likely developmental changes in a child’s understanding 
of their health and illness (Bearison, 1998). It is also the responsibility of the moderator 
to encourage interaction between participants in a relaxed and friendly way, they must 
be aware of when some members become bored, uncomfortable or confused 
(Porcellato et al, 2002).  Focus groups with children should also involve the setting of 
ground rules; allowing the participants to feel at ease and comfortable in the knowledge 
their discussions will remain anonymous.    
Vaughn et al (1996) state children over 6 years old can be very effective participants in 
focus groups, as they are likely to be spontaneous and exhibit fewer socially desirable 
responses.  Their need to be socially acceptable is lower than their more mature peers.  
Older children often have higher anxieties about peer reactions; therefore report it is 
best to have broadly similar aged participants, due to both differing cognitive abilities 
and sensitivities of children of different ages.  It is recommended that participants 
should not know each other prior to the group; this ensures no pre-existing 
relationships or patterns of leadership within the group (Krueger, 1994).  
The development of a conceptual framework using triangulation from; literature review; 
expert opinion; interviews and focus groups with the relevant population are discussed 
at length in Chapters 4, 5, and 6 of this thesis. 
3.3 Item development 
Ensuring that the newly developed instrument contains themes and concepts that are 
relevant to the target population, by accessing what they feel is important to their QoL, 
and developing a conceptual framework outlining these concepts is only the first stage.  
Hobart et al (2013) stated that scale construction is an iterative on-going process of 
hypothesis generation, testing and revision, requiring help from all available methods.  
During development it is important to remember that we are wrestling with two 
uncertainties; what is the definition of the variable and how best is it articulated with 
words. (FDA, 2009).   
Patrick et al (2011a & b) proposed that the challenge, when developing a new 
measure, is to use a method that permits moving back and forth between hypothetic-
deductive and inductive approaches.  This allows the development aims and the prior 
knowledge of the developers to remain important to the PRO measure, whilst allowing 
their understanding to change in response to any new information. These steps are 
detailed below in table 3.1. 
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Table 3.1   Good practice steps in PRO development  
 
  
 1.   Determine the context of use (i.e. medical product labelling) 
 2.   Develop the research protocol for qualitative concept elicitation 
 3.   Conduct the concept elicitation interviews and focus groups 
 4.   Analyze the qualitative data 
 5.   Document concept development and elicitation methodology 
             and results 
 6.   Develop items based on findings from concept elicitation 
 7.   Design cognitive interview process for the planned context of use 
                  Identify population 
 8.   Conduct cognitive interviews 
 9.   Make decisions to revise the patient-reported outcome instrument 
 10. Document cognitive interview results for evaluation of content validity 
 
 
A limitation of using qualitative methods to elicit concepts is the reliance on good faith 
and judgement of the investigative team.  Interpretation is made of which concepts are 
most relevant for inclusion, and could lead to bias within the developed questionnaire 
(Basch et al, 2011).  They suggest that the best way to ensure no bias is to report all 
concepts felt important by the patients and then be transparent about the rationale 
behind which items were chosen for inclusion.   
Early development of a PRO measure attempts to continue to promote high content 
validity and relevance to the target population.  Themes uncovered during one-to-one 
interviews and focus groups can be used to inform dimensions and items within the 
new questionnaire; effort is made to examine the terminology used by the children 
interviewed and construct items/questions, where possible, on their phrases and 
descriptions.  Carlton (2013), during the development of a HRQoL questionnaire for 
children with amblyopia, used the phrases vocalised by the children throughout their 
interviews to inform the choice of levels for the items.  Phrases such as; “a little bit”; “a 
lot”; and “very” informed the development of her severity based Likert scale.  Draft 
versions of items or the whole questionnaire can be reviewed by members of the 
relevant population or suitably qualified teachers to encourage feedback on content, 
readability and format.   Stevens (2009) undertook interviews with children to elicit 
concepts and themes to inform the items within a preference based quality of life 
measure.  She used the children’s terminology and phrases from the transcripts to 
inform the dimensions within the measure and to make decisions with regards to the 
use of a severity or frequency based scale, alongside gathering information on the 
most suitable recall period.   
Ensuring readability and understanding is an important part of questionnaire 
development; keeping items/questions simple and relevant; avoiding double barrelled 
questions; and where possible avoiding negatively worded items which may be 
distressing to respondents. (Stevens, 2009). 
Demonstrating transparency when describing and documenting the development of a 
new QoL or PRO measure is vitally important.  It should be apparent to the reader how 
the items or questions were derived, where and how the themes were uncovered, and 
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how they were transformed into suitable and relevant questions/items.  Developers 
should acknowledge whether the items were suggested and therefore uncovered by 
the target population, or written by experts independent of the relevant patient cohort.  
The newly developed PRO measure in its initial ‘version 1’ format then requires testing 
alongside the relevant population, followed by revision and further feedback. 
3.4 Pilot testing 
When examining the content validity of a new measure it is necessary to evaluate the 
importance and relevance of the dimensions and items within.  Steps six to ten within 
the above table (table 3.1) refer to the piloting of the items within the initial 
questionnaire/instrument.   Patrick et al (2011b) describe the use of short semi 
structured cognitive interviews following questionnaire completion to ensure participant 
understanding and comfort of the newly developed questionnaire.  They go on to 
suggest that these post completion individual cognitive interviews, with a wide range of 
subjects from the target population should probe subjects on what they think the 
question/item is asking (item intent), and what answer they feel is required.  Further 
questioning to ascertain whether this item is relevant to the dimension and population 
should also take place.  Subjects should also be asked about specific words and 
phrases within the items, to examine their understanding and if this understanding 
matches the aim and ideas of the developers.  This process of pilot testing is often 
more difficult with children; age, maturity, cognition and reading ability make 
ascertaining what a child thought about or understood whilst completing a 
questionnaire challenging.  The ability of the child to then feedback their thoughts and 
understanding to the researcher can also add to this complicated process.  Asking 
children to explain what they think a question is asking them, or why they answered in 
a particular way is beneficial, but needs to be undertaken in a non-threatening manner. 
Patrick et al (2011b) states that the information gathered from these cognitive 
interviews can be influenced by a subjects characteristics such as; literacy, experience 
with the disease condition, or experience in completing questionnaires.  This will be 
particularly relevant to the paediatric population, whose ability is varied across the age 
range, and therefore a sample used to address this content validity needs to be 
representative and include subjects of all ages.  
It is important to clearly observe a subject completing the recently designed 
questionnaire.  A note should be taken of any difficulties in reading or any facial 
expression which shows confusion.  Listening out for comments about items often 
gains more information.  Subjects may ask for more information about a particular item, 
or ask what is meant by a certain question.  If a respondent chooses to quietly 
complete the questionnaire, time could be taken to ask them how they feel a particular 
item could be improved or reworded (Patrick et al, 2011b).   
All of this information should be clearly documented throughout each stage.  Notes can 
be written whilst observing the subject completing the questionnaire.  This will enable a 
reflection of areas or items of concern; what issues have arisen during completion, and 
were any suggestions made for improvement.  Where subjects have paused during 
completion, may not have been immediately obvious to them at the time, but if several 
respondents all pause at the same item, this may indicate difficulty in understanding or 
ability to recall that information.  Post completion interviews can be recorded and 
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transcribed verbatim to enable thorough investigation of problem areas or items to take 
place.  This process of pilot testing allows revisions to the questionnaire to be made at 
this stage, prior to psychometric testing.  All changes made to the questionnaire as a 
result of the observations during completion and the subsequent interview should be 
documented to allow transparency. 
Any bias can be monitored during pilot testing and questionnaire completion.  
Acquiescence bias or repeated positive ‘yes’ saying can be influenced by how the 
question is phrased, and the addition of both positively and negatively phrase 
questions can be used to reduce this (Smith et al, 2005).  Social desirability or 
acceptability can also be a form of observed bias during questionnaire completion.  
This can be particularly prevalent in teenagers and young adults, as they strive to be 
like their peers.  Some respondents may avoid using the far ends of the Likert scale, 
and demonstrate central tendency; this can be examined statistically by monitoring any 
floor or ceiling effects.   
Walters (2009) states that psychometric techniques are only able to confirm validity by 
demonstrating that an instrument behaves as expected.  Patrick et al (2011a) within 
their paper describing instrument development and content validity, states that the use 
of quantitative data in the absence of prior knowledge, conceptual frameworks and 
qualitative considerations can lead to a theoretical instrument generating scores with 
unknown meaning.  For this reason initial assessment of validity, reliability and 
acceptability, alongside cognitive interviews and debriefing can assist in the 
development of an instrument with good content validity and more robust reliability. The 
acceptability of the questionnaire can be highlighted by examining the amount of 
missing data or observing any floor or ceiling effects.  Missing data can be problematic 
when developing questionnaires.     
Fayers and Machin (2007) state pilot testing should take place with a purposeful 
sample of 10-30 patients who are naïve to the earlier stages of concept elicitation and 
questionnaire development.  However they express caution with regards to beginning 
the item reduction process too early.  They feel it is important to maintain 
comprehensive coverage of causal items, as some symptoms may be rare, but may 
relate to a serious, extreme or life threatening state, which may be crucially important 
to those patients who experience it.  In the case of severely affected OI patients, the 
need to be handled to move from one space or area to another, may have a large 
impact on an individual’s QoL and should therefore remain included at this early stage 
in development.   
3.5 Psychometric testing of the new questionnaire 
There is a balance or trade-off between a questionnaire with good content validity, 
represented by the conceptual framework and one with excellent psychometric 
properties, which may result from early item reduction (Smith et al, 2005).  Eiser and 
Morse (2001) state that it is important not to undertake item reduction too early, as this 
may leave the developers with a psychometrically sound questionnaire which has poor 
relevance to the population it was developed for.  
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For a newly developed patient reported outcome measure or QoL questionnaire to be 
useful within the clinical and research fields, it must be robust.  Information on the 
validity, reliability and responsiveness of the questionnaire should be readily available 
and the methods used to field test the questionnaire should be reproducible.  Within 
their review paper published in 2011, Cano and Hobart suggest two important points: 
 
 “For these measurements to be fit for purpose they must provide clinically 
 useful,  meaningful and interpretable data.”  (pp 280) 
  
 “The central problem with health measurement is that we cannot currently be 
 sure what most rating scales are measuring.  This is because the methods in 
 place to ensure validity fall short of what is actually required.”  (pp 279) 
 
These two statements make demonstrating and assessing the robustness of a newly 
developed questionnaire a difficult process, and therefore developers have to make 
decisions around initially what is important to measure, and how best to go about it. 
 
New QoL instruments, in order to be useful, should satisfy the four basic properties of 
validity, reliability, responsiveness (ability to detect change) and interpretability.  
3.5.1 Reliability 
Reliability is the stability, in QoL scores, between repeated administrations in a 
population who have not experienced any health change or change in QoL. This 
includes stability: over time (i.e. test re-test reliability); between raters or interviewers 
(i.e. inter-rater reliability); between location - such as between hospital and home.  
Another form of reliability is internal reliability or internal consistency reliability.  QoL 
scales with multiple items, rather than a single global question, are thought to allow a 
broad coverage of the overall construct, and therefore improve the reliability of the 
questionnaire, as the amount of random error is reduced.  For scales which use 
multiple items to assess a particular dimension of QoL, all items should be consistent, 
meaning that they should all measure the same concept (Walters, 2009).   Fayers and 
Machin (2007) however offer a different opinion, particularly when causal items are 
involved.  Causal items are often symptom related, and can therefore be highly 
correlated with a disease or treatment, but not necessarily be related to one another.  
Fayers et al (1997) suggest that if a patient suffers from a certain symptom or side 
effect, its presence may lead to a reduction in their QoL (i.e. vomiting in cancer 
patients).  Hence it is inferred that the symptom may have caused the deterioration in 
QoL and therefore items describing these symptoms are causal.  Conversely, items 
which may result from a perceived poor QoL, such as anxiety or depression, are 
named ‘effect’ or ‘indicator’ items.  As causal items are often related to symptoms, 
there is no guarantee that they will be correlated with one another, and may therefore 
not behave in a similar way to effect/indicator items, which lend themselves to 
psychometric testing.  Alternatively those items which are not highly correlated with 
each other, but are present within the same dimension, may indicate they are not well 
placed, or that the dimension is redundant. Care needs to be taken to examine these 
items closely; could they be causal items or items which are vitally important to the 
patient population?  
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3.5.2 Validity 
 
Validity is the extent to which an instrument measures what it is intended to measure. 
Validity is a difficult and some would say impossible thing to prove in the case of QoL 
measurement, since there is no ‘gold standard’ (Fayers and Machin, 2007).  There are 
several types of validity discussed in the literature.  
Content validity looks to see if the items of an instrument are sensible and 
comprehensively cover the domain of interest. Face validity, which is often considered 
to be a form of content validity, assesses if the items in a QoL instrument, appear on 
the face of it to cover the domain of interest clearly and unambiguously. The main 
distinction between the two types of content validity is that face validity concerns the 
critical review of the items of a new instrument after it has been constructed but before 
use, whereas the item coverage and relevance is usually looked at during the 
instrument construction. 
Ensuring high content validity has previously involved experts using their judgement to 
determine whether the items are relevant to the target population (Lynn, 1986).  
Children with OI and their families are considered as experts in their disease and its 
management.  They are also the group who will be completing the newly developed 
questionnaire, and are therefore well placed to validate the themes and sub themes 
previously elicited.   
Criterion validity is the extent to which the new QoL scale has an association or 
correlation with external criteria such as other established instruments or measures 
(which are generally regarded as more accurate) (Walters, 2009).  Criterion validity 
examines the newly developed tool alongside the current gold standard.  It is difficult to 
assess in the absence of a gold standard measure on which to compare the newly 
developed tool.  This is often the case during the development of a disease specific 
instrument, as the reason for its development was the absence of a suitable alternative, 
and therefore a comparison to a gold standard is not possible. 
 
Construct validity is the extent to which an instrument measures the construct or 
concept that it is designed to measure.  This involves forming a theoretical model that 
describes the constructs being assessed and the expected relationships between these 
constructs.  Data is then collected, and a judgement is made as to the extent to which 
these relationships are confirmed.  If the results confirm prior expectations then the 
instrument may be valid.  
Construct validity is usually divided into three types: known groups validity; convergent 
validity; discriminant validity. Known-groups validity is based simply on the assumption 
that certain specified groups of subjects may be expected to score differently from 
other groups, and the new instrument should be sensitive to these differences.   
A scale that cannot sensibly distinguish between groups with known differences is not 
likely to be useful. A more complex aspect of construct validity is convergent validity. 
Convergent validity shows that a postulated dimension of QoL correlates appreciably 
with those dimensions that theory suggests it should. Convergence can be assessed 
by examining the correlations between each item and the total score (Fayers and 
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Machin, 2007).  Convergent validity is supported when item correlations are moderate 
(0.3 or greater). 
Conversely, discriminant validity recognises that some dimensions of QoL are 
expected to be relatively unrelated and that their correlations should be low. 
Convergent and discriminant validity are effectively the two opposite sides of the same 
coin and are usually considered together (Walters, 2009).  Some psychometric 
methods can identify items which correlate highly with each other. This may be an 
indicator that one or several of these items are unnecessary; may be measuring the 
same concept or tapping into the same theme and are therefore possibly redundant.  
 
3.5.3 Responsiveness 
Responsiveness is the extent to which an instrument is able to detect a clinically or 
practically important change in QoL status. That is, when the concept changes, the 
scores for the QoL instrument measuring that concept should change. This is the 
sensitivity of a measure to health change. Strictly speaking it is a form of validity and 
hence again it is difficult to prove. It can be assessed by effect size statistics i.e. ratios 
of mean changes to standard deviations (Walters, 2009). 
3.5.4 Statistical methods 
Quantitative methods are often used to psychometrically test the newly developed 
questionnaire/instrument.  Magasi et al (2012) feel these methods explore and confirm 
the dimensionality of multiple item scales, evaluating any item bias and examine the 
relationships among the health concepts.  They go on to say that dichotomization of the 
qualitative and quantitative processes within questionnaire development is fool hardly; 
and that an iterative mixed methods process should be adopted.   
Other areas of interest when examining and reporting  the acceptability, data quality 
and robustness of a newly developed questionnaire are; missing data; missing forms; 
and floor or ceiling effects.  Missing data within a questionnaire can occur if there is 
poor understanding of an item, or if a patient is uncomfortable with the subject matter; 
although this may be reduced if trained personnel are present during completion or the 
questionnaire is reviewed immediately after.  These items, if deemed inappropriate, 
could be rewritten or if after careful consideration they are not felt vitally important to 
the participant population, they may be eliminated.  To ensure important items are not 
eliminated it may be necessary to look back at the qualitative item generation and 
validation stages of questionnaire development.  Items eliminated on statistical or 
psychometric properties alone may have a detrimental effect on content validity. 
Floor and ceiling effects describe the number of individuals that lie at the lowest and 
highest end of available scores respectively. If there are a large percentage of 
individuals, or the majority of scores sit within the lower end, there is said to be a floor 
effect for that particular item.  Ceiling effects are said to occur when the reverse 
happens.  Some causal items related to symptoms may lead to floor or ceiling effects, 
especially if they are symptoms which are rare to the majority of participants, but may 
represent a severe situation, which is very relevant to those patients who are affected 
by it. (Fayers and Machin, 2007).  This may occur when considering handling in the 
paediatric OI population; the majority of mildly effected individuals would never have 
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experienced being handled or lifted on a regular basis, and would therefore never have 
been fearful of being handled poorly.  This would lead to a potential ceiling effect within 
any item which asks about fear of handling. 
Psychometric scales have been used in health outcomes and health measurement 
since the 1980’s.  However QoL instruments consist of a group of items which are 
believed to relate to a general definition of QoL; including a mixture of both causal and 
effect items.  Classic test theory uses a number of statistical methods to provide 
evidence of the scientific robustness of the newly developed questionnaire.  Tests such 
as;  
 Cronbach’s alpha, to examine internal consistency;  
 Pearson/Spearman correlations to identify similarities between 
dimensions within different questionnaires or the current ‘gold standard’ 
questionnaire, or to explore any known-groups validity. 
 
This analysis is based on raw scores, or the transformation of raw scores to a 0-100 
scale, and assumptions are made.  Most health care scales or QoL measures construct 
scores by counting the responses to the items.  Ordered or Likert scales are not 
necessarily providing interval data.  That is to say the difference between 0 and 1, and 
1 and 2 may not be equal.  The same can be said for the total score; the change in 
summated QoL score from 5 to 10, may not represent the same amount of change that 
is observed from 25 to 30.  Psychometricians however, argue that the ordinal scores 
generated by health measures or questionnaires are adequate approximations of 
interval-level measurement (Hobart and Cano, 2009).   
Many papers suggest Cronbach’s alpha is a suitable statistic to use when examining 
internal consistency of items to each other and to the item total (Ravens-Sieberer et al, 
2010; Wiklander et al, 2013; Fayers and Machin, 2007).  It is postulated that 
coefficients of above 0.7 are regarded as acceptable.  Cronbach’s alpha can also 
demonstrate the effect of removing an item from the dimension or questionnaire; if the 
reliability of the dimension remains the same after item removal, it may be that the item 
is contributing very little to the dimension or questionnaire as a whole.  Item-total 
correlations (ITC) are another method to examine how well items within a scale are 
correlated.  Nunnally and Bernstien (1994) suggest item-total correlations between 0.4 
and 0.6 indicate items are moderately correlated with the scale; a higher value 
indicates greater correlation between items and the scale.  In some instances where 
very high ITC values are noted, this may be an indication of item redundancy.  Item-
total correlations of < 0.3 demonstrate poor item fit within the scale or dimension. 
 
 
3.5.5 Modern psychometric measurement 
 
Factor analysis can be used to further validate and confirm the structure and construct 
validity of the newly developed measure.  Factor analysis can be either confirmatory or 
exploratory.  The latter assigns no pre-assumptions to the data analysis; the initial 
(confirmatory factor analysis) looks to examine whether the initial questionnaire format 
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is suitably divided into dimensions and whether the items within the dimensions are a 
good statistical fit with each other and to the dimension as a whole.   
Eiser and Morse (2001) suggest that there is discussion surrounding whether factor 
analysis is the ideal method for establishing construct validity.  This method is often not 
possible when only small sample sizes are available for analysis, which can often occur 
in more rare diseases.  In this instance it is important to examine other ways to divide 
the large group of items to produce separate dimensions of highly inter-correlated 
items.  Fayers et al (1997) agree with the above notion and argue that less emphasis 
should be placed on factor analysis to inform construct validity in favour of less 
numerical methods; including debriefing questionnaires and consensus interviews. 
More modern measurement methods such as Rasch theory attempt to obtain data 
which fits a particular or pre-defined model, they no longer just describe the data in 
relation to the sample used, as occurs in classical test theory, therefore the outcome is 
not sample dependent.  Rasch methodology examines the relationship between the 
unobservable ‘true’ measurement of the attribute or trait, and the probability of 
responding to the particular response option of the item within the scale/questionnaire.  
Where a person lies on an interval-level construct, determines which response option 
they choose for an item, for example Hobart and Cano (2009) state they would expect 
a person with severe disability to be unable to complete as many functional tasks on a 
particular scale.  They would therefore answer ‘no’ more frequently than their less 
disabled peers.  This seems quite logical when discussing functional tasks or objective 
measurement of physical ability.  However can we be sure that a more subjective topic 
such as QoL will behave in the same way?  Will more severely affected individuals 
necessarily report poorer QoL?  Can we predict who will respond about their QoL in a 
certain way from their ability or severity of disease?  Teresi et al (2008) states, that 
individuals with similar ability should respond in similar ways to individual items, 
regardless of group membership.  Rasch methodology aims to demonstrate that this is 
the case.  
Cano and Hobart (2011) describe this model as examining the legitimacy of summing 
items to generate a score. 
 “The model sets out the requirements that must be met for the rating scale data 
 to generate internally valid, equal-interval measurements that are stable across 
  both items and people”   (pp 284) 
There are many conflicting recommendations for the minimum number of subjects 
required for carrying out a factor analysis. Fayers and Machin (2007) suggest that it 
may be necessary to include several hundred patients.  Similarly, there are no 
definitive answers for what sample size one needs for an IRT analysis (Fayers and 
Hays, 2005, pp71). With polytomous and ordered categorical item responses (similar to 
the newly developed OIQoL), using a minimum of 250 respondents is suggested, but a 
cohort of around 500 is recommended for more accurate parameter estimates (Fayers 
and Hays, 2005, p71).  
Factor analysis, item response theory and structural equation modelling can be used to 
further inform the quantitative testing of the newly developed instrument.  This latter 
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quantitative evaluation is beyond the scope of this PhD research and will be further 
discussed in chapter 9 of this thesis. The following chapters describe the methods 
undertaken to develop the new OI specific QoL measure, adhering where possible, to 
the best practice guidelines described within this chapter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
References 
 
Barbour, R. (2001) Checklists for improving rigour in qualitative research: a case of the 
tail wagging the dog?  BMJ, 322(7294), 1115-1117. 
Basch, E., Abernethy, A. P., Reeve, B. B. (2011) Assuring the Patient Centeredness of 
Patient-Reported Outcomes: Content Validity in Medical Product Development and 
Comparative Effectiveness Research. Value in Health, 14(8), 965-966. 
Bearison, D. J. (1998) Pediatric psychology and children’s medical problems. In W. 
Damon (Series Ed.), I.E. Siegal & K.A. Renninger (Vol. Eds.), Handbook of child 
psychology: Vol 4. Child psychology in practice ( 5th ed., pp. 635-711). New York:  
Wiley. 
 
Bevans, K. B., Riley, A. W., Moon, J., Forrest, C. B. (2010)  Conceptual and 
methodological advances in child-reported outcomes measurement. Expert Review of 
Pharmacoeconomics & Outcomes Research, 10(4), 385-396. 
 
Bloor, M., Frankland, J., Thomas, M. and Robson, K. (2001) Focus Groups in Social 
Research. London: Sage. 
 
Britten, N. (1995) Qualitative Research: Qualitative interviews in medical research. 
British Medical Journal, 311(6999), 251-253. 
Bryman, A. (2004) Social Research Methods (2nd ed.). Oxford: Oxford University 
Press. 
Cano, S.J. and Hobart, J.C. (2011) The problem with health measurement. Patient 
preference and adherence,  5, 279-90. 
 
Carlton, J. (2013) Developing the draft descriptive system for the child amblyopia 
treatment questionnaire (CAT-Qol): a mixed methods study.  Health and Quality of Life 
Outcomes,11, 174.  Available from: http://www.hqlo.com/content/11/1/174.  Accessed 
2nd November 2015.  
 
Clift, L., Dampier, S., Timmons, S. (2007) Adolescents' experiences of emergency 
admission to children's wards. Journal of Child Health Care, 11(3), 195-207. 
Eiser, C., and Morse, R. (2001) Quality of Life measures in chronic diseases of 
childhood.  Health Technology Assessment, 5(4). February 2001.  Available from: 
http://www.journalslibrary.nihr.ac.uk/__data/assets/pdf_file/0004/64948, Accessed 15th 
December 2010. 
Fayers P.M and Hand D.J.(1997)  Factor analysis, causal indicators and quality of life.  
Quality of Life Research, 6, 139-50. 
Fayers, P.M., Hays, R.D. (editors) (2005) Assessing quality of life in clinical trials: 
methods and practice. 2nd edition. Oxford, Oxford University Press.  
 
 
 
36 
Fayers, P. and Machin, D. (2007) Quality of Life.  The assessment, analysis and 
interpretation of patient-reported outcomes (2nd ed)  Chichester: John Wiley and sons 
Ltd. 
Fern, E. F. (1982) The use of focus groups for idea generation: The effects of group 
size, acquaintanceship, and moderator on response quantity and quality. Journal of 
Marketing Research, 19, 1-13. 
 
Gorecki, C., Lamping, D. L., Brown, J. M., Madill, A., Firth, J., Nixon, J. (2010) 
Development of a conceptual framework of health-related quality of life in pressure 
ulcers: A patient-focused approach. International Journal of Nursing Studies, 47(12), 
1525-1534 
Green, J. and Hart, L. (1999) The Impact of Context on Data, in R.S. Barbour and J. 
Kitzinger (eds) Developing Focus Group Research. London: Sage. 
Greenbaum, T. (1988) The practical handbook and guide to focus group research. 
Lexington, MA., Lexington books. 
 
Guyatt G. H. and Cook D. J. (1994) Health status, quality of life, and the individual.  
Journal of the american medical association, 272 (8), 630-631. 
 
Heary, C. and Hennessy, E. (2002) The use of focus group interviews in pediatric 
health care research.  Journal of Pediatric Psychology, 27, 47-57. 
 
Heimann-Ratain, G., Hanson, M., Peregoy, S. M. (1985)The role of focus groups in 
designing a smoking prevention program. Journal of School Health, 55, 13-16. 
 
Hill, C.L., Baird, W.O., Walters, S.J.  (2014)  Quality of life in children and adolescents 
with Osteogenesis Imperfecta: a qualitative interview based study.  Health and Quality 
of Life Outcomes.  16(12), 16th April 2014.  Available from: 
http://www.hqlo.com/content/12/1/54.  Accessed 16th April 2014. 
 
Hobart J., Cano S., Baron R., Thompson A., Schwid S., Zajicek J., Andrich D.  (2013)  
Achieving valid patient-reported outcomes measurement: a lesson from fatigue in 
multiple sclerosis.  Multiple Sclerosis, 19(13), 1773-1783. 
 
Hobart , J. (2011) Measurement in Clinical Trials:  FDA COA Workshop session 3 
Content Validity.  Washington DC. 19th October 2011 
 
Hobart J and Cano S.  (2009) Improving the evaluation of therapeutic interventions in 
multiple sclerosis: the role of new psychometric methods.  Health Technology 
Assessment [online], 12:1, February 2009.  Available from: 
http://www.researchgate.net/profile/Stefan_Cano/publication/24010086 [Accessed 10th 
December 2010]. 
 
Hoppe, M. J., Wells, E. A., Morrison, D. M., Gillmore, M. R., Wilsdon, A. (1995) Using 
focus groups to discuss sensitive topics with children. Evaluation Review, 19, 102-114. 
 
 
 
37 
Hummelinck, A. and Pollock, K. (2006)  Parents' information needs about the treatment 
of their chronically ill child: A qualitative study. Patient Education and Counselling, 
62(2), 228-234 
 
Janicke, D., Marciel, K., Ingerski, L., Novoa, W., Lowry, K., Sallinen, B. (2007)  Impact 
of psychosocial factors on quality of life in overweight youth. Obesity, 15, 1799-1807. 
 
Kozinetz , C.A., Warren, R,W,, Berseth, C.L., Aday, L.A., Sachdeva, R., Kirkland, R.T. 
(1999)  Health status of children with special health care needs:  Measurement issues 
and instruments.  Clinical Pediatrics.   38,  525-533. 
 
Krueger, R. (1994) Focus Groups. A practical guide for applied research, Sage 
Publications. 2nd Edn. 
 
Kuurila, K., Kaitila,I.,  Johansson, R., Grenman, R.  (2002)  Hearing loss in finnish 
adults with osteogenesis imperfecta: a nationwide survey.  Annals of Otology, 
Rhinology and Laryngology, 111(10), 939-946. 
 
Landgraf, J. M., Abetz, L., Ware, J. E. (1996) Child Health Questionnaire (CHQ): A 
user's manual. Boston, MA: The Health Institute, New England Medical Center. 
Landgraf, J. M. (2005) Practical considerations in the measurement of health related 
quality of life in child/adolescent clinical trials.  In P. Fayer & R. D. Hays (Eds.), 
Assessing quality of life in clinical trials. (2nd Ed). Oxford: Oxford University Press.  
 
Landgraf, J. M., Abetz, L.,  Ware, J. E. (1996) Child Health Questionnaire (CHQ): A 
User's Manual.  Health Institute, New England Medical Center. 
 
Lasch K., Marquis P., Vigneux M., Abetz L., Arnould B., Bayliss M., Crawford B., Rosa 
K.  (2010) PRO development: rigorous qualitative research as the crucial foundation. 
Quality of Life Research, 19, 1087-1096. 
 
Lewis, A. (1992) Group child interviews as a research tool.   British educational 
research journal 18, 423-423. 
 
Lynn, M. R. (1986) Determination and quantification of content validity. Nursing 
Research, 35, 382-385. 
 
Magasi, S., Ryan, G., Revicki, D., Lenderking, W., Hays, R., Brod, M., Snyder, C., 
Boers, M., Cella, D. (2012) Content validity of patient-reported outcome measures: 
perspectives from a PROMIS meeting. Quality of Life Research, 21(5), 739-746. 
Maxwell, J. A. (1996). Qualitative research design: An interactive approach Thousand 
Oaks, CA: Sage. 
 
Mays, N. and Pope, C. (1995a) Qualitative Research: Observational methods in health 
care settings. British Medical Journal, 311(6998), 182-184. 
 
 
 
38 
Mays, N. and Pope, C. (1995b) Rigour in qualitative research. British Medical Journal, 
311, 109-112. 
 
McEwan, M. and  Espie, C. (2004)  Quality of life and psychosocial development in 
adolescents with epilepsy: a qualitative investigation using focus group methods." 
Seizure. 13, 15-31. 
 
Nunnally J and Bernstein I (1994).  Psychometric Theory.  3rd ed.  New York:  
McGraw-Hill. 
 
Parahoo, A. (1997)  Nursing Research: Principles, process and issues. London: 
Macmillan. 
 
Patton, M. (1987) How to use qualitative methods in evaluation. . London: Sage 
Publications. 
Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., 
Ring, L. (2011a) Content Validity.  Establishing and Reporting the Evidence in Newly 
Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product 
Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1. Eliciting 
Concepts for a New PRO Instrument. Value in Health, 14(8), 967-977. 
 
Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., 
Ring, L. (2011b) Content Validity Establishing and Reporting the Evidence in Newly 
Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product 
Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2. 
Assessing Respondent Understanding. Value in Health, 14(8), 978-988.  
 
Porcellato, L., Dugdill, L., Springett, J.  (2002) Using focus groups to explore children’s 
perceptions of smoking: reflections on practice.  Health Education, 102(6), 310-320. 
 
Quine, S. and Cameron, I. (1995) The Use of Focus Groups with the Disabled Elderly.  
Qualitative Health Research 5(4), 454-462. 
 
Ravens-Sieberer U, Erhart M, Rajmil L, Herdman M, Auquier P, Bruil J, Power M, Duer 
W, Abel T, Czemy L, Mazur J, Czimbalmos A, Tountas Y, Hagquist C, Kilroe J.  (2010).  
Reliability, construct and criterion validity of the KIDSCREEN-10 score: a short 
measure for children and adolescents' well-being and health-related quality of life. 
Quality of Life Research, 19(10), 1487-500. 
 
Sandeberg M, Johansson EM, Hagell P, Wettergren L (2010)  Psychometric properties 
of the DISABKIDS Chronic Generic Module (DCGM-37) when used in children 
undergoing treatment for cancer.  Health and Quality of Life Outcomes [online], 8: 109, 
28th September 2010.  Available from: http://www.hqlo.com/content/8/1/109 [Accessed 
15th December 2010]. 
Schmidt, L.J., Garratt, A.M., Fitzpatrick, R.  (2001)  Instruments for Children and 
Adolescents: a Review Report from the Patient-reported Health Instruments Group 
(formerly the Patient-assessed Health Outcomes Programme) to the Department of 
 
 
39 
Health, July 2001. Available from: http://phi.uhce.ox.ac.uk/. Accessed 15th December 
2010. 
 
Smith, S. C., Lamping, D. L., Banerjee, S., Harwood, R., Foley, B., Smith, P., Cook, J. 
C., Murray, J., Prince, M., Levin, E., Mann, A., Knapp, M.  (2005)  Measurement of 
health-related quality of life for people with dementia: development of a new instrument 
(DEMQOL) and evaluation of current methodology.  Health Technology Assessment 
[online], 9(10), March 2005.  Available from: 
http://www.journalslibrary.nihr.ac.uk/__data/assets/pdf_file/0004/64966 [Accessed 10th 
December 2010]. 
 
Starfield, B., Riley, A., Green, B., Ensminger, M., Ryan, S., K, K. (1995) The 
adolescent child health and illness profile.  A population-based measure of health. 
Medical Care, 33(5), 553-566. 
Stevens, K.  (2009) Developing a descriptive system for a new preferenced-based 
measure of health-related quality of life for children.  Quality of Life Research, 18(8), 
1105-1113. 
 
Teresi J, Ramirez M, Lai J, Silver S.  (2008). Occurrences and sources of differential 
item functioning (DIF) in patient-reported outcomes measures:  Description of DIF 
methods, and review of measures of depression, quality of life and general health.  
Psychological science Q, 50(4), 538-612. 
 
Tong, A., Sainsbury, P., Craig, J. (2007) Consolidated criteria for reporting qualitative 
research (COREQ): a 32-item checklist for interviews and focus groups. International 
Journal of Qualitative Health Care, 19(6), 349-357. 
Upton, P., Lawford, J., Eiser, C. (2008) Parent-child agreement across child health-
related quality of life instruments: a review of the literature. Quality of Life Research, 
17(6), 895-913. 
 
US Department of Health and Human Services (USDHHS) (2009) Draft guidance for 
industry.  Patient Reported Outcome Measures:  Use in Medical Product Development 
to Support Labelling Claims. Available from 
http://www.fda.gov/downloads/Drugs/GuidenceComplianceRegulatoryInformation/Guid
ences/UCM193282.pdf  Accessed 16th March 2010. 
 
Vaughn, S., Schumm, J.S., Sinagub, J. (1996)  Focus groups interviews in education 
and psychology.  Thousand Oaks, CA: Sage. 
 
Walters, S. J. (2009) Quality of life outcomes in clinical trials and health care 
evaluation: a practical guide to analysis and interpretation. Chichester: Wiley. 
 
Wiklander M, Rydstrom L, Ygge B, Naver L, Wettergren L, Eriksson L.E.  (2013). 
Psychometric properties of a short version of the HIV stigma scale, adapted for children 
with HIV infection.  Health and quality of life outcomes [online], 11, 195, 14th November 
2013.  Available from: http://www.hqlo.com/content/11/1/195 [Accessed 15th 
December 2013]. 
 
 
 
40 
Chapter 4 
Systematically Reviewing the Literature        
4.1 Background 
The aim of this chapter is to document and describe the process undertaken to 
systematically review the literature surrounding suitable paediatric Quality of life (QoL) 
measures for the Osteogenesis Imperfecta (OI) population.  As there is currently no 
known ‘gold standard’ QoL questionnaire for children with OI, it was necessary to 
examine QoL measures and assess their relevance in relation to the paediatric OI 
population.   It was therefore important to systematically review the literature to ensure 
that no suitable instrument exists, prior to the development of an OI specific QoL 
measure.  In addition it was anticipated that this review would also highlight additional 
concepts which are relevant to the paediatric OI population, and thus inform the 
initial/early development of the conceptual framework (see Chapters; 5, 6, 7). 
 
Previous studies have reviewed and examined QoL questionnaires in the paediatric 
population (Eiser and Morse, 2001; Macabe, 2003; Stevens, 2008; Solans et al, 2008), 
and undertaken systematic literature reviews to do so.  Others have used a systematic 
review to examine the conceptual framework behind paediatric quality of life measures 
(Davis et al, 2006; De Civitia et al, 2005) identifying the definitions employed and the 
resultant structure.   
 
The different definitions used to describe quality of life or health related quality of life 
make reviewing the literature surrounding QoL measures a difficult task.  For further 
information regarding the definition of QoL or HRQoL refer to Chapter 2.  It is important 
to note at this stage however, that this chapter will attempt to review QoL and HRQoL 
measures developed for the paediatric population, and not those questionnaires 
developed to measure functional ability or assessments of QoL which focus on 
functionality.  Additional concepts such as health status, functional ability and standard 
of living will not be included within this review. 
 
Eiser and Morse (2001) examined QoL measures in chronic disease of childhood.  
Their literature review generated 19 generic and 24 disease specific questionnaires.  
Their search strategy is detailed below (figure 4.1), and included literature between 
January 1980 - July 1999.  This search was repeated by McCabe (2003), who repeated 
the previous search from July 1999 - January 2002.  This search strategy was again 
repeated by Stevens (2008) for the period January 2002 - December 2005.  She 
excluded disease specific questionnaires, as she was examining the generic paediatric 
population.  She found a further ten paediatric instruments and six adolescent versions 
which uncovered 12 unique instruments.  An overview of these instruments can be 
seen in Table 4.1. 
 
Solans et al (2008) examined previously published reviews, including Eiser and Morse 
(2001) alongside a new literature review (2001 – December 2006) of paediatric generic 
and disease specific QoL instruments. They found 30 generic and 64 disease specific 
instruments, of which 51 were newly uncovered.  They comment that although many of 
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the instruments met acceptable standards for psychometric properties, there are 
additional benefits in involving children during the development of QoL 
instruments/questionnaire that relate to content validity which was not often 
commented on.  The availability of information pertaining to the developmental 
methods used during QoL instrument construction is not always readily available and 
not consistently reported in previous reviews (Eiser and Morse, 2001; Solans et al, 
2008).  Solans et al (2008) also highlighted some of the limitations of the QoL 
instruments; discrepancies between child and parent ratings; the limited number of 
questionnaires available for child completion; and the cultural appropriateness of 
measures for use in different context from the original. 
 
4.2 Objectives 
 
This chapter describes the process of repeating these literature reviews (Eiser and 
Morse, 2001; McCabe, 2003; Stevens, 2008), bringing the previous reviews up to date 
(December 2010, at the time of search) and assessing the relevance of the identified 
measures as a suitable QoL questionnaire/instrument for the paediatric OI population.  
If a suitable measure was deemed appropriate for children with OI; it’s method of 
development was transparent and involved the paediatric population, and it was found 
to include themes potentially  important to the paediatric OI population, then it may not 
be necessary to develop an OI specific QoL questionnaire. 
 
4.2.1 Review Questions 
 
 What generic paediatric QoL measures are available for use with the OI 
population? 
 Are any disease specific QoL measures available, whose population may 
describe similar symptoms to those of the OI population? 
 Are these questionnaires both relevant and appropriate to this group of patients 
and do they allow self completion? 
 Where measures are found that are suitable for the paediatric OI population, 
are these appropriately developed using a well informed and documented 
conceptual framework? 
 
4.3 Method 
 
The search strategy sought to identify studies documenting paediatric QoL measures, 
which were either generic or disease specific, but relevant to the OI population 
(musculoskeletal bias). 
The search was run (January 2006 – December 2010), attempting where possible to 
duplicate and therefore update the previous searches (Eiser and Morse, 2001; 
McCabe, 2003; Stevens, 2008) (See figure 4.1 for search strategy).  The databases 
searched were: Medline; BIDS ISI science citation; BIDS ISI social science citation; 
psych info; Embase and CCTR.  Reference lists were then hand searched for further 
papers describing QoL instruments, measures or questionnaires.  Due to limited 
funding and the nature of this study (PhD study), papers were reviewed by only one 
individual (Claire Hill). 
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1. (Quality of life) and (Child* or adolesc*) 
2. (Health status or functional status or well-being) and (child* or adolesc*) 
3. Chronic illness or chronic disease or arthritis or asthma or cancer or cystic 
 fibrosis or diabetes or epilepsy or AIDS or trauma or burns or technology 
 dependent or low birth weight 
4. 1 and 2 
5. 2 and 3 
6. 4 and (measure* or scale or index) 
7. 5 and (measure* or scale or index) 
8. Self report or self-report or self assessment or self-assessment or child* report 
or  adolesc* report 
9. 4 and 8 
10. 5 and 8 
11. 1 and 8 
12. 2 and 8 
13. (parent or mother or carer) and (report or assessment) 
14. 4 and 13 
15. 5 and 13 
16. 1 and 13 
17. 2 and 13 
18. (6 or 7 or 11 or 12 or 16 or 17) and (reliab* or valid*) 
    (Eiser and Morse, 2001; McCabe, 2003; Stevens, 2008) 
 
Figure 4.1.  Search strategy used for the review. 
 
 
4.3.1 Study Selection Criteria 
 
Inclusion Criteria 
 Generic QoL measures/instruments/questionnaires found on previous search 
strategies (Eiser and Morse, 2001; McCabe, 2003; Stevens, 2008) 
 Newly discovered generic QoL measures/instruments/questionnaires (January 
2006 – December 2010) 
 Disease specific measures/instruments/questionnaires where the disease may 
have similarities to OI (i.e. skeletal dysplasia, fibrous dysplasia, joint or skeletal 
conditions). 
 
Exclusion Criteria 
 Studies describing non-English measures/questionnaires, or measures 
developed outside the UK and not appropriately anglicised. 
 Functional assessments or health status questionnaires where no QoL or 
Health related QoL is described 
 Disease specific measures for conditions unrelated to or dissimilar to OI. 
 
4.3.2 Data Extraction 
 
Potentially suitable titles and abstracts were appraised; full text articles that fitted the 
inclusion criteria were reviewed.  Data was extracted to include instrument title, 
respondent choice (child/proxy), included age range, number of items, title and number 
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of domains, and where available the stated purpose of the instrument/measure.  Any 
information on method of development or conceptual framework was also recorded. 
 
4.3.3 Data Synthesis 
 
Due to the nature of qualitative research it is unlikely that a standard systematic review 
with meta analysis would be an appropriate method to synthesise the data.  The 
following review will therefore use a narrative synthesis type methodology. This refers 
to an approach to the systematic review and synthesis of findings from multiple studies 
that relies primarily on the use of words and text to summarise and explain the findings 
of the review (Popay et al, 2006).  Key features of the questionnaires/measures will be 
highlighted; the main features will be tabulated to aid comparison; major patterns, 
similarities and differences within the instruments will be noted and the suitability of the 
instruments will be considered. 
 
4.3.4 Analysis 
 
Previously acknowledged questionnaires or measures are documented separately to 
those recently generated (see tables 4.1 and 4.2).  Where possible information was 
documented on the method used to develop the questionnaires; a transparent method 
of development is a requirement of a suitable QoL measure for the paediatric OI 
population.  This allows openness and understanding of the conceptual framework 
behind each of the QoL questionnaires. 
 
4.4 Results      
 
The updated search produced 369 articles, with 17 duplicates; therefore 352 abstracts 
were reviewed for possible inclusion.  Forty-five articles discussed those previously 
documented instruments by Eiser and Morse (2001), McCabe (2003), Stevens (2008), 
Solans (2008).  (See Table 4.1 for details of these previously reviewed measures).  
One hundred articles were related to disease specific or adult measures.  These 
diseases (and their subsequent symptoms) were not closely related to OI or the 
symptoms described or exhibited by those living OI.  As their validity for use with the OI 
population would be poor, these measures are not included for review 
  
Seventy-seven articles were either not written in English language or were developed 
for non English cohorts.  These were not included for review due to translation issues 
(time and funding) and cultural differences between differing paediatric populations.  
One hundred and twenty articles described quality of life in paediatric populations but 
not actual QoL measures/instruments/questionnaires.  On closer examination of the 
abstracts this latter group included literature reviews, descriptions, qualitative 
interviews and commentaries related to QoL, but not describing QoL measures per se. 
 
The remaining ten articles described nine instruments 
(scales/measures/questionnaires) which were either generic or disease specific 
measures where symptoms may be appropriate or similar to those described or 
observed in the paediatric OI population.  See table 4.2 for newly described measures. 
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Table 4.1   QoL measures previously reviewed by Eiser and Morse (2001), McCabe (2003), Stevens (2008). 
 
Instrument Respondent Age Range Number of 
Items 
Domains Purpose 
 
 
Child Health and 
Illness Profile – 
Adolescent 
Edition 
 
Child/ 
Adolescent 
 
11 to 17 years 
 
107 plus 46 
optional 
disease/injury 
specific items 
 
6 (activity, comfort, perceived well-
being, disorders, achievement and 
resilience) 
 
“The purpose of the instrument is to assess health 
in epidemiologic surveys, to determine the 
existence of systematic differences in health in 
subpopulations (including the socioeconomically 
disadvantaged), and to provide a basis for 
assessing the impact of changes in health services 
or health policies”.  (Starfield et al,1995). 
Development of the questionnaire describes a 
mixture of literature review, focus groups with 
children and parents, alongside consultation with 
HPs and researchers. 
 
 
Child Health 
Questionnaire 
 
Child/Proxy 
(MAPI) 
 
5 to 18 years 
(MAPI) 
 
87 (youth form) 
98 (parent 
form) 
50 (parent 
form) or 28 
(short form) 
(MAPI) 
 
(CF87) 12 (physical functioning, 
role/social functioning, general health 
perceptions, bodily pain, role/social 
emotional, role/social behavioural, self-
esteem, mental health, behaviour, family 
activities, family cohesion, change in 
health). 
(PF50  and PF28) 14: general health, 
change in health, physical functioning, 
bodily pain/discomfort, limitations in 
school, work and activities with 
friends due to physical problems and 
due to emotional and behavioural 
difficulties, behaviour, mental health, 
and self-esteem.  Emotional and time 
impact on the parent, limitations in 
family activities and family cohesion 
(CHQ) 
 
 
 
“The goal was to develop a comprehensive 
instrument that would be useful across a variety of 
healthcare settings and applications including 
academic research, clinical trials, physician offices, 
clinics, hospitals and health maintenance 
organisations”.  (Landgraf et al,1996) 
Developed using literature review and review of 
other available instruments. 
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The Child Quality 
of Life 
Questionnaire 
 
Child/Parent 
 
9 to 15 years 
 
 
45 
15 (Getting about, doing things for 
self, soiling or wetting, school, out of 
school activities, friends, family 
relationships, discomfort due to 
bodily symptoms, worries, 
depression, seeing, communication, 
eating, sleep and appearance).   
 
“assessment of quality of life in nine to fifteen year 
old children”. (Graham et al, 1997) 
Literature describes top down approach to 
development involving expert opinion and literature 
review. 
 
 
Dartmouth Picture 
and Word COOP 
Charts 
 
Child 
 
12 years 
upwards 
 
6 
 
6 (physical fitness, emotional 
feelings, school work, social support, 
family communications and health 
habits). 
“To assess health and social problems of 
adolescents”. For use as survey instruments and as 
a tool for detection of important problems.  (Wasson 
et al, 1994).  Developed using expert advice from 
clinicians and health measurement professionals. 
 
Exeter Health 
Related Quality of 
Life Measure 
 
Child 
 
6 to 12 years 
 
16 (reduced to 
12 in a later 
version)  
(each 
measured 
twice) 
 
1 (health related quality of life). 
“The EHRQL is designed to determine the impact of 
disease on everyday activities from the child’s 
perspective and was constructed to assess self-
reported HRQL in children from the standpoint of 
perceived discrepancies between actual and 
preferred or ideal selves”.  (Eiser et al,1999) 
Development based on a theoretical model; that 
poorer QoL is the result of discrepancies between 
an individual's actual and ideal self. 
 
 
Functional Status 
II (R) 
 
Parent 
 
0 to 16 years 
< 1 year 
1 year 
2 – 3 years 
> = 4 years 
 
43 (long) 
14 (short) 
 
8 (communication, mobility, mood, 
energy, play, sleep, eating and 
toileting). 
The original FS I was developed to measure 
individual child health status and characterize 
populations, the FS II is a revised version of this 
measure.  This instrument was primarily designed 
to be a measure of the health status of children with 
chronic physical conditions. (Stein and Jessop, 
1990).  Based on the Sickness Impact Profile which 
was developed using top down literature review and 
expert opinion. 
 
 
Generic Health 
Questionnaire 
 
Child/Parent 
 
6 to 16 years 
(linguistically 
able children) 
 
25 
5 (general affect, peer relationships, 
attainments, relationship with 
parents, general satisfaction). 
“To develop a measure suitable for assessing the 
quality of life for children with chronic illness”. 
(Collier 1997)  Development unknown. 
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How Are You? 
 
Child/Parent 
 
8 to 12 years 
 
29 
 
4 (physical activities, cognitive 
activities, social activities and 
physical complaints). 
“Developed in response to the need for a 
questionnaire that measures general as well as 
disease specific aspects of QoL children with a 
chronic illness”.  The main purposes of HAY are to 
identify children who need additional care and to  
evaluate interventions.  (Bruil et al,1997)  Literature 
reports construction in co-operation with medical 
specialists followed by factor analysis. 
 
KINDL 
 
Child 
 
8 to 16 years 
 
40 
 
4 (Functional capacity everyday life, 
psychological well-being, physical 
state, social relationship). 
 
Takes a psychometric approach.  Generic 
instrument for quality of life assessment.  (Ravens-
Sieberer, 1998).  Literature reports interviews with 
children to uncover concepts, followed by two pilots 
including a total of 28 children. 
Paediatric Quality 
of Life Inventory 
Child/Parent 8 to 18 years 45 (15 core, 30 
supplemental) 
3 core and 8 supplemental (Physical 
functioning, psychological 
functioning, social functioning, pain, 
nausea, procedural anxiety, 
treatment anxiety, worry, cognitive 
problems, perceived physical 
appearance, physician/nurse 
communication). 
“is designed to be a generic paediatric quality of life 
measure to be utilized non categorically ie across 
various paediatric chronic health conditions”. 
“to measure HRQoL outcomes for paediatric 
chronic health conditions”. (Varni et al, 1999).  
Generic questionnaire developed by interviewing 
patients and their families, alongside discussion 
with paediatric health professionals. 
 
Perceived Illness 
Experience 
 
Child/Parent 
 
7 years 
upwards 
 
34 (in original).  
Subsequently 
revised to 
include a 
further 2 items 
on the physical 
appearance 
subscale and a 
new food 
subscale.  No 
details of how 
many items this 
contains. 
 
9 (interference with activity, 
disclosure of illness, school/work, 
peer rejection, parental behaviour, 
manipulation, pre-occupation with 
illness, food and physical 
appearance). 
 
Originally developed to measure perceived illness 
experience in people with cancer, but may be used 
with other groups of children/young people with 
chronic illness.  
“The study is an attempt to devise a method to 
assess the perceived impact of the illness from the 
child’s point of view”.  (Eiser et al, 1995)  (Eiser 
1999).  Literature reports semi-structured interviews 
with children and adolescents used to develop 
generic questionnaire. 
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Quality of Life 
Profile – 
adolescent 
version 
 
Adolescent 
 
14 to 20 years 
 
54 
 
3 and 9 sub domains: 
Being (Physical, Psychological, 
Spiritual) 
Belonging (Physical, Social 
Community) 
Becoming (Practical, Leisure, 
Growth) 
 
 
 
“to develop a model and associated instrumentation 
to assess the quality of life persons with 
developmental disabilities”.  (Raphael et al, 1996). 
Diagnostic tool developed by generating individual 
graphic QoL profiles based on responses to the 
EORTC-QLQ-C30.   
 
TAPQOL 
 
Parent 
 
1 to 5 years 
 
43 
 
4, 12 sub domains 
Physical Functioning (sleeping, 
appetite, lung problems, stomach 
problems, skin problems, motor 
functioning). 
Social Functioning (problem 
behaviour, social functioning). 
Cognitive Functioning 
(communication). 
Emotional Functioning (positive 
mood, anxiety, liveliness). 
 
 
“to measure parent’s perceptions of HRQoL in 
preschool children and to evaluate the impact of 
diseases and treatments on the different domains 
of young children’s lives”.  (Fekkes et al, 2000). 
Discussions with HRQoL experts, paediatricians, 
psychologists and parents of children aged 1-5 year 
olds were used to develop this generic proxy 
instrument. 
 
Warwick Child 
Health and 
Morbidity Profile 
 
Parent 
 
0 to 5 years 
 
16 (ten primary 
and six 
subsidiary) 
 
10 (general health, acute minor 
illness behavioural, accident, acute 
significant illness, hospital admission, 
immunization, chronic illness, 
functional health and health related 
quality of life). 
 
“to provide a cross-sectional and longitudinal record 
of parentally reported health and morbidity of 
individual children and child populations”.  (Spencer 
and Coe, 1996) 
“has been designed to give a comprehensive 
picture of child’s health and illness experience from 
the parental perspective”.  
(Spencer  and Coe,1996).  A top down approach 
including expert opinion followed by a two tier pilot 
phase. 
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Health Utilities 
Index Mark 2 
 
Child/Parent 
 
6 to 16 (used in 
children down 
to 12 months in 
one study) 
 
15 
 
7 (Sensation, mobility, emotion, 
cognition, self-care, pain and fertility). 
“to construct a utility or social preference based 
multi-attribute health and well-being index 
applicable to children aged 4 – 16 years”  (Cadman 
et al, 1986).   
“HUI evolved in response to the need for a 
standardized system to measure health status and 
HRQL to describe:  
1. The experience of patients undergoing 
therapy. 
2. Long-term outcomes associated with 
disease or therapy. 
3. The efficacy, effectiveness and efficiency of 
healthcare interventions. 
4. The health status of general populations”.  
(McCabe et al, 2005).   
Attribute levels designed to cover the full range of 
possibilities/abilities.  The preference based 
measure was given to subjects who were asked to 
rate items on a 0-100 scale (VAS).  
 
 
Health Utilities 
Index Mark 3 
 
Child/Parent 
 
6 to 16 years 
 
15 
 
8 (vision, hearing, speech, 
ambulation, dexterity, emotion, 
cognition and pain). 
 
“For measuring the overall health status and health 
related quality of life of individuals, clinical groups 
and general populations “.  (Furlong et al,1998) 
Improvements made to HUI II to construct this 
measure. 
 
 
16 Dimensions  
 
Child  
 
12 to 15 years 
 
16 
 
16 (mobility, vision, hearing, 
breathing, sleeping, eating, speech, 
elimination, usual activities, friends, 
physical appearance, mental 
function, discomfort and symptoms, 
depression, distress and vitality. 
 
 
 
To develop a generic self assessment HRQoL 
measure for early adolescents.  (Apajasalo et 
al,1996a) 
Based on the 15D preference based measure, top 
down development followed by population survey 
comparing 15D to HUI III and EQ5D. 
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17 Dimensions 
 
Child 
 
8 to 11 years 
 
17  
 
17 (mobility, vision, hearing, 
breathing, sleeping, eating, speech, 
elimination, usual activities, friends, 
physical appearance, mental 
function, discomfort and symptoms, 
depression, distress and vitality. 
 
 
Generic measure of HRQoL measure for pre 
adolescents.  (Apajasalo et al,1996b)  
As above for 16D 
 
Quality of Well-
Being 
 
Parents/ 
Adolescent 
children 
 
4 to 18 years 
 
3 plus 27 
symptoms 
 
3 (physical functioning, social/role 
functioning and mobility) plus 27 
symptoms 
 
“The purpose of the system is to express benefits 
and side effects of the program in terms of 
equivalences of completely well- years of life”.  
(Kaplan et al,1989).  Literature reports an 
exhaustive list of symptoms and problems being 
developed into a preference weighted measure of 
symptoms and functioning to express well being on 
a 0-1.0 scale.  No information is given to state how 
the items were elicited. 
 
 
TACQOL 
 
Self (>8 years) 
Proxy (<8 years) 
 
6 – 15 years 
 
108 (parent 
form) 
 
7 (parent form) (pain and symptoms, 
basic motor functioning, autonomy, 
cognitive functioning, social 
functioning, global positive emotional 
functioning, global negative 
emotional functioning) 
 
 
 
“to develop a generic instrument to assess 
children’s HRQoL”.  (Vogels et al,1998). 
Development based on existing literature and 
previously developed questionnaires of health 
status and HRQoL 
 
SF-10 
 
Parent/ 
Guardian 
 
5 – 18 years 
 
10 
  
Developed to address the need for scientifically 
valid health status assessment for the paediatric 
population (Saris-Baglama et al, 2006). 
Parent completed measure adapted from the CHQ, 
top down development. 
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Child Health and 
Illness Profile – 
child version 
(CHIP-CE) 
 
Self (child)/ 
Proxy (parent) 
 
6 – 11 years  
 
45 standard, 76 
comprehensive 
parents report 
 
5 (12 sub domains) for self (child) 
report (CRF). 
Satisfaction, comfort, resilience, risk 
avoidance, achievement. 
6 (17 sub domains) for proxy (parent) 
report (PRF).  All the above plus 
disorders.   
 
To assess the health of children (Health Services 
and Sciences Research Resources Database). 
 
“.. appears to be an effective tool for assessing 
children’s perceptions of their own health and well-
being that can be used to describe the health and 
functioning of populations of children.  It is likely to 
be useful in monitoring outcomes of policies and 
services”.  (Riley et al, 2004).  Development 
involved cognitive interviews with elementary 
school aged children. 
 
 
 
KIDSCREEN 
 
 
Self/Proxy 
 
8 -18 years 
 
3 versions: 
52, 27, 10 
 
10, 5, 1 Correspondingly 
10 (Physical Well-Being, 
Psychological Well-Being, Moods 
and Emotions, Self-perception, 
Autonomy, Parent relation and Home 
Life, Social Support and Peers, 
School Environment, Social 
Acceptance (Bullying), Financial 
resources 
5 (Physical Well-Being, 
Psychological Well-Being, Parents 
and Autonomy, Social Support and 
Peers, School Environment) 
1 (General HRQoL Index) 
 
 
 
 
 
 
 
 
Objective: “Designed to obtain a self-report and an 
external assessment of health-related quality of life 
in children and adolescents in a wide range of ages 
and independently of current health status” 
(Ravens-Sieberer et al. 2006).  Literature reports 
focus groups with children from six European 
countries, parental questionnaires, a Delphi survey 
with health professionals and literature review to 
construct this generic questionnaire. 
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TedQL 
 
Self/Proxy 
 
3 – 8 years 
 
4 versions: 
22, 23, 30, 22 
 
 
4 versions correspondingly: 
 
5 (Physical competence, peer 
acceptance, maternal acceptance, 
psychological functioning and 
cognitive functioning)  
5 (Physical competence, peer 
acceptance, family acceptance, 
psychological functioning and 
cognitive functioning. 
 
 
 
 
To assess HRQoL in children aged 3 – 8 years 
(Cremeens et al, 2007). 
Development involved reviewing 53 previously 
developed child report measures and child 
interview data. 
 
YQoL–R/YQoL-S 
 
Self 
 
11 – 18 years 
 
2 versions: For 
group level 
perceptual: 
YQoL-S: 
(version for 
surveillance) 
8 YQoLR: 
(version for 
program 
evalutation and 
research) 41 
 
4 (self, relationship, environment, 
general quality of life) 
 
“to assess multidimentionally the generic QoL of 
youth ages 11 – 18 (Patrick et al, 2002) 
Literature reports extensive review of adolescent 
HRQoL literature, alongside interviews with 11-18 
year olds with and without disabilities and focus 
groups to develop this generic measure. 
 
 
 
 
 
 
HSCS-PS 
 
Clinician/ 
parent 
 
2.5 – 5 years 
 
3 – 5 levels per 
dimension 
 
12 (vision, hearing, speech, mobility, 
dexterity, self-care, emotion, learning 
and remembering, thinking and 
problem solving, pain and discomfort, 
general health, behaviour) 
 
 
To develop a multi-dimension health status 
classification system to describe pre-school 
children 2.5 – 5 years of age.  (Saigal et al, 2005). 
Revision of HUI II and III alongside expert opinion 
was the methodology behind this instrument. 
 
 (Stevens, 2010)                
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Table 4.2  QoL measures uncovered and reviewed from recent literature review. 
 
 
 
Instrument Respondent Age Range Number of Items Domains Purpose 
 
 
Healthy Pathways 
Child Report 
Scale 
 
Self 
 
6 – 21 years 
 
88  
 
16 (Physical comfort, emotional 
comfort, negative stress 
reactions, physical activity, 
vitality, peer connectedness, 
family connectedness, teacher 
connectedness, active coping, 
aggression/bullying, peer 
hostility, bullying victim, life 
satisfaction, self worth, body 
image, academic performance, 
school engagement). 
 
..to revise the CHIP by combining the 2 editions 
(6-11, 12-21) to create the Healthy Pathways 
report scale which improves the assessment of 
health and quality of life during transition into 
adolescence. (Bevans et al, 2010).  Revision 
made to CHIP to develop this questionnaire.  
CHIP initially developed using bottom up 
methodology. 
 
The Adolescent 
Pain Behaviour 
Questionnaire 
 
Parent 
 
11 – 19 years 
 
23  
 
(facial expression, socialisation, 
physical actions or body 
gestures, reactive pain 
behaviours, pain altered daily 
behaviours. 
 
Parent report measure of adolescent pain 
expression, verbal and non verbal ways.   
(Lynch-Jordan et al, 2010)  Development via top 
down methodology using literature review and 
expert opinion. 
 
DISABKIDS - 
Smiley 
Child  
Proxy – 
(younger 
children) 
 
4 – 7 years 
 
6  
 
Single domain 
 
“Assessment of general quality of life and level of 
distress caused by chronic disease”. (Chaplin et 
al, 2008)  Themes and items uncovered from 
interviews and focus groups with the target 
population. 
 
DISABKIDS – 37 
Long version 
 
Child/Proxy 
 
8 – 18 years 
 
37  
 
6 (independence, physical 
limitation, emotion, social 
exclusion, social inclusion, 
treatment). 
 
Assessment HRQoL in children and adolescents 
with chronic conditions and perceived impact of 
treatment.  (Sandeberg et al, 2010) Bottom up 
development as above. 
 
 
 
53 
 
DISABKIDS – 12 
Short version 
 
Child/Proxy 
 
8 – 18 years 
 
12 
 
2 (about your life, about your 
medical treatment). 
As above but to transfer conceptual structure of 
the D Cam as a frame work for a shorter form. 
(Muehlan 2010 doctoral thesis) Development via 
bottom up methodology as above. 
 
Multidimensional 
Student’s Life 
Satisfaction Scale 
– adolescent 
version 
 
Child/Self 
 
8+ years 
 
77 
 
5 (family, friends, school, self, 
living environment). 
 
To measure children’s overall life satisfaction  
(Gilligan and Huebrier, 2007). 
Top down development involved review of life 
satisfaction and adolescent development 
literature alongside a pilot phase with 
adolescents. 
 
Child Activity 
Limitations 
Questionnaire 
 
 
Child/Proxy 
 
5 – 18 years 
 
Self   8 – 18 
years 
 
21 
 
1 (over last 4 weeks). 
 
Designed to assess functional impairment 
secondary to chronic and recurrent pain in 
school.  To assess the impact of pain on daily 
activities.  (Hainsworth et al, 2007).  Developed 
from the child activity limitations interview to 
enable a paper version, initial development was 
via a top down approach. 
 
 
Paediatric 
Rheumatology 
Quality of Life 
Scale 
 
 
Child/Proxy 
 
0 – 18 years 
 
10 
 
2 (physical health and 
psychological health). 
 
To develop a short and simple measure of 
HRQoL for children with JIA. 
(Filocanio et al, 2010)  Developed using expert 
opinion, literature review and interviews with the 
target population, hence a combination of bottom 
up and top down methodologies were used. 
 
Manchester – 
Minneapolis 
Quality of Life 
Survey 
 
 
Child 
 
8 – 11  years 
(child) 
12 – 18 years 
(youth) 
 
29 
 
5 (emotional functioning, 
physical functioning, physical 
appearance, school functioning, 
social functioning). 
To foster regular HRQoL assessment in daily life.  
The anglicised MMQL –UK was developed for 
use with both healthy and chronic conditions.   
(Hutchings et al, 2008)  Anglicisation of a 
previous measure developed by top down 
methodology. 
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From the tables above it is easy to see that six measures were proxy only.   18 
measures allowed completion by both self and proxy.  Eleven measures encouraged 
only self completion.   
 
4.5 Discussion 
 
The following discussion considers the beneficial aspects of QoL instruments which the 
author believes to be important to the paediatric OI population.  The main areas for 
deliberation were: 
 
 Self completion by the child or adolescent, although younger children may 
require assistance with reading a lengthy questionnaire.  
 The availability of a single questionnaire spanning the child-adolescent age 
group, allowing more reliable, sensitive longitudinal follow up. 
 Transparent bottom up methodology involving the paediatric population to 
ensure good content validity for the intended cohort. 
 A suitable questionnaire should include items which are relevant and purposeful 
to the paediatric OI population, again to ensure high content validity in the OI 
cohort, but also to encourage completion. 
   
In the search to find a previously developed questionnaire that might meet all the 
above suggested criteria, each of these elements is discussed separately and the 
previously identified QoL measures (tables 4.1 and 4.2) are critiqued for these 
beneficial qualities.  Should one of the generic QoL instruments or a suitably similar 
disease specific instrument meet all the criteria discussed, then it will be unnecessary 
to develop an OI specific QoL questionnaire.  However, the lack of a suitable 
questionnaire will reinforce the need for such a measure with the paediatric OI 
population. 
 
4.5.1 Allowing self completion. 
  
An important factor when considering the suitability of a QoL instrument for the 
paediatric OI population is the ability to self report.  A large amount of literature 
examines the ability of children to self report from an early age.  From the age of five it 
is noted that children are able to self report their QoL (Varni et al, 2007; Connolly and 
Johnson, 1999).  Working alongside children and young people with OI for the last 16 
years has informed the author that this cohort are not limited in their cognition or 
leaning, and are therefore able to participate in instrument completion.  Children and 
young people with OI spend a large amount of time attending hospital and are 
therefore accustomed to answering questions about their medical condition and 
general health.  Many patients as they move into adolescence are keen to have their 
own voice heard and opinions justifiably acknowledged.  Therefore the need for them 
to self report their QoL is paramount. 
Previous research has examined the disparity between a child’s self report and that of 
their proxy (often parent) report of their QoL (Eiser and Morse, 2001; Eiser and Varni, 
2013).  Eiser and Varni (2013) found that proxy reports often poorly correlate with self 
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report in subjects such as feelings of pain, emotional distress, fatigue or 
gastrointestinal symptoms.  The need for an instrument that allows and encourages 
self reporting or self reporting with assistance, during the QoL measurement process is 
felt imperative for the OI population.  The otherwise poor reporting of some dimensions 
(pain, fear, emotional distress) by proxy respondents may lead to low validity and poor 
measurement quality.  
 
The DISABKIDS concept (DISABKIDS-37, DISABKIDS-12 and DISABKIDS-smiley) 
was developed in reaction to the child being placed at the centre of outcome 
measurement and the subsequent need for a child self report (Chaplin et al, 2008).  
The group also identified criteria which they felt was important for a QoL measure, such 
as self completion and the need for the measure to be brief and simple to complete.  
The DISABKIDS questionnaires do however have proxy components.  However the 
group state that this contributes to the overall measure of HRQoL and is not a 
substitute for it.  Many other instruments include a self completion questionnaire for 
children or adolescents (see tables 3.1 and 3.2).  However, this is not the case for the 
Functional Status II (Stein and Jessop, 1990), TAPQOL (Fekkes et al, 2010), Warwick 
Child Health and Morbidity Profile (Spencer and Coe, 1996), SF-10 (Health services 
and sciences research resources database), HSCS-PS (Saigal et al, 2005), or the 
Adolescent Pain Behaviour Questionnaire (Lynch-Jordan et al, 2010), who all use 
proxy respondents only. 
 
4.5.2 The availability of a single questionnaire. 
 
Scientific evidence highlights the need for continued health measurement from 
childhood throughout transition into early adulthood (Bevans et al, 2010).   For this 
reason the availability of a QoL measure which allows continued measurement 
throughout childhood and adolescence would meet this need.  The ability to review 
quality of life over time, alongside developmental progression and other potential 
influences ensures continuity and reproducibility.  Many instruments use different 
scales and/or questions for differing age groups (DISABKIDS, Pedsql).  For example 
they provide child, adolescent and young adult versions.  These versions may appear 
to be similar in nature, but in fact may differ a great deal, with the addition or omission 
of age-related items or whole dimensions.  This can make monitoring health care and 
QoL issues complicated as children transition into adolescence and later on to become 
young adults.  QoL measures that provide age related modules fail to address the 
differing rates at which children mature.  Consequently researchers and health 
professionals may find it difficult to ensure that they are using the correct module for 
the maturity of the child/adolescent in their care.  For example some girls of 11 years 
old may be more mature than their peers, particularly when compared to their male 
counterparts (Bevans et al, 2010).  Some instruments only allow completion by a 
narrow age range, often younger children or adolescents only (TAPQOL, Fekkes et al, 
2000), Warwick child health and morbidity profile (Spencer and Coe, 1996), Dartmouth 
picture and word COOP charts (Wasson, 1994).  This again does not allow comparison 
or monitoring throughout a child’s development, questioning the validity of ongoing 
assessment.  
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Instruments such as the Healthy Pathways Child report scale attempted to address this 
confusion.  They developed a questionnaire to incorporate assessment of children’s 
opinion of their own health, illness and well being during periods of transition, 
particularly from childhood to adolescence (Bevans et al, 2010).  As a result of this, the 
Healthy Pathways Child report scale is a single measure covering ages 6-21 years, 
which ensures continued measurement of QoL throughout childhood, into adolescence 
and beyond.  The Child Health Questionnaire (Landgraf et al, 1996), Functional Status 
II (R) (Stein and Jessop, 1990), Generic Health Questionnaire (Collier, 1997), 
Perceived Illness Experience (Eiser et al, 1999), Health Utilities Index (II and III) 
(Furlong et al, 1998), Quality of well being (Kaplan et al, 1989), SF-10, Child Activity 
Limitations Interview (Palermo et al, 2008) and the Paediatric Rheumatology QoL scale 
(Filocamo et al, 2010) also cover a wide age range, ensuring measurement throughout 
childhood.  In the United Kingdom, many children with OI are reviewed in tertiary and 
secondary NHS hospitals from birth, through childhood, into adolescence and through 
transition clinics to adult based centres.  The availability of a single QoL questionnaire 
would ensure that individuals with OI were appropriately and reliably monitored 
throughout their complete childhood.  
 
4.5.3 Transparent methodology 
 
The development of QoL instruments can follow different methods.  Some developers 
use a top down approach; the literature is reviewed and discussed by a panel of 
experts, who then go on to develop a measure incorporating what they feel are the 
most valid and appropriate items and dimensions for inclusion.  Others follow a more 
bottom up approach; the target population is canvassed via one-to-one interviews or 
focus groups to establish what they themselves feel are the most appropriate items or 
themes for inclusion.    The need for rigorous development to ensure validity is an 
important factor within instrument development (Patrick et al, 2011).  Finding a suitable 
and robust QoL instrument for the OI population that had been well developed and then 
psychometrically tested was required.  Importance was placed on those instruments 
which had been developed with bottom up methodology, using a transparent 
conceptual framework involving children and/or their families.  As this latter approach 
would ensure better content validity  
 
The Healthy Pathways Child Report scale (Bevans et al, 2010) includes items taken 
directly from the CHIP (Starfield et al, 1993) or from other well known measures, such 
as KIDSCREEN (Ravens-Sisberer, 2006).  New additional items were developed by 
clinical experts, following a top down approach and not from the children or families 
themselves.  This methodology was replicated by Lynch-Jordan et al (2010), who used 
a similar top down process during their development of the adolescent pain behaviour 
questionnaire, which included literature review and expert opinion.  The HSCS-PS 
(Saigal et al, 2005), Child Quality of Life Questionnaire (Graham et al, 1997) and the 
Dartmouth Picture an word COOP charts (Wasson et al, 1994) all followed a similar top 
down approach, lacking input and incite from the target population.  It is difficult to 
conclude that the items, dimensions and structure of the questionnaires are valid and 
relevant to the intended populations, when questionnaires are developed using this top 
down methodology.  
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A similar methodology was used by Hutching et al (2008) during the development of 
the Manchester-Minneapolis quality of life survey.  Their aim was to anglicise and 
shorten the original version, but their only population involvement took place during 
psychometric evaluation.  Ensuring the content validity of this shortened version may 
prove more difficult if the intended population was not involved in selecting which items 
were removed.  Items deemed important and relevant by the participants themselves, 
may well have been removed prior to psychometric testing.   
 
Conversely, the DISABKIDS instruments were developed using bottom up 
methodology, which included focus groups with the child and their parents.  These 
focus groups identified the statements which, following a pilot phase later became the 
items for inclusion.  A similar methodology was also used to develop the Child Health 
Questionnaire (Landgraf et al, 1999), who used a combination of literature review 
alongside focus groups and interviews with parents and children to develop their QoL 
measure.  A combined use of both top down and bottom up approaches were used by 
Filocamo et al (2010) during development of the HRQoL measure for paediatric 
rheumatic diseases.  The group included an expert panel of six Rheumatologists with 5 
– 26 years experience, literature review, analysis of other paediatric HRQoL 
instruments and 37 face-to-face interviews with the relevant population. 
For further details of methodology used in questionnaire development see Tables 4.1 
and 4.2. 
 
4.5.4 Relevant and Purposeful concepts. 
 
For a questionnaire or measure to be valid for the OI population it would be necessary 
for it to include dimensions and items which were deemed relevant.  The figure below 
(Figure 4.2) documents the initial conceptual framework as it was developed from the 
experience of the chief investigator during her 16 year history of working with children 
and families who have OI.  There are clearly several concepts which are generic in 
nature and would be relevant to all children (physical functioning, worry, emotional 
functioning, pain, fear, cognitive, social well being, hobbies, friends and school/missing 
school).  However, there are two concepts within the framework that are not 
necessarily generic and valid to all the population or other disease states; these two 
concepts are fractures and immobilisation.  The addition of these two concepts, which 
are pertinent to the OI population, suggests that many generic 
questionnaires/measures are not sensitive to important themes within the lives of the 
paediatric OI population.  Therefore the content validity of these generic questionnaires 
will be uncertain.  For more information on the development of the conceptual 
framework see chapters five, six and seven. 
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Figure 4.2  Original initial concept framework for QoL of children with OI - Researcher 
knowledge and experience                 
 
 “The importance of content validity in developing patient reported outcomes 
 (PRO)  instruments is stressed by both the US Food and Drug Administration 
 and the European Medicines Agency.”  (Patrick et al, 2011, pp967) 
 
Patrick et al (2011) describe content validity as the ability of a questionnaire to 
measure the concepts and themes that are important and relevant to the target 
population.  These concepts should be present within the questionnaire for the content 
validity of it to remain high.  The easiest and most practical way to ensure good content 
validity of a questionnaire is to develop it alongside the target population, eliciting 
themes from a purposive sample of the relevant population/cohort.   
 
As previously discussed the DISABKIDS questionnaires (Chaplin et al, 2008; 
Sandeberg et al, 2010; Muehlan, 2010) were developed using focus groups with 
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parents and children to establish the concepts and statements to be included within the 
questionnaire.  The questionnaires therefore have good content validity for the 
paediatric population.  However, as the measures are generic in nature, they do not 
include any items which encompass fractures or immobilisation, and therefore the 
content validity for the OI population may be lower. 
 
This chapter has discussed the criteria required for a previously developed QoL 
questionnaire or measure to be suitable for the paediatric OI population.  It must 
include items, dimensions and therefore concepts which are valid for this group.  It 
should also allow for self completion by children, as there are known concerns with 
regard to differences between the child and their proxy respondents (Eiser and Varni, 
2013). The questionnaire must also have been well developed, using a suitable and 
well documented method, which involves the children and their families in the process 
of defining the conceptual framework.  Finally, it should incorporate a single 
questionnaire format, covering a large age range, thus allowing sensitive monitoring 
throughout childhood into adolescence and transition into adult care. 
 
None of the QoL measures, instruments or questionnaires reviewed included items 
related to fractures, or the immobilisation and resultant loss of independence and 
function.  The Child Health Questionnaire (Landgraf et al, 1996) met two of the criteria 
deemed important for a suitable and appropriate QoL measure for the OI population.   
It involved the use of a single questionnaire covering the whole age group and allowed 
self completion of the questionnaire by the child.  However it did not encompass any 
items which were related to fractures, and was developed using items from previous 
tools alongside expert opinion.  A further measure which met two of the requirements 
was the DISABKIDS group of questionnaires (Chaplin, 2008; Sandeberg, 2010).  The 
measures were developed with bottom up methodology, using focus groups with the 
target population and allow self completion by the child.  However they are presented 
as several age specific questionnaires, which do not necessarily reflect the variation in 
developmental change of the child.  This lack of a single questionnaire format reduces 
the flawless ability of the measure to follow developmental change of the child 
throughout childhood and transition into adulthood. 
 
4.5.5     Strengths and limitations 
 
Reviewing the literature systematically to examine the readily available QoL 
measures/questionnaires has demonstrated that there is no current OI specific QoL 
measure already in existence.  It has also highlighted that on initial examination there 
are several generic and a couple of disease specific measures, which on first glance 
may be suitable for the paediatric OI population.  However on closer investigation they 
didn’t meet the criteria required. 
 
The inclusion criteria deemed necessary for this review was, with hindsight, very strict.  
This made the inclusion of some possibly suitable measures quite difficult.  Had these 
criteria relaxed a little, some of the QoL measures uncovered may have appeared 
more suitable.  However this would have proved a difficult undertaking, as it was felt 
important to include only well developed measures, where the methodology was 
transparent and involved children and/or their parents within the concept elicitation 
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phase, alongside the ability to self complete a single questionnaire coving a wide age 
range.  Reduced stringency in relation to these strict criteria may have led to the 
acceptance of the Healthy Pathways Child Report scale as a suitable QoL measure for 
the OI population; but the questionnaire is lengthy (88 items) and includes some items 
which are not relevant to the Paediatric OI population.  Further considerations with 
regards to this questionnaire will be discussed in chapters 9 and 10 of this thesis. 
 
Although the aim of this research was to develop a questionnaire for self completion; 
an opportunity was missed to develop a parent/carer proxy QOL measure alongside 
the child self report.  As described by the DISABKIDS developers, this would not be 
used as a substitute for the child self report, but would rather enhance the information 
gathered from the child or adolescent alone. 
 
4.6 Conclusion 
 
This review demonstrates that there is currently (up to December 2010) no suitable, 
ideal QoL measure available for the paediatric OI population.  Some of the instruments 
reviewed were developed well (DISABKIDS, Healthy Pathways Child Report) or 
allowed for self completion (child health questionnaire).  Others provided a single 
questionnaire format, allowing accurate monitoring throughout development into 
transition (Healthy Pathways Child Report).   
A small sample of instruments met two of the important criteria, required for a QoL 
questionnaire for the paediatric OI population (Child Health Questionnaire, 
DISABKIDS-smiley, DISABKIDS-37, and DISABKIDS-12, Healthy Pathways Child 
Report).  However none of the instruments met all of the initial criteria.  This highlighted 
the need to develop a valid OI specific QoL measure for the paediatric OI population, 
using transparent bottom up methodology, allowing self completion of a single 
questionnaire. 
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Chapter 5 
Concept/theme elicitation  
5.1 Aim 
This chapter incorporates both the initial development of the conceptual framework and 
further theme generation (concept elicitation) with the use of qualitative interviews. 
The chapter will highlight the experience and thought processes of the primary 
researcher prior to and following the systematic review (Chapter 4).  This previous 
chapter highlighted the lack of a suitable Quality of Life (QoL) measure to meet the 
needs of the paediatric OI population.  No previously available QoL questionnaire 
incorporated excellent development methodology, alongside valid items/dimensions 
which would ensure a robust patient reported outcome measure for this cohort.  Within 
this chapter the need for transparency surrounding the experience of the principle 
researcher will be documented and discussed.   
The chapter will also document the background, method and results of the semi 
structured interviews, which in turn elicited additional themes and concepts to further 
inform the overall conceptual framework. 
5.2 Introduction 
5.2.1 Conceptual framework 
The development of a QoL questionnaire or patient reported outcome measure 
necessitates qualitative research and methodologies, particularly in the early stages 
during the elicitation of concepts from the target population and formation of a 
conceptual framework.  To ensure transparency of all aspects of the developmental 
process, promoting openness and honesty, it is important to demonstrate reflexivity.  
The background and early evolving concepts, alongside the beliefs, assumptions and 
expectations of the researcher who is central to the process should be acknowledged, 
documented and discussed.  
The conceptual framework is a diagrammatical representation of the key concepts or 
theories surrounding a particular topic, and the relationship between these concepts.  
In the case of the conceptual framework encompassing QoL in children with OI; it 
includes themes and concepts which are deemed important to this group, identified 
from several sources.  These may include the patient cohort, literature review, personal 
experience of the researchers, the experience of parents/carers of children with OI, or 
exploratory research.  The development of the conceptual framework and its place 
within the overall development of patient reported outcome measures has already been 
discussed in chapter 3. 
The original conceptual framework for the development of the OI specific QoL 
questionnaire is shown in Chapter 4 (Figure 4.2).  It was constructed from the 
knowledge and understanding of the researcher alone; from 16 years experience of 
working with children with OI.  It was not documented using the literature per se, but 
will have incorporated reflections from the articles and reference material read by the 
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researcher over the years.  It includes the initial thoughts of the researcher when 
considering QoL in children with OI.    
There is a gap in the literature with regard to QoL in the paediatric OI population.  
Bowling (2009) commented that the most up to date research is not found within the 
written literature, and therefore experience and knowledge should be gained from all 
sources.  Maxwell (2005) suggests that separating your research from other aspects of 
your life detaches you from a large source of experiential information and knowledge.  
This experiential knowledge needs to be acknowledged as subjective and an 
understanding of the origin of this experience needs to be transparent.      
As it is important to be transparent about the experience and background of the 
researcher within the field of OI, it is necessary at this stage to document that 
experience and therefore the following narrative is written in the first person. 
I began working within the field of OI in 1999.  I had had some experience of 
the condition prior to this date whilst working at a district general hospital, but 
began to develop a larger cohort of patients when a service was set up in 
Sheffield.  I cannot really remember when I became more interested in a 
person’s/patient’s QoL rather more than their pure function.  I am not sure 
whether it happened as I began to work more with the OI population.  Whether 
I questioned myself about the need to be functional versus having a good QoL, 
and whether the two were interlinked, had a symbiotic relationship or were 
dependent on one another.  I began to feel that having a good function or 
being able to function independently was not necessarily a pre requisite for a 
good QoL.   
I remember a time before, when I felt to be independently functional must be 
my goal for all my patients.  As I worked more with the teenage OI population I 
realised I could not push my drive for function onto them.  They often did not 
want to know.  I questioned myself whether they just could not  be bothered to 
work towards improved function; stubbornly refused to take my advice; were 
happy with how they were; or were may be frightened to change or push their 
boundaries in case this resulted in fractures. 
Overtime (I am not sure how long) I began to realise that you can function well, 
be independent, but not necessarily feel you had a good QoL.  There are so 
many other important parts of life or factors that had an effect. 
As I write this I realise it may have occurred during the time prior to my work 
with the OI population, when I worked alongside a Rheumatologist and now 
friend, Rod Amos.  We ran a weekly clinic for children with arthritis and some 
children with non-specific aches and pains would often be referred.  We talked 
at length about the effect family relationships, peer support and schooling had 
on the reported experiences and life style of children and teenagers.  He would 
often quote ‘a life changing experience may be required’, for some patients 
whose physical signs did not match that of their reported QoL. 
I now find I discuss my patient’s function much more in the light of how it 
affects the quality of their life, and how things we may be able to put in place 
 
 
67 
may improve their function, and whether they feel this will have a positive 
effect on their QoL.  Then finally whether they think this increase or benefit is 
worth, in their opinion, the effort it may take. 
In 2009 I began to facilitate focus groups of young adults at the voice 
conference run by the Brittle Bone Society (BBS).  Several of the participants 
described terrible experiences of physiotherapy as they had grown up.  They 
had been pushed to be more functional, to gain standing often via the use of 
standing frames, and had suffered further fractures and pain as a result.  This 
further confirmed my thoughts and mind set around function and QoL.  With all 
the will in the world I can attempt to empower a person and encourage them to 
be more functional.  I can give them a glimpse of what I think they may be able 
to achieve, but the truth of this process is that if they feel the effort required 
outweighs the functional improvement gained, then they will be less inclined to 
complete what I suggest.  Everyone’s view of what equates to a good QoL is 
different.  Some may strive for function, and feel that to be more functional 
gives them a better QoL, others may feel more time spent socialising with 
friends is more important, and to some educational achievement may be the 
way forward.  I have begun to realise that getting a grasp or glimpse of what is 
important to each individual and/or their family unit and what will have a 
positive effect on that person’s QoL is more important than pushing for 
improved function.   
The review of the literature surrounding QoL and QoL in OI (Chapter 2) was used to 
produce a second conceptual framework (Figure 5.1).  It documents numerous 
concepts and sub concepts which were thought by the researcher, following the review 
of the literature, to be relevant to QoL and the paediatric OI population.  It does not 
describe the relationship between individual concepts, due to the nature of its origin in 
independent literature articles and books, but is a pragmatic list of those concepts 
suggested and discussed.  Six main areas of QoL were documented, initially without 
any thought about the relationships between them:  
  
1. Physical Functioning 
 2. General Health  
 3. Physical Symptoms 
 4. Emotional Wellbeing 
 5. Social wellbeing 
 6. Cognitive Functioning 
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The relationship of these six main QoL themes were then examined with regards to the 
QoL concepts discussed in the paediatric OI literature, this second framework can be 
seen pictorially in Figure 5.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.  Conceptual framework following review of the literature. 
 
The penultimate conceptual framework is documented later in this chapter; following 
discussion and reflection the two previously documented conceptual frameworks 
(Chapter 4, figure 4.2 and Chapter 5, figure 5.1) were reviewed alongside the themes 
uncovered from the OI population.  The relationship between the concepts and sub-
concepts are noted within this latter framework (Figure 5.2).  The differences between 
each of these frameworks (Chapter 4, figures 4.2 and Chapter 5, figure 5.1), and the 
progression within the development of the latter conceptual framework (Figure 5.2) is 
documented in table format in the discussion section of this chapter (Table 5.2).  
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Physical Symptoms 
Pain 
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Hypermobility 
Mobility 
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Cognitive 
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5.2.2 Review of qualitative approaches. 
The use of interviews as a means of eliciting concepts and themes to inform PRO 
development, alongside interview methodology has already been discussed in Chapter 
3.  Qualitative research relies heavily on interviews and focus groups to gain subjective 
information from a population. There are benefits and flaws with both types of 
methodology; interviews allow a private one-to-one narrative or discussion to take 
place in confidence, and therefore are more suitable for personal subjects or sensitive 
issues, which individuals may find difficult to discuss in front of others.  Focus groups 
however allow more discussion; ideas and anecdotes are shared, and topics 
suggested by one participant often incite enthusiasm, encouraging information to be 
shared by another. Interviews were chosen as the most suitable method to uncover the 
themes relevant to QoL within the paediatric OI population.  With minimal information 
regarding the subjective report of QoL in children with OI, the sensitivity of the topic 
was not known.  The nature of the cohort which included parents and children who 
covered a wide age range (6-18 years), alongside varying degrees of disease severity, 
did not easily suit a focus group setting.  Until more information was gained 
surrounding the sensitivity of the topic, interviews offered a safer environment in which 
to gain deeper understanding and insight. 
Interviews were deemed the most suitable method, as they would allow participants the 
freedom to discuss their thoughts and opinions, suggesting new topics as they arose; 
enabling the researcher to delve deeper into topics where appropriate.  The researcher 
would also be aware if the interviewee had misheard or not understood the question 
posed. 
Shuy (2002) examined the difference between in person and telephone interviews.  
They concluded that face-to-face interviews are often longer than those conducted by 
telephone, but that interviews conducted in person were better for sensitive issues, 
allowed data from observation and enabled the interviewer to respond to signs of 
participant confusion and/or distress. 
Britten (1995) states that experienced doctors and medical professionals may well 
already possess the skills required for a good qualitative interview, but may need to 
monitor their interview technique.  To improve this transition, time should be taken to 
appraise previously recorded interviews, asking others to review and make comments.  
A pilot interview or pre testing of interview schedule will familiarise the interviewer with 
the questions and can infuse them with a greater sense of confidence (Bryman, 2004).  
The principle researcher has over 15 years experience of interviewing both children 
and their parents within a medical setting.  Therefore the use of a pilot interview 
enabled this technique to be appraised within a research setting. 
Patrick et al (2011) suggested conducting interviews and/or focus groups to inform the 
content and structure of the new instrument.  They used individual interviews to elicit 
concepts from their population who suffered from pressure ulcers, as the data 
uncovered was quite sensitive.  Participants included both newly diagnosed and long 
term patients, as it was thought the two subgroups may differ in their experience of 
their condition. 
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Gorecki et al (2010) during their study sought to refine and further develop their 
working conceptual framework for HRQoL, by undertaking face-to-face semi structured 
interviews with 30 patients, who were experiencing pressure ulcers, to elicit any new 
relevant information.  Emphasis was placed on the importance of the qualitative phase 
of questionnaire development, in an attempt to ensure the content was both important 
and relevant to the patient population.  They also highlighted the benefits of wide 
variation within the purposive sample, allowing observation of the differences between 
the subgroups within the population.  Graneheim and Lundman (2004) agreed; they 
found that choosing participants with various and numerous different experiences 
increases the possibility of shedding light on the research question. 
Brod et al (2014), during the development of their instrument, interviewed a purposive, 
convenience sample of growth hormone deficient patients, which allowed for as much 
variability in age, ethnicity and income, to elicit concepts.  These new concepts were 
used to enhance the conceptual framework of previous themes extracted from the 
literature.  Review of the literature and one-to-one semi structured interviews were also 
used to further inform a conceptual framework developed by Welk et al (2013), during 
the production of the patient-reported neurogenic bladder symptom score. They went 
on to produce a comprehensive potential item list of symptoms and complications, 
which was then reviewed by an expert panel for assessment of content validity. 
Conflict of interest can arise within a study when a researcher is also a health 
professional known to the participants prior to study commencement. This is often an 
area which is not discussed within published papers, yet when its presence is 
acknowledged, it is important to remain transparent throughout all stages of the 
research; reflexivity can be used to aid this process. As I was both researcher and 
clinician throughout this research, I acknowledge that patients and their families may 
have felt both a duty to participate and to respond positively to my questions.  Potential 
effects on the interview process are considered within the discussion section of this 
chapter.   
5.3 Method 
As previously mentioned the population was well known to the chief investigator and 
this had allowed a hypothesized working conceptual framework for the health and 
related quality of life outcomes to be developed (Chapter 4, figure 4.2) using clinical 
expert opinion.  Phenomenology was deemed the most appropriate methodology for 
this study. Phenomenology studies conscious experience as experienced from the first 
person point of view, and considers how individuals make sense of the world around 
them (Bryman, 2004).  Through observation attempts are made to gain access to an 
individual’s common sense thinking and how they interpret the reality within which they 
live.  It was important to gain access to the paediatric OI population’s thoughts, feelings 
and experience of living with their diagnosis and the effects it had on their everyday life. 
Gaining a closer, more thorough understanding of how they viewed their QoL and how 
this was affected by their disease, its treatment and the regular hospital visits this 
involved was vital.  Without this closer understanding, any newly developed QoL 
instrument would not necessarily measure what was deemed important or relevant to 
the paediatric OI population, and this may subsequently effect their inclination to 
complete it.  Alongside the paediatric OI patients’ view, were the views of their 
 
 
71 
parents/carers and the health professionals involved in their medical or therapy care.  
Gaining insight into the similarities and difference between the children and the adults 
who cared for them was also an important adjunct.  Proxy respondents have already 
been shown to be a poor replacement for self completion in several areas of QoL 
(Eiser and Varni, 2013); would the OI population report similar differences? 
One-to-one semi-structured interview methodology with a purposive sample of children, 
parents/carers and health professionals provided a safe, confidential environment in 
which to provide opinions and beliefs about QoL, and how this QoL may have been 
affected by a diagnosis of OI.  Although, unlike a focus group setting, it is 
acknowledged that the interview would limit discussion and a sharing of opinions, it 
was felt that at this early stage of concept elicitation a more secure situation would put 
participants at ease.   
To permeate this experiential information twenty five semi-structured interviews were 
undertaken.  These included; ten children aged 7 to 18, diagnosed with Osteogenesis 
Imperfecta (OI), who attended a tertiary Metabolic Bone Disease Clinic in the UK; ten 
parents of children diagnosed with OI attending the same clinic; and five health 
professionals specialising in the treatment of children with OI.  The sample was 
purposive; children were balanced for severity and age, parents for severity of the child 
in their care and health professionals for their discipline.   
Table 5.1.  Characteristics of the samples 
Participant Length of 
interview 
(minutes) 
Age Severity of 
OI 
(child)  
Profession 
(Health Professional) 
C1 (Child) 28 16 Moderate  
C2 26 16 Mild  
C3 13 8 Moderate  
C4 44 12 Moderate  
C5 34 6 Severe  
C6 28 13 Moderate  
C7 34 14 Mild  
C8 30 10 Mild  
C9 26 14 Severe  
C10 34 17 Severe  
P1 (Parent) 52 30 Moderate  
P2 38 28 Moderate  
P3 50 38 Moderate  
P4 40 37 Severe  
P5 44 30 Mild  
P6 37 40 Severe  
P7 42 39 Moderate  
P8 18 42 Mild  
P9 43 44 Mild  
P10 42 52 Severe  
HP1 (Health Professional) 48 44  Occupational 
Therapist 
HP2 20 54  Nurse 
HP3 34 28  Occupational 
Therapist 
HP4 37 33  Physiotherapist 
HP5 30 52  Consultant Medic 
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The local research ethics committee reviewed and approved the study protocol 
(appendix 1).  The participants (children and parents) were contacted by letter outlining 
the nature of the study (appendix 3), including an information leaflet (appendix 4) and 
asking for consent to discuss the research further.  The information leaflet explained 
the nature of the interviews, who would be present and what to expect, making it clear 
that participants could stop the interview at any time.   During their next hospital 
attendance, consenting individuals were then approached and given the opportunity to 
discuss the research and ask any questions. Consent was gained from participating 
parents and health professionals (appendix 5).   For children who agreed to participate, 
consent was gained from both parents and young adults (16-18 years) and assent was 
gained from children (7- 15 years).  Sample characteristics including; age, gender, 
severity of OI (of child), number of siblings, number of siblings affected with OI, 
parental history of OI, marital and employment status of parent were recorded 
The interviews took place in a quiet room, away from the clinic or ward environment.  
Children were given the choice to be interviewed alone or with a parent or carer 
present.   The interviewer was known to all participants as a Physiotherapist within the 
Metabolic Bone Disease clinic.   It is acknowledge that this could lead to conflict of 
interest; with patients, parents and colleagues feeling a sense of duty to participate 
(Richards and Schwartz, 2002).   
The interviews were semi-structured; parental and child interviews included a warm up 
question asking them to talk a little about themselves, health professionals were asked 
to describe their experience of working with the paediatric OI population.   Participants 
were informed that there were no right or wrong answers and that their views and 
opinions were what was required.  All participants were made aware of the dictaphone 
recording the interview.   An interview schedule (appendix 6) was used to encourage 
on going focus throughout the interview.  The interviewer was previously known to the 
children and parents in a clinical role.  Consistent with qualitative methodology several 
warm up questions were used at the onset; parental and child interviews included a 
warm up question asking them to talk a little about themselves; health professionals 
were asked to describe their experience of working with the paediatric OI population 
(Hill et al, 2014).   It was suggested the children interviewed, state their age, where 
they lived, who was in their family, where they went to school or college, if they had any 
hobbies or where they went on their last holiday.  Following this starter question, 
participants were asked if having OI, or having a child with OI, had an effect on any of 
the activities they had described.  The interview aimed to encourage participants to 
consider how OI affects children’s quality of life.  Parents and children were then asked 
to describe their usual day from getting up in the morning to going to bed at night; who 
helped?  Did they have to do anything differently because of their or their child’s OI?  
By asking both parents and children to discuss their daily routine, participants were 
encouraged to analyse their daily activities and explore how OI affected what they did 
or did not do.  When interviewing the children probing was used to draw out any 
differences between themselves and their siblings or peers.  I asked the children what 
it was like to have OI; were there any good or bad things about having OI?  Could they 
access the same hobbies and activities as their siblings or peers?  How did having OI 
make them feel?  Parents who had more than one child were asked if they felt they 
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treated both children similarly; was their child with OI given the same opportunities as 
their siblings or peers? 
Health professionals were asked; What are the main problems that arise for children 
with OI and their families?  How do OI and fractures impact on the life of a child?  
Again, can they access the same hobbies, schools and extra-curricular activities? 
The final question used for all participants was; if you could change or improve one 
thing for children with OI, what would that be? 
The interviews were transcribed verbatim, and rechecked on several occasions for 
accuracy.  Significant statements were identified, extracted and organised, undergoing 
framework analysis (Richie and Spencer, 1994).  A sample of interview transcripts 
(n=5) were reviewed by an experienced qualitative researcher [WB].  The interview 
data was read, and re-read and reoccurring themes were identified.  A tabulated 
framework was used to organise all themes and sub themes.  Participant’s quotes were 
placed directly into the table under theme and sub theme headings.  Themes were then 
explored and any connections or overlap between themes considered.  These were 
explored diagrammatically using a Venn diagram to enable a clearer picture of themes 
to evolve.   
5.4 Results 
The first 25 individuals (10 children, 10 parents and 5 health care professionals) 
approached, agreed to participate in the study.  The age range of the interviewees was; 
children 6 to 17 years, parents 28 to 52 years and health professionals 28 to 54 years.  
The parents interviewed had children with a mixed range of severity of OI; two of those 
parents interviewed were fathers.  The health professionals included two occupational 
therapists, one physiotherapist, one specialist nurse and one consultant.  All 
specialised in the treatment of children with OI with a wealth of experience, ranging 
from 2-16 years.  Interviews ranged from 13 minutes to 52 minutes in length (See 
Table 5.1). 
Most of the children appeared to feel at ease when discussing at length their daily 
routine, identifying times and situations where they needed additional support, or had 
to do things differently from their siblings or peers.  Although one child was able to talk 
about her Osteogenesis Imperfecta (OI) and describe her daily routine, she became 
upset when the interview touched on differences between her and her peers/siblings so 
the interview was stopped to avoid undue stress (Hill et al, 2014).  All other interviews 
went well; the parents and health professionals appeared comfortable and at ease with 
the subject matter.    
A large number of topics were discussed by the interviewees.  These included; being 
safe and careful, being different, needing extra support, the need for adaptations or 
equipment, feelings of fear, isolation, pain, fractures and reduced function following 
fracture, tiredness, independence, effect on siblings, altered family routine, time lost 
from work, letting go, planning, stress, motivation and determination.  Health 
professionals due to their lack of constant proximity to the children and their families 
often discussed topics from both the child and the parent’s perspective.  Children 
described topics which were more relevant to them specifically; parents discussed 
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family based topics, often with emphasis around the additional planning and 
organisation involved in caring for a child with OI (Hill et al, 2014).  An exhaustive list of 
elicited themes can be found in Appendix 2. 
Six main themes were identified as relevant to QoL from the analysis; each included 
two or more sub themes.  The six main themes are; being safe and careful; reduced 
function; pain; fear; independence and being different, these are documented in Table 
5.2.  These main themes were selected as they were reported by all three groups and 
were thought relevant to the child’s quality of life, rather than that of the parents or 
whole family.  Although the complexity of the language varied, all participant groups 
discussed the impact of the six themes on the QoL of children with OI.  However, the 
emphasis/spread was different for each group.  Themes such as; reduced function 
(fractures and equipment) and isolation (being different) saturated quite early (n=5), 
within the children interviewed.  Being safe was discussed readily by all children 
interviewed, but more frequently by parents.  The themes fear and being safe saturated 
earlier within the parent group, and fear was more readily discussed by health 
professionals (Hill et al, 2014).  On reviewing the interview transcripts all the main 
themes were identified within the first eight interviews (4 children, 2 parents, 2 AHPs), 
although not all the sub themes were identified at this stage, and required completion 
of almost all interviews to fully saturate.   
 
Table 5.2.   Main themes and sub themes  
 
 
  
 
 
 
 
 
 
 
 
5.4.1 Being Safe 
Being safe was a theme most often identified by all three groups of participants.  There 
was no difference between children of primary or secondary age in their identification of 
the need to be safe, the only difference was the way they described it.  Younger 
children observed adults not letting them do certain activities to keep them safe and 
Main Themes Sub themes 
Being safe and careful Avoidance of activities  
 Trying to be safe 
Reduced function Reduced function with 
fractures 
 Equipment/adaptation 
 Tiredness/fatigue 
Pain General aches and pains 
 Pain of fractures 
 Pain relief 
Fear Fear of fracture 
 Activities/handling 
 Needle phobia 
Independence 
 
Being different 
Pushing for independence 
Overprotection 
Isolation from peers 
 Being different 
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noticed how their parents would stay close by to ensure safety (Hill et al, 2014).  One 
child, when asked why they had a buddy for a certain activity, replied “to keep me safe 
of course”.   
Secondary school aged children talked about having additional adult support to 
promote safety, but also how they avoided activities and busy areas to keep safe; for 
example:  
Child (C7):  Erm, there is an LSA that takes me into lessons, erm so that sort of 
 if people were running and I sort of got knocked or something, there 
 would be someone there. 
Another more able bodied child did not need additional support to move around school, 
but stated “I leave at the same times as everyone else, I’m just extra careful”.  Careful 
was a description used more often by the older children (Hill et al, 2014).   
 C2:   I have to be careful about what I do in PE. 
 C6:   The only thing is that I have to be more careful. 
C10:   you know another negative is that I am always breaking bone easily and 
 it is always in the back of my mind, when doing stuff I have got to be 
 careful cos if I break something, it comes with a lot of consequences 
 you know. 
Parents, like the older children, talked about keeping their child safe and avoiding fast 
and unpredictable activities.  One parent felt she avoided activities that involved a lot of 
children running around; “a situation where accidents could happen”.  Parents also 
observed their child remaining on the periphery of activities and not taking risks; for 
example: 
Parent (P9):  On reflection, she has been very danger aware from a very early 
 age, so as a consequence I try to let her drive it.   
P9:   Yeah and what I would often see is she would do they same, but she 
 would be right on the periphery. 
P8:   He wouldn’t do anything that would put him at risk, you know, he is not 
 one for climbing trees, or sitting on someone’s shoulders or anything like 
 that, so he is quite sensible (laughs). 
Health professionals observed parents from an early stage doing everything they could 
to keep their child safe from fracture. 
Health professional (HP1):  they are very protected, and they are very cautious 
about who they allow near them, and so their social experiences are 
quite limited in those early days and the handling and the bonding is 
reduced.   
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5.4.2 Reduced Function 
Reduced function was also described by all three groups.  There was no difference 
noted between those children with severe or milder disease. Primary school children 
reported using wheelchairs because they became tired, and that their function was 
reduced when on crutches.  One young child described going in his wheelchair 
“Because my legs got tired”.  Older children talked about having to do things in a 
different way.  They did not always talk about missing out on activities, but had to adapt 
the activities or choose to do a slightly different activity alongside their more able 
bodied peers.  This was especially apparent at times when a fracture involved a 
dominant hand (Hill et al, 2014). 
C9:   It’s, sometimes it can restrict me, but…I don’t know, it’s, I’m not the 
same if that makes sense....Yeah, because you are in a wheelchair like, 
sometimes it’s like harder to do things that other people could do with 
ease. 
C2:   Well I can’t do as much for myself, if it’s my right wrist I can’t write, I 
can’t open things, I can’t pick stuff up as I can’t do as much with my left. 
Others described the different equipment they used to improve their function, these 
included walking with crutches and using wheelchairs for mobility.  One teenager 
required a science stool with a backrest, and commented that her school had to order a 
special one.  Another reported using “chunky pens, so that I can grip them easier”. 
Parents and health professionals also observed reduced function, but commented 
more on the additional help children with OI required, particularly if they had sustained 
a lower limb fracture and were non-weight bearing.  They described the tiredness they 
observed in their children when they had experienced a busy school day (Hill et al, 
2014). 
P7:   when Evie broke her leg last, in December, she couldn’t, they didn’t 
want her going on the stairs so, every time she went to the loo, I was 
behind her, or Pete was behind her and then we were in front of her 
when she was coming down from the loo.  So I think the level of care 
that we provided when she was in plaster, was like really high and 
everywhere she, we didn’t want her walking, because I was worried 
about her other leg and we just sort of rallied around her all the time, so 
she didn’t make her snacks like she usually does, it was like no, you 
stay, because there is a step into the kitchen. 
P3:   he doesn’t do any after school activities, because by 3 o clock he’s 
whacked, he is whacked.  He comes in erm, and he can like lay on the 
sofa for half an hour, an hour and just not do anything.    
HP3:   a lot of them don’t want to be reliant on someone to help them and they 
want to be able to manage by themselves but yet they have to accept, 
you know, help and just practical tasks like toileting and bathing and you 
know, getting in and out of bed of a morning, if you have a fracture, 
becomes that bit more difficult and time consuming. 
 
 
77 
Another health professional described the restrictions placed on some activities for 
older children such as; trampolining, horse riding, high impact sports and PE.   They 
felt younger children were also restricted from simple activities such as slides at a play 
ground, which if pursued could lead to fractures, demonstrating a link to being safe (Hill 
et al, 2014). 
5.4.3. Pain 
Pain was mentioned by children, parents and health professionals when discussing 
quality of life in OI.  There was no apparent difference due to severity of OI noted.  
Younger children talked about “ouchys” and things “hurting”.  Older children described 
pain, hurt and ache, often relating to fractures, but occasionally just the general aches 
and pains experienced by people with OI.  One older child described his back ache as 
“always there, it comes and goes like a pain threshold”.   
Parents talked about finding it hard to see their child in pain.  Those who had OI 
themselves felt guilty for passing on the gene, when the pain experienced following a 
fracture was discussed.  Some parents commented on how much pain their child had 
suffered before they had received Bisphosphonates.  They talked about their child 
appearing lifeless and finding activities difficult due to their level of pain (Hill et al, 
2014).  
C10:   when I have a fracture, it is obviously very painful, but what upsets us 
the most is the fact of the consequences, because I mean I have had 
that many I believe that I am used to the pain and in comparison the 
screaming and the crying as I grew up, now I don’t really cry, I just you 
know, emphasise that I am in pain, but the worse thing is the 
consequences 
P2:   It’s just really hard sometimes and for me when I see her in pain I feel 
quite guilty about that, because I know that it’s obviously come from me. 
Some parents discussed the advantages of early pain relief and splinting immediately 
following fracture and this was mirrored in the comments made by health professionals 
(Hill et al, 2014).  They felt providing pain relief as soon as possible was a necessity, 
particularly following fractures.   
 HP4:  Earlier pain management and almost the parent is the only person  
           really who is there early enough, because you never get the same            
           doctor twice and you never get the same treatment twice, and I think 
           there needs to be some sort of care plan in place where the parents 
           know that they are allowed to give….. 
5.4.4          Fear 
Younger children had no concept of fear.  However, secondary school aged children 
described how the fear of fractures would hold them back from undertaking some 
activities, they were fearful of busy or dangerous areas and some reported needle 
phobia (Hill et al, 2014)  
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C1:   More scared of breaking a bone, I was always, it would hold me back a 
lot from doing more activities.  My Mum would say “do you want to go 
there?” and I would be like “oh I might break a bone so I won’t”.   
C6:   Erm, I don’t mind hospital, it’s only the erm, needle, because I am partly 
needle phobic, and other than, once the needles in I aren’t too bothered. 
C7:   but when I was younger, I was like scared about having a fracture, not 
so much my arms, but, I’ve done them enough times, but legs and stuff.  
You know what if I was in a dangerous area and I broke a leg or 
something. 
Parents did describe fear in their children of all ages; they observed fear of some 
activities and needle phobia, but also reported their extended families fear of handling 
their child, and the fear they experienced when their child went to school.  One parent 
described her brother as “panicking he might break her”, when she had asked him to 
hold her daughter, and noted that most of her family chose not to pick up and handle 
her.  Health professionals observed fear in parents, children and other professionals 
with regard to handling and fractures; they did not differentiate for age or severity 
where fear was concerned.  They noticed children with OI often restricted the number 
of family members that were allowed to handle them and pick them up.  One health 
professional felt that older children often became anxious when they handled them for 
the first time, particularly if they had only been handled by their parents (Hill et al, 
2014). 
P10:  I think...there’s always a fear that he is going to break a bone, at all 
times.   
P7:   I’d love to take the kids there, but I couldn’t, I’d, I’d, I’d just be too 
scared, I’d be just, there’d be too many people who were going in their 
own directions and I would be too frightened to do that.   
HP1: When they first go to school, schools are terrified of them whether they  
are mildly affected or severely affected, it doesn’t really matter, they are 
all terrified.  And the child will be excited about going to school, and 
everybody is missing that. 
5.4.5          Independence 
Parents and children differed in their discussions around independence.  Secondary 
school children described striving for independence and preferring to be independent 
even when they had sustained a fracture.  One child described having pushed to be 
like everyone else at school, only agreeing to sit out of PE when her legs got too tired 
to carry on.  Others talked about walking or propelling themselves to school with their 
friends (Hill et al, 2014). 
Younger children did not talk about independence at all; this may be due to age and 
expectation.  Young children of all abilities are cared for by their families; therefore 
striving for independence is often not anticipated in this age group.  Alternatively 
parents described struggling from an early age with letting go and over protection.  
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They observed their child’s drive and motivation for independence, but often reported a 
need to accompany children to extracurricular activities, and in some cases 
acknowledged their inability to let go (Hill et al, 2014). 
C2:   I’ve always been independent, because I’d prefer to be independent.  
They have said I can have a scribe for my GSCEs, but I don’t want one, 
I’d rather write it myself. 
C10:  Erm, but for doing stuff such as washing, erm cleaning my teeth etc, I 
normally just get into my wheelchair, which I park next to my bed, and 
erm, wheel up to the sink and do that with no problems. 
P7:   because they are very independent now they have been on 
pamidronate, well, no, Erin especially, she doesn’t rely on wheelchairs 
very much at all now, so she’s her own independent 12 year old.   
P9:    she used to say to me “do you have to come” and I used to say I do 
have to be there, I’ll get out of your face, I’ll get out of your hair, I’ll deal 
with another group, I won’t be anywhere near.  May be it was mine on 
reflection, the more I think about it, maybe it was me that actually need 
to go. 
The health professionals frequently observed the conflict within the child’s life when 
they struggled for independence with the overprotection of their families and school.  
They also commented on the difficulties surrounding children moving into education 
where they were no longer within the sole care of their parents.  All health 
professionals described the young OI population as a motivated and determined group, 
striving for independence (Hill et al, 2014).  One stated “they are a great example of 
what can be achieved by determination and courage”. 
HP1:  when it comes to independence at home, and thinking about faster 
wheelchairs and leaving home, going to college and all that sort of thing, 
there becomes this new anxiety, the children, the youngsters want it, 
and the mums think they are going to stay at home forever.  And there is 
this sort of letting go process, and they learn to drive, and have their 
independence that way and it’s a very exciting time for them, but it is 
very nerve racking for families to let them go. 
 
5.4.6         Being Different 
The final theme described by all children, parents and health professionals was the 
feeling of being different or isolation.  Younger children talked about not being allowed 
to play football or run fast.  They described feeling left out of some outdoor school trips, 
not being invited to parties, and feeling sad that there were things they could not do.  
One child became upset when she talked about being unable to skip or run and the 
interview was terminated as a result.  The older children echoed the thoughts of the 
younger ones; they felt excluded from some activities which were potentially dangerous 
to them because of their OI.  In addition they found some extracurricular activities 
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became too physically demanding as their peers became older and stronger (Hill et al, 
2014). 
Interviewer (I):  Why did you finish scouts?   
C1:  It was venture scouts after that and that’s a lot more physically 
 demanding, more camps and I just couldn’t handle it….I did try it.  I got 
 too tired.  
I:   How did that make you feel?  
C1:… bit sad that I couldn’t join, cause all the scouts upgraded to venture 
scouts, and all my mates went up to there. 
C8:   It makes me feels a bit left out because I can’t do a lot of things that I 
 want to do.   
Parents and health professionals observed this isolation in the children they cared for.  
They reported children being excluded from PE and sports day, but also not being able 
to keep up with their peers or siblings.  In some instances parents commented on their 
child looking different because of the equipment they required, and the effect this had 
on a child who wanted to look like everyone else.  This was not severity dependent and 
was echoed across the different severity groups.  One health professional felt that 
children with OI could access most opportunities with some modification, but added this 
took “extra effort from teachers and schools, social groups and medical professionals.”  
(Hill et al, 2014) 
P1:   Erm, for sports day we don’t usually tend to take him, because he feels 
too left out, you know because like 100m sprints.  He can take part in 
like the bean bag throwing you know, but that’s just like one event.  
There’s all the rest like egg and spoon, so he can’t wheel himself and 
hold that.  So we tend really not to send him, 
P9:   The birthday party invite would come, it’s a skating party, it’s a roller 
blade-ing party. It’s a horse riding party, no we can’t go.   
HP5:   They are not going to be able to engage in the same range of activities.  
They may be limited sometimes in terms of what they do, not simply in 
terms of their physical disability, but by other people’s perceptions of 
what that disability means.   
The overall process of concept elicitation, followed by the development of the 
conceptual framework, started with themes derived solely from expert or clinician 
opinion (figure 4.2.  Chapter 4).  These were then appraised alongside the themes 
identified within the literature (figure 5.1  Chapter 5), which were then finally reviewed 
and enhanced by the themes revealed following the one-to-one interviews with those 
individuals living with or experiencing OI on a daily basis (figure 5.2).  Table 5.3 
denotes the themes identified at each stage of this process and the commonality 
between stages. 
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Table 5.3.  Overview of conceptual frameworks 
 
 
5.5       Discussion 
This section of the thesis describes the use of qualitative interviews with children, 
parents and health professionals to identify how OI impacts on the quality of life and 
well-being of children and their families and what issues are important to them.  These 
issues/themes were then used to inform and further develop the conceptual framework, 
ensuring high content validity within the development of the OI specific QoL measure 
(Figure 5.2). 
There is a paucity of research on the views of both children and parents on the impact 
of OI on QoL (Hill et al, 2014).  From the 25 interviews undertaken, six main themes 
were identified, extracted and organised using framework analysis and included; being 
Researcher (fig. 4.2) Literature (fig. 5.1) 
Interviews (fig. 
5.2) 
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Physical 
functioning 
Physical 
functioning 
Reduced 
Function 
Reduced function due 
to fractures 
Physical symptoms General health  Tiredness/fatigue 
 
Physical 
symptoms 
 Equipment/adaptation 
Pain  Pain 
General aches & 
pains 
Fractures   Pain of fracture 
Immobilisation   Pain relief 
Emotional 
functioning 
Emotional 
wellbeing 
 
 
 
Fear  Fear Fear of fracture 
Worry   
Fear of 
activity/handling 
   Needle phobia 
  
Being safe and 
careful 
Avoidance of 
activities 
   Trying to be safe 
Cognitive 
functioning 
Cognitive 
functioning 
Independence 
Pushing for 
independence 
   Overprotection 
Social well being Social wellbeing Being different Isolation from peers 
Hobbies   Being different 
Friends     
School    
Missing school    
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safe, reduced function, pain, fear, independence, being different.  A recent Portuguese 
descriptive case study described some similar themes to those identified here.  They 
interviewed children with OI, their siblings and parents and reported themes such as; 
consequences of fractures and impairment, weakness and vulnerability, exclusion at 
school, worries surrounding pain and susceptibility to fracture and positivity (Santos 
and Barros, 2011).  
Stevens (2010) interviewed 74 children aged 7-11, from two city schools, about their 
quality of life.  The aim was to develop a health utilities index for children using the 
interviews as a means to identify themes.  The majority of children were in good health 
(93%), no individuals reported complex disability.  Her themes included; worried, sad, 
annoyed, hurt, learning, daily routine, tired, joining in activities, sleep, embarrassed and 
jealous.  Although some of the themes she uncovered were similar to those highlighted 
by the paediatric OI population (worried, hurt, tired, daily routine), others were not.  
This may be explained by the lack of children with complex needs within her cohort.  
Quality of life is a difficult concept to describe, and descriptions vary across the 
literature. Previous definitions (Fayers and Machin, 2007) are focused on functional 
ability and health status.  However, both experience and the literature tells us that 
quality of life is not necessarily based on a child’s ability to function, and there is no 
evidence to suggest this is the case (Davis et al, 2006).   Difficulties arise when 
attempting to measure quality of life if it is not well predefined. Some studies define it 
as functional ability or a sense of wellbeing (Solans et al, 2008), others report health 
related QoL (Muldoon et al, 1998). It is difficult to make comparisons between research 
papers, if different definitions are used. From the number of themes identified within the 
interviews, only a small proportion relate to functional ability. Reduced function was 
more often mentioned if the child had sustained a fracture.  This was true for all ages, 
severity of disease and interviewees (Hill et al, 2014). 
Several studies have discussed the difference found between children and their 
parents with regard to their understanding of QoL (Eiser and Morse, 2001a; Eiser, 
1997; Upton et al, 2008; Waters et al, 2009). This research supports the view that 
differences also exist between the children and their health professionals (Morris et al, 
2007). It also highlights a large number of similarities between children and their 
parents within the six main themes identified, although there were several important 
disparities apparent within the interviews. Parents talked about how their child’s OI 
affected their own QoL; their ability to work; undertake family activities; and the 
additional planning required to achieve some outdoor pursuits. Parents on the whole, 
failed to mention their child’s independence, without discussing the over protection they 
felt it necessary to provide. Eiser (1997) suggests strong correlations between parent 
and child ratings are unlikely.  However, it is important to identify those contexts in 
which parents can be expected to make an accurate judgement. Parents are not 
therefore, necessarily considered an accurate source of information when identifying 
issues around their child’s QoL (Eiser and Morse, 2001b; Upton et al, 2008; 
Theunissen et al, 1998).  Thus  parents of children with OI may well be a suitable 
advocate when reporting on themes such as; reduced function, being safe and careful, 
and pain, but may not be an adequate proxy overall. 
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The research undertaken found strong agreement between the groups for themes; 
being safe and careful, functional ability particularly following fracture, isolation from 
activity and pain. Although all three groups agreed on the nature of these themes, their 
justification for the theme was different. There was not agreement however when 
discussing independence and fear. Young children of all abilities are cared for by their 
families, so therefore independence is often not anticipated in this age group. With the 
exception of the very young children, fear was a theme reported by all those 
interviewed. The impact of fear varied across the group; children had a fear of certain 
activities that previously resulted in a fracture, parental fear related to anxiety of 
handling and of safety/separation when the child was at school/nursery or play dates. 
As expected, younger children were unaware of the over protective actions of their 
parents, which is a stark contrast to the older children expressing their dislike of 
parents’ attempts to keep them safe and doing everything for them (Hill et al, 2014). 
As anticipated many of the themes have a link to fractures; the fear surrounding 
potential fracture, the avoidance of sustaining a fracture, the resultant pain and 
reduced function following fracture, and the effect of repeating an activity which 
previously lead to a fracture (Hill et al, 2014). It has been previously acknowledged 
(chapter 3) that no other literature or QoL measure contains any link to fractures and 
the effect they can have on a child’s QoL.  
Several of the themes identified from the interviews are similar to those in other quality 
of life measures.  This similarity does not however cover all themes identified.  Some 
established QoL measures contain elements of these themes, but no one current QoL 
measure covers all themes identified, and therefore supports the need to develop a 
disease specific QoL measure for children with OI.    This is particularly relevant for the 
cross cutting themes being safe and careful and fractures.  The CHIP-CE includes the 
theme ‘Risk avoidance’, but attempts to assess more risk taking behaviour and its 
social implications (Riley et al, 2004), rather than the need to be careful in an attempt 
to stay safe and fracture free. 
Themes such as independence, function and some items related to discomfort and 
pain are included in the Child Health and Illness Profile (CHIP-AE) (Starfield et al, 
1995), TACQOL (Vogels et al, 1998) and DISABKIDS-37 (Bullinger, 2002). 
The KIDSCREEN 52 (Ravens-Sieberer et al, 2007), has several similarities with the 
themes identified from the interviews.  Its dimensions include; social acceptance, 
autonomy, moods and emotions, self perception, physical well being, social support 
and peers, but lacks a dimension which is equivalent to the theme being safe and 
careful. 
Being safe and careful was a recurrent theme throughout all interviews.  Parents and 
children of all ages and severity continued to describe times and events when they had 
to be safe and careful, all in an attempt to avoid fracture.  Children avoided busy areas 
at school, often choose not to attend parties which involved some form of risk and 
steered clear of activities such as roller blading and trampolining.  Parents and health 
professionals observed this risk avoidance, often watching the child with OI standing on 
the periphery of activities.    By constantly attempting to ensure safety, it is suggested 
that both the children and their parents are endorsing a level of isolation.   
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Isolation was another theme described by both parents, children and health 
professionals, but there was disparity in their explanation.  Health professionals talked 
of isolation from school following fracture; parents voiced concern regarding isolation 
from parties and some activities; and children more often described the social isolation 
of being placed in the learning support area during school break time.  This was often 
instigated by adults to maintain their safety, highlighting potential cross cutting between 
the themes being safe and isolation. 
Pain was described throughout all interviews.  Children of all ages and severity 
described the pain they experienced following fracture, the aches and pains of daily life 
with OI, and the need for pain relief.  The words used to describe the pain were all that 
differed, with younger children using immature language.  Parents and health 
professionals also reported the effects of pain on the child in their care and the need for 
immediate pain relief following fracture. 
Most of those children interviewed only reported reduced function at times of fracture.  
Several of those interviewed were wheelchair users, but only one teenager with severe 
OI reported reduced function compared to her peers on a daily basis when fracture 
free.  It is difficult to ascertain from the interview whether this adolescent had better 
insight, or was just prepared to be more honest.  Parents described reduced function 
related to fractures and made comparisons between the amount of additional care and 
practical support required compared to their siblings and peers.   
With the exception of the younger children (6-12years), fear was a theme reported by 
all those interviewed.  The impact of fear varied across the group; children had a fear of 
certain activities that previously resulted in a fracture, parents’ fear related to anxiety of 
handling and of safety/separation when the child was at school/nursery or play dates 
(Hill et al, 2014). 
Wright and colleagues (1993) describe the “vulnerable child/overprotective parents” 
syndrome, where children who are perceived as physically weaker by their parents 
may receive less encouragement to achieve their maximal physical and emotional 
capabilities.  This is a view which is supported with a degree of conflict between the 
overprotective parents, the health professionals encouraging independence in activities 
of daily living and the older child striving for independence.  As expected younger 
children were unaware of the over protective actions of their parents, this is not echoed 
by their older counterparts who repeatedly expressed their distaste. 
As anticipated many of the themes have a link to fractures; the fear surrounding 
potential fracture, the avoidance of sustaining a fracture, the resultant pain and 
reduced function following fracture, and the effect of repeating an activity which 
previously lead to a fracture (Hill et al, 2014).  Initially, the theme fractures was 
considered to be an independent dimension; with further investigation it became 
apparent that fractures was a theme cross cutting many other more independent 
themes and was therefore not distinct enough for a dimension of it’s own.  This link was 
neither age nor severity dependent. 
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5.5.1 Conceptual Framework 
The updated conceptual framework is documented in Figure 5.2.  It incorporates the 
information and concepts documented within the previous two frameworks, but places 
greater emphasis on the concepts elicited from the children themselves and those 
elicited from parents and health professionals relating directly to the child’s QoL.  The 
decision was made to document the framework in this way, as the overall aim of the 
research was to develop a QoL questionnaire for children and young people with OI.  
Less emphasis is therefore placed on concepts related to the QoL of parents.   
The overriding, most frequently discussed and therefore most important theme was 
being safe and careful.  Although not discussed within the literature it appeared to be 
linked to several other previously discussed themes.  Children avoided crowds and 
busy areas; choose not to attend parties or take part in high impact ‘dangerous’ 
activities; their parents handled them with care; all to avoid having a fracture.  Thus, 
‘not’ being safe and careful can lead to a fracture, which in turn causes pain, reduced 
function and a lack of independence.  This in turn can make a child or young person 
isolated from school and their peers.  As a result children with OI and their families 
become fearful of activities and environments which may result in a fracture.  This 
suggested cyclic nature can be seen in Figure 5.2, however further validation of this 
cycle alongside the OI population is required. 
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Figure 5.2.  Cycle of main themes and sub themes following interviews in the event of 
a fracture 
Note cross cutting of sub themes relating to fractures in italics. 
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The commonalities between the themes and concepts derived at each stage of this 
phase of the research are demonstrated in Table 5.3.  Those early postulated clinician 
based themes, such as; physical functioning; pain; fear/worry; cognitive functioning and 
social well being, have unity with both themes uncovered from the literature and one-
to-one interviews.  This enhances the validity of these themes and their place as 
potential dimensions or items within an OI specific QoL measure.  However some 
themes uncovered from the literature were less closely linked to those identified from 
the one-to-one interviews or clinical experience.  Participants didn’t describe their 
general health as a problem when discussing their QoL and only spoke of their 
emotional well being in relation to the worry and fear of fracture.  This further highlights 
the previous notion that a generic QoL measure would not fully meet the needs of the 
paediatric OI population. 
Throughout this stage of the research the role played by the principle investigator has 
included both researcher (interviewer, transcriber, analyst) and clinician.  This has 
necessitated transparent thought processes (previous narrative), methods and 
analysis. The gradual developmental process undertaken to develop the final 
conceptual framework (Figure 5.2) has allowed the reader to observe this journey and 
assess the outcome.  It is important to be transparent about the effects of being both 
clinician and researcher during this process, and acknowledge potential conflict of 
interest.  That the researcher was previously known to the participants could have had 
an effect on their decision to participate.  Notably all those subjects who were 
approached, did agree to take part.  Richards and Schwartz (2002) suggest that when 
a participant has prior knowledge of the interviewer, they may feel a sense of duty, and 
feel pressurised to participate.  However, those participants who have no prior 
knowledge of their researcher will have a different set of bias; such as confidence with 
strangers, lack of trust, fear and anxieties of the unknown (Hoddinott and Pill, 1997).   
Hoddinott and Pill (1997) investigated whether it was possible for a GP to ‘wear two 
hats’.  They interviewed pregnant women about their thoughts behind breast feeding.  
Some of the women were from the interviewer’s own practice, the others from an 
independent practice.  Interviews were more successful with those participants who 
knew her profession, as they had a pre existing trust in their GP.  Indeed, she found it 
took considerable effort to establish a relationship with those participants who knew her 
as a researcher only.  They concluded that whether a GP could interview their own 
patients depended on the research question, and how closely associated it is with 
aspects of medical care.  Our participants were interviewed with regard to how their OI 
affects their QoL, and were not asked directly about the service and treatment 
provided. 
Richards and Emslie (2000) state that professional background does have an effect on 
the interview process, as does personal characteristics such as gender, age, social 
class and ethnicity.  A doctor and sociologist respectively, they interviewed 60 middle-
aged men and women with heart disease who were informed of their professional 
status. They concluded from their interviews, observations and reflective diary that 
often the professional background of the interviewer (in this case doctor) muted the 
other characteristics such as age and gender, which did not occur when the 
participants were interviewed by a ‘researcher’. 
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This prior knowledge of participants can produce mixed results; during this piece of 
research it enabled the researcher to be aware of subtle signs of distress within the 
interviewees, and probably lead to the awareness of emotional upset within the 
interview which was subsequently stopped.  Having a prior knowledge of the disease 
and its manifestations also allowed the researcher to become readily immersed within 
the subject matter and demonstrate empathy with the participants, encouraging a rich 
source of interview data from which to extract themes.  Conversely, this prior 
immersion dictated a need to record each stage of the development of the final 
conceptual framework to prevent confusion between themes already known and felt by 
the researcher (as a clinician) and those uncovered from the literature and one-to-one 
interviews.  It has already been acknowledged that some of the information 
documented within the initial conceptual framework (Figure 3) may have been 
influenced by the literature that the researcher has previously read to inform her role as 
a clinician.  
Reflexivity implies having a self awareness about prior knowledge and preconceptions.  
By representing previous personal and professional experience, preconceived ideas 
about what is to be investigated, and the motivation behind the research, transparency 
can be addressed (Reventlow and Tulinius, 2005, Malterud, 2001).  Throughout the 
research reflective information was recorded; thoughts and feelings were documented 
following each interview, which allowed transparency and self critique of the methods 
undertaken. 
5.6 Strengths and limitations 
This phase of the research included one-to-one interviews directly with children aged 6-
18 years, parents and health professionals, eliciting concepts from those individuals 
who have first-hand experience of Osteogenesis Imperfecta.  This methodology 
ensured good content validity of the themes and concepts uncovered.  Including 
children aged 6-18 years allowed concepts to be uncovered from the full age range of 
the target population, ensuring no individual’s opinions were missed.  The interviews 
which took place with parents allowed a comparison of the concepts described by the 
parents and children to made, and offered an element of triangulation and validation of 
these concepts.   
The decision to use interviews at this stage of the research rather than focus groups 
was a further strength; it allowed an initial incite and understanding into QoL in OI in a 
non threatening, safe, one-to-one based setting prior to discussion within focus groups.   
The six main themes were described by both the parents and the children; however the 
parents also referred to some concepts related to parenting, work commitments, 
holidays and family outings.  These additional themes may have enabled the early 
development of a parental QoL questionnaire; a missed opportunity which would 
benefit further consideration and research at a later stage.  A further limitation and 
missed opportunity was the chance to develop a parental proxy questionnaire to 
enhance the child/adolescent self-report, but not replace it. 
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The main limitation to this phase of the research was that the principle researcher was 
also known to the children and parents as a paediatric physiotherapist.  This could 
have encouraged individuals to participate, as they may have felt more comfortable 
doing so with someone they already knew.  Had the subject matter have been to do 
with patient care or treatment that the families were receiving, the principle researcher 
as the interviewer would have had a detrimental effect on the trustworthiness of the 
data.  However this was not the case; the topic of conversation was not related to 
treatment or hospital care, and therefore less affected by the interviewer. 
5.7 Conclusion 
This data presents an early step in developing items for a disease specific QoL 
measure for children with OI. Six main themes were identified; being safe and careful, 
reduced function, pain, fear, being different and independence. There was generally 
good agreement between the three groups of interviewees, although discrepancies did 
occur between parents and children with regard to the themes independence and fear. 
Consequently although parents may well be a suitable advocate when reporting on 
themes such as; reduced function, being safe and careful, and pain, they are not an 
adequate proxy overall (Hill et al, 2014).   
Several of the themes uncovered showed similarity to other QoL measures, but the 
addition of being safe and careful, particularly in relation to fractures, demonstrated the 
need for a disease specific measure for children with OI (Hill et al, 2014).  
The next chapter will therefore endeavour to document the next phase in the 
development of a disease specific QoL measure for completion by children aged 6-18 
years.  Further generation of potential missing data/themes, followed by validation of 
previously uncovered themes will be sort within the next phase of questionnaire 
development.     
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Chapter 6 
Concept Validation    
6.1 Aim 
The following chapter describes the background, method and results of theme and 
concept validation for the prospective OI specific quality of life (QoL) tool.    Six main 
themes were uncovered during the item generation phase, involving 25 semi structured 
interviews, documented within the previous chapter (Chapter 5).  These themes were:  
 
 Being safe and careful,  
 Reduced function,  
 Pain,  
 Fear,  
 Being different  
 Independence.   
 
The main aim of this chapter was to validate the previously elicited concepts (themes 
and sub themes) and ensure no relevant items or themes had been missed.  The 
method chosen to achieve this triangulation was qualitative focus groups with children 
and parents who have experienced OI.  This validation process would further inform 
the conceptual framework and ensure high content validity of the proposed disease 
specific QoL instrument. 
 
6.2 Background 
The background and methodological aspects of focus groups have already been 
discussed in more detail in Chapter 3.  This section will report some of the literature 
where focus groups have been used to identify or validate concepts and themes for 
inclusion in patient reported outcome measures or quality of life questionnaires; the 
usefulness of these methods is also considered. 
Eiser and Morse (2001) state that a common way of defining items for a QoL measure 
is to undertake preliminary interviews with patients and clinicians, ensuring a newly 
developed questionnaire is relevant to the target population.  However they express 
concern with using this methodology alone, as the items generated may be based on 
the views of only a small number of patients, who agreed to take part, and may not be 
a good representation of the population as a whole.  For this reason further qualitative 
methods to validate the concepts uncovered and explore any missing themes with 
additional groups from the target population is thought to further increase content 
validity.   
For logistical reasons it is impossible to interview all individuals effected by a particular 
disease to ensure all concepts are uncovered, for this reason a representative sample 
are invited.  As discussed by Eiser and Morse (2001), if this sample is a poor 
representation of the population as a whole, the items generated may not reflect the 
true picture.  A process of validation thus strengthens the confidence in the uncovered 
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themes and makes certain no items are missed. Questionnaires which are not valid or 
deemed relevant to the target population will not be as acceptable and completion 
rates may be low as a result.  Focus groups offer further opportunity to gather 
information about QoL in OI; what patients think about having OI and how it can affect 
their QoL.  Previously generated concepts and themes can be revealed to the focus 
group participants and they can be encouraged to discuss the concept further, making 
note of any themes or concept they may feel are missing.  The following paragraphs 
give an overview of previous research studies which have utilised focus group 
methods. 
Heary and Hennessey (2002) reviewed 93 articles where focus groups had been used 
in children.  This review was in an attempt to bridge the gap in knowledge base within 
the literature, and provide some guidelines on how to involve children in focus groups.  
More than half the studies were exploratory, involving topics such as; informing health 
promotion programs, development and expansion of health services and to guide the 
application of a theoretical model.  They reported some studies using focus groups to 
pre-test a tool by assessing it’s acceptability to potential respondents.  
Amos et al (1997) and Mwanga et al (1998) used focus groups to generate initial 
themes and subsequent items for inclusion within a questionnaire, although neither 
group made explicit links between the focus group data and the questionnaire items.  
There is therefore no understanding of how the themes generated by the focus group 
were developed into the items within the questionnaire.  One exception however was 
French et al (1994), during their development of the Childhood Asthma Questionnaire 
(CAQ).  They asked a mixed group of children, some with asthma and some without, to 
discuss some aspects of their lives.  These included activities after school, games and 
physical education.  The factors of greatest importance that were generated by the 
children were subsequently turned into questionnaire items.  Their discussion also 
directed the format of the tool.  Their later research (French et al, 1998) used focus 
groups again to modify the CAQ for another culture. 
Stanton and Aronson (1993) triangulated data from focus groups and interviews they 
undertook with children.  They compared the data obtained in focus groups with that 
obtained via interviews using a pile-sorting technique.  Individuals were asked to 
organise cards with phrases or pictures into clusters or categories based on a 
perceived shared dimension.  They reported the benefits of this technique, as age and 
gender differences emerged from the pile-sorting, which were not apparent from the 
initial focus groups.  Heary and Hennessey (2002) found credibility was only addressed 
by a couple of studies they had reviewed.  Kidd et al (1997) presented each focus 
group with the themes that had emerged from the previous groups for discussion and 
clarification.  Running more than one focus group allows a process of verification and 
deepening of findings from the earlier groups.  It allows the moderator to feedback 
information from the previous literature, focus groups or interviews.   
Focus groups can vary in length, but Heary and Hennessy (2002) following their article 
review found focus groups for under ten year olds were less than 45 minutes, 10-14 
year olds maintained discussion for approximately 60 minutes, and young adults talked 
for a maximum of 90 minutes.   
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Recording focus groups can involve making notes contemporaneously during the group 
discussion, making notes of the focus group immediately after the group, or recording 
the focus group onto either audio or video/DVD media.  The audio recording equipment 
needs to be placed centrally to enable all participants’ contributions to be heard.  All 
attempts should be made to reduce the external noise, as this will make the 
transcription process more difficult.  A hospital setting is often not the best place in 
which to run a focus group, due to extraneous noise, such as ambulances (Bloor et al, 
2001).  The use of a video tape will aid the transcription process, allowing the 
transcriber additional visual clues as to which participant is talking and when.  Of 
course this may necessitate a second moderator, who is seated outside the core 
participants within the group.  
6.3 Method 
It was deemed necessary to assess the content and suitability of the themes/items 
generated from the concept elicitation phase of this research (Chapter 5) and the 
resultant conceptual framework.  Examining if the relationship between the uncovered 
themes and sub themes is well represented within the conceptual framework, 
alongside ensuring that the target population are in agreement with the themes and the 
framework was the aim of this chapter.     
The conceptual framework (see Figure 5.2, Chapter 5) was developed directly from the 
paediatric OI population (children, parents, HPs) in conjunction with expert 
opinion/experience and literature review; reasonable content validity was therefore 
assumed within this sample of the OI population, but this required further validation 
with an independent cohort, some of whom were naive to the previous concept 
elicitation process. 
The methodology chosen to validate the conceptual framework or assess the credibility 
of the themes was focus groups.  This methodology was considered appropriate as it 
attempts to allow a planned discussion in a non threatening way, enabling the 
researcher to explore the thoughts and opinions of the group with regard to the 
concepts previously elicited.  It was proposed that using focus groups for this purpose 
would encourage active discussion surrounding the themes, empowering the children 
to behave as experts within their field.  The use of ‘theme/sub theme’ cards had the 
potential to act as a visual prompt to the discussion taking place.  The justification 
behind running more than one focus group was to encourage further verification and a 
deepening of findings.  As children and young people with OI have no limitation with 
learning and are anecdotally often outgoing as a result of a large degree of adult 
contact, they are well able to communicate and voice their opinion. 
It is important to mention at this point in the thesis that the principle researcher had 
initially planned to run focus groups with all ages of children, for whom the QoL 
questionnaire would be developed.  However this was not possible; the local ethics 
committee did not offer a favourable opinion to the original plan to hold focus groups for 
younger children, or the suggestion of running a focus group that included mixed ages.  
The preliminary method had to be adjusted, and for that reason the focus groups were 
as described below. 
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The aim was to recruit children of similar ages, ensuring there were no previous 
relationships or friendships within the group, to reduce any potential intimidation which 
may be encountered.  Recruitment aimed to achieve a small group of young people, 
ensuring enough individuals to elicit discussion, but not too large to allow all voices to 
be heard.  Many children and young people with OI have altered mobility and use 
wheelchairs or walking aids, this leads to larger space requirements for the running of 
the focus group.  As a clinician already known to the cohort, this allowed prior 
knowledge of the cognitive and social abilities of participants, and therefore aided the 
planning and moderation of the group. 
Two focus groups were chosen; the first group’s purpose was twofold; to validate the 
themes already discovered, uncovering any items which may have been missed and 
secondly to place the themes in order of importance.  The second focus group was 
used for further validation, but also to uncover information and opinions regarding the 
most suitable format, the potential measurement scale and recall time for the OI 
specific QoL measure.   
Potential participants were approached via post with an invitation letter and reply slip 
(see appendix 3) detailing the study.  They were made aware that the study was multi 
faceted with three phases, and informed that they may be approached for inclusion to 
other phases of the study.  An information sheet and consent form (see appendix 4 and 
5) were also included in the mail out.  Two weeks following receipt of the returned reply 
slip, possible focus group participants were followed up by a telephone call, to answer 
any questions and discuss possible inclusion.   
Potential participants were asked to travel to SCH for the focus group.  Attempts were 
made to arrange the focus group to coincide with routine appointments, although this 
was not possible for all participants. 
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Table 6.1.  Inclusion and Exclusion criteria 
 
 
 
Recruitment Inclusion Exclusion 
 
Focus Group 1 
Up to 10 children and 
adolescents 
 
SCH patients 
Age 13-18 years. 
Medical diagnosis of 
OI. 
Attending SCH for out 
patient review or 
inpatient treatment. 
Ability to understand 
English. 
Consent/assent from 
patient and/or 
parent/carer. 
Unknown diagnosis. 
Non consent. 
Previous inclusion in 
semi structured 
interviews. 
 
 
Focus Group 2 
Up to 10 children, 
adolescents and 
parents 
 
 
SCH patients, and 
parents of SCH 
patients 
Patient aged 13-18 
years with medical 
diagnosis of OI 
OR 
Parent of child (age 0-
12 years) with medical 
diagnosis of OI. 
AND 
Previous inclusion in 
semi structured 
interviews. 
Ability to understand 
English. 
Consent/assent from 
patient and/or 
parent/carer. 
Unknown diagnosis of 
patient/child. 
Non consent. 
 
 
6.3.1 Focus Group 1 (FG1) 
The initial focus group took place in a meeting room at Sheffield Children’s Hospital on 
20th October 2011. It included 4 adolescents aged 13 – 16 years old, three females and 
one male.  None of the focus group participants had taken part in the initial item 
generation interviews.  The group were seated around a circular table, two of the group 
were wheelchair users and therefore good accessibility was ensured.  Biscuits and 
drinks were readily available to enhance comfort.  The use of a table in the centre can 
make children feel less self conscious (Henessey and Heary, 2005).   
The focus group was video and audio recorded, and therefore required two facilitators; 
one to moderate the interaction of the group and the second to use the DVD recorder.  
A dictophone was placed in the centre of the group to provide good audio coverage of 
the conversations taking place within the group. Initially a warm up topic was used to 
encourage conversation and assist the participants to feel at ease.  It was suggested 
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the group tell each other their name and something about themselves, such as an 
activity they like to undertake.  Both facilitators took part in this activity, promoting a 
relaxed comfortable atmosphere. 
An interview schedule (appendix 6) was used to aid on going concentration on the 
topic; cards denoting main themes and sub themes were used to encourage 
conversation around the themes previously uncovered within the one-to-one interviews 
(Chapter 5).  Attempting to validate these themes and therefore enhance credibility.  
The facilitator encouraged conversation around any possible new themes, attempting 
to identify any topics thought relevant to QoL in OI, which had been missed from the 
previous one-to-one interviews.  If discussion became slow the facilitator asked 
questions about the participant’s thoughts and opinions around a theme to encourage 
further conversation and discussion.  
Towards the end of the focus group the adolescents were encouraged to place the 
main themes in order of importance or relevance to quality of life in children with OI.  
This was done practically by ordering the cards with main themes on the centrally 
placed table.  Participants were asked to discuss why they had placed the cards in the 
chosen order. 
Once the focus group came to an end, individuals were thanked for their participation 
and both the DVD recorder and dictaphone were switched off. 
6.3.2 Focus Group 2 (FG2) 
Focus group 2 took place on 21st December 2011.  It included two adolescents affected 
by OI, aged 14 and 17 years old and a parent of two young children affected with OI, 
who had all been previously interviewed. It was deemed important to capture the 
opinion of the previous interviewees regarding the suitability and credibility of the 
quality of life items generated.   Whether they felt those themes included were pertinent 
and similar to those they had expressed during their one-to-one interviews.   
The focus group was again video and audio recorded, requiring two 
facilitators/moderators to accommodate this.  A dictaphone was again placed in the 
centre of the group to provide good audio coverage of the conversations taking place.  
Similar warm up activities were used to encourage the participants to feel at ease with 
each other and their surroundings.  This group differed slightly in that the participants 
had arrived early, met in the waiting room, and had therefore begun chatting 
immediately prior to the focus group taking place.   Again an interview schedule 
(appendix 6) was used to encourage on going concentration throughout the focus 
group.  The topic cards and previously ordered themes were used as visual cues.  The 
moderator encouraged discussion around the uncovered main and sub themes, 
attempting to discover whether the participants deemed them appropriate and relevant 
to their or their child’s quality of life.  Attempts were also made to ascertain whether 
they had remembered expressing similar themes previously during their one-to-one 
interviews.  Discussion was also encouraged around the format of the quality of life 
measure, the possible suitable recall time for children; and number of options within the 
suggested Likert scale was considered.  The inclusion of adolescents and a parent 
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enabled sensible discussion with regard to recall time of children and young people, 
and therefore all ages of child could be discussed. 
Both focus groups were transcribed verbatim, and rechecked on several occasions for 
accuracy.  Significant statements were identified, extracted and organised, undergoing 
framework analysis (Richie and Spencer, 1994).  Agreement or disagreement was 
noted between the initial themes uncovered and the feedback within the focus groups.  
Any new main or sub themes were identified and their relationship with previously 
identified themes was explored. 
6.4 Results 
 
6.4.1 Focus Group 1 
 
Ten young people were contacted via a letter for possible inclusion within the focus 
group. Eight agreed to take part, but due to timing of the focus group, other 
appointments and travel to Sheffield Children Hospital, four declined to take part for 
logistical reasons.  Therefore focus group 1 included four young people; a male aged 
13 years, and three females aged 13, 16 and 16 respectively (See Table 6.2). 
 
Table 6.2.  Characteristics of the samples 
 
 Participant* Age 
(years) 
Severity of OI Previously 
Interviewed 
Focus Group 
1 
Amelia 16 Severe No 
 Lola 16 Moderate No 
 Olivia 13 Moderate No 
 Harry 13 Mild No 
Focus Group 
2 
Jenny Parent Moderately 
effected children 
Yes 
 Juliette 14 Mild Yes 
 Sam 17 Mod Yes 
*Pseudonyms used to replace given names to ensure anonymity.   
 
The participants arrived with their respective parents, and gathered for only a short 
time within a waiting area, but had not formally met or introduced themselves.  A 
couple of the participants had arrived slightly early and their families had been 
introduced; they therefore had already begun to become at ease with each other.  The 
focus group took place in a small room away from parents and carers, with the 
participants seated around a circular table.  The DVD recorder was set back from the 
group towards the corner of the room; the Dictaphone was cited more centrally on the 
table. 
The duration of the focus group was 42 minutes.  Three of the participants were quite 
chatty from the onset, one participant was less so, taking longer to warm up.  Once all 
participants had warmed up to the subject matter conversation flowed well, and all 
participants appeared to be at ease.  The group consisted of young people and 
therefore a lot of joking, laughing and storytelling took place.  The young people 
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compared stories about fractures taking place, canulations going badly and parties they 
had or hadn’t attended in an attempt to gain common ground.  
 
Harry:  May be we are like partially solar powered, cos if I’m warm I don’t hurt 
 and I’ve got more energy.  
Amelia:  It’s true.   
Lola:  Yeah, like when it snows and that I get like right stiff.  
Moderator (M):  Ah ha.   
Lola:  It pains  
 
Amelia:  I just feel like tin man me when it’s cold.   
Lola and Olivia:  (laugh).   
M:  Does someone need to oil you?   
Amelia:  (laughing) yeah, you just feel like you can’t move and you are like 
 ‘ahhhh’  
 
Harry:  They were incredibly over protective; it took me until year 5 until I was 
 allowed to go to the toilet. 
All:  (huge amount of laughing) 
Harry:  They wouldn’t let me go on my own to the toilet until year 5!  And then at 
 lunch time I was either sat 
Amelia:  Where were you peeing then? 
Lola and Olivia:  (laughing +++) 
 
Following a warm up question the first theme was set on the table.  The main theme 
card was placed in the centre of the table, with the sub themes ‘being safe’ and ‘being 
careful’ placed around the main theme.  The facilitator introduced this theme ‘Being 
safe and careful’, and asked the participants what they thought about it, whether it was 
relevant to their quality of life and if they felt it should be included within the quality of 
life questionnaire. 
Initial thoughts were similar to those described within the one-to-one interviews; the 
participants were describing trying to be safe and careful, avoiding busy areas, crowds 
and difficult environments in an attempt to avoid a fracture.  
 
Amelia:  I think, I don’t ever let myself get into that situation.  So when I’m in 
 that situation I think right I’ll do this and then I’ll be fine.   
Moderator (M): Do you?   
Amelia:  Yeah, so say if there’s like a crowd, I’ll try and avoid it and just go to 
 one side till that crowd has gone.   
M:  Yeah.   
Amelia:  Or if I’m near anything dangerous then I’ll try and move around it.  
 
Harry:  Yeah if there’s a crowd I always go a few minutes early at least.   
M:  Yeah, do you do that at school?   
Harry:  Yeah, it’s like if you are not 5 minutes early then you have to go 5 
 minutes late.   
Lola:  Yeah, I do that.   
M:  Yeah. And what is it that you are kind of being safe and careful from?   
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Amelia:  Breaking.   
Lola:  Yeah  
 
An interesting discussion took place in relation to blue sclera and fracture risk, with 
participants commenting on their eye colour as a warning sign for imminent fracture. 
This is a topic that has been talked about for a number of years within the OI 
population, but as far as I am aware no research exists currently to prove or disprove 
this link.  It demonstrates how the group will use this potential link to further avoid risk 
taking behaviours when they deem their scleral colour changing.  Although a proportion 
of individuals with OI do not exhibit blue sclera, and therefore not all have the ability to 
monitor the intensity of this colour change in relation to imagined fracture risk. 
 
Amelia:  My eyes go blue as well……They go really blue at the bottom, I don’t 
 know why 
Lola:  Yeah (nodding)…… 
Harry:  My Mum has this thing, if it’s really blue then you are going to break 
  today 
Amelia:  uhha 
Harry:  If it’s not very blue then you’re probably not going to break 
Amelia:  Look in a mirror on a morning and then…… 
Lola:  (interrupts) that’s why I always look at my eyes. 
Olivia:  Do you do that? 
Amelia:  I do sometimes, like if I’m going out with my friend, I’ll look in the mirror 
 and look at my eyes and see if I am weak, or not, and then I’ll decide 
 what I’m gunna do that day.  I don’t know why, I’m not normal…… 
Lola:  No cos my Mum’s told me if your eyes are right blue then you might 
 fracture, so I look in the mirror every day at my eyes. 
 
The second theme to be introduced to the group was ‘Reduced function’, this main 
theme card was again placed in the centre of the table, with sub themes ‘tiredness’, 
‘fractures’, ‘equipment’ and ‘adaptation’ placed around the main theme.  In this 
instance, several participants began nodding their heads in agreement, particularly with 
the sub theme ‘tiredness’…… 
 
M:  ….. and also another thing that came up was tiredness.   
Amelia:  Emmm (laughs) (nods)   
M:  Oh you nodded your head then.   
Amelia:  (laughs).   
Lola:  Yeah, (nods).   
Harry:  (Nods) yeah tiredness.  
 
M:  When do you get tired? 
Amelia:  Near pamidronate time……. 
Harry:  (nodding) Yeah, one to two weeks usually.   
Amelia:  Yeah, 2 weeks before I go really tired and sore. 
Lola:  I’m always hyper after I’ve had my pamidronate. 
 
 
 
102 
One participant made a small link to feeling tired once she had sustained a fracture.  A 
further participant made a link between pain and tiredness; as I watched him make the 
link he appeared to have the realisation that from his experience the two themes could 
not be separated, one precipitated the other, he almost questioned whether they were 
one and the same theme.   
 
Lola:  When I get fractures I’ll feel right tired, I go right tired and achy 
Harry:  I think they actually intertwine, don’t they?  Because if you have got 
 pain, then it makes you tired.   
Amelia:  Yeah true.   
Harry:  And you have to fight it……(inaudible)   
Amelia:  Yeah that’s true that I never thought of that.  
 
This link appeared to remain strong for him and the other participants throughout the 
rest of the focus group  
 
Amelia:  I must admit though that I did break my rib a few months ago and that I 
 was still a bridesmaid the day after. 
M:  Were you? 
Amelia: Yeah.  I was in the bridesmaid fitting and broke my rib, and I still went 
 the day after to be bridesmaid.  I was just drugged up. 
All:  (laughing) 
M:  You’d had loads of pain relief. 
Amelia:  Yeah 
M:  To cope with it 
Amelia:  Yeah.  But I think if. I think if it was an arm or summat like that, I think 
 I’d dodge it. 
 
This was further supported when the participants continued to refer to tiredness, rather 
than reduced function later within the focus group. 
Reduced function in relation to fractures was identified, but small bone fractures were 
not described as something that interfered with daily life, or rather the participants 
didn’t allow them to.   
 
M:  How about when you have had a fracture? 
Amelia:  I don’t know. 
M:  Can you get around as easy and stuff or 
Amelia:  No not really, but I just figure, a way round and do something different 
 instead of doing what I was planning on doing. 
Harry:  It depends…. 
Amelia:  It…. 
Harry:  It does depend on what the fracture is as well 
M:  How so? 
Harry:  If you break your little toe, you are not going to really notice 
Amelia:  No you are not going to 
Harry:  You’re just ‘oh, my toes red’, still walking, keep going (laughing) 
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Further questioning around fractures and probing revealed more information with 
regard to coping strategies.  It is difficult to ascertain whether participants were being 
factual or saying what they felt their peers would expect them to say.  
 
Amelia:  (referring to fractures) I think people who have had them most cope 
  with them better. 
M:  Yeah 
Amelia:  Like people who walk, I don’t think they cope with them as well, as, I 
 don’t know, than somebody who has had a lot.   
M:  What do you think? 
Harry:  That your amount of fractures increases your pain resistance  
  because….. 
M:  Do you?   
Harry:  The more pain you have the higher your resistance to it is really. 
 
The need for equipment was discussed least of all in relation to reduced function.  Two 
participants discussed their bath seat; but more from a comfort and enjoyment sense 
rather than functional improvement.  One participant talked about her downstairs 
bathroom, which functionally enabled her to be more independent, a second participant 
talked about the need for better bathroom facilities and waiting for the addition of a wet 
room, as she couldn’t safely function without the help of her Mum. 
 
Amelia:  I have got a bench to help me get in and out of the bath…..And a chair, 
 like a chair lift to get me in and out. 
Lola:  I’ve got a chair lift 
Amelia:  Which is good 
M:  You’ve got a chair lift?  (directed at Lola) 
Lola:  Yeah, for like getting out of the bath 
Amelia:  Aren’t they comfy, you can just sit on them and …… 
Lola:  Yeah I just sit back on mine, just sit pressing the buttons 
Amelia:  I do (laughs) 
 
Olivia:  Yeah and I’ve got a shower whats, you just like go in to and you just like 
 sit on a chair.  It’s not got like one of those things on (mimics the bottom 
 step of a shower), you know to…. 
 
Amelia:  Yeah, we have got a downstairs toilet thing and we are getting a new 
 wet room thing, to make it easier for me to get in and out of the shower 
 myself……Yeah once we get the wet room then I can just crawl in. 
 
The third theme to be introduced to the group was pain.  This prompted discussion 
around pain in cold weather and the stiffness associated with it. 
 
Harry:  May be we are like partially solar powered, cos if I’m warm I don’t hurt 
 and I’ve got more energy 
Amelia:  It’s true 
Lola:  Yeah, like when it snows and that I get like right stiff……It pains 
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Quite soon the conversation turned round to pain relieving medication, and how 
general aches and pains and fractures are managed.  Initially the need for pain relief 
was down played, but as the participants became a bit more comfortable with the 
subject they began to talk more readily. 
 
 
Amelia:  I just have pain killers with me and just if I feel pain I just take one.  But 
 then I don’t feel pain that much unless it’s cold or something. 
 
M:  So do you all take pain relief or medication for pain? 
Amelia:  I only do if I’ve broke….. 
Lola:  If I get pain in my legs (touches thighs) I take pain relief 
 
M:  Do you all take pain relief if you have a fracture? 
Amelia:  Yeah 
Lola:  Yeah 
Harry:  Yeah…… 
Amelia:  Yeah, so that then you can move and be treated after you have broke 
 it, if you get what I mean.  So as soon as you hear it, you take one, and 
 then you can be treated after. 
 
Discussions around pain soon turned into talking about how they felt when they had a 
fracture.  How the fracture made them feel and how they experienced pain and dealt 
with it.  Three participants talked a bit more in depth about their experience surrounding 
fractures, commenting on the sound of fractures, how they knew they had sustained a 
fracture and anecdotes relating to this. 
 
Harry:  its weird hearing a fracture isn’t it.  It’s just like ‘click’ (demonstrates 
 breaking a length of bone with hands) 
Amelia:  (covers ears) it’s horrible, it like goes arrgh! 
Lola:  I hate hearing cracks; I just don’t like cracks at all. 
Harry:  It’s like getting a twig and going like that (demonstrates breaking a twig 
 with hands), a twigs that’s just…..  
Lola:  I just hate that noise. 
Amelia:  (interrupts) you can’t feel it though straight away, can you like and then 
 you’re like was that broke? And then you go, ‘oh yeah it was’. 
Lola:  Yeah 
M:  So do you have to like move it to know it’s broken? 
Amelia:  Yeah 
Harry:  I can remember when I was younger and I broke one while walking and 
 it was just, I didn’t immediately get pain, so this is what happened to my 
 body…..(demonstrates with hands)  I was like walking along, and my leg 
 went and started to do this, getting lower and lower to the floor. 
All:  (laughing) 
Me:  And then you got pain 
Harry:  I got to the bus to get back on to school and I was like just on the floor 
 going like ‘hello’ (demonstrates clinging on to the bus rail) 
All:  (laughing) 
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Harry:  Please help 
Lola:  Yeah 
 
When the main theme fear was placed on the table, one of the more severely affected 
participants was quick to talk about her experience of being handled by other people 
and the fear she felt surrounding that.  She described still being fearful of being 
handled by some carers she had known for years, and avoiding being handled where 
possible.  When pushed to say why she disliked this handling, she admitted it was 
because they may cause her to fracture. 
 
Amelia:  It’s like my carers, even though I have known them for like 4 years I 
 won’t, I don’t like them touching me still.   
M:  Do you still let them? 
Amelia:  I still let them sometimes, but they don’t need to.  If they don’t need to 
 then I won’t let them go near me. 
 
Discussions around fear soon moved on to talk about fear of needles and canulation. 
 
Harry:  I don’t trust junior Doctors any more with cannulas…….. 
Harry:  The vein collapses 
Amelia:  Oh mine come out 
Harry:  You know, I have nightmares of it falling out.  Is it going to happen this 
  time? 
Amelia:  Mine fell out when I was doing physio with Davina. 
All:  (laughing) 
 
When asked if they had always been scared of needles, or had needle phobia, 
discussion took place as to why they had become fearful, what had caused it and how 
it made them feel. 
 
Harry:  No it’s developed.  It developed after the 7, constant attempts to do 
 it…….(jokes)  ‘is this going to work?  No, this one?  No’  Why do people 
 just keep going, someone actually stabbed the same vein twice in a row.  
 What is the point of that? 
Olivia:  (Laughs) 
Harry:  That vein didn’t work, go away. 
Amelia:  I know, you just kind of feel like telling them to shut up don’t you. 
Lola:  They couldn’t get blood out of mine once and they had to try about 5 
  times. 
Amelia:  I ended up with like plasters all over me hand and up here 
 (demonstrates up arm), I nearly passed out. 
All:  (laughs) 
Amelia:  And then they goes, ‘oh we’ll have to try it somewhere else’, and I was 
 like ‘you have got to be kidding’ 
Lola:  I cried once because they were trying to get blood out of me and it was 
 hurting me hand. 
Amelia:  Yeah, they did it once and it just kept pouring out of me. 
Lola and Olivia:  (laugh) 
 
 
106 
Harry:  I’m not scared of blood and I’m not scared of the thing in it, but I am 
 scared of them putting it in!  Do you get what I mean? 
Lola:  Yeah, you’re not scared of…. 
Amelia:  (interrupts) yeah, I don’t think I moan a right lot me, I don’t think I’m 
  that bad. 
 
Placement of the theme ‘Being Different’ was controversial, with one participant stating 
‘bit weird!’  The group didn’t seem comfortable with the title of this theme and what it 
represented, even though it had been stated and discussed during the one-to-one 
interviews.  The group immediately choose to talk about being isolated from certain 
activities, rather than the concept of being different from their siblings or peers.   
 
One participant felt she could understand why some small children felt isolated from 
parties, and reported that she had done the same, although she had been invited to 
parties she often chose not to go.  Other members of the group agreed with her, and 
several reasons behind their choice were given. 
 
 Amelia:  I think that, (points to that paper) I can see why the nippers were, 
  because its danger……some kids’ parties are dangerous anyway. 
 
 Amelia:  Too dangerous.  And I don’t like kids running about anyway, so I just, 
  just like ‘don’t leave me here!’ 
 
 Lola:  Because there is like everyone running around and I just don’t like it.  I 
  feel like I get paranoid that the kids are gunna knock me over. 
 
Discussion around being different or isolation did not produce as much conversation as 
the other topics, although the group did eventually talk about other people’s perception 
of them, and not being allowed to do things they felt they could.   
 
 Harry:  Some people do try and stop peo….you from doing things, but… 
 Amelia:  They do 
 Harry:  But you know you can do it.  I get asked at school ‘it I flick your arm will 
  it snap?’ 
 All:  (laughing) [unable to locate who says what]  They do me, that was me that. 
 Amelia:  Say you could try it and see what happens 
 All:  (laughing ++++++) 
 Amelia:  Try it and see! 
 Lola:  Someone asked me ‘if I touch you, will you break your arm?’  and I went 
  no. 
 Harry:  And there’s the opposite end ‘if I kick your arm as hard as I can, will it 
  break?’  It would break if you did that to anyone’s arm.  (laughs) 
 Lola and Olivia:  (laughing) 
 Amelia:  Let me try it to you. 
 All:  (laughing) 
 
The final item that was brought to the table was ‘Being independent’.  Immediately this 
was placed on the table, participants within the group pointed to the sub theme ‘over 
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protection’.  This was occurring in their view at home and school, with grandparents, 
parents and carers over protecting them.  One participant described how it had taken 
several years before he was allowed to go to the toilet on his own at school, and having 
to sit with an adult at lunchtime rather than his friends.  This produced a large amount 
of frivolity and jokes, and the moderator had to wait a while for the group to settle as a 
result. 
When asked why they felt people over protected them, they all felt it was to prevent 
them doing something that would lead to a fracture. 
 
 Olivia:  They….they think it’s their responsibility to make sure that you don’t do 
  anything….. 
 Amelia:  I hate having over protections though where they are like don’t even 
  move  or breathe or you’ll break. 
 Lola:  (laughs) 
 Amelia:  I hate that, like they’ll say to me ‘don’t do that you’ll break’ and I’m like 
  ‘I won’t, I’ll be fine’. 
 Harry:  And they sit you down and say ‘stay there’ 
 Amelia: Yeah, the….(inaudible) .in school goes to one of my friends ‘don’t even 
  touch  her’, I were like ‘shut up!’  They can still give me a hug or  
  summat like  that because I don’t care, and they are like ‘don’t even go 
  near her’.  So I just went, I told them to shut up. 
 
The sub theme ‘letting go’ was also discussed, with participants agreeing this should 
also be included within the themes, as three of the participants felt they suffered as a 
result of some family members not letting go.  One participant however felt his parents 
were very good, although incidentally he was the only participant with a parent affected 
by OI. 
 
 Lola:  Well my, my Mum she don’t like let me do stuff that I want to do, if you 
  know what I mean. 
 Me:  What like? 
 Lola:  Like if I want to go to a sleep over she has to like think it over and until 
  she can say an answer.  Because like I wanted to go to my friends sleep 
  over and she said I can’t because it’s like too difficult, but I want to like 
  make my own  decisions about if I want to go to.  I know like what my 
  restrictions are.  I know what like; I know what not to do and what to do. 
 
 Amelia:  Yeah I must admit I do as well, because my Mum had to think stuff 
  over as well, before I go and do something.  And I keep thinking none of 
  my friends have to do that, so why should I.  And then I keep thinking 
  that she needs to, if you get me…….and so I just think oh I’ll let you do 
  it, but I keep thinking I want to do that myself. 
 
Towards the end of the interview I asked the group if there were any themes or topics 
that they felt had not been covered within their focus groups discussion.  One 
participant suggested PE, and a discussion around this topic developed: 
 
Olivia:  PE? 
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Amelia:  Ohh, I just sleep for an hour.  I just sit there for an hour doing my own 
  thing. 
Lola:  I have to do extra work because I don’t do PE. 
Harry:  They force me to do homework whilst everyone else is having fun. 
Me:  So do none of you do PE? 
Amelia:  No, I just used to get my work out and just play games on the  
  computer.   
Olivia:  There’s a teacher in our school that’s like got a son that’s in a 
 wheelchair, so she’s put it over to the head, and now I am doing like 
 gym stuff. So I like go on the exercise bikes and the rowing machines 
 and everything in the gym. 
Me:  Brilliant. 
Olivia:  I didn’t for the first 2 years I were like, I were like doing homework and 
 everything. 
Me:  So you were completely kept out of PE? 
Amelia:  We just used to play kiddie games and I didn’t like that.  You know like 
 those skittles that you get for kiddies parties, you got some of them 
 when you were allowed to have friends over to come and play it with us.  
 But now they don’t do anything, so I don’t do PE or anything. 
Harry:  One thing I have to do, I got a new head of PE one year, and we had to 
 persuade them, that football is a contact sport (laughs). 
 
Towards the end of the group I ask them to place the themes in order of importance to 
quality of life in OI.  Discussion took place, but the overall outcome was that being safe 
and careful, was the most important theme; followed by independence, then fear, with 
pain and reduced function of equal importance and isolation/being different as the least 
important theme. 
 
6.4.2 Focus group 2 
 
Six young people and ten parents were contacted via a letter for possible inclusion 
within the focus group.  Ten agreed to take part, but due to timing of the focus group, 
other appointments and travel to Sheffield Children Hospital, seven declined to take 
part for logistical reasons.  Focus group 2 took place in December 2011 and included 
two young people; a male aged 13 years, female aged 17 and one parent (mother), 
who had two children diagnosed with OI and had OI herself (See Table 6.2). 
 
The participants arrived and gathered for only a short time within a waiting area, but 
had not formally met only introduced themselves.  The focus group took place in a 
small room away from parents and partners, with the participants seated around a 
circular table.  Drinks and biscuits were made available, and the room was fully 
accessible, although all participants were ambulant without the use of equipment.  Two 
facilitators were present; one to record the focus group on DVD, set back from the 
group, the other to moderate the group was again sited more centrally. 
 
The duration of the focus group was 51 minutes.  The participants were quite chatty, 
but not over familiar.  All appeared comfortable talking about OI, not seeming to need a 
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warm up.  This group was less humorous then the previous, but the dynamics were 
different, with slightly older young people and a parent.   
 
This group followed a similar format to the previous group; main themes and sub 
themes were placed on the table to aid discussion and focus the conversation.  The 
first theme to be placed on the table was being safe and careful, which initially was felt 
important to older children by the parent in the group.  She felt that her children were 
currently too young (ages 5 and 6) to think about always remaining safe and being 
careful. 
 
Jenny:  A little bit yeah, how I feel sometimes, because obviously at the 
 moment it’s more me thinking for them I don’t think necessarily both my 
 children think “be safe and careful”. 
 
Conversely, one teenager felt she often thought about being careful, and that although 
she often wanted to take part in some activities, once she had considered the 
consequences, she decided not to. 
 
Juliette:  You always have to think of activities, and sometimes you might want 
 to do it, but then you have to think if you do it and something happens, 
 what are the consequences of what you have risked doing.  So like 
 when everyone else did ice skating and roller blading and I couldn’t do 
 it, and I know it just made you think, should I have done it and risked it, 
 but then you think it’s a condition that could get worse from that 
Sam:  I would have to say it is always like on my mind, but not like sort of at the 
 front, you know what I mean, sort of I am not always considering 
 everything but naturally after a while you just start…. 
Jenny:  It becomes human nature? 
Sam:  Yeah 
Juliette:  Emmm 
Sam:   You just get used to….. 
Jenny:  Emmm 
Sam:  And I think it would feel weird and a bit sort of riskier not to…..and just 
 like go  in for something, I don’t think I would enjoy it.  Because I am 
 used to now always thinking things through and sort of getting 
 everything organised so that hopefully nothing is to go wrong. 
 
The parent participant felt that her need to keep her children safe and be careful about 
what activities they took part in, had relaxed as a result of the bisphosphonate 
treatment they had received.  She felt previously she would have worried more about 
what they participated in, but more recently this worry had reduced. 
 
Jenny: And two years ago there is no way I would have done it, because they 
 were having break after break after break after break, but when you do 
 have time where there is sort of, a bit of a gap and things aren’t 
 happening all the time, you feel like, you become a little bit more relaxed 
 perhaps then……You know I want them to have the life that, you know, 
 other children have. 
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The second theme placed on the table was again reduced function.  Participants 
discussed the issues of tiredness and equipment, but the discussion didn’t move on to 
reduced function relating to fractures until the parent within the group mentioned it.  
This may have been because both the teenagers within the group had not suffered a 
bad fracture recently, they may not have remembered a time when their function had 
been severely affected by a fracture.  Conversely they may not have felt reduced 
function due to fractures had a large effect on their QoL. 
 
Juliette:  I think tiredness is quite, yeah, strong one, because you get tired more 
 easily like, if I was to go shopping for the day, I’ll have to have more 
 breaks than someone else who hasn’t got OI, because I’ll just get tired 
 easier.  
Jenny:   It’s just everything is all a bit too much really, especially towards the 
 end of  treatment, when they are ready for the next cycle it’s just, it does 
 seem to become quite apparent, it’s just you know, a lot more of a 
 struggle than what it is….. 
 
It was only the parent in the group that commented on reduced function after fracture, 
and talked about serious fractures, which within the OI population, usually means lower 
limb. 
 
Jenny:  Yeah, yeah and you know, sort of mostly so.  I think definitely reduced 
 function after fracture, especially if it is a serious fracture, erm, that can 
 be, have a big impact definitely.  
 
The third theme to be discussed was pain.  General aches and pains, pain relief and 
pain of fractures were suggested as sub themes which had been extracted from the 
previous interviews.  The majority of the discussion took place around general aches 
and pains and pain relief.  The parent within the group described having to give her two 
children some pain relief towards the time when their next Bisphosphonate treatment 
was due.  One teenager stated she always carried pain relief with her so she could 
take it if required. 
 
Juliette:  So I have took to carrying, like pain relief with me, everywhere I 
 go…….Just in case, then if any general pain comes, then I can just take 
 it, and then it slows it off.  
 
Comments were made about the effect of Bisphosphonate treatment on pain relief or 
the perception of pain and the need for pain relief on the run up to their next 
Bisphosphonate treatment. 
 
Sam:  Yeah, but then after that first treatment, everything was like feeling better 
 than normal, and then I got used to it, used to feeling good…..And then I 
 started to feel actual aches and pains…..That I wasn’t realising wasn’t 
 an ache and pain before, because it was all the time….. 
Jenny:  It was part of your life, yeah, you just felt that’s what it was all about.   
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Jenny:  I have to give Ellie and Tamsin, erm calpol, towards the end of 
 treatment, they do complain a lot about their legs aching.  
 
Fear was discussed amongst the group, but this centred around intervention and 
needle phobia, and fear of fractures.  All participants had experienced some fear of 
needles or needle phobia in their children. 
 
Juliette:  I’m petrified of needles when I have treatment, I’m horrible with it.  Like 
 I can’t have my Mum there when they put the cannula in, she panics me 
 more.   
Jenny:  really frightened, but I think, I don’t know obviously how old you two 
 were when you started your treatment, but I think they have got an 
 advantage now of being younger, because they are just used to it, and 
 when you are young.  I don’t know whether you are just, do you know 
 what I mean?  They, they have only been this year that they started 
 seeing that lady (psychologist) and talking through their needle therapy.  
 And more Ellie, but obviously Tamsin came along and just joined in, but 
 erm, no, now there is no worry, I mean they are still obviously it’s a bit 
 painful, you know, no one likes it….. 
 
I asked one teenager in the group if they felt they were scared of needles themselves 
or the pain produced by the procedure. 
 
Sam:  I think it’s a bit of both, because I know that they are gonna put it in and 
 then take it out again, because it has never gone in first time.  So you 
 know, I am just waiting for it to happen.    
 
Fear relating to fractures was described by the situation within which they occurred or 
the potential consequences of sustaining a fracture. 
  
 Moderator (M):  How about fear of fractures then? 
Juliette:  When it’s icy…..And you, you want to go out, but it’s if you slip, what 
 could happen  
 
One participant described a fear of hospitals, rather than a fear of the fracture itself, 
stating “It’s more the fear of hospitals, then pots, then might be having surgery……”.  
She also felt it was more the consequences of a fracture…. 
 
Juliette:  Cos it makes you think well if that happens then I’m gunna be behind 
 on college, and everything else is just gunna, it’s gunna have to affect 
 my Mum’s work and it’s just everything that’s gunna follow on after.  
 
None of the participants discussed any fear from handling or being handled or moved 
by another person.  This may have been due to the fact that the individuals within this 
group were mild to moderately effected and as a result were only perhaps handled by 
others during times of fracture. 
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Following the first focus group, the main theme entitled ‘being different’ was now 
described by the title ‘isolation’, as participants had appeared uneasy about its previous 
name.  Individuals within this second focus group still discussed feeling different from 
their peers stating “I think you just get treated different because you have OI”.   
 
Juliette:  at college they always try to, and like, like I don’t know, they just treat 
 you different cos you’ve got a condition, and with your friends, if you are 
 doing something and you, and you can’t do it properly, they’ll be straight 
 there like to help you.  
 
The parent within the group felt one of her daughters disliked being treated differently, 
or being singled out at school. 
 
Jenny:  She didn’t like that, cos I mean she was sat in this chair, and it supports 
 her spine, but the entire class basically threw themselves round her and 
 like oh my god, what’s this new thing.  And she hated it, she hated being 
 the centre of attention, err, but she does happily say ‘you know I can’t do 
 this because I’ve got brittle bones’.   
 
Another participant felt conflicted about being treated differently…. 
 
Sam:  And like you almost want them to treat you the same and then make the 
 little changes, not treat you completely differently and allow you to do 
 things the same as everyone else.  
 
Being different or isolation was discussed within the group, with reference to being 
separated from friends at break times, or teachers having to have their parents’ 
permission for everything that they wanted to do.  It was more closely linked with 
wanting to be independent and not appearing to be different within this focus group. 
 
Sam:  I think with break times, you do find that they seem to presume that 
 because you have OI, you can’t go outside and that you need to be 
 inside, and sitting down…..and they were like saying, but we have not 
 got your parent’s permission to go outside, and its like, why would I 
 need my parent’s permission to do what everyone else is doing, you 
 know, it’s just a seat but it’s outside and not inside, what’s the major 
 issue?  
 
All individuals within the group describe themselves or their children striving for 
independence and having a determination in their approach to life. 
 
Juliette:  It makes it feel like they don’t think that you can do it.  They are taking 
 it away from you, that you can’t do it, when I probably could, if given the 
 opportunity to do it.   
 
Juliette:  I think it’s because I’ve got OI, I’m more determined to do things.  
 Because I know I can do them, so I want to do them, because it’s 
 something I actually can do.   
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Jenny:  I’m blasted with a picture of her, she had got presents for her teachers, 
 three bags, and she’s very little and she is determined that she is 
 carrying these to school, all the way from the car.  They were getting 
 dragged on the floor, all sorts.  Putting them back down, starting again, 
 but she did it.  
 
Overprotection was described by the group.  One participant laughed when she stated 
her husband tells her when she is getting too over protective,  “…..like in the 
playgrounds and stuff.  Like, ‘for God’s sake you have to let them go’.” 
 
 Juliette:  I think my Mum has only just stopped being over protective.  Cos she 
  has now realised that I can make my own decisions and I’ve made them 
  quite good for the last year, but when I go out she’s like going, ‘who are 
  you with’, so that she knows exactly where I am…..She’s got to know 
  where they live, so that if anything did happen she’s there, she  
  can be there.   
 
The opportunity was taken with this second focus group to discuss the possible format 
of the potential quality of life measure; how they envisaged the questions or statements 
reading, the layout of the questionnaire, the possible Likert scale and the recall 
duration.   
 
Juliette:  ….and I think for children it should be easier to understand, like with 
 smiley  faces or cartoon characters….. I think it should be more of a 
 question.   
 
Sam:  I’d also say like a little box at the bottom of may be each question, where 
 you can put a little comment if you have got one.  
 
When asked about the recall period the parent within the group felt her children would 
remember a short time before, but not any great length of time.  She laughed when she 
thought about her younger child (age 5), stating she might only remember the day 
before, but felt her older one (age 6) would recall things better. 
 
Jenny:  yeah she would be able to reflect back, a little bit further, but not a 
 month, or even a couple of weeks really, you are talking about the last 
 5-7 days.  
 
The whole group felt that the questionnaire should remain neutral, not asking 
negatively phrased questions, or may be should include a balanced amount of both 
negative and positively worded questions. 
 
 Sam:  It needs to be neutral. 
Juliette:  Yeah, like a mixture of both…..if it is all negative, then they are just 
 going to think well, don’t they want to know what I can do? 
Jenny:  Yeah, you know what I can do, but then you think, well actually if this is 
 what I can’t do, it just gets back in your head, and you think oh God, you 
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 know, these things I have not thought about for ages and  (laughs) can’t 
 do that, can’t do that 
Juliette:  You don’t think about it because you can’t do it, and then you have to 
 sit there and go; oh well now I think about it I can’t do that.   
 
The overall feeling from this second focus group was that the questionnaire should 
include a balance of both positive and negatively phrased questions, so that those 
completing it do not feel upset about what they may not be able to achieve.  They felt it 
should have a recall period of no more than a week, as younger children and some 
adolescents would not be able to remember further back.  An area for further 
comments was suggested, but this may make the questionnaire too subjective and 
more difficult to compare before and after any intervention, for this reason this 
suggestion was not taken forward during questionnaire development. 
 
Discussion took place, but the overall outcome was that being safe and careful, was 
the most important theme; followed by independence, then fear, with pain and reduced 
function of equal importance and isolation/being different as the least important theme.  
This rating of importance is demonstrated in Table 5.3, where the necessary changes 
made to the main themes and sub themes are also detailed.   
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Table 6.3.  Overview of Main themes and sub themes following Interviews and Focus 
Groups 
Interviews (fig. 
5.2. Chapter 5) 
 Focus Groups  
Main Themes Sub Themes Main Themes Sub Themes 
Reduced 
Function 
Reduced function due 
to fractures 
Being safe and 
careful 
Avoidance of activities 
 Tiredness/fatigue  Trying to be safe 
 Equipment/adaptation   
Pain General aches & pains Independence Pushing for independence 
 Pain of fracture  Overprotection 
 Pain relief  Letting go 
Fear Fear of fracture Fear Fear of activity/handling 
 Fear of 
activity/handling 
 Needle phobia 
 Needle phobia  Fear of fracture 
Being safe and 
careful 
Avoidance of activities Pain General aches & pains 
 Trying to be safe  Pain relief 
   Pain of fracture 
Independence Pushing for 
independence 
Reduced Function Tiredness /fatigue 
 Overprotection  Reduced function due to 
fractures 
   Equipment/adaptation 
Being different Isolation from peers Isolation Isolation from peers 
 Being different  Being different 
     
   Isolation from PE 
    
 
  
Change made to item name or order of sub themes within the main theme 
category. 
 
Increased intensity of colour denotes less important theme. 
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6.5 Discussion 
 
The format of the focus groups varied in nature due to the different characteristics of 
the participants within the groups.  Focus group 1, with no parental influence was 
noisy, fun and had less structure.  The adolescents appeared to want to make a good 
impression with their peers, and therefore joking, laughing and story-telling took place. 
Previously concerns have been raised that children may be intimidated, adopting 
themes voiced by other members of the group (Lewis, 1992); this was not the case in 
focus group 1.  The second group had a different dynamic.  The one parent present 
within the group appeared to make it more serious, discussion still took place, but there 
was less camaraderie and story-telling.   With hindsight it may have been beneficial to 
run separate parent and adolescent focus groups, which may have reduced the serious 
nature of the second focus group, but this would have lacked the balance of opinion 
and voices from adolescents and younger children, even though the latter was via 
proxy.  Both focus groups appeared comfortable with the subject matter, and there 
weren’t any periods when conversation was difficult or long silences were apparent. 
 
Christensen (2004) states that children are often more comfortable in a focus group 
setting; conversation with their peers is very natural for them, whereas one-to-one 
discussions with adults may be more unfamiliar.  However children with OI have often 
spent a large amount of time with adults within a hospital setting, and as a result are 
often confident with adults.  The younger participants within this research knew the 
primary researcher as a physiotherapist within the Metabolic Bone Disease Team, so it 
is unlikely that they were fazed by either the one-to-one interviews or focus groups; the 
audio or DVD recording conversely was a new concept.    
 
It is important to remember that children’s vocabulary and use of language can be very 
different from that of adults, which if not monitored can lead to misunderstandings 
(Punch, 2002).  Children of 12 years and over have an increased ability to reason 
abstractly, solve verbal and mental problems and make decisions using deductive logic 
(Vaughn and Lill, 1990).  It is therefore beneficial, when planning to use focus groups 
with children, to spend time with them, learning about the way the child participants use 
language (Kortesluoma et al, 2003).  The primary researcher facilitating the focus 
groups works with children of all ages on a daily basis; as a result is aware of children’s 
language and vocabulary, encouraging comfortable flow and moderation. 
 
One member of focus group 1 was a little slower to settle in to the discussion, perhaps 
finding the outgoing nature of the other three members a bit overwhelming.  For this 
reason this focus group was more heavily facilitated in the initial phases, with the 
moderator feeling the need to direct questions to involve all participants.  Eventually 
everyone became more involved and comfortable, appearing to become empowered 
by the topic/process.  This individual may have been more comfortable with an 
interview type setting, but with a period of increased moderation they soon became 
more at ease.  
 
Porcellato et al (2002) used 12 single sex focus groups from six primary schools in 
Liverpool, UK.  Each focus group included 4-5 children (mean age 7 years), who were 
preselected, to ensure the involvement of a proportion of chatty children.  The 
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moderator was then given the responsibility of encouraging the shy children to speak 
out.  They chose to use the recording of the children’s voices on the tape recorder as 
an introduction and ice breaker, as several of the participants were inquisitive about it.   
The DVD recorder acted as an ice breaker in focus group 1; the participants were 
initially uncomfortable with its presence, but soon found it fun and began joking around. 
  
A child friendly repertoire of patience, warmth, humour and flexibility is suggested as 
suitable attributes for a focus group facilitator by Kennedy et al (2001).  Christensen 
(2004) stated she was happy to present herself as a friendly adult who was willing to 
share appropriate personal information and who wants to learn from children by 
listening to what they think and feel.  Her intent was to create a partnership rather than 
hierarchical relationship.  As the participants of both focus groups were familiar with 
working alongside the primary researcher in her role as a physiotherapist within the 
team, they were already aware and somewhat at ease with her as a moderator; a non 
hierarchical approach was adopted.  
 
Both focus groups were relatively small.  Vaughan et al (1996) had suggested small 
same sex groups for focus groups involving children, and with this in mind Porcellato et 
al (2002) recruited groups of four to five children of the same gender and age for their 
study to explore children’s perspectives of smoking.   
 
The focus groups within this study contained four and three individuals respectively.  
The intention was to use small focus groups of children with differing severities of OI, 
including approximately five to six participants.  Logistically this proved more difficult 
than expected.  Focus group one was a little easier to recruit to, as the participants 
were naive to the research and it was therefore not a necessity that they had taken part 
in the interviews within the item generation phase (Chapter 4).  However, focus group 
two involved participants who had already been interviewed earlier in the study 
(chapter 4), thus the number of participants meeting the inclusion criteria was 17.  As a 
tertiary centre, patients and their families travel from all areas of the UK; asking families 
to travel long distances outside of their appointment time would mean extra time away 
from school and work.  Attempting to gain a small group from this 17, who were willing 
to attend Sheffield Children’s Hospital for the focus group alone proved more difficult; a 
pragmatic approach was adopted and hence only three participants were involved in 
this second group. 
 
These scheduling issues were also described by Gibson (2007) who felt focus groups 
with children and young people can prove difficult; working around the school 
timetable, homework, exams, after school activities and geographical region (distance 
to travel) in relation to the venue of the focus group, all lead to difficulties within 
arranging the focus group (Gibson, 2007). 
 
Greenbaum (1988) suggest the use of single sex groups may be more suitable for 
some topics.  They state that younger children’s dislike of the opposite sex can hinder 
the discussion within focus groups.  Alternatively they note older teenager’s interest in 
the opposite sex can also have a negative effect on the group.  During both validation 
focus groups there appeared to be no negative effect caused by the nature of the 
mixed groups, the young people responded and interacted well with each other, without 
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appearing ill at ease when discussing topics alongside the opposite sex.  This may 
have been due to the fact the topic was quality of life, and not seen as sensitive in 
nature.  There are also mixed views within the literature with regard to friendship 
groups and the effect this may have on focus group dynamics.  Some authors feel that 
having a prior knowledge of peers can help with the discussion and comfort within the 
group (Watson and Robertson, 1996).  Others disagree; stating that peer pressure in 
groups of known individuals hindered the smooth running of the focus group 
(Spethmann, 1992).  None of the members of the validation focus groups knew each 
other prior to taking part, although the members of focus group 1 did meet informally 
for a short time prior to the group.  As a result of this, they had already begun talking 
and getting to know one another.  
The main aim of focus group one was to validate and triangulate the themes 
extrapolated from the 25 initial interviews and assess whether the group felt any 
important themes had been missed.  Both face and content validity were examined via 
this focus group method, as the adolescents were used as both representatives of the 
target population, and as experts within the field of OI, particularly when this disease 
was examined relative to a child’s QoL.   
French et al (1994) used focus groups in a similar way during their development of a 
childhood asthma questionnaire.  They used groups of children, with and without 
asthma, who discussed various aspects of their lives.  The themes of greatest 
importance were used to inform questionnaire items and the overall format.  A little 
later they used further focus groups to modify their questionnaire to other cultures. 
 
The decision of what format would be used to record the interview was a difficult one.  
Audio recording would have just required the use of one moderator, but concern 
around missing vital visual data, or confusing participants voices lead to the use of both 
audio recording and DVD recording of both groups.  This necessitated the need for two 
moderators, as a second was required to visually record the group on DVD.  The use of 
both recording media proved vital during transcription, particularly of focus group 1.  
This group contained three teenage girls and one teenage boy.  Geographically all the 
girls were from Yorkshire or Lancashire, and often discriminating between their three 
accents was difficult when using audio recording alone.  The use of the DVD recording 
enabled the researcher to be aware of which young person was speaking at any one 
time, and therefore improved the reliability of the data; although this resulted in a more 
lengthy transcription process. 
 
Hennesey and Heary (2005) state that the moderator’s role is three fold: 
 To make the group comfortable and at ease 
 To keep the discussion focused on the topic and keep all participants involved. 
 To ensure that an accurate account of the views of the group is captured. 
 
The groups appeared at ease with both recording media, and the use of the DVD 
recorder within the first focus group in some respects acted as an ice breaker. The 
participants were initially a little nervous about its use, but the moderator using the 
DVD recorder reduced any anxiety by introducing humour and encouraging the 
participants to feel at ease.  The group soon forgot about its existence and the focus 
group was recorded throughout. 
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Gibson (2012) found that the use of an audio recorder to record interviews or focus 
groups actually engaged the child participants, as they likened the process to those 
interviews they had seen on the television, and therefore elicited interest in the 
process.  They found allowing children to play with the recording media and play back 
what they had recorded, resulted in shared laughs and an enjoyable experience, 
therefore producing an increased desire to engage in the process. 
 
All six main themes uncovered from the initial 25 interviews were discussed within 
focus group one (See Table 5.3).  However, one theme not discussed during focus 
group one was ‘being different’.  The participants touched on the subject when they 
described being isolated from some activities and at those times when their peers had 
asked them about their OI.  This latter discussion appeared to revolve around fractures, 
and how easy it was to cause a fracture in someone with OI.  But also included 
discussion with peers around the pain of fractures and whether it was equitable 
between individuals with and without OI.  It is the view of the primary researcher 
following almost 20 years experience of working with children and young people that 
children, particularly adolescents, are keen not to be seen as different from their peers.  
The group appeared uncomfortable with the notion that they may feel different from 
their friends who didn’t experience OI, and this is in contrast to some of the 
adolescents interviewed.  One adolescent, who was previously interviewed, actually 
described being different from her peers, as she spent most of her waking hours within 
a wheelchair.  When this was brought up within focus group one, one participant stated 
that she felt that suggestion was weird.  I am unsure whether this contradiction was 
due to the nature of the perceived camaraderie or peer pressure within focus group, or 
just demonstrated the difference between individuals. 
 
Neither of the focus groups involved any friendship groups and therefore it is unlikely 
that peer pressure was completely to blame.  Spethmann (1992) felt that peer pressure 
was diminished in the focus groups they ran, when representative groups rather than 
friendship groups were used.  The participants were on the whole unhappy with the 
term ‘being different’, but comfortable when describing their isolation from activities and 
events with their peers.  As a result of this discomfort, there was a need to make an 
alteration to the conceptual framework, enabling it to become a true reflection of the 
views of the OI population (see Figure 5.1 and Table 5.3 for further information). 
The participants of focus group 2 appeared comfortable with the theme isolation 
(previously being different); participants used the terms interchangeably, the parent 
describing her children’s dislike of being treated differently, and the young people 
talking about their isolation from activities.  As a result of this, being different continued 
to remain a sub theme within the main theme, isolation. 
 
Discussion around being isolated when attending parties and not being able to do all 
activities that their peers could take part in, demonstrated a link between ‘isolation’ and  
‘being safe and careful’ within this group.  Several of the participants felt they didn’t 
attend parties when they were younger due to a need to keep themselves safe and 
avoid dangerous, busy areas, where they could be knocked.  A connection was also 
noted between tiredness and fractures, and tiredness and pain within this focus group.  
One individual (Harry) had struggled to separate tiredness and pain during his 
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discussions, and felt he rarely had one without the other.  These connections have now 
been updated within the revised conceptual framework (Figure 6.1). 
 
Two new further sub themes were also elicited by focus group one.  These were ‘letting 
go’, which was in turn closely related to ‘over protection’, and isolation or difficulties in 
participating in physical education (PE).  These two sub themes have now been added 
to the conceptual framework (Figure 6.1)(Also see Table 6.3 for more information). 
 
The theme ‘pain’ and it’s relation to fractures produced quite a dramatic effect within 
the majority of the focus group one participants.  They remembered their previous 
experience of fracture, how it had felt and what it sounded like.  This memory of the 
sound caused some participants to cover their ears, others pulled a face, cringing and 
shuddering their shoulders.  This joint experience and understanding brought the group 
together, negating much need for facilitation at that time.  Pain was also discussed 
within focus group 2, as they acknowledged the pain they saw in their children and the 
aches and pains they took pain relief to reduce. 
 
Fear of fracture or fear of the consequence of fractures (hospitalisation, immobilisation 
etc) was discussed by both groups.  Focus group one however, discussed needle 
phobia, which was not discussed to such an extent by focus group 2.  There was a 
discrepancy noted between the more severely affected participants and their more 
mildly affected peers, in relation to fear of handling.  The main participant to 
acknowledge this fear of handling and being handled was the most severely affected 
individual.  None of the other participants, in either focus group, commented on fear in 
relation to handling, but this may have been due to their lack of knowledge and 
appreciation of the need to be handled, as they had more independent function.  This 
theme may be important to incorporate within the questionnaire as it may demonstrate 
differences between subgroups and provide some measure of discriminative validity.  
For this reason the sub theme ‘fear of being handled’ remained an important aspect 
when describing QoL in children and young people with severe OI, negating its removal 
from the conceptual framework. 
 
There was one noticeable difference within the sample chosen to take part in focus 
group 1.  Three members had genetically had a spontaneous mutation leading to their 
OI, and therefore had no other family member with OI.  One participant (Harry) 
however, had a family history of OI, with his mother also having the diagnosis, and 
experience of living with the condition.  During their discussion about independence 
and parents/carers not letting go, Harry felt he had not experienced parental over 
protection, yet the other participants all commented on it in one form or another.  
Perhaps this first hand experience of OI had led his Mother to view the need to over 
protect slightly differently to the other parents.  This theme may also be important to 
include within the questionnaire; it was obviously an important issue for a large 
proportion of the focus group one participants, but may also demonstrate differences 
between respondents during questionnaire completion. 
 
The aim of focus group 2 was to further validate the previously uncovered items, but to 
also examine the thoughts and opinions around how the questionnaire should be 
formatted, what the recall period should be and how best to word the items within the 
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questionnaire.  Again all main themes previously uncovered were considered 
appropriate and valid for inclusion within the QoL questionnaire.  Several sub themes 
however were not picked up and discussed within this second focus group.  These 
included; reduced function associated with fracture, pain related to fracture and fear of 
being handled.  The lack of any discussion surrounding the first two sub themes may 
have been due to the composition of the group.  The two adolescents within the group 
were only moderately affected with OI, and neither had sustained a serious long bone 
fracture for a number of years.  This may therefore not have been seen as a high 
priority to those participants.  The parent within the group did not address either of 
these issues, and yet her children had previously had a number of serious long bone 
fractures, requiring immobilisation.  The lack of discussion around this latter theme may 
again have been due to the make-up of the focus group.  It is often younger children 
and those who are more severely affected that have to be handled or lifted on a regular 
basis by others.  As this focus group did not involve someone who was severely 
affected, this may have been the reason behind the exclusion of this topic. 
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Figure 6.1.  Revised conceptual Framework 
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The revised conceptual framework (Figure 6.1) is now an up-to-date reflection of the 
concepts relevant to QoL in paediatric OI, and their relationship between one another.  
For further detail on what changes took place following validation, between the 
interview and focus group processes refer to Table 6.3.  The conceptual framework is 
cyclic in nature, as this demonstrates the cyclic character of OI and how it affects 
individuals.  It is difficult to separate this circle of potential events, symptoms, attitudes, 
behaviours and their consequences, which in turn feedback into this cycle to reinforce 
an altered behavioural pattern and outlook.  Further qualitative research to validate this 
cyclic conceptual framework would be useful to further understand this process and 
strengthen understanding. 
 
Focus group two was also used to gather information regarding the format of the 
questionnaire, recall period, types of questions to be included and the scoring system.  
Walters (2009) suggests that initial literature review and interviews with the target 
population can be used to inform generation of the dimensions and then the items 
within a questionnaire. He goes on to state that following this, it is important to consider 
how the questionnaire will be administered, the choice of recall period, the format of the 
questions, type of response options and/or scoring system.  There is little information 
available within the literature to describe how best to take the list of previously 
generated items and turn them into well worded questions.  Some suggestions made 
by Walter’s (2009) are: 
 
 Make questions and instructions brief and simple. 
 Avoid unclear type faces. 
 Avoid questions which may be answered as ‘not applicable’. 
 Avoid potentially embarrassing questions. 
 Consider involving both positive and negatively worded questions. 
 
This transparent approach to questionnaire development is unique.  The participants 
within focus group two discussed several of the suggestions described above.  The 
parent of two younger children felt a recall period of any longer than one week would 
be too difficult for her children to remember.  She felt her younger child (age 5 years) 
would struggle to remember more than a couple of days.  Both adolescent participants 
felt a month was too long.  During the focus group, participants were asked to consider 
the use of positively or negatively worded questions, and how they felt about answering 
them.  Both adolescents felt the questions should be either neutral, or include a 
balance of both types of question.  No reason is given for this suggestion in Walter’s 
(2009), but a couple of the focus group participants described feeling quite down after 
answering a negatively worded questionnaire, stating it made them realise what they 
couldn’t achieve rather than identify what they were able to accomplish. 
 
The scoring system was not discussed at length during the focus group, but comments 
were made about the potential ambiguous nature of some Likert scales.  One individual 
did suggest the use of comment boxes to enable clarification of the chosen answer.  
This, although a valid suggestion, would provide very subjective open ended data, 
which would prove difficult to replicate when the questionnaire was repeated at 
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intervals over a long time period.  For this reason, comment boxes are not deemed 
appropriate for the newly developed measure. 
 
6.6 Strengths and Limitations 
 
A strength of this focus group phase was its ability to offer some validation and 
triangulation to the previously undertaken interviews.  Each of the themes/concepts 
uncovered from the one-to-one interviews were offered to the focus groups for 
discussion, allowing them, as a group, to approve or refute each one or provide 
possible missed concepts.  Allowing a naïve group of individuals from the target 
population to confirm the relevance and suitability of the concepts, strengthens the 
process and the content validity of the subsequent conceptual framework. 
 
The number of individuals within the second focus group was quite small; alongside the 
mix of a parent and two adolescents, this may have led to a less productive group.  
Logistical reasons led to the group being smaller than planned, and the composition 
including both parent and adolescents could have altered the mechanics.  With 
hindsight, it may have proved more useful to run independent parent and adolescent 
focus groups, this may have altered the dynamic within the second of the two focus 
groups, and the young people may have felt more relaxed and able to express their 
thoughts and opinions. 
  
A further limitation of this phase of the research was the lack of younger children within 
the focus groups.  The initial proposal included a focus group involving younger 
children, but this was not approved by the local research ethics committee, who were 
not happy to include the younger children within this phase.  The addition of a younger 
child’s focus group would have offered further strength to the conceptual framework. 
 
6.7 Conclusion 
 
Focus group methodology proved useful in validating and further enhancing the content 
of the previously developed conceptual framework.  It also allowed discussion of the 
format, Likert scale and recall time of the potential QoL questionnaire.  This 
methodology proved both engaging and suitable for young people.  The groups soon 
appeared to feel at ease, with all participants able to express themselves clearly.  The 
experience of the researcher in working with children and young people aided the 
smooth running of the focus groups.   
 
This distinctive approach of transparent methodology surrounding concept elicitation, 
validation and the ongoing development of the conceptual framework, to inform item 
and dimension construction is one of the strengths of this research process.  Revisions 
and updates have been made to the conceptual framework as a result of this validation 
process.  This revised framework can now be used as the basis for the dimensional 
structure of the OI specific QoL questionnaire. 
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Chapter 7 
Questionnaire and Item Development 
The following short chapter discusses and documents the development of the OI 
specific QoL questionnaire.  This phase is often not well reported within the literature; 
as a result information with regard to how previously uncovered themes and concepts 
are used to develop items and dimensions within a QoL questionnaire is unknown.   
The previously elicited concepts and themes uncovered during the interviews and 
focus groups led to the development of the conceptual framework (See Figure 6.1.      
Chapter 6).  This framework, alongside the terminology used by the participants, was 
then used to inform dimension and item development.  The subsequent approach 
taken to develop the QoL instrument is documented below.   
7.1 Background    
The development of disease specific QoL measures has increased over the last 
decade.  This increase has been driven by the limits placed on paediatric research, by 
the use of generic self-report and/or parent/proxy measures (Zeller and Modi, 2009).  It 
is often the lack of suitable disease specific tools to measure physical and emotional 
symptoms that has often been the driving force behind further tool development. 
A variety of approaches have been used to develop QoL measures including: adapting 
adult QoL questionnaires to suit the paediatric population (Landgraf, 2005); expert 
opinion, alongside discussion and extrapolation from literature (Zeller and Modi, 2009); 
interviews and focus groups with the target population to elicit themes (Bruce et al, 
2010); interviews and/or focus groups with healthy children (Stevens, 2010); or an 
iterative process involving several previously mentioned techniques to construct a 
population specific conceptual framework (Hobart et al, 2013). 
Further information on questionnaire development has already been documented in 
Chapter 2. The background information below details previous pieces of research 
documenting the development of QoL questionnaires. 
Previous papers written about QoL measure development are often not explicit about 
the methods they have used to transform the themes uncovered from interview, focus 
group or the literature, into dimensions and items for inclusion within the questionnaire 
Chaplin et al (2008) describes the use of focus groups with the target population and 
their parents during the development of their DISABKIDS Smiley questionnaire for 4-7 
year olds.  They state that statements are elicited from the focus groups which were 
then reduced to just six items, following a pilot phase.  No information is offered as to 
how these statements were chosen, and how they were transformed into items.  This is 
a common theme across several other questionnaires and QoL measures (Patrick et 
al, 2002; Ravens-Sieberer et al, 2006; Riley et al, 2004).  Some papers, similarly to 
Chaplin et al (2008), describe initial themes being structured into items, with minimal 
methodological information on how this was achieved.  Newly developed items may 
then be distributed to experts in a particular field, encouraging assessment of 
completeness, wording, face and content validity (Bruce et al, 2010).   
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Bevan et al (2010) combined the two modules of the Child Health and Illness Profile 
(CHIP) to produce the Healthy Pathways Child Report Scale, which enabled 
measurement of HRQoL across a wide age range (6-21 years).  Within their 
methodology they report refining and expanding the previously developed conceptual 
framework from the CHIP, but no information is given with regards to how this took 
place and whether the target population was involved in the refinement.  Many authors 
(Brod et al, 2014) are not open or transparent about item and dimension development 
often making large leaps within their methodology making reproduction almost 
impossible.  Others state initial versions are presented to a focus group including 
parents and children with first-hand experience of the specific disease in question 
(Parkin, 1997).  Corona et al (2011) describes using qualitative methods to elicit 
concepts, resulting in the documentation of an exhaustive list of new reoccurring topics.  
These are subsequently validated using medical expert opinion to decide which themes 
should be included. 
Once the dimensions and items are written, the order of the items and their readability 
needs to be assessed.  Reading the questions and answers out loud often uncovers 
poorly worded or confusing items, allowing revision.  Attempts should also be made to 
group similar items together within a dimension, to aid fluidity and reduce the need for 
patients to jump topics.  Some authors use focus groups or one-to-one 
interview/discussion with members of the target population to aid the development of 
the individual items or the response scale (Stevens, 2009).  Others develop several 
variations of the items or questions within their preliminary questionnaire, asking the 
target population for their opinion on the format, wording and available responses 
(Carton, 2013). 
Once the initial version of the questionnaire is complete, it is important to continue to 
evaluate and assess the content validity of the scale and the understanding and 
appropriateness of the items.  It is important to demonstrate that the respondents can 
both understand and interpret the items/questions in a consistent manner (Patrick et al, 
2011b).  Although this is the final stage of development and alteration prior to 
psychometric testing, questionnaires should be re-evaluated on a regular basis, as 
treatment options and patient perspectives change, and this may lead to an alteration 
in the understanding of the concepts (Basch et al, 2011). 
7.2 Method 
The combination of both top down (literature and experience) and bottom up (interview 
and focus group) methodologies used within this piece of work enabled the 
amalgamation of all the information (themes) uncovered.  The diagrammatic 
representation of the themes uncovered within the semi structured interviews was used 
to inform the overall concept.   As a result information was added to allow further 
development of the conceptual framework (See figure 5.2. Chapter 5).  Supplementary 
concepts were added to the framework following the focus groups, to further inform the 
process of questionnaire development and construction of the dimensions within it (see 
Final conceptual framework. Figure 6.1. Chapter 6). 
Themes were explored for connections/links and cross cutting.  Initial attempts were 
made to place the sub themes into three more generic headings; functional, emotional 
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and impact.  This was soon found to be an over simplified view of QoL in paediatric OI.  
From the final conceptual framework (Figure  6.1. Chapter 6) it can be seen that an OI 
specific QoL measure is required to meet the needs of the paediatric OI population, as 
no other generic measure included information on, or the effects of fractures or 
potential fractures on QoL.   This conceptual framework also demonstrates that the 
theme fractures cross cuts many other themes, further supporting this need for an OI 
specific measure.  This information was felt important to a child with a disease such as 
OI, where fractures, immobilisation with cast or splints and orthopaedic intervention 
was common place.   
Other generic QoL measures included items relating to avoiding risk, but these tended 
to be around risk taking behaviour rather than the need to be safe and careful to avoid 
fractures (e.g. CHIP-CE (Riley et al, 2004; MAPI, 2006).  Those children previously 
interviewed, their parents and health professionals (HPs), all described avoiding 
fractures by being safe and careful, avoiding crowds and making judgements about the 
consequences of their actions.         
The conceptual framework alongside the item generation and validation was then used 
to identify dimensions for the QoL questionnaire.  Changes that arose within the 
concepts as the study progressed and the relationship between these themes can be 
seen more closely in Table 6.3 Chapter 6. 
7.2.1 Dimensions and Items 
The main themes previously uncovered were directly placed as dimension headings.  
These were the most frequently discussed themes from the one-to-one interviews.  As 
previously mentioned (Chapter 6) the original theme ‘being different’ was replaced with 
the theme ‘isolation’, as this appeared more acceptable when discussed within the first 
of the two focus groups. Several of the individuals in the focus group denied being 
different to their siblings and peers, but were more comfortable describing the isolation 
they felt from activities, parties and other social settings. 
It was speculated that the master list of suggested QoL issues for children and young 
people with OI, generated from the one-to-one interviews would be used as potential 
items for inclusion within the OI specific QoL measure.  This list was exhaustive (see 
appendix 2) and would have lent itself to a very lengthy questionnaire.  Therefore items 
which were reported by all three groups (children, parents and HPs) most frequently 
were chosen for inclusion.  Where possible sub themes and the verbatim comments 
made by both interviewees and focus group participants were therefore used to 
construct the items within each specific dimension; aiding the content validity and 
overall understanding and acceptability of the questionnaire.  The choice was made to 
base the items on a description of frequency rather than severity.  This decision was 
made as the children within the one-to-one interviews and focus groups repeatedly 
described things related to how often they occurred and rarely in relation to how severe 
they were.  
Items such as avoiding crowds and busy areas, making judgements about activities 
and sports were moved directly into the dimension entitled being safe and careful.  On 
several occasions two items were used to describe a particular topic.  This again was 
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directed by the information uncovered during the interviews and focus groups, when 
participants had described similar situations or concepts in differing ways.  This could 
have been due to differences in age or experience across the participant group, 
severity of the individual or may have been the product of differing use of language and 
colloquial speech.  Where concepts or subjects had been described in two or more 
separate ways within the interviews or focus groups, it was decided several items 
would be created.  These items/questions may later be reduced following psychometric 
testing to achieve the most relevant and appropriate version. 
Where possible the wording used by the young participants within the interviews and 
focus groups was used to construct the items.  This was felt to improve the overall 
validity of the QoL measure, but also to make it more relevant to the target population.  
This increased relevance and therefore comfort would also hopefully aid completion 
and avoid unanswered ambiguous questions; leading to improved content validity of 
the final measure (Guyatt and Cook, 1994).  It would also encourage missing data to 
be kept to a minimum. 
Some themes were more difficult to construct and format into an unambiguous item.   
Occasionally it was difficult to grasp the essence of what a child had expressed during 
the interview and put it into a useful, readable format for an item. 
Item construction began towards the completion of theme/concept elicitation.  As the 
themes were uncovered, the verbatim quotes and evidence to support each theme 
began to become a question or incite an item.  Quotes such as “….and then it gets too 
busy, I’ll go into the library” and “I leave a few minutes early…..before people start 
pushing out of the classroom” become “I have to be more careful about the things I do” 
or “I go to quieter areas at school to keep me safe”.  Which after careful consideration 
and revision became; “Do you keep away from busy areas to keep you safe?” and “Do 
you keep away from crowds to keep you safe?” Some quotes were taken verbatim, 
documented in the format of a question and placed directly into the questionnaire. 
E.g. “I have to take a lot of rest breaks in the day” , became… 
 “Do you have to take rests in the day?” in the initial version  (copy located at the 
 end of this chapter). 
We chose to use a categorical response scale for scoring the questionnaire in the 
format of a Likert scale.  A frequency based category was developed as both 
interviewees and focus group participants discussed concepts, issues or feelings 
occurring; sometimes; always; often etc. rather than describing an intensity or severity.   
A five point Likert scale was developed as literature has demonstrated that participants 
completing a questionnaire can appropriately manage 5-7 response options (Streiner 
and Norman, 1995).  However, Stevens (2010) notes that eight year olds can 
accurately use a 5 or 7 point scale, but that younger children tend to use more extreme 
responses.  There is little evidence within the literature to suggest what recall period is 
suitable for children.  Previously developed questionnaires vary from present day ‘now’ 
to several weeks.  Discussion that took place within focus group 2 (Chapter 6) 
suggested that no longer than one week would be appropriate for younger children 
(age six years), and those older children would manage this recall length with ease. 
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Following the discussion and subsequent information uncovered within focus group 2 
(Chapter 6), it was decided where possible; to positively word the items as negative 
statements and wording had been described as disheartening and upsetting.   
To promote good item format and understanding it was felt important to ask the advice 
of two primary school teachers, with regard to readability and wording.  They were 
provided with a couple of examples of the items which were proving difficult to create, 
asking them if they could better construct and reword the item to aid the understanding 
of younger children. They were consulted on a couple of occasions, and this appeared 
to improve the readability of those items.  The primary researcher discussed the word 
‘activities’, with regards to the younger children and their level of understanding, but 
they both felt that this term would be well understood by all children of reading age.  As 
expected the term ‘over protection’ was brought up as a possible concern with regards 
to understanding; after lengthy discussion it was agreed that a suitable alternative 
could not be thought of and therefore ‘over protection’ remained within the 
questionnaire.   
Initial items were tested for reading ability on a small convenient sample of 6 - 8 year 
olds.  These included my children and a couple of their school friends, whose parents 
had shown an interest in the topic and were keen to help out. This process highlighted 
items which needed development or rewording. 
The children demonstrated no problems reading the overall questionnaire.  A couple of 
items were however difficult for them to understand, and they questioned what the item 
was trying to ask them.  One child (age 7) did question the phrase ‘over protect’, but 
this was readily explained by another child (age 8) within the group.  The word ‘fracture’ 
caused discussion, but they understood the term ‘broken bone’.  This may be due to 
the fact the children had no experience of OI, and none of them had ever sustained a 
fracture or broken bone.  Following discussion it was felt that children with OI would 
have an awareness of this term, but that close monitoring of such items would take 
place during pilot testing.     
Questions such as “Did you trust people to handle you well?” and “Did you worry 
someone would handle you wrong and cause a fracture?”, became “Did you worry that 
someone might move you wrong to cause a broken bone?” and “Have you worried 
about new people handling you?”.  After reviewing the first draft questionnaire, one of 
the primary school teachers suggested the question ‘Do the teachers at school allow 
you as much freedom as you would like?’ as an alternative to ‘over protection’.  
Following this advice the question “Do the teachers at school over protect you?” 
became “Do the teachers at school allow you as much freedom as you would like?”, 
but this was changed back following discussion with the children, who felt they 
understood the initial version without any concern.  However following discussion with 
clinical experts and fellow researchers (supervisors), this further question suggested by 
the primary school teachers to tease out information with regards to over protection 
and freedom, was then added at a later stage to ensure understanding and coverage of 
the themes uncovered in the concept elicitation stage.  
This process of readability testing did identify concerns with the initial Likert scoring.  
One child felt the initial version was too complex, and not sequentially how a child 
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would view their outcome options.  As a result of this discussion the Likert scale was 
reworded, in an attempt to improve understanding and readability.  They suggested a 
differently worded five point Likert scale (see below), which on reflection was far better 
than the initial (adult) planned version.  
Initial Likert Scale 
Always          Almost Always         Sometimes Almost Never  Never 
Likert Scale following changes 
Always          Most of the time          Sometimes      Not Much             Never 
 
This final version is included for reference at the end of this chapter, and is the version 
used to pilot on 25 individuals aged 6 - 18 years.  Previous versions are also available 
for reference in Appendix 7, ensuring transparency of the changes occurring to the 
items during this review and development process. 
7.3 Discussion 
If authors are not transparent about their methodology when developing items and 
dimensions it is difficult to determine whether the resultant questionnaire is suitable for 
the target population or specific disease.  Moreover, content validity is not ensured. 
Bruce et al (2010) describe a similar methodology to the one documented within this 
thesis in Chapters 4, 5 and 6.  They reviewed the literature and ran focus groups to 
uncover themes to develop their HRQoL measure in paediatric long-term 
anticoagulation therapy.  Once saturation had been reached the exhaustive list of items 
and their conceptual framework was given to a panel of experts (two Doctors, a nurse, 
a pharmacist) who then developed the HRQoL measure.  No description is provided as 
to how the measure is developed and therefore the process could not easily be 
repeated.  Our methodology attempted to be more transparent, using the direct 
wording from the interviews and focus groups, alongside the main themes within the 
conceptual framework as the basis for the items. 
Patrick et al (2011a) states the process between concept elicitation and testing of the 
instrument is its development.  This is an iterative process of drafting, evaluating and 
revising.  They state that selecting the content of an instrument involves comparing 
interview and/or focus group data, to literature and expert opinion. They go on to state 
that the language used within the items should be as close as possible to the language 
of the interview and focus group participants.  We chose to replicate this within our 
methodology and attempted to include the participant language from both the 
interviews and focus groups.  However as the OI specific QoL measure is for child self 
completion, we tried where possible to use the child’s interview quotes alone to 
populate the instrument, as using health professional or parental quotes would not 
have promoted high content validity for children. 
Corona et al (2011) also describes running a similar methodology to Bruce et al (2010); 
they used semi-structured interview questions which had been informed by the 
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literature, to elicit concepts from parents of children with early onset scoliosis.  These 
concepts were then rated by both expert and parental groups with regard to their 
relevance and subsequent inclusion within the early onset scoliosis questionnaire; they 
were also asked to provide any possible missing items or concepts.  This group do not 
detail how these revised items become formatted or organised within the instrument 
and we are left to assume that the list of items are imported directly into the 
questionnaire.  No information is given about the recall period or the potential Likert or 
appropriate rating scale.  Alternatively the methodology used to develop the OI specific 
QoL measure describes how several of the items were developed and adapted, and 
how a small group of young children and primary school teachers were used to 
improve the readability of the items and the suitability of the Likert scale. 
Shaikh et al (2009) developed their patient reported outcome measure for children with 
streptococcal pharyngitis slightly differently.  Their initial concepts were gathered from 
literature reviews followed by an expert panel teleconference to confirm items and 
discuss completion instructions, format and choice of wording.  These concepts were 
then discussed with 18 school aged children within an interview setting, where they 
were asked to rate the items.  The mean ‘importance’ of each item was then used to 
rank them; low ranking items were omitted.  Again they provide minimal information on 
how these items became questions or statements within the measure, negating 
understanding or reproduction of the process. 
Like other groups Brod et al (2014) used literature reviews, telephone interviews with 
experts and patients, and focus groups to inform the development of their conceptual 
framework, from which the items for their disease specific instrument was developed.  
They were not transparent about how the items were worded or rated, and if they had 
an external help in doing so. 
However several groups were more open about their methodology.  Edwards et al 
(2005) demonstrated excellent openness and transparency of their methodology to 
develop a crainiofacial-specific QoL assessment in adolescents.  They provided a 13 
step method highlighting how concepts were elicited, then transformed into items and 
later validated using cognitive debriefing.  They attempted to stay as close as possible 
to the wording uncovered from the interviews.  Parkin et al (1997) were also 
transparent about their methodology, allowing repeatability.  They generated items for 
the pool from the literature, peer interviews, parental and family interviews.  Item 
reduction took place with children and parents, who were asked to rank the importance 
of each item.  This reduced set of items comprised the basis for the first version of their 
questionnaire examining HRQoL in children with spina bifida.  Stevens (2010) 
interviewed over 70 children to elicit concepts and items for her health utility measure 
for school children.  She used the wording uncovered in the interviews as the basis for 
the QoL measure to ensure good content validity. 
These latter groups used appropriate transparent methodology ensuring good face and 
content validity, as opinion and feedback was sought from a relevant population at 
several stages during the development process.  This was also the aim of the 
methodology used during the development of the OI specific QoL measure.   
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7.4 Strengths and limitations 
Transparency throughout all stages of questionnaire development has allowed the 
children’s own thematic based quotes to be used as items within the OIQoL, 
encouraging high content validity and acceptability of the newly developed 
questionnaire.  Its readability, understanding and scoring format was assessed and 
improved with the help of a small sample of young children, to ensure suitability, 
comprehension and comfort across the younger age range.  This transparent process 
has not always been documented previously in studies describing the development of 
QoL instruments or patient reported outcome measures. 
Gaining the opinion and assistance of primary school teachers was a useful exercise to 
assess readability and aid the construction of some items which were more difficult to 
conceptualise.  Working with a small group of younger children to improve the 
understanding of the Likert scale was also a useful exercise and strengthened the 
newly developed questionnaire.  However using a small purposive sample of the OI 
population to rank the importance and relevance of the newly constructed items would 
have improved this process and increased both content validity and appropriateness of 
the included items. 
Gaining further understanding about the nature of the Likert scale would also have 
proved worthwhile.  Using the target population to assess the levels within the Likert 
scale would have enabled a greater understanding of the intervals between each level, 
and whether they were close to being equal.  This would have offered more validity to 
the Likert scale, which although is a set of ordered discreet items, having more 
information with regards to the behaviour of these items, or the nature of the items as 
perceived by the target population would have been beneficial. 
 
7.5 Conclusion 
The process undertaken to develop the disease specific QoL measure for children with 
Osteogenesis Imperfecta incorporated both top down and bottom up methodology.  
This enabled the views and opinions of both experts within the field and families to be 
incorporated alongside previous literature, ensuring content validity.  Previous studies 
have often taken a single approach only, either choosing to review the literature and 
develop the measure with the help of experts within the particular field, or to make 
adjustments to an adult based instrument.  This can lead to poor validity and the 
development of a tool which misrepresents the population it is attempting to measure. 
The use of a conceptual framework enables transparency and openness during the 
development, and allows review of the developers thought process and the actions 
taken during instrument or questionnaire development to be monitored and 
reproduced.  Many authors are not open or transparent about item and dimension 
development often making large leaps within their methodology making reproduction 
almost impossible.   
Following production of the initial version of a quality of life measure it is important to 
examine the acceptability, understanding, ease of reading and completion of the 
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measure on the target population.  To do this the measure needs to be piloted on a 
small sample from the relevant population, and post completion interviews undertaken.  
The following chapter describes this pre-testing process and any changes made as a 
result.  
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Version 1. OIQoL 
Being safe and careful 
 
 
Thinking about your last week 
 
 
 
 
 
Does someone give you extra help to keep you safe? 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you keep away from busy areas to keep safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you keep away from crowds to keep safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you try to keep safe to stop you breaking a bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you keep away from some activities to stop you having a 
broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you think before playing sports to avoid having a broken 
bone? 
 
 
Always Most of the time Sometimes       Not much Never 
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Reduced Function       
 
Thinking about your last week…. 
 
Have you felt tired in the day? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Have you felt tired by the end of the day? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you have to take rests in the day? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Has having a broken bone stopped you doing things? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Has it been more difficult to move around because of a 
broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Have you had to do things differently because of a broken 
bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you use equipment to help you to move around? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you have to use equipment to help at school or home? 
 
 
Always Most of the time Sometimes       Not much Never 
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Pain 
 
Thinking about your last week…. 
 
 
 
 
 
 
 
 
 
 
Have you had pain in your back? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Have you had pain in your legs or arms? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Have you had to take medicine for pain? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Have you had to take medicine because you broke a bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Did you have pain because you had a broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Have you missed meeting up with your friends because you 
had pain? 
 
 
Always Most of the time Sometimes       Not much Never 
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Fear 
 
 
Thinking about your last week…. 
 
 
 
 
 
 
 
Have you been worried about breaking a bone?   
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you get scared about doing something that might make 
you break a bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you worry about coming into hospital?   
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you get scared about needles? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Did you worry that someone might move you wrong and 
cause a broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Have you worried about new people handling you?   
 
 
Always Most of the time Sometimes       Not much Never 
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Isolation 
 
Thinking about your last week…. 
 
 
 
 
 
 
 
 
 
Did you see your friends outside of school? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Are you able to do everything your friends do? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Did you get to do lots of different activities? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Did you do PE at school?   
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you feel different because you have to be more careful 
than your friends? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Have people treated you differently because you have brittle 
bones?   
 
 
Always Most of the time Sometimes       Not much Never 
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Independence 
 
Thinking about your last week…. 
 
 
 
 
Did you like to do things for yourself?   
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Did your family encourage you to do things for yourself? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do you have as much freedom as your friends?   
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do your family let you make your own decision about what is 
safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do the teachers at school over protect you?   
 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do the teachers at school stop you doing things that you think 
are safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Do your family let you choose your own activities?   
 
 
Always Most of the time Sometimes       Not much Never 
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Chapter 8 
Pilot of pre-testing of the initial questionnaire 
The aim of the pilot study was to examine the instrument development process, to 
assess the patient’s understanding of the initial draft instrument and address any need 
for alterations and revisions.  This chapter aims to identify any need for further 
questionnaire development and make an early assessment of validity and reliability. 
8.1 Background 
Smith et al (2005) state that best practice guidelines should be followed when 
developing questionnaires, items and response scales.  The questionnaires should be 
simple and clearly phrased to minimise ambiguity and bias; include easy to follow 
instructions; incorporate a short time frame, and have mutually exclusive response 
options.  
Patrick et al (2011b) describe the pilot stage taking place following initial instrument 
development and item crafting, during the concept elicitation process.  They go on to 
describe the need to assess whether the questionnaire captures those aspects that are 
important to the respondents, and whether the respondents understand how to 
complete the instrument.  The background literature related to the pilot testing of newly 
developed QoL questionnaire and PRO measures has already been discussed in 
Chapter 3, the following information describes research studies detailing the pre-testing 
or pilot testing of newly developed instruments, and how previous authors have 
undertaken this process. 
Smith et al (2005) report several methods which can be used to assess a participants’ 
understanding of the items within a newly developed questionnaire.  Techniques such 
as asking the respondent to rephrase the question as they understand it; or asking 
respondents to think aloud as they complete items; or after each item, asking the 
respondent how they arrived at the particular answer that they chose, can be 
employed.  These methods are felt difficult to employ with participants who have 
dementia (Smith et al, 2005), and therefore would be more difficult to undertake with 
younger children.  Observing children completing the questionnaire is an easier method 
from which to gain information and feedback about its suitability and ease of 
completion.  This would enable feedback without the children struggling to find the 
vocabulary to describe what they think the question is asking them.  During completion 
they could be asked what they are thinking, why they have paused on a particular item 
or why they feel it took them longer to answer some items.  This will also encourage 
feedback and information without the subjects feeling compelled to be positive. 
Groenvold (1997) describes using a short ‘debriefing form’ following questionnaire 
completion with a group of 14 breast cancer patients.  This included questions such as; 
how long had it taken to fill in the questionnaire; whether they had received assistance 
from others in completing the questionnaire; whether any items were confusing or 
difficult to respond to; whether any items had been upsetting; and whether they had 
any further comments.  Within a sample of adult patients this may work well, but with 
children would be more difficult to achieve.  This is a useful method, and less time 
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consuming than face-to-face interviews, but does not allow any observational data to 
be recorded and may be open to acquiescence bias, as respondents attempt to be 
over positive about the questionnaire and over confident about their ability to complete 
it.  Others have used post completion cognitive interviews with the target population to 
ascertain understanding, readability, comfort and suitability of the newly developed 
measure, prior to psychometric testing and item reduction (Gorecki et al, 2013). 
A semi structured interview guide can be used to keep the cognitive interview on track, 
encouraging a four stage process (Tourangeau, 1984).  The interview should aim to 
gain insight into: 
  The understanding of each question/item, 
  The information that the subject can pull from memory, 
  The judgement the subject is making about what information is required, 
  How the subject forms their response. 
Shaikh et al (2009) used post completion interviews with eleven school aged children 
during their development of the patient reported outcome measure for children with 
Streptococcal Pharyngitis.  They questioned the children about any difficulties in 
understanding instructions, or understanding the meaning of each item.    
Questions can also be asked about the recall period; in our instance, is it possible to 
think back over the last week about symptoms or problems?  Is this time period too 
long or too short?  Observations of respondents having difficulty remembering back 
over the last week, or doing this with ease should be documented.  If respondents do 
not understand a question, or the question is ambiguous is any way, respondents may 
choose not to complete it.  Questions or items can also be missed if the respondent 
feels uncomfortable with the subject matter, or feels they do not want to answer due to 
the nature of the question.  Smith et al (2005) reported an acceptable questionnaire 
would have less than 5% missing data and there would be less than 10% floor or 
ceiling effects noted on summary scores.   As a result of this pre-testing changes and 
improvements can be made to the newly developed questionnaire. 
It is of course not possible to address all the issues or suggestions raised by the 
subjects, although it is important to demonstrate that the questionnaire is 
understandable and relevant to the target population.  When an item is revised it is 
important to document this process, being transparent about why and how the changes 
were made. QoL instrument development does not take place in a linear fashion; the 
process is iterative, involving ongoing modification and validation.   
Several groups have used a pilot or pre testing phase to gain some insight into the 
acceptability and psychometric properties of the initial version of their newly developed 
questionnaire.  Shaikh et al (2009) during their development of a patient reported 
outcome measure for children with a streptococcal pharyngitis examined inter-item 
correlations and Cronbach’s alpha for their scale to determine whether the scale 
reflected the same construct.  Inter-item correlations of less than 0.2 and Cronbach’s 
alpha greater than 0.7 was considered to demonstrate good internal consistency. 
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Brod et al (2014) developed a disease specific measure to assess the impact of growth 
hormone deficiency treatment in adults.  During their validation phase, immediately 
following cognitive debriefing, they measured validity by using their newly developed 
tool alongside previously developed well known measures.  They examined the level of 
missing data, floor and ceiling effects, item-to-total and item-to-item correlations to 
inform item reduction. 
Tsakos et al (2012) used psychometric analyses on their SOHO-5 instrument, which 
involved assessment of internal reliability (Cronbach’s alpha, item-total and inter-item 
correlations), alongside evaluation of content and face validity.  The latter were based 
on patient comprehension of the questions and expert review as to whether the 
questionnaire covered what had been discussed within the previous item generating 
focus groups.   
Although some psychometric analysis is undertaken in the pilot stage, early item 
reduction when patient numbers are relatively low, is usually based on the judgement 
of the investigator.  The latter stages when psychometric methods are undertaken with 
larger patient numbers, allows more scope for item reduction (Fayers and Machin, 
2007). 
8.2 Method 
Twenty five children aged 6-16 years took part in the pilot phase of questionnaire 
development.  The sample was purposive for age and severity of OI.  The participants 
were sampled from those attending a tertiary Metabolic Bone Disease Clinic at the 
Sheffield Children’s Hospital, UK for treatment or active monitoring.  Patients were 
excluded if they had already taken part in phase 1 of the study (Chapters 5 and 6), if 
they had an unknown diagnosis or did not consent.    
Patients were initially approached via post with an invitation letter and reply slip (see 
appendix 3) detailing the study.  Potential participants were made aware that this study 
was multi-faceted with three phases and that they may be approached for inclusion to 
other phases of the study.  An information sheet (appendix 4) and consent form (see 
appendix 5) were included in the mail out.  Those patients who expressed an interest to 
take part in the study were given the opportunity to discuss the study further and ask 
any questions, during their next visit to SCH.  A quiet area, away from the hustle and 
bustle of usual hospital life, was arranged for the visit. 
Informed consent was gained from the parent and written assent from the patients 
under 16 years of age.  Young people aged 16-18 years could consent to take part, but 
consent was also sought from their parent or carer.   Consented individuals received a 
copy of their consent/assent form for their records.  
Each of the 25 children and adolescents were asked to attempt to complete the newly 
developed OI specific QoL questionnaire (OIQoL).  Although the questionnaire was 
developed to be self-completed, parental supervision was allowed and often dependent 
on reading age and ability of the child.    
Completion of the questionnaire was observed by the primary researcher (CH); any 
help required was recorded, alongside the type and amount of help provided.  Notes 
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were taken by the researcher, identifying and recording questions which were asked, 
comments that were made, pauses that took place, and any facial expression 
indicating confusion.  Where respondents required additional help this was gained from 
their parent or carer.  If items/questions were deemed particularly difficult questions 
were directed towards the researcher, and discussion took place.  The notes made by 
the researcher and any reflections made were documented.  Completed questionnaires 
were retained by the researcher, and the answers obtained were input into an Excel 
spread sheet to aid statistical analysis. 
Following completion of the questionnaire participants were asked to provide feedback 
in the format of a post completion interview.  These were semi structured in nature and 
a schedule was used to guide the interview (see Appendix 6), encouraging the 
respondent to describe and evaluate their experience of completing the questionnaire.  
Subjects were asked questions such as:  
 What did you think about the questionnaire?  
 Was the questionnaire easy to answer?  
 Were there any questions that you did not understand?   
 Were there any questions that did not make sense?   
 Were there any questions that you did not like or didn’t want to answer?   
 Did any questions upset you?   
Respondents were then given the opportunity to suggest any changes and/or 
improvements to the questionnaire or the individual items within it.   
The interviews were audio recorded and transcribed verbatim.  The transcripts 
underwent framework analysis, looking to identify reoccurring themes and therefore 
issues with any items within the questionnaire, the wording or format of the overall 
questionnaire.  Common problems were examined and documented, allowing changes 
and improvements to be made to the questionnaire as a result. 
SPSS (version 20) was used to examine some simple psychometric properties of the 
initial version of the questionnaire.  Any patterns within missing data were documented; 
if items were regularly not completed, this may indicate an issue with a respondent’s 
understanding of the item, or comfort around its completion.  Floor and ceiling effects 
were examined for each individual item, although causal items related to symptoms 
were noted.  Cronbach’s alpha scores were used to analyse reliability of the 
questionnaire, examining the internal consistency between items and the overall score 
for each dimension and the questionnaire as a whole. 
 
8.3 Results 
The first twenty five individuals approached to take part in this phase of the study 
agreed to do so.  The participants range from 6 to 16 years and included eleven boys.  
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There was mixed severity of OI including; eight children with mild disease; twelve 
children who were moderately affected and five children with severe disease.  Seven 
children required help to complete the questionnaire, and these participants were those 
younger children aged 6-10 years (see table 8.1).  This help included reading the 
questionnaire, discussing the most appropriate answer, providing examples of activities 
or situations which had arisen over the last week to support the item in question and in 
one case, encouraging ongoing completion towards the end of the questionnaire. One 
parent commented that: 
 Mum (PS1):  I think it’s appropriate that somebody is with him so that you can 
 explain some of the questions, because sometimes you might have, you think 
 it’s one answer, but when you read the question again, you’re doing the wrong 
 answer…..it’s  just a case of not reading it too quickly.  
All twenty five participants managed to complete the whole questionnaire (39 items), 
and all twenty five agreed to take part in the post completion interview.  Interviews 
ranged from 2 minutes 49 seconds to 7 minutes in length.  Each completed 
questionnaire was coded numerically from the Likert scale (Always = 1, Never = 5) and 
the scores were input into SPSS to allow statistical analysis.  Raw scores were then 
transformed to a 0-100 scale; taking into account those items which are reversed 
scored (items Q27, Q28, Q29, Q30, Q33, Q34, Q35, Q36, Q39).  To achieve this items 
which are reversed score were recoded.  Item scores were then added together to 
produce dimension scores, which were subsequently transformed to a 0-100 scaled 
score. 
The mean age of the participants were 14.0 years and ranged from 6 to 16 years, 56% 
(14/25) were female, 32% (8/25) had mild OI, 48% (12/25) had moderate OI and 20% 
(5/25) had severe OI,   28% (7/25) had help to complete the questionnaire. 
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Table 8.1.  Characteristics of the sample (n=25) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.3.1 General reflections 
Overall the questionnaire was well received.   
 Me:  What did you think about the questionnaire then? 
 PS1:  They were brilliant. 
 Me:  Was it easy to answer? 
 PS1:  Emm, most of the time (boy, aged 7) 
 
 Me:  What did you think about the questionnaire? 
 PS12:  Yeah, it was good? 
 Me:  Was it easy to answer? 
 PS12:  Yeah (girl, aged 16) 
  
Some of the younger children found concentrating on its completion more difficult, 
becoming a little bored towards the latter pages.  Those older children appeared able 
to remain focused throughout and were enthusiastic.  Some of the teenagers were 
Participant Age Severity of OI Sex Help Given 
PS1 7 Mild M Yes 
PS2 8 Mild F Yes 
PS3 10 Mild F No 
PS4 13 Moderate F No 
PS5 8 Moderate F No 
PS6 6 Severe F Yes 
PS7 10 Moderate F No 
PS8 14 Moderate F No 
PS9 8 Moderate F No 
PS10 8 Moderate F No 
PS11 10 Moderate M No 
PS12 16 Mild F No 
PS13 8 Mild M Yes 
PS14 9 Moderate F Yes 
PS15 14 Mild M No 
PS16 15 Moderate F No 
PS17 12 Moderate M No 
PS18 6 Severe F Yes 
PS19 10 Moderate M Yes 
PS20 14 Severe F No 
PS21 8 Moderate M No 
PS22 15 Mild M No 
PS23 9 Mild M No 
PS24 10 Severe M No 
PS25 11 Severe M No 
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happy for the diversion from the mundane visit for a four hour infusion.  A couple of the 
older participants PS12 and PS16 asked if they could complete their questionnaire 
away from their parents, as they would be nosy.  This was allowed as on both 
occasions and the parents were happy to do so.  One parent showed good insight into 
her 13 year old daughter when she commented; 
 Mum (PS4):  …..I think some kids might not tell the truth in front of their parents.   
Most pauses took place when participants attempted the questions surrounding 
fractures in the last week (items Q10, Q11, Q12), and those which described pain 
(items Q18, Q19).  Occasionally this was due to participants rushing in and completing 
the question before considering if the fracture or resultant pain had actually occurred in 
the last week.   
Discussion took place around several items; those previously mentioned relating to 
fractures and/or resultant pain (items Q10-12, Q18, Q19), but also some later items 
within the questionnaire.  Younger children often had a discussion around items within 
the isolation category, as parents commented on their chosen answers and this 
sparked discussion and explanation of their choice.   
 Mum:  ……I think your (points to Son) interpretation of the questions isn’t 
 always the same as mine (laughs)…. 
 Me:  Or the answer?.... 
 Mum:  Or the answer for that matter (laughs) 
 
Older children often discussed items within the independence dimension, as they were 
pushing for more independence, a reduction in any over protection and to be like their 
friends.  Many children confirmed what equipment should be included in items Q13 and 
Q14, but were happy to complete the item once they had verified a certain piece of 
equipment could be included. 
One of the eight year old girls was very mature in her approach to completion.  She 
read each question carefully in her head and then thought about the answer before 
marking it down.  She had attended hospital with her Dad, who did not offer any help 
with questionnaire completion, so her understanding was checked on a couple of 
occasions, but it appeared to be fine.  She was at ease with the topic, although did joke 
about how long the questionnaire was and how many pages there were to complete. 
The youngest child to complete the questionnaire was a 6 year old girl.  She had good 
reading ability and understood what was asked of her.  Her Mum had initially asked her 
to read out the questions, but she was quite self conscious and eventually completed it 
herself with Mum looking over her shoulder.  When she came to the isolation 
dimension, she did state that some of the items were quite hard, and although she read 
them with ease, she seemed to take longer deciding on the answer.  She appeared a 
little distracted when she completed the independence dimension (the last dimension in 
the questionnaire), and when interviewed post completion, she did think the 
questionnaire was too long, but her Mum felt the length was fine. 
 Me:  What did you think to the questionnaire?  You can be honest? 
 PS6:  Erm, I thought it was good. 
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 Me:  Did you think it was a bit long? 
 PS6:  Erm, yes (laughs) 
 
Several of the girls (PS2, PS3, PS7, PS8, PS12, PS16, PS20) were very enthusiastic 
to take part in the study, a couple were even keen to know how the questionnaire had 
been developed and what other children with OI felt about having the condition (PS,19, 
PS20).  One young girl aged 6 had attended with her Nana, who one thought would 
have wanted to stay with her during completion.  This was not the case and when help 
was required, this was offered from the researcher.  
There was only one participant (PS9) who stated they felt upset by the questionnaire.  
She had completed the first four sections with ease, but disliked the dimension entitled 
‘isolation’.   
 Me:  Were there any questions that you didn’t like or you didn’t want to answer? 
 PS9:  Yes (girl, age 8) 
 Me:  Which ones didn’t you like? 
 PS9:  The ones about my friends and what I can’t do. 
 Me:  Why did you not like those? 
 PS9:  (quietly) I felt sad. 
 
She had continued to complete the rest of the questionnaire, and Mum reported she 
was often a little teary about being different from her friends.  This participant was 
given the option to stop the questionnaire when she became upset, but she and her 
Mum felt she would like to complete it.  
One child (PS24) had difficulty reading the print (font size 12).  Although his eyesight 
was corrected by glasses, the correction was not good enough for him to read the 
small print.  This sparked discussion about his local school being very supportive and 
providing all his reading material in large print.  In this instance his Mum chose to read 
the questionnaire out loud to him, but this issue may need remedying in the future, and 
a copy could be made available for children and young people who require a larger 
print.   
8.3.2 Being safe and careful 
This section was completed with ease by all of the participants.  One young boy (PS1) 
asked his Mum about ‘crowds’, and once she gave an example of a crowd, he 
confidently answered ‘never’ on the Likert scale.  This demonstrated a discrepancy 
between ‘crowds’ and ‘busy areas’, as he had stated he always avoided busy areas.   
A second participant also showed a tendency to prefer the item about busy areas, 
although he didn’t ask any questions, he answered this item much quicker than the 
item about crowds (PS19).   
Some participants discussed the need to leave lessons early to avoid busy areas, 
which demonstrated good content validity, as this sub theme had arisen several times 
within the interviews and focus groups in phase 1 of this study (Chapters 5 and 6). 
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One 9 year old participant (PS14) asked about item Q6, which stated ‘…do you think 
before playing sports to avoid having a broken bone’.  Once we had discussed this and 
I had given her an example, she answered it with ease. 
A further 14 year old boy with mild disease (PS15) asked about what I meant by 
‘keeping safe’.  He is mildly affected and very active.  Once I explained what this 
meant, he immediately answered ‘never’ on the Likert scale.   
8.3.3 Reduced function 
This section proved more complicated to answer for two reasons.  Firstly it talked about 
broken bones; and secondly whether a broken bone had resulted in any reduced 
function.  
In the last week….. 
Item Q10:  Has having a broken bone stopped you doing things? 
Item Q11:  Has it been more difficult to move around because of a broken bone? 
Item Q12:  Have you had to do things differently because of a broken bone? 
The time scale for the items continued to be ‘In the last week…..’, but several 
participants (PS1, PS3, PS4, PS5, PS6, PS8, PS10, PS11, PS17, PS18, PS19, PS21, 
PS22, PS23, PS24) struggled with this concept, often forgetting to just think about the 
last week.  The above participants rushed into completing these item, potentially 
immediately thinking about the last time they had sustained a fracture, rather than 
whether this fracture had occurred in the last week.  These items lead to a lot of 
discussion and reminders of the time scale, often participants had to be encouraged to 
go back and rethink an item considering only the last week.  The primary researcher’s 
sensitivity to issues arising from these items was improved by previous knowledge of 
the participants and their recent fracture history. 
 Me:  Was it easy to answer? 
 PS11:  Some of the questions were easy and some of the questions were hard 
 Me:  Which ones were hard? 
 PS11:  Err, like erm, oh I’ve forgotten what they were now 
 Me:  Have a look 
 PS11:  Oh, like, erm, ‘do you find it hard when you erm, like when you move 
 around’, because it’s like from last week, so it’s quite hard to think like, oh I 
 forgot about that and then you have to cross it out and stuff 
 
Three of the participants who correctly answered these items without hesitation or 
questions, were the older participants (PS12, PS15, PS16).  Several others had no 
issues with these three items, as they all had a current fracture at the time of 
questionnaire completion (PS7, PS9, PS13, PS14, PS20).  For this reason the items 
were potentially answered with little thought given to the time scale. 
This dimension also included items relating to the use of equipment to aid function. 
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In the last week….. 
Item Q13:   Do you use equipment to help you to move around? 
Item Q14:  Do you have to use equipment to help at school or home? 
A few participants asked me to confirm what equipment should be included (PS4, PS5, 
PS12), and one felt a short list of equipment to aid their memory would be a good idea 
(PS5).  All other participants completed these items with ease, although discussion was 
often sparked between what equipment the child did use in school; had access to in 
school and at home; and what they actually chose to use.  Parents often thought that 
children were using prescribed equipment in school, when actually their child had 
chosen not to use them, but had not made their parents aware of this.  
8.3.4 Pain 
This dimension appeared to be answered well by most participants, although it did 
include items which talked about fractures within the last week, and these items were 
where participants had more problems. 
In the last week….. 
Item Q18:  Have you had to take medicine because you broke a bone?  
Item Q19:  Did you have pain because you had a broken bone? 
Some participants (PS2, PS3, PS6, PS15, PS18, PS24) needed to be reminded again 
about the time scale around the above two items.  Once a discussion had taken place 
about when they had sustained their last fracture, they were then able to answer the 
items with ease.  These items were problematic for fewer participants than the fracture 
related items within the previous dimension (reduced function).  This may have been 
due to those discussions about the time scale already taking place during completion of 
this previous dimension.  Again those participants who had sustained a recent fracture 
had no problems with items Q18 and Q19. 
One 10 year old boy made comment about the inclusion of items related to pain in his 
back and legs (items Q15 and Q16).  He felt these symptoms were ‘just like him’, and 
again this demonstrates some content validity from the subthemes uncovered within 
the interviews and focus groups in phase 1 of the study (Chapters 5 and 6).  
Two of the participants talked openly during completion about playing or meeting up 
with their friends (item Q20).  One 6 year old girl (PS18) with severe OI described 
always being able to play with her friends in the garden, but that her friends always 
altered their play to suit her, and often played with dolls on the floor.  The second 
participant to discuss meeting up with her friends (PS14) stated that she didn’t meet 
them outside of school for two reasons; they did not follow the same culture as her, and 
her Mum had reduced trust of other parents being able to deal with potential fractures 
and what may constitute as a risk for her. 
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8.3.5 Fear  
This dimension was well completed and there were minimal questions and discussion 
related to items within this section. 
This dimension includes items which refer to handling and lifting of children and young 
people with OI.   
In the last week…..  
Item Q26:  Have you worried about new people handling you? 
The third participant to complete the questionnaire (PS3) was a 10 year old girl, who 
was mildly affected with OI.  She stated that she didn’t want a stranger handling her 
(referring to item Q26), and I wondered whether she had understood the question, as it 
is not often necessary for a child with mild OI to be handled or lifted unless they had a 
fracture.  This subject was not pursued during the interview, as discussions around 
what was socially acceptable handling were not relevant to the research.  
Children and young people with severe OI however, are often ‘handled’ or ‘lifted’ as 
they are non ambulatory, and require this additional support to transfer.  One 14 year 
old who was mildly affected (PS15) actually asked why he would need to be handled 
and this lead to a discussion about more severely affected individuals.  This was not an 
issue for any other participants when completing this dimension.  All other items within 
this dimension were answered with ease.   
8.3.6 Isolation 
The younger children were not sure what was meant by ‘isolation’, and had to have this 
term explained by parents or the researcher (PS1, PS13).  This dimension was 
previously entitled ‘being different’, as several of the interviewees from phase one 
(Chapter 5, Item Generation) of the study had described themselves as being different.  
However, when this was presented as a sub theme to focus group participants, they 
were uncomfortable with the terminology, and hence the term ‘isolation’ had been 
chosen as an alternative.  
Some parents commented on the fact that they hadn’t realised how their children felt 
about having OI until they had completed the questionnaire, and referred particularly to 
this dimension.  This again is a strong argument for the need to gain self completion of 
a patient reported outcome measure, and further demonstrates the possible reduced 
validity of questionnaires answered by proxy alone. 
Item Q32 produced some discussion amongst parents and their children.  This item 
asks; ‘Have people treated you differently because you have brittle bones?  One parent 
questioned how truthful his 13 year old daughter (PS4) had been when she had 
answered this item.  Another teenage girl (PS12) admitted she had experienced some 
bullying, both at school and in her neighbourhood, as a result of having OI.  One 10 
year old (PS19) reported that he was occasionally isolated from his friends when they 
were doing contact sports, but that they often adapted the game to allow him to join in.    
Item Q30:  Did you do PE at school?   
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This item was found to be the most problematic item within this dimension.  PE is an 
activity that is done in school, and therefore if you complete the questionnaire during 
your school holidays, your reason for not doing PE is not related to isolation, but to 
logistics.  This was discovered by two participants during their completion (PS9, PS10).  
This item obviously required change prior to psychometric testing. 
Item Q29: Did you get to do lots of different activities? 
The majority of children completed this item with ease and didn’t require any additional 
help.  One of the younger participants (PS6), a 6 year old girl with severe disease, did 
however disagree with her mother when she completed this item.  She stated that she 
didn’t do many things, but her Mum corrected her with quite a list of activities that she 
took part in each week.  This was not an area of concern for the other participants, but I 
am unsure as to whether she answered this way because of feeling different from her 
friends, or whether she was just quite young and lacked understanding or the ability to 
compare herself to her peers or siblings. 
Item Q28:  Are you able to do everything your friends do? 
All participants except one (PS20) completed this item with ease.  This 14 year old girl 
attends both mainstream and special school education, due to her severity of OI.  She 
felt it was difficult to answer this question well, as she was more able than many of her 
friends in special school, but less able than those in her mainstream school.   
8.3.7 Independence 
Item Q37:  Do the teachers at school over protect you? 
Three children asked what over protect meant.  Two boys aged 7 and 10 (PS1 and 
PS24) and a 9 year old girl (PS2).  One Mum used the analogy of ‘being wrapped up in 
cotton wool’.  In one instance (PS23) the description of ‘over protect’ produced 
discussion about the teachers at school; although he felt they tried to over protect him, 
after he had discussed things with them they often agreed to allow him to do those 
activities that he felt were safe.  Once a description had been given all were able to 
answer the question with ease.   
Some of the young people felt they lacked independence as their families insisted they 
had to be watched whilst completing activities.  One teenage girl (PS12) felt her 
independence was limited by the neighbourhood in which she lived, and not her OI. 
8.3.8 Psychometric evaluation 
All items within each dimension were answered by all participants. There was therefore 
no missing data found across the whole questionnaire.   
Most items demonstrated a good spread of data across all response options.  Items 
Q23, Q24, Q25, Q30 and Q34 had one response item which recorded zero, but this 
was not at the floor or ceiling, or persistently the same response option.  Floor and 
ceiling effects were noted in several items (table 8.3), but this was possibly due to the 
items being related to symptoms (causal items), poorly worded items or items which 
were more relevant to a subgroup of patients within the sample.   
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Table 8.2  Reliability Statistics (n=25) 
Dimension N of 
items 
Cronbach’s 
alpha 
Mean 
score 
(1-5) 
Median 
score 
(0-100) 
SD 
(0-100) 
Minimum 
score 
Maximum 
score 
Being safe and 
careful 6 0.87 2.0 16.7 23.1 1.6 2.5 
Reduced 
function 8 0.65 3.6 65.6 17.8 2.4 4.2 
Pain 6 0.61 3.9 66.7 18.3 3.3 4.4 
Fear 6 0.70 3.6 70.8 21.8 2.9 4.1 
Isolation 6 0.50 3.0 45.8 19.7 2.9 3.2 
Independence 7 0.46 2.7 39.3 17.7 1.9 3.6 
 
Cronbach’s alpha demonstrated adequate internal consistency for the complete 39-
item questionnaire (0.79), but reduced scores for dimensions; Pain (0.61); Isolation 
(0.50); and independence (0.46).  No improvement in Cronbach’s alpha score would be 
gained from eliminating any item within the being safe and careful dimension, and only 
minimal improvement would be gained in dimensions; reduced function; fear; isolation 
and independence if items were removed.  However, it is suggested that internal 
consistency reliability of the pain dimension would improve with the elimination of item 
Q15.   
Some items demonstrated poor correlation within their dimension, with low item-to-total 
correlation (ITC < 0.30), although this was not the case for the dimensions ‘being safe 
and careful’ and ‘fear’, where all items correlated well within the dimension (see tables 
8.4 and 8.7).  The tiredness items (Q.7, Q.8, Q.9) within the reduced function 
dimension correlated poorly with the other items (ITC 0.04, 0.17, 0.06 respectively) 
(see table 8.5).  Back pain (item Q.15) correlated poorly within the pain dimension (ITC 
-0.17), but the other items within this dimension demonstrated good correlation (see 
table 8.6).  Many items within the dimension entitled independence demonstrated poor 
correlation, the only item demonstrating good correlation referred to the overprotection 
provided by school teachers (Q.37) (see table 8.9).  
Some item-item correlations within each dimension were high; items Q10 and Q12 (r = 
0.83), Q11 and Q12 (r = 0.82), Q21 and Q22 (r = 0.80), but the highest item-item 
correlation was found between items Q18 and Q19 (r = 0.91).  These latter items were 
related to fear of fracture, and being scared of activities which may lead to fracture, the 
value greater than 0.90 gives rise to concerns regarding redundancy of one of these 
items. 
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Table 8.3.  Percentage items responses to the 39 OIQoL item 
 
 
Item Question Always (%) Most of the time (%) Sometimes (%) Not much (%) Never (%) 
Q1 Does someone give you extra help to keep you safe? 44 32 12 8 4 
Q2 Do you keep away from busy areas to keep safe? 44 28 12 8 8 
Q3 Do you keep away from crowds to keep safe? 20 36 20 12 12 
Q4 Do you try to keep safe to stop you breaking a bone? 56 24 16 4 4 
Q5 Do you keep away from some activities to stop you having a broken bone? 
48 28 8 12 4 
Q6 Do you think before playing sports to avoid having a broken bone? 60 12 16 0 12 
Q7 Have you felt tired in the day? 4 20 40 28 8 
Q8 Have you felt tired by the end of the day? 24 36 24 8 8 
Q9 Do you have to take rests in the day? 8 12 12 28 40 
Q10 Has having a broken bone stopped you doing things? 8 4 12 12 64 
Q11 Has it been more difficult to move around because of a broken bone? 
12 4 12 8 64 
Q12 Have you had to do things differently because of a broken bone? 4 8 20 12 56 
Q13 Do you use equipment to help you to move around? 8 8 24 12 48 
Q14 Do you have to use equipment to help at school or home? 24 16 4 12 44 
Q15 Have you had pain in your back? 8 20 24 16 32 
Q16 Have you had pain in your legs or arms? 4 28 36 8 24 
Q17 Have you had to take medicine for pain? 8 12 20 8 52 
Q18 Have you had to take medicine because you broke a bone? 4 4 12 4 76 
Q19 Did you have pain because you had a broken bone? 4 8 16 4 68 
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Q20 Have you missed meeting up with your friends because you had pain? 
8 4 12 16 60 
Q21 Have you been worried about breaking a bone? 
12 4 12 28 44 
Q22 Do you get scared about doing something that might make you break a bone? 
16 4 24 32 24 
Q23 Do you worry about coming into hospital? 16 0 28 20 36 
Q24 Do you get scared about needles? 36 0 20 24 36 
Q25 Did you worry that someone might move you wrong and cause a broken bone? 
12 0 12 32 44 
Q26 Have you worried about new people handling you? 4 4 24 20 48 
Q27 Did you see your friends outside of school? 20 16 16 16 32 
Q28 Are you able to do everything your friends do? 8 16 40 20 16 
Q29 Did you get to do lots of different activities? 12 36 16 12 24 
Q30 Did you do PE at school? 32 20 12 0 36 
Q31 Do you feel different because you have to be more careful than your friends? 
28 4 32 8 28 
Q32 Have people treated you differently because you have brittle bones? 
36 4 20 20 20 
Q33 Did you like to do things for yourself? 56 16 16 8 4 
Q34 Did your family encourage you to do things for yourself? 56 20 16 0 8 
Q35 Do you have as much freedom as your friends? 16 28 16 20 20 
Q36 Do your family let you make your own decision about what is safe? 28 24 8 20 20 
Q37 Do the teachers at school over protect you? 12 24 16 16 32 
Q38 Do the teachers at school stop you doing things that you think are safe? 
16 12 20 12 40 
Q39 Do your family let you choose your own activities? 28 28 28 12 4 
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Table 8.4.  Table to demonstrate item-item correlation, item-total correlation and Cronbach’s alpha scores for being safe and careful 
dimension. 
 
 
 
 
 
 
 
 
Q1 Does 
someone 
give you 
extra help 
to keep 
you safe? 
Q2 Do 
you keep 
away 
from busy 
areas to 
keep 
safe? 
Q3 Do 
you keep 
away 
from 
crowds to 
keep 
safe? 
Q4 Do 
you try to 
keep safe 
to stop 
you 
breaking 
a bone? 
Q5 Do you 
keep away 
from some 
activities to 
stop you 
having a 
broken bone? 
Q6 Do you 
think before 
playing sports 
to avoid 
having a 
broken bone? 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q1 Does someone give you extra help to keep 
you safe? 1.00      0.45 0.87 
Q2 Do you keep away from busy areas to keep 
safe? 0.71 1.00     0.66 0.83 
Q3 Do you keep away from crowds to keep 
safe? 0.41 0.47 1.00    0.73 0.82 
Q4 Do you try to keep safe to stop you 
breaking a bone? 0.27 0.56 0.64 1.00   0.72 0.83 
Q5 Do you keep away from some activities to 
stop you having a broken bone? 0.03 0.19 0.60 0.60 1.00  0.55 0.85 
Q6 Do you think before playing sports to avoid 
having a broken bone? 0.34 0.64 0.68 0.65 0.75 1.00 0.82 0.80 
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Table 8.5.  Table to demonstrate item-item correlation, item-total correlation and Cronbach’s alpha for Reduced Function scores 
dimension. 
 
 
 
 
 
 
Q7 
Have 
you felt 
tired in 
the 
day? 
Q8 
Have 
you felt 
tired by 
the end 
of the 
day? 
Q9 Do 
you 
have to 
take 
rests in 
the 
day? 
Q10 Has 
having a 
broken 
bone 
stopped 
you doing 
things? 
Q11 Has it 
been more 
difficult to 
move around 
because of a 
broken bone? 
Q12 Have 
you had to 
do things 
differently 
because of a 
broken 
bone? 
Q13 Do 
you use 
equipment 
help you 
to move 
around? 
Q14 Do 
you have 
to use 
equipment 
to help at 
school or 
home? 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q7 Have you felt tired in the day? 
1.00        0.04 0.67 
Q8 Have you felt tired by the end of the 
day? 
0.40 1.00       0.17 0.65 
Q9 Do you have to take rests in the day? 
0.22 0.24 1.00      0.06 0.68 
Q10 Has having a broken bone stopped 
you doing things? 0.07 0.11 0.02 1.00     0.60 0.54 
Q11 Has it been more difficult to move 
around because of a broken bone? -0.04 0.13 -0.10 0.66 1.00    0.59 0.54 
Q12 Have you had to do things differently 
because of a broken bone? -0.08 -0.02 -0.12 0.83 0.82 1.00   0.56 0.56 
Q13 Do you use equipment help you to 
move around? -0.14 0.12 0.03 0.26 0.39 0.34 1.00  0.48 0.58 
Q14 Do you have to use equipment to help 
at school or home? -0.18 -0.13 0.03 0.21 0.24 0.18 0.58 1.00 0.26 0.64 
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Table 8.6.   Table to demonstrate item-item correlation, item-total correlation and Cronbach’s alpha scores for the Pain dimension 
 
 
Q15 
Have 
you had 
pain in 
your 
back? 
Q16 
Have 
you had 
pain in 
your 
legs or 
arms? 
Q17Have 
you had 
to take 
medicine 
for pain? 
Q18 Have 
you had to 
take 
medicine 
because you 
broke a 
bone? 
Q19 Did you 
have pain 
because you 
had a broken 
bone? 
Q20 Have you 
missed 
meeting up 
with your 
friends 
because you 
had pain? 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q15 Have you had pain in your back? 
1.00      -0.15 0.74 
Q16 Have you had pain in your legs or 
arms? 
0.62 1.00     0.30 0.56 
Q17Have you had to take medicine for pain? 
-0.09 0.33 1.00    0.68 0.37 
Q18 Have you had to take medicine 
because you broke a bone? -0.41 -0.04 0.66 1.00   0.51 0.48 
Q19 Did you have pain because you had a 
broken bone? -0.44 0.02 0.65 0.91 1.00  0.55 0.46 
Q20 Have you missed meeting up with your 
friends because you had pain? -0.23 -0.10 0.34 0.36 0.48 1.00 0.26 0.58 
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Table 8.7.  Table to demonstrate item-item correlation, item-total correlation and Cronbach’s alpha scores for Fear dimension 
 
 
 
Q21 Have 
you been 
worried 
about 
breaking a 
bone? 
Q22 Do you 
get scared 
about doing 
something that 
might make 
you break a 
bone? 
Q23 Do 
you 
worry 
about 
coming 
into 
hospital? 
Q24 Do you 
get scared 
about 
needles? 
Q25 Did you 
worry that 
someone might 
move you wrong 
and cause a 
broken bone? 
Q26 Have you 
worried about 
new people 
handling you? 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q21 Have you been worried about breaking a 
bone? 1.00      0.72 0.57 
Q22 Do you get scared about doing 
something that might make you break a 
bone? 
0.80 1.00     0.57 0.62 
Q23 Do you worry about coming into 
hospital? 
0.23 0.18 1.00    0.30 0.71 
Q24 Do you get scared about needles? 0.24 0.06 0.66 1.00   0.34 0.70 
Q25 Did you worry that someone might move 
you wrong and cause a broken bone? 0.63 0.50 -0.14 0.02 1.00  0.40 0.67 
Q26 Have you worried about new people 
handling you? 0.33 0.34 -0.07 0.14 0.42 1.00 0.33 0.69 
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Table 8.8.  Table to demonstrate item-item correlation, item-total correlation and Cronbach’s alpha scores for Isolation dimension. 
 
 
Q27 Did 
you see 
your 
friends 
outside of 
school? 
Q28 Are you 
able to do 
everything 
your friends 
do? 
Q29 Did 
you get to 
do lots of 
different 
activities? 
Q30 Did you 
do PE at 
school? 
Q31 Do you feel 
different because 
you have to be 
more careful than 
your friends? 
Q32 Have 
people treated 
you differently 
because you 
have brittle 
bones? 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q27 Did you see your friends outside of 
school? 1.00      0.38 0.32 
Q28 Are you able to do everything your 
friends do? 0.09 1.00     -0.03 0.52 
Q29 Did you get to do lots of different 
activities? 
0.38 0.41 1.00    0.51 0.25 
Q30 Did you do PE at school? 0.24 0.22 0.61 1.00   0.39 0.30 
Q31 Do you feel different because you have 
to be more careful than your friends? 0.17 -0.58 0.09 -0.01 1.00  0.07 0.50 
Q32 Have people treated you differently 
because you have brittle bones? 0.12 -0.21 -0.18 0.01 0.39 1.00 0.07 0.50 
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Table 8.9  Table to demonstrate item-item correlation, item-total correlation and Cronbach’s alpha scores for the Independence 
dimension. 
 
 
 
 
Q33 Did 
you like to 
do things 
for 
yourself? 
Q34 Did your 
family 
encourage you 
to do things for 
yourself? 
Q35 Do 
you have 
as much 
freedom 
as your 
friends? 
Q36 Do your 
family let you 
make your 
own decision 
about what is 
safe? 
Q37 Do the 
teachers at school 
over protect you? 
Q38 Do the 
teachers at 
school stop you 
doing things that 
you think are 
safe? 
Q39 Do 
your family 
let you 
choose 
your own 
activities? 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q33 Did you like to do things for yourself? 1.00       0.21 0.53 
Q34 Did your family encourage you to do 
things for yourself? -0.07 1.00      0.23 0.52 
Q35 Do you have as much freedom as your 
friends? 0.25 -0.02 1.00     0.29 0.50 
Q36 Do your family let you make your own 
decision about what is safe? 0.12 0.36 0.47 1.00    0.30 0.49 
Q37 Do the teachers at school over protect 
you? 0.26 0.17 0.20 0.14 1.00   0.55 0.37 
Q38 Do the teachers at school stop you 
doing things that you think are safe? 0.12 0.02 -0.23 -0.17 0.47 1.00  0.06 0.59 
Q39 Do your family let you choose your own 
activities? -0.06 0.28 0.28 0.09 0.40 -0.01 1.00 0.31 0.49 
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Table 8.10  Change made following pilot 
 
 
Dimension Item Number Change Made 
All All except PE related item New item stem “In the last 
week….” To be 
incorporated into all items. 
Isolation 30 New wording of item to 
cover the event of school 
holidays.  Now reads “In a 
normal school week do you 
do PE?” 
Isolation Items  27 -  32 Dimension now placed at 
the end of the overall 
questionnaire.  Items now 
numbered  34 - 39 
Independence Items 33 - 39 This dimension was 
previously the 6th, but 
became the 5th once 
changes were made to PE 
related item 
 
 
8.4 Discussion 
The need to pilot the initial version of the questionnaire proved imperative.   
Several changes were made to the questionnaire as a result of this pilot phase (See 
table 8.10).  The most major change took place within the wording of the items, and the 
question stem.  Many children and young people found the instruction ‘In the last week’ 
appearing only once, at the beginning of each dimension quite difficult.  Each 
dimension has at least six items and having to remember that each item refers only to 
the last week proved difficult for several respondents, and this was more noticeable for 
those younger children. It was therefore decided that each item would begin ‘In the last 
week….’ 
Smith and colleagues (2005) found that the time frame of one week was suitable for 
their population; it was short enough to remember, but long enough to be meaningful.  
All of our respondents were capable of remembering what had happened and what 
they had taken part in over the last week.  The issue within the format of the newly 
developed questionnaire (OIQoL), was not that of the time frame, but the format of how 
often children were reminded of that time frame within each dimension.  Children often 
rushed into the question, particularly those relating to fractures, without reminding 
themselves of the time frame, and needed to be facilitated to think again and consider 
just the last week. 
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The fact that the primary researcher was also a physiotherapist within the Metabolic 
Bone Disease team enabled increased sensitivity as to when fractures had taken 
place; allowing the researcher to prompt participants who may have answered 
incorrectly to re-read the question and re-consider the time frame. 
This rushing in was also experienced by a few of the older respondents, who had to be 
reminded about the time scale for the questions related to fractures within the last 
week.  They commented within the post completion interviews, that they had found 
those items more difficult to answer.  As a result of this the question stem within all 
items except one (see discussion below), was altered to state: 
Item 10:  In the last week has having a broken bone stopped you doing things? 
Item 11:  In the last week has it been more difficult to move around because of a      
    broken bone? 
Item 12:  In the last week have you had to do things differently because of a broken 
    bone? 
One question within the isolation dimension (Q. 30) asked: 
Thinking about your last week… 
Did you do PE at school? 
 
This question initially appeared to be fine, but when given to a respondent during their 
school holidays, this was not the case.  PE is an activity which is undertaken during 
school time, and therefore during holiday from school it is unlikely that the respondent 
had participated in PE.  For this reason this question was altered, becoming ‘In a 
normal school week do you do PE?’  This altered the overall question stem for this 
item, and the stem….’In the last week….’ was no longer appropriate.  This is the only 
item within the questionnaire that now lacks this repeated question stem.  As a result 
this item no longer flowed well in its current position (Q30) and was considered for 
replacement and resultant reformatting of the questionnaire.  Following discussion with 
the research team, it was decided this item should now be placed at the end of the 
isolation dimension.  To improve readability and aid completion, the isolation dimension 
was placed at the end of the questionnaire, allowing all other items to follow the 
question stem ‘In the last week….’ enhancing flow throughout the questionnaire. 
 
Some of the younger participants required assistance with the meaning of a couple of 
items.  One item (Q2) asking about busy areas was easily completed by all 
respondents; conversely the similar item (Q3) asking about crowds required some 
additional input with one of the younger children.  Discrepancy was highlighted 
between these two items, as one participant reported he always stayed away from 
busy areas to keep safe, but never avoided crowds. Both these items demonstrated 
good internal consistency, if either item was removed from the scale the Cronbach’s 
alpha score would drop slightly.  For these reason neither item was removed from the 
questionnaire at this stage.  Both demonstrated good content validity during the 
development of the conceptual framework and item generation phase (Chapter 5).  
Further psychometric evaluation will inform which, if any of the items requires removal. 
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Some discrepancy was uncovered between the younger children (PS1, PS13) and their 
older counterparts.  These two younger children were not sure about the meaning of 
the word isolation, which was used as a dimensional heading, and this terminology had 
to be explained by their parents.  This dimensional heading had already undergone 
change following the validation focus group with young people (See Chapter 6).  In the 
event of the younger children regularly not understanding the term isolation, it may be 
necessary to rethink this dimension heading, once further information has been gained 
when the questionnaire is assessed with a larger sample. 
 
Differences in understanding were noted between mildly effected and more severely 
effected individuals with regards to some items.  One teenager aged 14 (PS15) had 
difficulty understanding the need for him to consider activities prior to taking part in 
order to keep safe.   This participant was very mildly effected and active, taking part in 
sporting activities both in and outside of school.  He questioned why individuals with OI 
would have to think about keeping safe, and obviously did not feel he needed to.   
 
Cano and Hobart (2011) state that health measurement can be described in two ways;  
measuring health outcomes as the extent to which certain universal needs are met, or 
viewing health outcomes as being constructed from individual evaluations of what is 
personally important.  This can lead to flaws in health measurement of a population 
where disease severity is very varied.  If individuals see their health outcome as a 
perception of their life circumstance, and this is dependent on the psychological 
makeup of the individual, then one cannot assume that each individual will value 
different circumstances in the same way.  In this instance, the respondent with mild 
disease did not view his need to keep safe in the same way as the participants who 
suggested the items during the one-to-one interviews or those that validated the items 
during the focus groups.  This may have been due to difference in severity of disease, 
but may also be due to differences in psychological make up.  
Consideration as to whether it is necessary to remove this item, or alter it to make it 
comprehensible to all participants is required.  This individual was the only one in the 
sample that made comment about this item, and all other participants completed it 
without question.  It may be that this teenager was so mildly affected that he had never 
before considered the need to remain safe.  It may be that he did not want to appear 
weak in any way and wanted to portrait a tougher, more socially acceptable veneer.  At 
this stage in questionnaire development it was decided to retain this item within the 
tool, and monitor it psychometrically during the next stage of instrument development. 
This more mildly effected individual had also questioned why someone would need to 
handle him, as item Q26 had asked.  This again is an issue related to the severity of 
OI, with several more severely effected individuals commenting about their fear in 
being handled, particularly if they did not know the capabilities of the adult who was 
planning to assist in their transfers. Parents of very young children also reported their 
other family members being fearful of handling their new baby, and expressing 
concerns of poor handling leading to fractures, often avoiding handling as a result.  No 
other mildly affected individuals within the sample reported any concerns with either of 
these two items, and possibly had more understanding of the varying severities of the 
disease and the effects this may have.  For these reasons, this item was also not 
removed, as the content validity of the questionnaire may have been reduced as a 
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result.  If this item did not test well in the psychometric evaluation on a larger sample, 
then it may need to be removed at that point.   
 
Eiser and Morse (2001) expressed concern that the removal of items at this early 
stage, especially if only proving an issue to a small sample of respondents, could lead 
to reduce validity of the overall questionnaire. 
 
Cano and Hobart (2011), within their two key messages, warn that psychometric 
statistics, when considered in isolation, can be misleading.  They confirm that 
establishing a clinically meaningful content validity from the onset; developing a 
conceptual framework to ensure the questionnaire measures the concepts relevant to 
the target population, is a vital step in questionnaire development. 
 
The items Q13 and Q14 sparked discussion between some respondents and their 
parents/carers, and consequently with the research team.  These items asked 
participants to consider the equipment they had used within the last week.  Most of the 
respondents were happy to complete these items without discussion with parents, and 
several completed the item, stating that they had not often or had never used 
equipment.  Those participants who were being observed by both the researcher and 
their parent/carer were often then questioned as to why they had answered more 
negatively with regard to equipment.  Some parents stated ‘What about your cushion?’, 
and were then informed by their son/daughter that although they had been given a 
piece of equipment to use within the school environment, they had opted not to do so.  
This was obviously not something that had been discussed before, and parents were 
under the illusion that their child was using the equipment at school, when this was not 
actually the case.  This posed uncertainty around the ability of parents/carers to act as 
reliable and accurate proxy respondents, and reinforced the need to gain self 
completion of the QoL questionnaire.  This has been repeatedly reported in children 
with chronic or life long conditions, when attempting to gain understanding of whether 
children are prepared to undergo treatments, and their appreciation of the expected 
outcome or success (Ingerski et al, 2010: Varni et al, 2008). 
The discrepancies between children’s self report and their parents’ proxy report have 
been described within the literature (Upton et al, 2008), and were previously often 
regarded as measurement error (Eiser and Varni, 2013).  It is important to consider that 
if discrepancies do occur between children and their parents/carers, then who is right?  
 
The US Food and Drug administration (FDA, 2009) states that paediatric patient self 
reported HRQOL is a form of patient reported outcome measure (PRO), and should 
therefore be reported directly by the patient, without the need for interpretation from 
parents, carers or clinicians.  Eiser and Varni (2013) conclude that both opinions are 
important, and both respondents add useful information to the measure of HRQOL.  
However, they go on to state that ultimately, it is the child who knows best his or her 
thoughts, feelings of pain, emotional upset, fatigue or internal symptoms. 
  
It is also noted within the literature, that parental proxy report of their child’s quality of 
life, can be dependent on their own state of well being; those mothers that are more 
anxious, rate their child’s HRQOL lower than those mothers that are less distressed 
(Janike et al, 2007).  It is also important to make note, that some children will attempt to 
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protect their parents from distressing information, and this will contribute to the differing 
opinion of parents compared to their children (Metcalfe et al, 2008).  Eiser and Varni 
(2013) conclude that parents are not in a position to monitor their children in many of 
their social and functional interactions.  This is more apparent for school aged children 
and especially older adolescents, who are often not in an easily, regularly observable 
environment.   
 
All participants had completed all areas of the questionnaire; there was therefore no 
missing data from the 25 participants who undertook the questionnaire.  Moreover, this 
may have occurred as participants were observed when completing the questionnaire.  
Smith et al (2005) states the usual criterion for missing data is 5%, although in their 
study evaluating HRQOL in people with dementia their missing data was particularly 
high, they had to raise their criterion to 30%, which then allowed elimination of the most 
extreme items and a sufficient number of items for further psychometric testing.   
There was good coverage of response options for all items within the questionnaire; 
with only an occasional zero score which was not at the floor or ceiling.   This 
demonstrated a good use of all the available Likert levels for all items within the 
questionnaire. No participant commented on the need for additional or fewer Likert 
response options during the post completion interviews.  Vincent et al (2007) undertook 
post completion interviews during their construction and validation of a QoL 
questionnaire for neuromuscular disease.  They found that participants preferred a 
seven point Likert rather than a five. 
 
Floor and ceiling effects were noted for items which were either causal in nature 
(related to symptoms of OI), or affected only a small minority of more severely affected 
individuals.   Items Q10, Q11, Q12, Q18 and Q19 are all related to fractures and 
therefore a high number of participants responding ‘never’ occurred as only a small 
sample of participants within this pilot had sustained a fracture within the last week.  
This automatically led to a ceiling effect on items related to fracture.  Items Q4, Q5 and 
Q6 are related to staying safe and reducing risk to avoid sustaining a fracture, these 
items are again likely to be causal in nature, related to OI and the need to stay fracture 
free.  Only two items demonstrated very high item-item correlation (Q18 and Q19); 
these items related to pain resulting from a fracture, and the need to take medication 
due to fracture pain.  It is easy to understand why these two items correlated highly; 
additional assessment of potential redundancy will be required during further 
psychometric testing on a larger cohort. 
Although some items within the OI specific QOL measure did not correlate sufficiently 
well with others in their dimension (ITC>0.3), they were not removed at this stage.  As 
missing data was not an issue, it was felt there was no concern regarding comfort or 
relevance of the items.  As the items were developed through direct patient interview, 
informing the conceptual framework, it was felt removal of such items with high 
relevance to the patient group, would not ensure continued high content validity.  Early 
removal of items on psychometric grounds, which demonstrate high relevance to the 
participant group, can produce a strong statistical measure which has low content 
validity, particularly when the psychometric analysis was based on small numbers 
(n=25).  Eiser and Morse (2001) state: 
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 “The practice of excluding certain items on the basis of statistical criteria can 
 lead to some bias.  Items that may be important to individuals are excluded 
 while items that fulfil psychometric requirements may be included, even if they 
 would not be endorsed by any single individual.”  (pp 90). 
 
Content validity of the questionnaire was further supported by the comments made by 
one 10 year old respondent, who felt some of the items within the pain dimension were 
‘just like him’.  These items related to the pain he experience in his back and limbs, a 
reoccurring theme which was reported within the one-to-one interviews and the focus 
groups. 
8.5 Strengths and Limitations 
Observed pre-testing of the questionnaire with the addition of post completion 
interviews, allowed pauses to be monitored, and questions to be asked.  This first hand 
feedback from the target population with regards to understanding, readability and 
relevance proved invaluable, enabling changes to be made to the initial version of the 
OIQoL questionnaire and an obvious strength to the overall process of PRO measure 
development.   
Although the methodology had an obvious strength, it also had its limitations.  The 
participants having previous knowledge of the principle researcher as their 
physiotherapist may have affected the post completion interviews.  It may have led to 
more ‘yes’ saying, with participants providing more positive feedback during the 
interview, not wanting to disappoint or upset the interviewer. 
The interviewer being present and taking notes during questionnaire completion will 
also have had an effect on the lack of any missing data.  Participants will have felt 
compelled to complete the questionnaire, as they were being observed doing so.  A 
true measure of the amount of missing data will have to be calculated during further 
testing, where participants will not be observed throughout completion. 
Those items/questions that ask about pain related to fracture may have led to the floor 
and ceiling effects; anyone who hasn’t sustained a fracture in the last week will 
immediately fall at the extreme end of the range (i.e. Never); therefore providing an 
immediate ceiling effect for those items.  Choosing not to make changes to these items 
at this stage, prior to any psychometric evaluation, was in hindsight a poor decision, 
which led to flaws within the questionnaire being moved forward into the next stage of 
testing.  These questions will need revision or removal prior to testing on a larger multi-
site sample. 
 
8.6 Conclusion 
The pilot phase of the study enabled changes and modifications to be made to the 
overall questionnaire.  These modifications were mainly surrounding the format of the 
items in relation to the time scale.  During the pilot, problems arose when the time 
scale ‘In the last week….’ was written only once at the beginning of each dimension.  
Children and young people with OI seemed to have no problem recalling what had 
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happened within the last week, but needed to be reminded of this time scale on a more 
regular basis.  The addition of ‘In the last week’ to the item stem will hopefully 
encourage children and young people to be more mindful when answering the 
questionnaire.  The addition of this new item stem will aim to reduce the possibility that 
children will rush into items, especially those related to fractures, and encourage them 
to think whether the fracture had occurred within the last week.  
Changes to item Q30 ‘Did you do PE at school?’, were made as those children who 
had attempted to use the questionnaire during the school holidays, were at a loss as to 
how to answer this item.  Due to the occurrence of school holidays, it was impossible 
for this item to follow the newly identified item stem ‘In the last week….’.  Item 30 was 
therefore altered to read; ‘In a normal school week do you do PE’, and was therefore 
placed at the end of the questionnaire to avoid further confusion.   
Some items initially proved difficult to understand to a couple of children who were 
mildly affected.  It was difficult to decide whether this was an individual problem, 
because the participant(s) was a very active and able young person, or whether this 
would be a reoccurring theme in a larger sample.  The same applied to the 
understanding of a couple of items with the younger participants. In this instance 
parental help, promoted better understanding and allowed informed completion.  This 
highlighted the need for occasional additional help with some of the younger 
participants.  
The issue of proxy completion was again highlighted, and the potential discrepancy 
between the thoughts of children and their parents in relation to their QoL during 
questionnaire completion was acknowledged.  Further work around identifying and 
understanding this discrepancy would be both interesting and useful.  It is again 
acknowledged that there may have been a missed opportunity to develop both child 
and parental questionnaires simultaneously, and perhaps this would be an area for 
future research. 
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Version 2.  OIQoL. 
 
Being safe and careful 
 
In the last week did someone give you extra help to keep you 
safe? 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you keep away from busy areas to keep 
safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you keep away from crowds to keep 
safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you try to keep safe to stop you breaking 
a bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you keep away from some activities to 
stop you having a broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you think before playing sports to avoid 
having a broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
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Reduced Function 
 
In the last week have you felt tired in the day? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week have you felt tired by the end of the day? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you have to take rests in the day? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week has having a broken bone stopped you doing 
things? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week has it been more difficult to move around 
because of a broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week have you had to do things differently 
because of a broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you use equipment to help you to move 
around? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you have to use equipment to help at 
school or home? 
 
 
Always Most of the time Sometimes       Not much Never 
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Pain 
 
 
 
 
 
 
 
 
 
 
In the last week have you had pain in your back? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week have you had pain in your legs or arms? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week have you had to take medicine for pain? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week have you had to take medicine because you 
broke a bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you have pain because you had a broken 
bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week have you missed meeting up with your 
friends because you had pain? 
 
 
Always Most of the time Sometimes       Not much Never 
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Fear 
 
 
 
 
 
 
 
 
In the last week have you been worried about breaking a 
bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you get scared about doing something 
that might make you break a bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you worry about coming into hospital? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you get scared about needles? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you worry that someone might move you 
wrong and cause a broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week have you worried about new people handling 
you? 
 
 
Always Most of the time Sometimes       Not much Never 
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Independence 
 
 
In the last week did you like to do things for yourself? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did your family encourage you to do things 
for yourself? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you have as much freedom as your 
friends? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did your family let you make your own 
decision about what is safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did the teachers at school over protect you? 
 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did the teachers at school stop you doing 
things that you think are safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did your family let you choose your own 
activities? 
 
 
Always Most of the time Sometimes       Not much Never 
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Isolation 
 
Important to note that this dimension was the penultimate one prior to the pilot, but the order was altered due to the format of the 
last question. 
 
 
In the last week did you see your friends outside of school? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week were you able to do everything your friends 
do? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you get to do lots of different activities? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week did you feel different because you have to be 
more careful than your friends? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In the last week have people treated you differently because 
you have brittle bones? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
In a normal school week do you do PE? 
 
Always Most of the time Sometimes       Not much Never 
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Chapter 9 
Psychometric Evaluation (Field testing) 
 
9.1 Aim 
 
The aim of this chapter is to describe the field testing stage of the newly developed 
disease specific QoL measure for children with OI (OIQoL).  The relevant background 
literature related to the methodological process of psychometric evaluation has already 
been discussed in Chapter 3. This chapter will highlight some research papers where 
psychometric evaluations of newly developed questionnaires and PRO measures have 
taken place. It will also explain why the methods used were chosen, the limitations of 
these methods and the ideas for further research and testing. 
 
9.2 Background 
 
The process of QoL questionnaire development is an iterative one; items and are 
generated, concepts uncovered, questionnaires are developed and piloted or pre-
tested, and the final version is field tested on a larger sample of the chosen population.  
At any stage changes may be made to the questionnaire, items may be eliminated in 
response to the ongoing development and testing.  These changes will require further 
testing and potential further changes may arise, hence the process is both fluid and 
cyclic.   
9.2.1 Acceptability 
Full forms of missing data within a multiple page questionnaire, may be a sign that the 
instrument is too lengthy and that the burden placed on the individual completing the 
questionnaire is too high.  The amount of items that are eliminated due to missing data 
needs to be examined closely, and an incremental percentage approach can be used 
to identify this.  Smith et al (2005) chose to eliminate items that had greater than to 
30% missing data, which left them with over 30 items within their questionnaire.  They 
noted that if they reduced the percentage of missing data to greater than 25%, this 
would leave only seven items.  A questionnaire with so few items may have reduced 
reliability and content validity, and therefore not reflect those themes which are 
important to the patient population. 
Gorecki et al (2009) examined floor and ceiling effects within their PU-QOL, a patient 
reported outcome measure for patients with pressure ulcers.  They choose a value of 
<15% as adequate for the proportion of the sample at the floor or the ceiling, based on 
information from McHorney et al (1995). 
9.2.2 Psychometrics 
Having an understanding of the properties that a questionnaire should adhere to is only 
part of the overall picture.  It is necessary to statistically demonstrate these 
psychometric properties and offer evidence of the newly developed questionnaires’ 
robustness.  There are several methods described in the literature to provide this 
statistical evidence, but which is the best or ‘gold standard’ approach is not clear.  The 
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literature appears to fall into two camps; classical test theory (+/- factor analysis) and 
the new psychometric methods such as, item response theory or Rasch theory, with 
some review papers unsure of which method is the most appropriate, if any, to 
demonstrate the overall validity and reliability (Cano and Hobart, 2011). 
 
Raven-Sieberer et al (2010) whilst examining the psychometric properties of the newly 
developed Kidscreen-10 used several statistical methods.  They used interclass 
correlation coefficients (ICC) to examine test-retest following a two week delay in 
questionnaire re-completion, stating an ICC>0.7 would demonstrate an acceptable 
level of reliability.  Pearson’s correlation was used to assess the criterion validity of the 
newly developed Kidscreen-10 alongside similar ‘gold standard’ questionnaire, with 
values of above 0.7 considered acceptable. 
 
Weiss et al (2013) tested an anglicised translated version of an Italian rheumatological 
QoL scale on their paediatric cohort.  They used the PedsQL to examine convergent 
and discriminant validity, and assessed known groups validity using correlations with 
disease activity or state, as described by an experienced rheumatologist.  They 
examined internal consistency reliability using Cronbach’s alpha and test-retest using 
intra class correlation coefficient.  They used both confirmatory and exploratory factor 
analysis to ascertain whether the two factor model obtained for the Italian version of the 
questionnaire also fit their data, and latterly to examine the model without any pre-
assumptions to uncover the number of theoretical dimensions required.   
Wiklander et al (2013) during their development of the HIV stigma scale, field tested 
their questionnaire on 58 children to examine percentage of missing data, floor and 
ceiling effects, internal consistency (Cronbach’s alpha) and criterion validity by 
assessing correlations with other HRQoL measures, alongside principle component 
analysis to inform factor structure.  They quoted Field (2009) when suggesting that a 
sample of 50 individuals would be satisfactory for factor analysis, and used a Kaiser-
Meyer-Olkin test for sample adequacy, alongside a Bartlett’s test for spericity to ensure 
the sample of 50 was suitable for factor loadings.  As a result of this they concluded a 
three factor solution was suitable. 
Gorecki et al (2013) during their development and validation of the PROM for patients 
with pressure ulcers, used both traditional psychometrics, as advised by the FDA 
criteria (2009), alongside new psychometric methods; Rasch measurement theory.  
They stated that to use Rasch methodology a sample size of 250 subjects would be 
required, but described this latter measurement as a formal method for evaluating a 
scale against a sophisticated mathematical measurement model.  Their first 
psychometric evaluation produced a 10-point scale, but the subsequent Rasch analysis 
found limitations in these scales, which required modification.  Particularly the 4-point 
item scoring system, which didn’t work for several items resulting in a change to a 3-
point system. 
9.2.3 Approach chosen 
The statistical methodology chosen to examine the psychometric properties of the 
newly developed OIQoL was dictated by the size of the available participant sample, 
the time available in which to complete this phase of the research, as it took place 
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within a PhD and the level of understanding of the primary researcher.  As a result of 
this traditional methodology was chosen, to provide an introduction to the psychometric 
properties of the new questionnaire, enabling some consideration of item reduction or 
revision based on acceptability and responsiveness.  Items were deemed redundant if 
they were correlated highly with another similar item (r > 0.90), if they incurred a high 
level of missing data (>10%), or demonstrated high levels of floor or ceiling effects; 
excluding those causal items affected by disease symptoms.  Preliminary information 
was gained with regards to reliability and validity of the questionnaire as a whole and 
the items within each dimension. 
The decision not to include any factor analysis (confirmatory or exploratory) was taken 
after lengthy discussion with the research team, and was again decided due to time 
and sample size constraints and the lack of statistical ability and experience of the 
principle researcher.  The need to examine the questionnaire further, with regards to its 
overall structure and the number and type of dimensions included is acknowledged.  
The need for further research and psychometric analysis on a larger sample is 
required. 
The choice to use traditional psychometric analysis in favour of more modern 
techniques (Rasch analysis and item response theory) was also chosen because of the 
relatively small sample size and the limited knowledge and experience of the primary 
researcher.   
 
9.3 Method 
 
The methodology for the final phase of this study involved a larger sample of 
participants recruited from patients known to the Metabolic Bone Disease Team at 
Sheffield Children’s Hospital.  Ninety five children and adolescents with a medically 
confirmed diagnosis of OI were asked to complete the newly developed OI specific 
QoL questionnaire on three separate occasions (see chapter 8 for version 2 of the 
OIQoL).  These were; at baseline, in out patient clinic or as an inpatient on the ward 
(time point 1); at one week later (postal assessment – time point 2); and approximately 
three months later at follow up clinic or via post (time point 3). 
 
Table 9.1   Inclusion and Exclusion Criteria 
 
 
    
Recruitment 
 
 
Inclusion 
 
Exclusion 
 
SCH patients 
 
Age 6-18 years. 
Medical diagnosis of OI. 
Attending SCH for out patient 
review or inpatient treatment. 
Ability to understand English. 
Consent/assent from patient 
and/or parent/carer. 
 
 
Unknown diagnosis. 
Non consent. 
 
 
Patients were approached via post with an invitation letter and reply slip (see Appendix 
3) which gave details of the study.  This was the final stage of this study; potential 
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participants were made aware that there have been previous stages to this multi 
faceted study, and the fact that some participants may have already taken part in 
previous phases was acknowledged.  An information sheet and consent form (see 
Appendix 4 and 5) were included in the mail out.  Two weeks following the receipt of 
the letter, potential participants were contacted by telephone to answer any questions 
they or their parent/carer may have and to discuss possible inclusion.  Patients who 
expressed an interest in taking part within the study or those who asked for further 
information were offered a suitable date to attend SCH. 
 
Potential participants were asked to travel to SCH to discuss the study further and to 
consent those individuals who agreed to participate.  Where possible this was arranged 
to coincide with a routine appointment for out patient review or inpatient stay.  These 
appointments occur on a regular basis (3-6 monthly) and patients can travel from far 
and wide.  For the principle researcher to travel to individual homes was logistically 
impossible within the realms of this study. 
  
Prior to inclusion within this study, all participants were given the opportunity to meet 
with the lead researcher to discuss the study and ask any questions they had.  This 
took place away from the clinic setting, which allowed any sensitive questions or 
information to be comfortably addressed.  All participants who agreed to take part 
within the study were required to provide consent.  Young people of 14 years and over 
were deemed competent to agree assent, but consent was still gained from their 
parent/carer prior to inclusion.  Younger children who were able to understand the 
research study agreed to assent and wrote their name on an assent form.   
 
Consented individuals were asked to complete both the newly developed OI specific 
QoL measure (OIQoL – see Chapter 8 for version 2), the PedsQL (see appendix 8) and 
EQ5D (see appendix 9), during a routine visit to SCH; the latter two questionnaires are 
generic measures of QoL.  Following completion of these baseline questionnaires 
(OIQoL, PedsQL and EQ5D), participating individuals were asked to complete a 
second copy of the questionnaires a week later, alongside a global rating of health 
question (see Appendix 10).  They were provided with an envelope which contained 
the second copy of the OIQoL, PedsQL, EQ5D, global rating of health question, and a 
stamped addressed envelope for return purposes. 
 
Three months later participating individuals were again asked to complete a third and 
final copy of the OIQoL, PedsQL and EQ5D, and second copy of the global rating of 
health question.  Those individuals who were returning to SCH for a routine out patient 
appointment or inpatient admission were provided with the questionnaires during this 
visit.  Those patients who are reviewed at SCH less frequently, received their third and 
final copy of the questionnaires via post, and were provided with a stamped addressed 
envelope for its return. 
 
Once returned the coded questionnaires were initially input into an Excel spreadsheet.  
Data was input and then rechecked for accuracy.  Any missing data was denoted 999. 
 
 Time point one; OIQoL-baseline, PedsQL-baseline, EQ5D-baseline  
 Time point two; OIQoL-one week, PedsQL-one week, EQ5D-one week, global 
rating of health-one week.  
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 Time point three; OIQoL- three month, PedsQL-three month, EQ5D-three 
month, global rating of health- three month. 
 
The majority of items within the newly developed OIQoL are scored incrementally, 
where ‘always’ scores 1, and ‘never’ scores 5.  However a few items are reverse 
scored (items Q27, 28, 29, 30, 33, 34, 35, 36, 39), where ‘always’ scores 5 and ‘never’ 
scores 1.  This enables an overall high score to represent better reported QoL. 
 
9.3.1 Acceptability and data quality 
 
Raw scores were then transformed to a 0-100 scale, taking into account those items 
which are reversed scored (items Q27, Q28, Q29, Q30, Q33, Q34, Q35, Q36, Q39).  
To achieve this items which are reversed score were recoded. 
 
Using a fictional Being safe and careful dimension with scores Q1=3, Q2=3, Q3=3, 
Q4=3, Q5=3 and Q6=3, the following paragraph describes how the data was 
transformed.  No recoding was required for this dimension as a higher score means 
less concern regarding being safe and careful and therefore higher QoL. Raw scale 
scores were computed by summing the items in the same scale; for the being safe and 
careful dimension this involves adding up the responses to the six items (Q1 to Q6).  
The raw score is then transformed to a 0-100 scale using the following formula: 
Transformed Scale Score = [(Actual raw score-lowest possible raw score)/Possible raw 
score range]*100. 
Therefore, for the being safe and careful dimension the transformed scale score is: 
 T_score=((raw_score -6)/24)*100 = 50. 
See Appendix 11 for SPSS syntax example for the being safe and careful dimension.  
Baseline scores were examined to identify characteristics of age, sex, and the severity 
of disease within the cohort.  The data was examined for the distribution of item 
responses; the frequency and position of missing data was examined, alongside the 
proportion of respondents at the floor and ceiling.  The percentage of item-level missing 
data was deemed appropriate if less than 10%.  Percentages at the floor and ceiling 
were deemed suitable if <50%, with a 5 point Likert scale expected percentage at each 
point if the data spread was even would be 20%.  Where large proportions of the cohort 
scored at the floor or ceiling, these items were examined as their link to symptoms or 
the effects of treatment may highlight causal items.  Those items which are not 
necessarily causal in nature, which demonstrate large floor or ceiling effects will be 
examined for potential revision or elimination. 
9.3.2 Scaling assumptions 
 
Ideally the items within the questionnaire should be seen to measure a common 
underlying construct; they should therefore demonstrate similar mean scores and 
standard deviations.  Correlations between the items will be explored, ideally items 
within the same dimension should correlated more closely.  Items which correlated very 
closely with one another may be a sign of redundancy.  Alternatively, causal items 
(Fayers and Machin, 2007) may be closely related to symptoms of disease or treatment 
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and may therefore not correlate well with one another, but clinically remain well sited 
within a particular dimension. 
 
9.3.3 Internal consistency reliability  
 
Cronbach’s alpha statistics for each dimension and for the scale as a whole will be 
examined.  Values of greater than or equal to 0.7 demonstrate adequate internal 
consistency.  Item to total correlation of 0.4 to 0.6 indicates that the items are 
moderately correlated, values of <0.3 indicate poor correlation. 
 
9.3.4 Known Groups validity 
 
Correlation methods will be used to examine the relationships between the items within 
the newly developed OIQoL and the total score for the dimension within which it is 
sited. Correlations between known groups, such as severity of disease or treatments 
received will also be examined to further inform construct validity of the newly 
developed OIQoL. 
The PedsQL is a generic paediatric QoL questionnaire, and therefore there is an 
expectation that the newly developed OIQoL will positively correlate with some items or 
dimensions within the scale.  This would demonstrate a level of criterion validity, 
although as the PedsQL is not deemed the ‘gold’ standard QoL questionnaire for the OI 
population (Chapter 4), this may not be the case.   
 
9.3.5 Test-retest reliability 
 
Those respondents who reported ‘no change’ in their global rating of health at time 
point two will be selected to examine the reliability of the test-retest at one week.  
Correlations will be used to examine scale stability; a correlation of >0.7 will indicate 
reliable scale stability between time point one and time point two (a duration of one 
week).  The intra-class coefficient (ICC) will also be explored for agreement between 
dimension scores; a value of >0.7 will identify good agreement between test and retest 
dimension scores.  Responsiveness at item level will also be examined with respect to 
the treatment that individuals received, mean differences between treatment groups will 
be explored. 
 
9.3.6 Time point three (3 months follow up) 
 
Those respondents who again reported ‘no change’ in their global rating of health at 
time point three will be selected to examine the reliability of the test-retest at three 
months.  Correlations will be used to examine scale stability, alongside intra-class 
coefficient, as was planned at test-retest at one week. Again, item level responsiveness 
will be explored and mean differences between treatment groups investigated. 
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9.3.7 Item reduction strategy 
 
Items will be considered for potential removal using the item removal strategy of: 
 Cronbach’s alpha <0.70, demonstrating reduced internal consistency within a 
particular dimension or scale. 
  Item-total correlation values <0.30, highlighting an items’ poor fit within the 
dimension or scale. 
 Item-item correlation >0.90, highlighting high correlation between items which 
may be indicative of redundancy of one or more items. 
 Floor and ceiling effects >50% 
 Item removal will only take place if the content validity of the questionnaire will 
not be unduly affected as a result.  This latter consideration will involve the 
judgement of the primary researcher alongside the concepts elicited and 
conceptual framework uncovered in the early sections of questionnaire 
development (Chapters 5 and 6). 
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Figure 9.1. Flowchart psychometric evaluation; reliability, validity, responsiveness. 
 
 
 
Invitation letter sent out to non 
independent sample of up to 150 
patients regarding inclusion in QoL 
measure and/or Assessment tool. 
Mail out to include information sheets 
and consent/assent forms 
Non interest Interested in QoL study 
Appointment made to attend SCH for 
QOL questionnaire, to coincide with 
routine care 
Discuss study with Chief 
Investigator.  Questions and 
answers Non 
consent 
Consent 
OI severity from medical notes 
QoL measure completed during 
out patient visit or inpatient stay 
1 week later copy of QoL 
measure sent  home with global 
question of well being. Stamped 
addressed envelope enclosed 
QOL measure completed 3 
months later during routine visit 
Data 
analysed 
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9.4 Results 
 
Almost all of the individuals that were approached to take part in this phase of the 
research agreed to do so.  Ninety eight individuals were initially approached, two 
declined to take part, one became distressed about another aspect of their 
treatment/care and it was therefore felt inappropriate to re-approach for consent.  One 
individual chose to delay her inclusion and consent for three months, as she was about 
to take her GCSE exams, but was still keen to participate.  The participants ranged 
from 6 to 18 years and included 41 boys (43%).  59% of participants were of primary 
school age, 37% were in secondary school, and the latter 4% were 17-18 years of age.  
There was mixed severity of OI including; 41 children with mild disease, 37 who were 
moderately affected and 17 children with severe disease.  
 
 
 
Median 10 
Range 6-18 
N=95 
 
 
Figure 9.2.  Histogram to demonstrate the age range of participants within the sample. 
 
 
Participants were asked to complete the questionnaires at baseline, one week and 12 
weeks follow up; 95 participants completed the questionnaires at baseline, 76 
individuals returned completed questionnaires at one week follow up, with 73 
individuals completing and returning the 3 month follow up.  Nineteen children therefore 
failed to return the one week follow up questionnaires, an initially loss of 20%, with an 
overall loss of twenty two participants at 3 months (23%). 
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9.4.1 Missing data 
 
All children managed to complete the full questionnaire, with only a small amount of 
missing data.  Of those 95 individuals who completed the questionnaires at baseline, 
only occasional items were not completed. Seven items (items Q6, Q24, Q34, Q35, 
Q37, Q38 and Q39) recorded 1% missing data, with only two items (items Q30 and 
Q36) missing 2%  See Table 9.3 for further details at an individual item level; table 9.2 
highlights baseline and missing data for each dimension.    
 
 
Table 9.2.  Summary descriptive statistics for baseline OIQoL dimension scores based 
on transformed data (0-100) n=95 
 
 Valid 
N 
No. 
Missing 
Mean Median SD Min Max 
OI Being safe and careful 
dimension (0-100) 
94 1 34.2 29.2 25.6 0.0 100.0 
OI PROM Reduced function 
dimension (0-100) 
95 0 61.4 62.5 20.3 12.5 100.0 
OI PROM Pain dimension (0-100) 95 0 74.3 79.2 20.7 16.7 100.0 
OI PROM Fear dimension (0-100) 94 1 73.8 79.2 21.6 12.5 100.0 
OI PROM Independence dimension 
(0-100) 
93 2 68.0 67.9 15.6 28.6 100.0 
OI PROM Isolation dimension (0-
100) 
93 2 56.5 54.2 19.6 8.3 100.0 
 
 
 
Table 9.3. demonstrates a small amount of item level missing data, mean and median 
scores for each individual item. 
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Table 9.3.  Summary descriptive statistics for baseline OIQoL item level score based 
on raw data n=95 
Item Question N Missing Mean Median SD 
1 In the last week did someone give you extra help to keep you safe? 95 0 2.44 2 1.34 
2 In the last week did you keep away from busy areas to keep safe? 95 0 2.52 2 1.33 
3 In the last week did you keep away from crowds to keep safe? 95 0 2.53 3 1.40 
4 
In the last week did you try to keep safe to stop you breaking a 
bone? 95 0 1.93 1 1.27 
5 
In the last week did you keep away from some activities to stop you 
having a broken bone? 95 0 2.53 2 1.43 
6 
In the last week did you think before playing sports to avoid having a 
broken bone? 94 1 2.28 2 1.48 
7 In the last week have you felt tired in the day? 95 0 2.53 2 1.12 
8 In the last week have you felt tired by the end of the day? 95 0 2.39 1 1.28 
9 In the last week did you have to take rests in the day? 95 0 3.46 3 1.17 
10 
In the last week has having a broken bone stopped you doing 
things? 95 0 3.99 5 1.48 
11 
In the last week has it been more difficult to move around because 
of a broken bone? 95 0 4.21 5 1.32 
12 
In the last week have you had to do things differently because of a 
broken bone? 95 0 4.13 5 1.38 
13 In the last week did you use equipment to help you to move around? 95 0 3.60 4 1.58 
14 
In the last week did you have to use equipment to help at school or 
home? 95 0 3.36 4 1.69 
15 In the last week have you had pain in your back? 95 0 3.49 3 1.25 
16 In the last week have you had pain in your legs or arms? 95 0 3.42 3 1.27 
17 In the last week have you had to take medicine for pain? 95 0 3.84 4 1.34 
18 
In the last week have you had to take medicine because you broke 
a bone? 95 0 4.58 5 1.04 
19 In the last week did you have pain because you had a broken bone? 95 0 4.32 5 1.27 
20 
In the last week have you missed meeting up with your friends 
because you had pain? 95 0 4.17 5 1.26 
21 In the last week have you been worried about breaking a bone? 95 0 3.68 4 1.32 
22 
In the last week did you get scared about doing something that 
might make you break a bone? 95 0 3.84 4 1.27 
23 In the last week did you worry about coming into hospital? 95 0 4.04 4 1.22 
24 In the last week did you get scared about needles? 94 1 3.72 5 1.58 
25 
In the last week did you worry that someone might move you wrong 
and cause a broken bone? 95 0 4.23 5 1.16 
26 In the last week have you worried about new people handling you? 95 0 4.17 5 1.17 
27 In the last week did you like to do things for yourself? 95 0 1.83 2 1.00 
28 
In the last week did your family encourage you to do things for 
yourself? 95 0 2.18 2 1.3 
29 In the last week did you have as much freedom as your friends? 95 0 2.59 2 1.31 
30 
In the last week did your family let you make your own decision 
about what is safe? 93 2 2.67 3 1.37 
31 In the last week did the teachers at school over protect you? 95 0 3.48 4 1.37 
32 
In the last week did the teachers at school stop you doing things that 
you think are safe? 95 0 3.98 4 1.23 
33 In the last week did your family let you choose your own activities? 95 0 2.20 2 1.22 
34 In the last week did you see your friends outside of school? 94 1 2.90 3 1.49 
35 In the last week were you able to do everything your friends do? 94 1 2.80 3 1.24 
36 In the last week did you get to do lots of different activities? 93 2 2.56 3 1.34 
37 
In the last week did you feel different because you have to be more 
careful than your friends? 94 1 2.99 3 1.43 
38 
In the last week have people treated you differently because you 
have brittle bones? 94 1 3.12 3 1.38 
39 In a normal school week do you do PE? 94 1 2.34 2 1.59 
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Table 9.4.   Raw items responses to the 39 OIQoL item 
Item Question n 
% missing 
data 
Always (%) 
Most of the time         
(%) 
Sometimes 
(%) 
Not much 
(%) 
Never (%) 
Q1 
In the last week did someone give you extra help to keep 
you safe? 95 0.0 33.7 20.0 25.3 10.5 10.5 
Q2 
In the last week did you keep away from busy areas to 
keep safe? 95 0.0 29.5 24.2 22.1 13.7 10.5 
Q3 
In the last week did you keep away from crowds to keep 
safe? 95 0.0 34.7 14.7 26.3 11.6 12.6 
Q4 
In the last week did you try to keep safe to stop you 
breaking a bone? 95 0.0 54.7 18.9 13.7 4.2 8.4 
Q5 
In the last week did you keep away from some activities 
to stop you having a broken bone? 95 0.0 32.6 23.3 17.9 11.6 14.7 
Q6 
In the last week did you think before playing sports to 
avoid having a broken bone? 94 1.0 48.4 10.5 17.9 8.4 13.7 
Q7 In the last week have you felt tired in the day? 95 0.0 20.0 30.5 32.6 10.5 6.3 
Q8 
In the last week have you felt tired by the end of the 
day? 95 0.0 31.6 28.4 16.8 15.8 7.4 
Q9 In the last week did you have to take rests in the day? 95 0.0 6.3 10.5 40.0 16.8 26.3 
Q10 
In the last week has having a broken bone stopped you 
doing things? 95 0.0 13.7 6.3 8.4 10.5 61.1 
Q11 
In the last week has it been more difficult to move 
around because of a broken bone? 95 0.0 8.4 7.4 5.3 12.6 66.3 
Q12 
In the last week have you had to do things differently 
because of a broken bone? 95 0.0 10.5 5.3 9.5 10.5 64.2 
Q13 
In the last week did you use equipment to help you to 
move around? 95 0.0 16.8 11.6 15.8 6.3 49.5 
Q14 
In the last week did you have to use equipment to help at 
school or home? 95 0.0 25.3 10.5 10.5 10.5 43.2 
Q15 In the last week have you had pain in your back? 95 0.0 6.3 15.8 30.5 16.8 30.5 
Q16 In the last week have you had pain in your legs or arms? 95 0.0 7.4 18.9 24.2 23.2 26.3 
Q17 In the last week have you had to take medicine for pain? 95 0.0 8.4 9.5 18.9 15.8 47.4 
Q18 
In the last week have you had to take medicine because 
you broke a bone? 95 0.0 3.2 5.3 6.3 1.1 84.2 
Q19 
In the last week did you have pain because you had a 
broken bone? 95 0.0 7.4 6.3 6.3 7.4 72.6 
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Q20 
In the last week have you missed meeting up with your 
friends because you had pain? 95 0.0 7.4 4.2 14.7 11.6 62.1 
Q21 
In the last week have you been worried about breaking a 
bone? 95 0.0 11.6 6.3 18.9 28.4 34.7 
Q22 
In the last week did you get scared about doing 
something that might make you break a bone? 95 0.0 6.3 10.5 18.9 21.1 43.2 
Q23 
In the last week did you worry about coming into 
hospital? 95 0.0 7.4 4.2 14.7 24.2 49.5 
Q24 In the last week did you get scared about needles? 94 1.0 17.9 7.4 9.5 13.7 50.5 
Q25 
In the last week did you worry that someone might move 
you wrong and cause a broken bone? 95 0.0 5.3 5.3 10.5 18.9 60.0 
Q26 
In the last week have you worried about new people 
handling you? 95 0.0 4.2 7.4 13.7 16.8 57.9 
Q27 In the last week did you like to do things for yourself? 95 0.0 48.4 28.4 16.8 4.2 2.1 
Q28 
In the last week did your family encourage you to do 
things for yourself? 95 0.0 43.2 21.1 18.9 8.4 8.4 
Q29 
In the last week did you have as much freedom as your 
friends? 95 0.0 25.3 27.4 21.1 15.8 10.5 
Q30 
In the last week did your family let you make your own 
decision about what is safe? 93 2.2 27.4 17.9 25.3 14.7 12.6 
Q31 
In the last week did the teachers at school over protect 
you? 95 0.0 12.6 11.6 21.1 24.2 30.5 
Q32 
In the last week did the teachers at school stop you 
doing things that you think are safe? 95 0.0 4.2 11.6 15.8 18.9 49.5 
Q33 
In the last week did your family let you choose your own 
activities? 95 0.0 36.8 28.4 18.9 9.5 6.3 
Q34 
In the last week did you see your friends outside of 
school? 94 1.0 25.3 15.8 23.2 12.6 22.1 
Q35 
In the last week were you able to do everything your 
friends do? 94 1.0 17.9 23.2 29.5 17.9 10.5 
Q36 
In the last week did you get to do lots of different 
activities? 93 2.2 30.5 17.9 22.1 18.9 8.4 
Q37 
In the last week did you feel different because you have 
to be more careful than your friends? 94 1.0 24.2 8.4 29.5 17.9 18.9 
Q38 
In the last week have people treated you differently 
because you have brittle bones? 94 1.0 16.8 18.9 16.8 28.4 17.9 
Q39 In a normal school week do you do PE? 94 1.0 45.3 21.1 7.4 4.2 21.1 
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Table 9.4 demonstrates the amount of missing data and the percentage of individuals 
at the floor and ceiling for each item.  This table reiterates the low level of missing data 
for all items within the OIQoL questionnaire and therefore offering evidence to support 
the acceptability and comfort of the questionnaire.   
 
9.4.2 Floor and ceiling effects 
 
Some items which demonstrated ceiling effects were causal items, related to either 
symptoms such as fractures or pain (items; Q10-14, Q15-20, Q21, Q22, Q25), or items 
which are important to more minority groups within the OI population, hence enabling a 
large amount of the participants to score at the higher end of the scale (Q25-26, Q31-
32). Mild floor effects are seen in items Q1-6, which are causal items and closely 
related to fractures or preventing fractures.  Some items (Q10, Q11, Q12, Q18, Q19, 
Q20) were poorly constructed, asking individuals two questions simultaneously, which 
promoted ceiling effects.  
 
 
 
 
                 
      Median 29.17         Median 62.50 
        Range 0-100         Range 12.50-100 
        N=94         N=95 
 
                
       Median 79.17          Median 79.17 
       Range 16.67-100         Range 12.50-100 
       N=95           N=94 
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       Median 67.86            Median 54.17 
       Range 28.57-100           Range 8.33-100 
       N=93             N=93 
 
 
Figure 9.3.  Histograms of data spread by dimension  
 
 
 
The above histograms demonstrate the spread of the dimension scores for the 
transformed data; for each dimension it can be seen that there is a relative even 
spread of scores across the item totals, with some dimensions skewed to the right 
(pain and fear) and the being safe and careful dimension skewed a little towards the 
left.  Those dimensions which are skewed to the right demonstrate higher QoL scores, 
which in relation to the pain and fear dimensions highlight more individuals reporting 
less pain and less fear. This may be due to the larger numbers of more mild-
moderately affected participants, the relatively small sample size, or a mild ceiling 
effect due to the inclusion of causal items or those items which were poorly 
constructed.  The skewed data for the being safe and careful dimension demonstrates 
a tendency for the sample to report more frequent efforts to stay safe and careful, and 
a resultant reduced QoL.  Items which have floor or ceiling effects greater than 50% 
need further investigation, some may be causal in nature, others such as handling in 
the more severely effected individuals effect only a small minority of the OI population.  
Some floor or ceiling effects may be due to the nature of the question, poorly worded 
items which involve two topics such as pain and fractures automatically place some 
individuals at the ceiling (Items Q10, Q11, Q12, Q18, Q19). 
 
9.4.3 Correlation 
 
The table in Appendix 12 demonstrates the item-item correlation for the 39 items within 
the OIQoL.  Most items have low (<0.3) to moderate (0.4 – 0.6) correlation with other 
items within the questionnaire.  Items Q1-Q6 correlate well with one another and this 
can be further seen in table 9.5; being safe and careful is the dimension with the most 
correlated items across the questionnaire, and therefore the dimension with the highest 
internal consistency.  From the table (Appendix 12) it can be seen that a few items 
correlate quite highly with one another.  Items Q2 and Q3 are well correlated and ask 
about an individuals’ wariness of busy areas and crowds (r = 0.72), it is therefore 
commonsense that these items may correlate with one another.  If the correlation had 
been higher, it may have highlighted some redundancy and potentially identified an 
item for elimination.  Items Q10 and Q11, Q10 and Q12, and Q11 and Q12 all exhibit 
higher correlation (r = 0.73, r = 0.75 and r = 0.86 respectively).  They are questions 
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relating to fractures preventing activity (Q10), fractures making function more difficult 
(Q11), and having to do things differently because of fractures (Q12); it therefore 
makes sense for these items to be highly correlated.  The highest correlation (Q11 and 
Q12, r = 0,86) may give rise for some concern regarding redundancy, and may lead to 
elimination of one of these items, should any other psychometric tests, such as 
Cronbach’s alpha, reinforce this concern.  Items Q12 and Q19 are also quite highly 
correlated (r = 0.71) and also relate to items describing fractures and the pain reported 
in the event of a fracture.  Items Q18 and Q19 both relate to pain following fracture and 
the need for pain relief in the event of a fracture. Both these correlations are again 
obvious, but not high enough to warrant concern with regard to redundancy. The only 
other correlations which warrants highlighting is that between items Q29 and Q35 (r = 
0.60) which is again a sensible notion; they are questions relating to having as much 
freedom as your friends and being able to do everything your friends can do.   
 
Table 9.5 presents Pearson’s correlations for each dimension within the OIQoL.  No 
one dimension correlates particularly highly with any other; most correlations are low to 
moderate 
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Table 9.5. Correlations between each of the six dimensions of the OIQoL. 
 
  OIQoL 
Being safe 
and careful 
dimension 
(0-100) 
OIQoL 
Reduced 
function 
dimension 
(0-100) 
OIQoL 
Pain 
dimension 
(0-100) 
OIQoL 
Independence 
dimension (0-
100) 
OIQoL 
Isolation 
dimension 
(0-100) 
OIQoL 
Fear 
dimension 
(0-100) 
OIQoL Being 
safe and 
careful 
dimension  
Pearson 
Correlation 
1      
(0-100) 
Sig. (2-
tailed)       
  N 94      
OIQoL 
Reduced 
function 
dimension (0-
100) 
Pearson 
Correlation 
0.44
**
 1     
  
Sig. (2-
tailed) 
0.00      
  N 94 95     
OIQoL Pain 
dimension (0-
100) 
Pearson 
Correlation 
0.29
**
 0.61
**
 1    
  
Sig. (2-
tailed) 
0.01 0.00     
  
N 94 95 95    
OIQoL 
Independence 
dimension (0-
100) 
Pearson 
Correlation 
0.06 0.16 0.29
**
 1   
  
Sig. (2-
tailed) 
0.56 0.13 0.01    
  N 92 93 93 93   
OIQoL 
Isolation 
dimension (0-
100) 
Pearson 
Correlation 
0.32
**
 0.36
**
 0.33
**
 0.37
**
 1  
  
Sig. (2-
tailed) 
0.00 0.00 0.00 0.00   
  N 92 93 93 91 93  
OIQoL Fear 
dimension (0-
100) 
Pearson 
Correlation 
0.28
**
 0.40
**
 0.31
**
 0.24
*
 0.32
**
 1 
  
Sig. (2-
tailed) 
0.01 0.00 0.00 0.02 0.00  
  N 94 94 94 92 92 94 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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9.4.4 Correlations between other questionnaires 
 
Table 9.6.  Correlation between the 6 dimensions of OIQoL dimensions and EQ5D 
 
 
  
OIQoL 
Being 
safe and 
careful 
dimension 
(0-100) 
OIQoL 
Reduced 
function 
dimension 
(0-100) 
OIQoL 
Pain 
dimension 
(0-100) 
OIQoL 
Fear 
dimension 
(0-100) 
OIQoL 
Independence 
dimension (0-
100) 
OIQoL 
Isolation 
dimension 
(0-100) 
EQ-5D 
Overall 
Utility 
(VAS) 
Pearson 
Correlation 0.11 0.34
**
 0.40
**
 0.19 0.17 0.34
**
 
Sig. (2-
tailed) 0.32 0.00 0.00 0.07 0.11 0.00 
N 92 93 93 92 91 91 
EQ-5D 
Overall 
Utility 
(Tariff) 
Pearson 
Correlation 0.04 0.30
**
 0.21
*
 -0.07 0.04 0.12 
Sig. (2-
tailed) 0.72 0.00 0.04 0.51 0.70 0.24 
N 93 94 94 93 92 92 
Correlation is significant at the 0.01 level (2-tailed).**      Correlation is significant at the 0.05 level (2-tailed).* 
 
 
Table 9.7.  Correlations between 6 dimensions of OIQoL and dimensions in PedsQL 
 
The above tables (9.6 and 9.7) demonstrate the relatively low correlations between the 
six dimensions within the OIQoL and the EQ5D and the low to moderate correlation 
  
OIQoL 
Being 
safe and 
careful 
dimension 
(0-100) 
OIQoL 
Reduced 
function 
dimension 
(0-100) 
OIQoL 
Pain 
dimension 
(0-100) 
OIQoL 
Fear 
dimension 
(0-100) 
OIQoL 
Independence 
dimension       
(0-100) 
OIQoL 
Isolation 
dimensio
n (0-100) 
PedsQL 
Physical 
Functioning 
(0-100) 
Pearson 
Correlation 0.39
**
 0.63
**
 0.52
**
 0.45
**
 0.22
*
 0.57
**
 
Sig. (2-
tailed) 
0.00 0.00 0.00 0.00 0.04 0.00 
N 93 94 94 93 92 92 
PedsQL 
Emotional 
Functioning 
(0-100) 
Pearson 
Correlation 
0.28
**
 0.35
**
 0.31
**
 0.45
**
 0.11 0.39
**
 
Sig. (2-
tailed) 
0.01 0.00 0.00 0.00 0.32 0.00 
N 93 94 94 93 92 92 
PedsQL 
Social 
Functioning 
(0-100) 
Pearson 
Correlation 
0.28
**
 0.35
**
 0.35
**
 0.39
**
 0.17 0.61
**
 
Sig. (2-
tailed) 
0.01 0.00 0.00 0.00 0.11 0.00 
N 93 94 94 93 92 92 
PedsQL 
School 
Functioning 
(0-100) 
Pearson 
Correlation 
-0.01 0.17 0.08 0.29
**
 0.01 0.27
**
 
Sig. (2-
tailed) 
0.93 0.10 0.48 0.00 0.91 0.01 
N 93 94 94 93 92 92 
Correlation is significant at the 0.01 level (2-tailed).**        Correlation is significant at the 0.05 level (2-tailed).* 
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between the OIQoL and the PedsQL.  However it is useful to make note of the higher 
correlations between the reduced function dimension of the OIQoL and the physical 
function dimension of the PedsQL, alongside the isolation dimension of the OIQoL and 
the social functioning dimension of the PedsQL. 
 
9.4.5 Known Groups Validity 
 
It was hypothesised that those individuals with more severe disease would report lower 
QoL scores than those children with milder disease.  Table 9.9 demonstrates that this 
was not the case across all dimensions.  However reduced function did show a 
difference between groups in both the original questionnaire (RF dimension 8 items) 
and within the revised version following potential item elimination (RF dimension 6 
items).  A difference was also noted between groups for the physical functioning 
dimension (PF) of the PedsQL, although this was not significant (see Table 9.9). 
 
Tables 9.8 a-f demonstrates significant differences between OI severities for items Q1, 
Q12, Q13 and Q22.  Items Q1, Q12 and Q13 all demonstrate significantly lower scores 
reported by those individuals with more severe disease.  Item Q1 shows a noticeable 
increment in reported extra help from those with severe disease (mean 1.6) to those 
with mild disease (mean 2.7).  Items Q12 and Q13 show the same significant trend in 
relation to moving differently due to fracture and using equipment, with milder affected 
individuals reporting higher mean scores.  Item Q22 however shows a different trend, 
which although still significant, demonstrates those individuals with moderate disease 
reporting a lower score in relation to fear of activities which may lead to fracture, hence 
they report more fear than their peers with more mild or severe disease.  Items Q10, 
Q11 and Q14 have almost significant differences between severity groups, but do not 
reach the threshold of 0.05. 
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Table 9.8.a  Table to demonstrate item level score differences between OI severity groups at baseline on raw data (Items Q1-6) 
 
            Confidence Interval   
Item Question   N Mean SD Lower  Upper  Sig. 
1 In the last week did someone give you extra help to keep you safe? mild 41 2.7 1.3 2.3 3.1 0.02 
   mod 37 2.5 1.4 2.1 3.0  
   severe 17 1.6 1.1 1.1 2.2  
   Total 95 2.4 1.3 2.2 2.7  
2 In the last week did you keep away from busy areas to keep safe? mild 41 2.8 1.5 2.3 3.2 0.22 
   mod 37 2.4 1.1 2.1 2.8  
   severe 17 2.1 1.4 1.4 2.8  
   Total 95 2.5 1.3 2.2 2.8  
3 In the last week did you keep away from crowds to keep safe? mild 41 2.6 1.5 2.2 3.1 0.32 
   mod 37 2.6 1.3 2.2 3.1  
   severe 17 2.1 1.4 1.3 2.8  
   Total 95 2.5 1.4 2.2 2.8  
4 In the last week did you try to keep safe to stop you breaking a bone? mild 41 2.0 1.4 1.5 2.4 0.48 
   mod 37 2.0 1.2 1.6 2.4  
   severe 17 1.6 1.0 1.1 2.1  
   Total 95 1.9 1.3 1.7 2.2  
5 
In the last week did you keep away from some activities to stop you having a broken bone? 
mild 41 2.4 1.5 2.0 2.9 0.73 
   mod 37 2.5 1.3 2.1 3.0  
   severe 17 2.8 1.6 2.0 3.6  
   Total 95 2.5 1.4 2.2 2.8  
6 In the last week did you think before playing sports to avoid having a broken bone? mild 40 2.4 1.4 1.9 2.9 0.12 
   mod 37 1.9 1.4 1.5 2.4  
   severe 17 2.8 1.7 1.9 3.6  
    Total 94 2.3 1.5 2.0 2.6  
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Table 9.8.b  Table to demonstrate item level score differences between OI severity groups at baseline on raw data (Items Q7-14) 
            Confidence Interval   
Item Question   N Mean SD Lower  Upper  Sig. 
7 In the last week have you felt tired in the day? mild 41 2.6 1.2 2.2 3.0 0.89 
   mod 37 2.5 1.1 2.1 2.8  
   severe 17 2.5 .9 2.1 3.0  
   Total 95 2.5 1.1 2.3 2.8  
8 In the last week have you felt tired by the end of the day? mild  41 2.6 1.4 2.2 3.1 0.31 
   mod 37 2.2 1.2 1.8 2.6  
   severe 17 2.4 1.1 1.8 2.9  
   Total 95 2.4 1.3 2.1 2.7  
9 In the last week did you have to take rests in the day? mild 41 3.5 1.2 3.1 3.9 0.82 
   mod 37 3.4 1.3 3.0 3.8  
   severe 17 3.6 .9 3.1 4.1  
   Total 95 3.5 1.2 3.2 3.7  
10 In the last week has having a broken bone stopped you doing things? mild 41 4.3 1.4 3.9 4.7 0.07 
   mod 37 3.9 1.5 3.4 4.4  
   severe 17 3.4 1.6 2.5 4.2  
   Total 95 4.0 1.5 3.7 4.3  
11 In the last week has it been more difficult to move around because of a broken bone? mild 41 4.6 1.1 4.2 4.9 0.07 
   mod 37 4.0 1.4 3.5 4.5  
   severe 17 3.8 1.6 3.0 4.6  
   Total 95 4.2 1.3 3.9 4.5  
12 In the last week have you had to do things differently because of a broken bone? mild 41 4.5 1.0 4.2 4.9 0.04 
   mod 37 3.9 1.5 3.4 4.4  
   severe 17 3.7 1.7 2.8 4.6  
   Total 95 4.1 1.4 3.8 4.4  
13 In the last week did you use equipment to help you to move around? mild 41 4.2 1.3 3.8 4.6 0.00 
   mod 37 3.5 1.6 3.0 4.1  
   severe 17 2.4 1.5 1.6 3.1  
   Total 95 3.6 1.6 3.3 3.9  
14 In the last week did you have to use equipment to help at school or home? mild 41 3.7 1.7 3.1 4.2 0.08 
   mod 37 3.4 1.6 2.8 3.9  
   severe 17 2.6 1.5 1.8 3.4  
    Total 95 3.4 1.7 3.0 3.7  
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Table 9.8.c  Table to demonstrate item level score differences between OI severity groups at baseline on raw data (Items Q15-20) 
 
            Confidence Interval   
Item Question   N Mean SD Lower  Upper  Sig. 
15 In the last week have you had pain in your back? mild 41 3.4 1.4 3.0 3.9 0.27 
   mod 37 3.4 1.2 3.0 3.8  
   severe 17 3.9 1.0 3.4 4.4  
   Total 95 3.5 1.3 3.2 3.8  
16 In the last week have you had pain in your legs or arms? mild 41 3.5 1.3 3.1 3.9 0.81 
   mod 37 3.3 1.2 2.9 3.7  
   severe 17 3.4 1.3 2.8 4.1  
   Total 95 3.4 1.3 3.2 3.7  
17 In the last week have you had to take medicine for pain? mild 41 3.9 1.4 3.4 4.3 0.83 
   mod 37 3.8 1.3 3.3 4.2  
   severe 17 4.0 1.3 3.3 4.7  
   Total 95 3.8 1.3 3.6 4.1  
18 In the last week have you had to take medicine because you broke a bone? mild 41 4.7 .8 4.4 5.0 0.29 
   mod 37 4.6 1.0 4.3 4.9  
   severe 17 4.2 1.4 3.5 5.0  
   Total 95 4.6 1.0 4.4 4.8  
19 In the last week did you have pain because you had a broken bone? mild 41 4.4 1.2 4.0 4.8 0.66 
   mod 37 4.4 1.3 3.9 4.8  
   severe 17 4.1 1.5 3.3 4.8  
   Total 95 4.3 1.3 4.1 4.6  
20 In the last week have you missed meeting up with your friends because you had pain? mild 41 4.3 1.1 4.0 4.6 0.62 
   mod 37 4.1 1.3 3.7 4.6  
   severe 17 3.9 1.6 3.1 4.8  
   Total 95 4.2 1.3 3.9 4.4  
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Table 9.8.d  Table to demonstrate item level score differences between OI severity groups at baseline on raw data (Items Q21-26) 
 
            Confidence Interval   
Item Question   N Mean SD Lower  Upper  Sig. 
21 In the last week have you been worried about breaking a bone? mild 41 3.8 1.3 3.3 4.2 0.87 
   mod 37 3.6 1.3 3.1 4.0  
   severe 17 3.7 1.4 3.0 4.4  
   Total 95 3.7 1.3 3.4 4.0  
22 In the last week did you get scared about doing something that might make you break a bone? mild 41 4.1 1.1 3.8 4.5 0.02 
   mod 37 3.4 1.4 2.9 3.8  
   severe 17 4.2 1.1 3.6 4.8  
   Total 95 3.8 1.3 3.6 4.1  
23 In the last week did you worry about coming into hospital? mild 41 4.0 1.2 3.6 4.4 0.96 
   mod 37 4.0 1.3 3.6 4.5  
   severe 17 4.1 1.1 3.5 4.7  
   Total 95 4.0 1.2 3.8 4.3  
24 In the last week did you get scared about needles? mild 40 3.7 1.5 3.2 4.2 0.99 
   mod 37 3.7 1.6 3.2 4.2  
   severe 17 3.8 1.7 2.9 4.6  
   Total 94 3.7 1.6 3.4 4.0  
25 In the last week did you worry that someone might move you wrong and cause a broken bone? mild 41 4.4 1.1 4.1 4.7 0.16 
   mod 37 3.9 1.4 3.5 4.4  
   severe 17 4.5 .8 4.1 4.9  
   Total 95 4.2 1.2 4.0 4.5  
26 In the last week have you worried about new people handling you? mild 41 4.3 1.1 4.0 4.7 0.55 
   mod 37 4.0 1.2 3.6 4.4  
   severe 17 4.1 1.3 3.5 4.8  
    Total 95 4.2 1.2 3.9 4.4   
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Table 9.8.e  Table to demonstrate item level score differences between OI severity groups at baseline on raw data (Items Q27-33) 
            Confidence Interval  
Item Question   N Mean SD Lower  Upper  Sig. 
27 In the last week did you like to do things for yourself? mild 41 2.0 1.2 1.7 2.4 0.23 
   mod 37 1.7 .9 1.4 2.0  
   severe 17 1.6 .6 1.3 1.9  
   Total 95 1.8 1.0 1.6 2.0  
28 In the last week did your family encourage you to do things for yourself? mild 41 2.3 1.3 1.9 2.7 0.12 
   mod 37 2.4 1.3 1.9 2.8  
   severe 17 1.6 1.1 1.0 2.2  
   Total 95 2.2 1.3 1.9 2.4  
29 In the last week did you have as much freedom as your friends? mild 41 2.3 1.2 2.0 2.7 0.12 
   mod 37 2.6 1.3 2.2 3.0  
   severe 17 3.1 1.5 2.4 3.9  
   Total 95 2.6 1.3 2.3 2.9  
30 In the last week did your family let you make your own decision about what is safe? mild 41 2.8 1.4 2.3 3.2 0.78 
   mod 36 2.6 1.3 2.2 3.0  
   severe 16 2.6 1.5 1.8 3.3  
   Total 93 2.7 1.4 2.4 2.9  
31 In the last week did the teachers at school over protect you? mild 41 3.8 1.2 3.4 4.2 0.09 
   mod 37 3.4 1.5 2.9 3.9  
   severe 17 2.9 1.3 2.3 3.6  
   Total 95 3.5 1.4 3.2 3.8  
32 In the last week did the teachers at school stop you doing things that you think are safe? mild 41 4.2 1.0 3.8 4.5 0.10 
   mod 37 4.0 1.3 3.6 4.4  
   severe 17 3.4 1.5 2.7 4.2  
   Total 95 4.0 1.2 3.7 4.2  
33 In the last week did your family let you choose your own activities? mild 41 2.2 1.2 1.8 2.6 0.99 
   mod 37 2.2 1.2 1.8 2.6  
   severe 17 2.2 1.3 1.6 2.9  
   Total 95 2.2 1.2 2.0 2.4  
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Table 9.8.f  Table to demonstrate item level score differences between OI severity groups at baseline on raw data (Items Q34-39) 
 
            Confidence Interval  
Item Question   N Mean SD Lower  Upper  Sig. 
34 In the last week did you see your friends outside of school? mild 41 2.9 1.5 2.4 3.4 0.96 
   mod 36 2.9 1.5 2.4 3.4  
   severe 17 3.0 1.5 2.3 3.7  
   Total 94 2.9 1.5 2.6 3.2  
35 In the last week were you able to do everything your friends do? mild 41 2.8 1.3 2.4 3.2 0.86 
   mod 36 2.8 1.3 2.3 3.2  
   severe 17 2.9 1.1 2.4 3.5  
   Total 94 2.8 1.2 2.5 3.1  
36 In the last week did you get to do lots of different activities? mild 41 2.3 1.4 1.9 2.8 0.36 
   mod 35 2.7 1.3 2.2 3.1  
   severe 17 2.8 1.3 2.2 3.5  
   Total 93 2.6 1.3 2.3 2.8  
37 In the last week did you feel different because you have to be more careful than your friends? mild 41 2.9 1.5 2.4 3.4 0.74 
   mod 36 2.9 1.4 2.5 3.4  
   severe 17 3.2 1.3 2.6 3.9  
   Total 94 3.0 1.4 2.7 3.3  
38 In the last week have people treated you differently because you have brittle bones? mild 41 3.0 1.4 2.6 3.5 0.92 
   mod 36 3.2 1.4 2.7 3.6  
   severe 17 3.2 1.3 2.5 3.8  
   Total 94 3.1 1.4 2.8 3.4  
39 In a normal school week do you do PE? mild 41 2.2 1.5 1.7 2.7 0.59 
   mod 36 2.6 1.7 2.0 3.1  
   severe 17 2.2 1.6 1.4 3.0  
   Total 94 2.3 1.6 2.0 2.7  
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Table 9.9.  Table to demonstrate dimension score differences between OI severity 
groups at baseline. 
    Mild  Moderate Severe p value 
OIQoL Being safe and careful  N 40 37 17 0.53 
(0-100) Mean 37.2 33.5 28.9  
  SD 28.4 23.6 23.5   
OIQoL Reduced function dimension  N 41 37 17 0.00 
(0-100) Mean 68.7 58.3 50.9  
  SD 20.1 19.1 17.5  
OIQoL Pain dimension (0-100) N 41 37 17 0.84 
  Mean 75.7 73.1 73.3  
  SD 19.4 20.6 24.7   
OIQoL Fear dimension (0-100) N 40 37 17 0.30 
  Mean 76.7 69.5 76.5  
  SD 18.8 24.3 21.5  
OIQoLIndependence dimension N 41 36 16 0.76 
(0-100) Mean 69.1 68 65.6  
  SD 14.9 15.1 18.8   
OIQoL Isolation dimension (0-100) N 41 35 17 0.92 
  Mean 57.4 55.7 55.9  
  SD 21.1 20.2 15.5  
EQ-5D Overall Utility (VAS) 
N 41 37 15 0.94 
  
Mean 71.6 69.9 71.4  
  
SD 22.4 23 17.8   
EQ-5D Overall Utility (Tariff)  
N 41 37 16 0.17 
  
Mean 0.9 0.9 0.9  
  
SD 0.04 0.06 0.06  
PedsQL Physical Functioning (0-100)  
N 41 37 16 0.07 
 
Mean 55.2 48.7 39.6  
  
SD 26.5 21.3 16   
PedsQL Emotional Functioning (0-
100) N 41 37 16 0.65 
 
Mean 67.7 65.9 71.6  
  
SD 23.2 17.1 18.3  
PedsQL Social Functioning (0-100)  
N 41 37 16 0.65 
 
Mean 69.5 65.5 66.9  
  
SD 20.9 18.3 15.2   
PedsQL School Functioning (0-100)  
N 41 37 16 0.56 
 
Mean 64 59.6 63.8  
  
SD 17.9 22.8 11.6  
PedsQL psychosocial health 
N 41 37 15 0.57 
summary score (0-100) 
Mean 67.1 63.7 67.3  
  
SD 17.1 15.7 9.4   
PedsQL Total scale score (0-100)  
N 41 37 16 0.48 
 Mean 64.1 59.9 60.5  
  SD 18.3 15.1 9.3   
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Tables 9.10.a  Table to demonstrate item level score differences between treatment 
groups (Pamidronate, Risedronate, Zoledronate, Nil) at baseline on raw data (items 
Q1-6). 
 
 
  N Mean 
Std. 
Deviation 
95% Confidence 
Interval for Mean   
Lower 
Bound 
Upper 
Bound Sig 
Q1 In the last week did  
someone give you extra help 
to keep you safe?  
NIL 14 2.57 1.34 1.80 3.35 0.06 
PAM 62 2.61 1.32 2.28 2.95  
RISE 15 2.00 1.31 1.27 2.73  
ZOL 4 1.00 0.00 1.00 1.00  
Total 95 2.44 1.33 2.17 2.71  
Q2 In the last week did you 
keep away from busy areas to 
keep safe?  
NIL 14 2.79 1.12 2.14 3.43 0.71 
PAM 62 2.53 1.34 2.19 2.87  
RISE 15 2.27 1.39 1.50 3.03  
ZOL 4 2.25 1.89 -0.76 5.26  
Total 95 2.52 1.33 2.25 2.79   
Q3 In the last week did you 
keep away from crowds to 
keep safe?  
NIL 14 2.79 1.37 2.00 3.58 0.40 
PAM 62 2.61 1.41 2.26 2.97  
RISE 15 2.00 1.25 1.31 2.69  
ZOL 4 2.25 1.89 -0.76 5.26  
Total 95 2.53 1.40 2.24 2.81  
Q4 In the last week did you try 
to keep safe to stop you 
breaking a bone? 
NIL 14 2.21 1.48 1.36 3.07 0.78 
PAM 62 1.90 1.24 1.59 2.22  
RISE 15 1.73 1.28 1.02 2.44  
ZOL 4 2.00 1.41 -0.25 4.25  
Total 95 1.93 1.27 1.67 2.19   
Q5 In the last week did you 
keep away from some 
activities to stop you having a 
broken bone? 
NIL 14 2.64 1.50 1.78 3.51 0.52 
PAM 62 2.48 1.42 2.12 2.85  
RISE 15 2.33 1.50 1.50 3.16  
ZOL 4 3.50 1.00 1.91 5.09  
Total 95 2.53 1.43 2.24 2.82  
Q6 In the last week did you 
think before playing sports to 
avoid having a broken bone? 
NIL 13 2.62 1.45 1.74 3.49 0.11 
PAM 62 2.27 1.52 1.89 2.66  
RISE 15 1.67 1.05 1.09 2.25  
ZOL 4 3.50 1.91 0.45 6.55  
Total 94 2.28 1.48 1.97 2.58   
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Tables 9.10.b  Table to demonstrate item level score differences between treatment 
groups (Pamidronate, Risedronate, Zoledronate, Nil) at baseline on raw data (items 
Q7-14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  N Mean 
Std. 
Deviation 
95% Confidence 
Interval for Mean   
Lower 
Bound 
Upper 
Bound Sig 
Q7 In the last week have you 
felt tired in the day? 
NIL 14 3.07 1.38 2.27 3.87 0.24 
PAM 62 2.40 1.06 2.13 2.67  
RISE 15 2.47 0.99 1.92 3.02  
ZOL 4 2.75 1.26 0.75 4.75  
Total 95 2.53 1.12 2.30 2.75  
Q8 In the last week have you 
felt tired by the end of the 
day? 
NIL 14 2.79 1.31 2.03 3.54 0.39 
PAM 62 2.26 1.30 1.93 2.59  
RISE 15 2.67 1.23 1.98 3.35  
ZOL 4 2.00 0.82 0.70 3.30  
Total 95 2.39 1.28 2.13 2.65   
Q9 In the last week did you 
have to take rests in the day? 
NIL 14 3.79 1.05 3.18 4.39 0.49 
PAM 62 3.48 1.10 3.21 3.76  
RISE 15 3.20 1.47 2.38 4.02  
ZOL 4 3.00 1.63 0.40 5.60  
Total 95 3.46 1.17 3.22 3.70  
Q10 In the last week has 
having a broken bone 
stopped you doing things? 
NIL 14 4.07 1.59 3.15 4.99 0.75 
PAM 62 4.02 1.49 3.64 4.39  
RISE 15 3.67 1.54 2.81 4.52  
ZOL 4 4.50 1.00 2.91 6.09  
Total 95 3.99 1.48 3.69 4.29   
Q11 In the last week has it 
been more difficult to move 
around because of a broken 
bone? 
NIL 14 4.43 1.28 3.69 5.17 0.22 
PAM 62 4.32 1.25 4.00 4.64  
RISE 15 3.80 1.37 3.04 4.56  
ZOL 4 3.25 2.06 -0.03 6.53  
Total 95 4.21 1.32 3.94 4.48  
Q12 In the last week have 
you had to do things 
differently because of a 
broken bone? 
NIL 14 4.50 0.94 3.96 5.04 0.05 
PAM 62 4.27 1.26 3.96 4.59  
RISE 15 3.33 1.84 2.32 4.35  
ZOL 4 3.50 1.73 0.74 6.26  
Total 95 4.13 1.38 3.85 4.41   
Q13 In the last week did you 
use equipment help you to 
move around? 
NIL 14 4.43 1.16 3.76 5.10 0.04 
PAM 62 3.53 1.57 3.13 3.93  
RISE 15 3.53 1.77 2.55 4.51  
ZOL 4 2.00 1.15 0.16 3.84  
Total 95 3.60 1.58 3.28 3.92  
Q14 In the last week did you 
have to use equipment to help 
at school or home? 
NIL 14 4.29 1.20 3.59 4.98 0.04 
PAM 62 3.16 1.70 2.73 3.59  
RISE 15 3.67 1.76 2.69 4.64  
ZOL 4 2.00 1.41 -0.25 4.25  
Total 95 3.36 1.69 3.01 3.70   
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Tables 9.10.c  Table to demonstrate item level score differences between treatment 
groups  (Pamidronate, Risedronate, Zoledronate, Nil) at baseline on raw data (items 
Q15-20). 
 
 
 
  N Mean 
Std. 
Deviation 
95% Confidence 
Interval for Mean   
Lower 
Bound 
Upper 
Bound Sig 
Q15 In the last week have 
you had pain in your back? 
NIL 14 4.00 0.96 3.45 4.55 0.27 
PAM 62 3.32 1.26 3.00 3.64  
RISE 15 3.73 1.28 3.02 4.44  
ZOL 4 3.50 1.73 0.74 6.26  
Total 95 3.49 1.25 3.24 3.75  
Q16 In the last week have 
you had pain in your legs or 
arms? 
NIL 14 3.64 1.22 2.94 4.34 0.90 
PAM 62 3.40 1.31 3.07 3.74  
RISE 15 3.33 1.11 2.72 3.95  
ZOL 4 3.25 1.71 0.53 5.97  
Total 95 3.42 1.27 3.16 3.68   
Q17 In the last week have 
you had to take medicine for 
pain? 
NIL 14 4.29 1.14 3.63 4.94 0.62 
PAM 62 3.77 1.31 3.44 4.11  
RISE 15 3.73 1.53 2.88 4.58  
ZOL 4 3.75 1.89 0.74 6.76  
Total 95 3.84 1.34 3.57 4.11  
Q18 In the last week have 
you had to take medicine 
because you broke a bone? 
NIL 14 4.86 0.53 4.55 5.17 0.22 
PAM 62 4.60 1.00 4.34 4.85  
RISE 15 4.13 1.51 3.30 4.97  
ZOL 4 5.00 0.00 5.00 5.00  
Total 95 4.58 1.04 4.37 4.79   
Q19 In the last week did you 
have pain because you had 
a broken bone? 
NIL 14 4.64 0.74 4.21 5.07 0.37 
PAM 62 4.37 1.23 4.06 4.68  
RISE 15 3.87 1.60 2.98 4.75  
ZOL 4 4.00 2.00 0.82 7.18  
Total 95 4.32 1.27 4.06 4.58  
Q20 In the last week have 
you missed meeting up with 
your friends because you 
had pain? 
NIL 14 4.21 1.12 3.57 4.86 0.96 
PAM 62 4.19 1.24 3.88 4.51  
RISE 15 4.00 1.51 3.16 4.84  
ZOL 4 4.25 1.50 1.86 6.64  
Total 95 4.17 1.26 3.91 4.43   
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Tables 9.10.d  Table to demonstrate item level score differences between treatment 
groups (Pamidronate, Risedronate, Zoledronate, Nil) at baseline on raw data (items 
Q21-26). 
 
 
 
  N Mean 
Std. 
Deviation 
95% Confidence 
Interval for Mean   
Lower 
Bound 
Upper 
Bound Sig 
Q21 In the last week have you 
been worried about breaking 
a bone? 
NIL 14 3.36 1.39 2.55 4.16 0.34 
PAM 62 3.85 1.30 3.52 4.19  
RISE 15 3.27 1.28 2.56 3.98  
ZOL 4 3.75 1.50 1.36 6.14  
Total 95 3.68 1.32 3.41 3.95  
Q22 In the last week did you 
get scared about doing 
something that might make 
you break a bone? 
NIL 14 3.79 1.42 2.96 4.61 0.27 
PAM 62 3.98 1.18 3.68 4.28  
RISE 15 3.27 1.39 2.50 4.03  
ZOL 4 4.00 1.41 1.75 6.25  
Total 95 3.84 1.27 3.58 4.10   
Q23 In the last week did you 
worry about coming into 
hospital? 
NIL 14 4.50 0.65 4.12 4.88 0.24 
PAM 62 3.95 1.35 3.61 4.29  
RISE 15 3.80 1.08 3.20 4.40  
ZOL 4 4.75 0.50 3.95 5.55  
Total 95 4.04 1.22 3.79 4.29  
Q24 In the last week did you 
get scared about needles? 
NIL 13 3.62 1.50 2.71 4.52 0.88 
PAM 62 3.79 1.60 3.38 4.20  
RISE 15 3.47 1.55 2.61 4.33  
ZOL 4 4.00 2.00 0.82 7.18  
Total 94 3.72 1.58 3.40 4.05   
Q25 In the last week did you 
worry that someone might 
move you wrong and cause a 
broken bone? 
NIL 14 3.86 1.35 3.08 4.64 0.11 
PAM 62 4.42 0.93 4.18 4.66  
RISE 15 3.73 1.67 2.81 4.66  
ZOL 4 4.50 1.00 2.91 6.09  
Total 95 4.23 1.16 3.99 4.47  
Q26 In the last week have you 
worried about new people 
handling you? 
NIL 14 4.21 1.19 3.53 4.90 0.08 
PAM 62 4.34 1.02 4.08 4.60  
RISE 15 3.47 1.36 2.72 4.22  
ZOL 4 4.00 2.00 0.82 7.18  
Total 95 4.17 1.17 3.93 4.41   
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Tables 9.10.e  Table to demonstrate item level score differences between treatment 
groups (Pamidronate, Risedronate, Zoledronate, Nil) at baseline on raw data (items 
Q27-33). 
 
 
  N Mean 
Std. 
Deviation 
95% Confidence 
Interval for Mean   
Lower 
Bound 
Upper 
Bound Sig 
Q27 In the last week did you 
like to do things for yourself? 
NIL 14 1.79 1.19 1.10 2.47 0.96 
PAM 62 1.85 0.99 1.60 2.11  
RISE 15 1.73 0.80 1.29 2.18  
ZOL 4 2.00 1.41 -0.25 4.25  
Total 95 1.83 1.00 1.63 2.03  
Q28 In the last week did your 
family encourage you to do 
things for yourself? 
NIL 14 2.29 1.14 1.63 2.94 0.41 
PAM 62 2.29 1.41 1.93 2.65  
RISE 15 1.80 1.01 1.24 2.36  
ZOL 4 1.50 1.00 -0.09 3.09  
Total 95 2.18 1.30 1.91 2.44   
Q29 In the last week did you 
have as much freedom as 
your friends? 
NIL 14 2.43 1.40 1.62 3.24 0.40 
PAM 62 2.71 1.31 2.38 3.04  
RISE 15 2.13 1.19 1.48 2.79  
ZOL 4 3.00 1.41 0.75 5.25  
Total 95 2.59 1.31 2.32 2.86  
Q30 In the last week did your 
family let you make your own 
decision about what is safe? 
NIL 14 2.86 1.41 2.05 3.67 0.54 
PAM 60 2.65 1.40 2.29 3.01  
RISE 15 2.80 1.32 2.07 3.53  
ZOL 4 1.75 0.96 0.23 3.27  
Total 93 2.67 1.37 2.38 2.95   
Q31 In the last week did the 
teachers at school over 
protect you? 
NIL 14 3.07 1.38 2.27 3.87 0.39 
PAM 62 3.45 1.43 3.09 3.82  
RISE 15 3.87 1.06 3.28 4.45  
ZOL 4 4.00 1.15 2.16 5.84  
Total 95 3.48 1.37 3.21 3.76  
Q32 In the last week did the 
teachers at school stop you 
doing things that you think are 
safe? 
NIL 14 4.36 0.84 3.87 4.84 0.40 
PAM 62 3.82 1.36 3.48 4.17  
RISE 15 4.20 0.94 3.68 4.72  
ZOL 4 4.25 0.96 2.73 5.77  
Total 95 3.98 1.23 3.73 4.23   
Q33 In the last week did your 
family let you choose your 
own activities? 
NIL 14 2.36 1.28 1.62 3.09 0.56 
PAM 62 2.26 1.28 1.93 2.58  
RISE 15 2.00 1.00 1.45 2.55  
ZOL 4 1.50 0.58 0.58 2.42  
Total 95 2.20 1.22 1.95 2.45  
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Tables 9.10.f  Table to demonstrate item level score differences between treatment 
groups (Pamidronate, Risedronate, Zoledronate, Nil) at baseline on raw data (items 
Q34-39). 
 
 
 
  N Mean 
Std. 
Deviation 
95% Confidence 
Interval for Mean   
Lower 
Bound 
Upper 
Bound Sig 
Q34 In the last week did you 
see your friends outside of 
school? 
NIL 14 3.36 1.55 2.46 4.25 0.01 
PAM 62 2.77 1.43 2.41 3.14  
RISE 14 2.43 1.40 1.62 3.24  
ZOL 4 5.00 0.00 5.00 5.00  
Total 94 2.90 1.49 2.60 3.21   
Q35 In the last week were you 
able to do everything your 
friends do? 
NIL 14 2.36 1.15 1.69 3.02 0.28 
PAM 62 2.94 1.33 2.60 3.27  
RISE 14 2.50 0.85 2.01 2.99  
ZOL 4 3.25 0.96 1.73 4.77  
Total 94 2.80 1.24 2.54 3.05  
Q36 In the last week did you 
get to do lots of different 
activities? 
NIL 14 2.21 1.05 1.61 2.82 0.70 
PAM 61 2.59 1.38 2.24 2.94  
RISE 14 2.64 1.34 1.87 3.41  
ZOL 4 3.00 1.83 0.09 5.91  
Total 93 2.56 1.34 2.28 2.83   
Q37 In the last week did you 
feel different because you 
have to be more careful than 
your friends? 
NIL 14 2.29 1.38 1.49 3.08 0.18 
PAM 62 3.08 1.43 2.72 3.44  
RISE 14 3.07 1.21 2.37 3.77  
ZOL 4 3.75 1.89 0.74 6.76  
Total 94 2.99 1.43 2.70 3.28  
Q38 In the last week have 
people treated you differently 
because you have brittle 
bones? 
NIL 14 3.07 1.33 2.30 3.84 0.07 
PAM 62 2.94 1.40 2.58 3.29  
RISE 14 4.00 1.04 3.40 4.60  
ZOL 4 3.00 1.41 0.75 5.25  
Total 94 3.12 1.37 2.84 3.40   
Q39 In a normal school week 
do you do PE? 
NIL 14 2.36 1.65 1.41 3.31 0.37 
PAM 62 2.19 1.49 1.81 2.57  
RISE 14 2.64 1.86 1.57 3.72  
ZOL 4 3.50 1.91 0.45 6.55  
Total 94 2.34 1.59 2.01 2.67   
 
Tables 9.10. a-f demonstrate significant differences between treatment groups 
(Pamidronate, Risedronate, Zoledronate, Nil (no treatment) for items Q12, Q13, Q14, 
and Q34.  Item Q12 demonstrates significantly lower scores for individuals on 
Zoledronate, with individuals on no treatment (Nil) reporting the highest score and 
therefore better QoL.  Items Q13 and Q14 demonstrate significantly lower scores for 
individuals on Zoledronate, again with individuals on no treatment reporting the highest 
score.  However, item Q34 demonstrates a different picture, with those individuals on 
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Zoledronate reporting a higher score (i.e. answering ‘never’ to the item; in the last week 
did you see your friends outside of school) and therefore lower QoL.  For this item 
(Q34) individuals on Risedronate reported significantly worse QoL. 
 
As it is anecdotally reported by patients that they feel better immediately following 
Pamidronate and that this feeling gradually wears off over the next three months, when 
prior to their next treatment they report beginning to feel achy and experience pain.  
This change in reported symptoms following a three month cycle is not reported by 
individuals who take Zoledronate, Risedronate or no treatment, as their treatment has 
less reported up and downs, is taken weekly in the case of Risedronate and six 
monthly in the case of Zoledronate.  Therefore it was considered that there may be a 
noticeable difference between those individuals treated with Pamidronate and the 
patients receiving other treatment options (tables 9.11 and 9.12). 
 
Again items Q13 and Q14 (Table 9.11) demonstrate a significant difference between 
treatments; with those receiving Pamidronate reporting a lower score (lower QoL).  
Item Q23 also demonstrates a significant difference with those individuals on 
Pamidronate reporting a lower score, which may have been due to their need to be 
admitted to hospital for an intravenous infusion.  However, item Q37 demonstrated a 
significant difference between treatments with those patients not receiving Pamidronate 
reporting a lower score (lower QoL). 
 
From table 9.12 it can be seen that items Q10, Q11, Q12, Q13, Q18 and Q19 all 
demonstrate significant difference between treatment options, with those individuals 
receiving Pamidronate gaining lower scores at the three month follow up, this may 
support the notion that individuals receiving Pamidronate report a return of some 
symptoms and a resultant reduction in QoL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
213 
Table 9.11.  Table to demonstrate item level score differences between Pamidronate and other treatment options (Rise, Zol, Nil) with 
hypothesised known groups at one week retest (raw data). 
 
  Pamidronate   Risedronate, Zoledronate, Nil   Confidence Interval   
Any drug treatment effects (yes or no) N Mean SD N  Mean SD Mean diff Lower Upper Sig. (2-tailed) 
Q1 In the last week did someone give you extra 
help to keep you safe?  
 
81 2.42 1.34 14 2.57 1.34 -0.15 -0.97 0.67 0.70 
Q2 In the last week did you keep away from 
busy areas to keep safe?  
 
81 2.47 1.36 14 2.47 1.12 -0.32 -1.02 0.38 0.36 
Q3 In the last week did you keep away from 
crowds to keep safe?  
 
81 2.48 1.41 14 2.79 1.37 -0.30 -1.14 0.53 0.45 
Q4 In the last week did you try to keep safe to 
stop you breaking a bone? 
 
81 1.88 1.24 13 2.21 1.48 -0.34 -1.22 0.55 0.43 
Q5 In the last week did you keep away from 
some activities to stop you having a broken 
bone? 
 
81 2.51 1.42 14 2.64 1.50 -0.14 -1.04 0.77 0.75 
Q6 In the last week you think before playing 
sports to avoid having a broken bone? 
 
81 2.22 1.49 13 2.62 1.45 -0.39 -1.31 0.53 0.38 
Q7 In the last week have you felt tired in the 
day? 
81 2.43 1.05 14 3.07 1.39 -0.64 -1.46 0.19 0.12 
Q8 In the last week have you felt tired by the 
end of the day? 
 
81 2.32 1.27 14 2.79 1.31 -0.47 -1.26 0.33 0.24 
Q9 In the last week did you have to take rests in 
the day? 
 
81 3.41 1.19 14 3.79 1.05 -0.38 -1.03 0.27 0.24 
Q10 In the last week has having a broken bone 
stopped you doing things? 
 
81 3.98 1.47 14 4.07 1.59 -0.10 -1.06 0.87 0.84 
Q11 In the last week has it been more difficult 
to move around because of a broken bone? 
81 4.17 1.33 14 4.43 1.28 -0.26 -1.04 0.53 0.50 
 
Q12 In the last week have you had to do things 
differently because of a broken bone? 
81 4.06 1.43 14 4.50 0.94 -0.44 -1.05 0.18 0.15 
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Q13 In the last week did you use equipment 
help you to move around? 
 
81 3.46 1.61 14 4.43 1.16 -0.97 -1.71 -0.23 0.01 
Q14 In the last week did you have to use 
equipment to help at school or home? 
 
81 3.20 1.71 14 4.29 1.20 -1.09 -1.86 -0.32 0.01 
Q15 In the last week have you had pain in your 
back? 
 
81 3.41 1.28 14 4.00 0.96 -0.59 -1.20 0.02 0.06 
Q16 In the last week have you had pain in your 
legs or arms? 
 
81 3.38 1.28 14 3.64 1.22 -0.26 -1.00 0.48 0.47 
Q17In the last week have you had to take 
medicine for pain? 
 
81 3.77 1.36 14 4.29 1.14 -0.52 -1.23 0.19 0.14 
Q18 In the last week have you had to take 
medicine because you broke a bone? 
 
81 4.53 1.10 14 4.86 0.54 -0.33 -0.71 0.06 0.09 
Q19 In the last week did you have pain because 
you had a broken bone? 
 
81 4.26 1.34 14 4.64 0.75 -0.38 -0.89 0.12 0.13 
Q20 In the last week have you missed meeting 
up with your friends because you had pain? 
 
81 4.16 1.29 14 4.21 1.12 -0.05 -0.75 0.64 0.87 
Q21 In the last week have you been worried 
about breaking a bone? 
 
81 3.74 1.31 14 3.36 1.39 0.38 -0.46 1.23 0.35 
Q22 In the last week did you get scared about 
doing something that might make you break a 
bone? 
 
81 3.85 1.25 14 3.79 1.42 0.07 -0.79 0.92 0.87 
Q23 In the last week did you worry about 
coming into hospital? 
 
81 3.96 1.28 14 4.50 0.65 -0.54 -0.99 -0.08 0.02 
Q24 In the last week did you get scared about 
needles? 
 
81 3.74 1.60 13 3.62 1.50 0.13 -0.83 1.08 0.79 
Q25 In the last week did you worry that 
someone might move you wrong and cause a 
broken bone? 
81 4.30 1.12 14 3.86 1.35 0.44 -0.37 1.25 0.27 
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Q26 In the last week have you worried about 
new people handling you? 
 
81 4.16 1.18 14 4.21 1.19 -0.05 -0.78 0.67 0.88 
Q27 In the last week did you like to do things for 
yourself? 
 
81 1.84 0.97 14 1.79 1.19 0.05 -0.66 0.76 0.87 
Q28 In the last week did your family encourage 
you to do things for yourself? 
 
81 2.16 1.34 14 2.29 1.14 -0.13 -0.83 0.58 0.72 
Q29 In the last week did you have as much 
freedom as your friends? 
 
81 2.62 1.30 14 2.43 1.40 0.19 -0.66 1.03 0.64 
Q30 In the last week did your family let you 
make your own decision about what is safe? 
 
79 2.63 1.37 14 2.86 1.41 -0.22 -1.08 0.63 0.59 
Q31 In the last week did the teachers at school 
over protect you? 
 
81 3.56 1.36 14 3.07 1.39 0.48 -0.36 1.33 0.24 
Q32 In the last week did the teachers at school 
stop you doing things that you think are safe? 
 
81 3.91 1.28 14 4.36 0.84 -0.44 -0.99 0.11 0.11 
Q33 In the last week did your family let you 
choose your own activities? 
 
81 2.17 1.21 14 2.36 1.28 -0.18 -0.96 0.59 0.62 
Q34 In the last week did you see your friends 
outside of school? 
 
80 2.83 1.47 14 3.36 1.55 -0.53 -1.47 0.41 0.25 
Q35 In the last week were you able to do 
everything your friends do? 
 
80 2.88 1.25 14 2.36 1.15 0.52 -0.19 1.23 0.14 
Q36 In the last week did you get to do lots of 
different activities? 
 
79 2.62 1.38 14 2.21 1.05 0.41 -0.26 1.07 0.22 
Q37 In the last week did you feel different 
because you have to be more careful than your 
friends? 
 
80 3.11 1.41 14 2.29 1.38 0.83 -0.02 1.67 0.05 
Q38 In the last week have people treated you 
differently because you have brittle bones? 
 
80 3.13 1.39 14 3.07 1.33 0.54 -0.76 0.87 0.89 
Q39 In a normal school week do you do PE? 80 2.34 1.59 14 2.36 1.65 -0.02 -1.02 0.98 0.97 
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Table 9.12.  Table to demonstrate item level score differences between Pamidronate and other treatment options (Rise, Zol, Nil) with 
hypothesised known groups at three months (raw data). 
 
  Pamidronate   Risedronate, Zoledronate, Nil   Confidence Interval   
Any drug treatment effects (yes or no) N Mean SD N  Mean SD Mean diff Lower Upper Sig. (2-tailed 
Q1 In the last week did someone give you extra help 
to keep you safe?  
 
64 2.84 1.32 9 3.11 1.69 -0.27 -1.59 1.05 0.66 
Q2 In the last week did you keep away from busy 
areas to keep safe?  
 
64 2.59 1.37 9 2.22 1.48 0.37 -0.79 1.54 0.49 
Q3 In the last week did you keep away from crowds 
to keep safe?  
 
64 2.77 1.33 9 2.33 1.41 0.43 -0.68 1.54 0.41 
Q4 In the last week did you try to keep safe to stop 
you breaking a bone? 
 
64 2.13 1.36 9 2.44 1.67 -0.32 -1.62 0.98 0.60 
Q5 In the last week did you keep away from some 
activities to stop you having a broken bone? 
 
64 2.59 1.44 9 1.89 1.27 0.70 -0.31 1.72 0.15 
Q6 In the last week did you think before playing 
sports to avoid having a broken bone? 
 
64 2.41 1.49 9 1.89 1.17 0.52 -0.42 1.46 0.25 
Q7 In the last week have you felt tired in the day? 
 
64 2.77 1.11 9 2.78 1.56 -0.01 -1.23 1.20 0.98 
Q8 In the last week have you felt tired by the end of 
the day? 
 
64 2.25 1.21 9 2.33 1.50 -0.08 -1.26 1.09 0.88 
Q9 In the last week did you have to take rests in the 
day? 
 
64 3.38 1.25 9 3.11 1.62 0.26 -1.00 1.52 0.65 
Q10 In the last week has having a broken bone 
stopped you doing things? 
 
64 4.34 1.26 9 5.00 0.00 -0.66 -0.97 -0.34 0.00 
Q11 In the last week has it been more difficult to 
move around because of a broken bone? 
 
64 4.47 1.19 9 5.00 0.00 -0.53 -0.83 -0.23 0.00 
Q12 In the last week have you had to do things 
differently because of a broken bone? 
64 4.39 1.20 9 5.00 0.00 -0.61 -0.91 -0.31 0.00 
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Q13 In the last week did you use equipment help 
you to move around? 
 
64 3.64 1.52 9 4.67 0.71 -1.03 -1.66 -0.40 0.00 
Q14 In the last week did you have to use equipment 
to help at school or home? 
 
64 3.31 1.64 9 3.33 1.87 -0.02 -1.49 1.45 0.98 
Q15 In the last week have you had pain in your 
back? 
 
64 3.33 1.39 9 2.67 1.32 0.66 -0.39 1.71 0.19 
Q16 In the last week have you had pain in your legs 
or arms? 
 
64 3.20 1.26 9 2.78 1.09 0.43 -0.45 1.30 0.31 
Q17In the last week have you had to take medicine 
for pain? 
 
64 3.70 1.38 9 3.78 1.09 -0.07 -0.95 0.80 0.86 
Q18 In the last week have you had to take medicine 
because you broke a bone? 
 
64 4.55 1.11 9 5.00 0.00 -0.45 -0.73 -0.18 0.00 
Q19 In the last week did you have pain because you 
had a broken bone? 
 
64 4.48 1.20 9 5.00 0.00 -0.52 -0.81 -0.22 0.00 
Q20 In the last week have you missed meeting up 
with your friends because you had pain? 
 
64 4.38 1.08 9 4.44 1.01 -0.07 -0.87 0.73 0.85 
Q21 In the last week have you been worried about 
breaking a bone? 
 
64 3.56 1.40 9 3.22 1.48 0.34 -0.83 1.51 0.53 
Q22 In the last week did you get scared about doing 
something that might make you break a bone? 
 
64 3.69 1.33 9 3.33 1.50 0.35 -0.82 1.53 0.52 
Q23 In the last week did you worry about coming 
into hospital? 
 
64 4.06 1.40 9 3.78 1.48 0.28 -0.88 1.45 0.60 
Q24 In the last week did you get scared about 
needles? 
 
64 4.09 1.44 9 3.00 1.94 1.09 -0.42 2.60 0.14 
Q25 In the last week did you worry that someone 
might move you wrong and cause a broken bone? 
 
64 4.19 1.22 9 3.67 1.41 0.52 -0.59 1.63 0.32 
Q26 Have you worried about new people handling 
you? 
64 4.33 1.16 9 3.67 1.66 0.66 -0.63 1.95 0.28 
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Q27 In the last week did you like to do things for 
yourself? 
 
64 1.72 0.81 9 2.56 1.42 -0.84 -1.94 0.27 0.12 
Q28 In the last week did your family encourage you 
to do things for yourself? 
 
64 2.17 1.23 9 2.11 1.27 0.06 -0.94 1.06 0.90 
Q29 In the last week did you have as much freedom 
as your friends? 
 
64 2.59 1.22 9 2.22 1.48 0.37 -0.79 1.53 0.49 
Q30 In the last week did your family let you make 
your own decision about what is safe? 
 
64 2.28 1.08 9 2.44 1.24 -0.16 -1.13 0.81 0.71 
Q31 In the last week did the teachers at school over 
protect you? 
 
64 3.80 1.30 9 4.00 1.41 -0.20 -1.31 0.91 0.69 
Q32 In the last week did the teachers at school stop 
you doing things that you think are safe? 
 
64 4.19 1.02 9 4.22 1.30 -0.03 -1.05 0.98 0.94 
Q33 In the last week did your family let you choose 
your own activities? 
 
64 2.14 1.13 9 1.89 0.93 0.25 -0.49 1.00 0.47 
Q34 In the last week did you see your friends 
outside of school? 
 
64 2.88 1.35 9 2.89 1.36 -0.01 -1.09 1.06 0.98 
Q35 In the last week were you able to do everything 
your friends do? 
 
64 2.88 1.27 9 2.89 1.27 -0.01 -1.02 0.99 0.98 
Q36 In the last week did you get to do lots of 
different activities? 
 
64 2.45 1.13 9 2.67 1.22 -0.21 -1.18 0.75 0.63 
Q37 In the last week did you feel different because 
you have to be more careful than your friends? 
 
64 3.31 1.22 9 2.44 1.51 0.87 -0.31 2.05 0.13 
Q38 In the last week have people treated you 
differently because you have brittle bones? 
 
64 3.17 1.23 9 3.00 1.73 0.17 -1.18 1.52 0.78 
Q39 In a normal school week do you do PE?  64 2.56 1.51 9 2.78 1.56 -0.22 -1.45 1.02 0.71 
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9.4.6 Internal Consistency of the OIQoL 
 
Cronbach’s alpha for the complete 39 item OIQoL is 0.86.  This is a score which is well 
above the 0.70 level required to demonstrate internal consistency as stated by Fayers 
and Machin (2007).  They also suggested for comparisons between individuals a 
higher Cronbach’s alpha score of 0.80 would be more appropriate.  
 
9.4.7 Examining each dimension 
 
Table 9.13.  Baseline statistics and Cronbach’s alpha scores for each of the 
dimensions in the OIQoL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9.13 presents Cronbach’s alpha scores for each dimension within the OIQoL.  It 
can be seen from this table that the first four dimensions have Cronbach’s alpha scores 
of above 0.70, the suggested level of requirement for a questionnaire with reasonable 
internal consistency.  However the latter two dimensions (Independence and Isolation) 
have much lower Cronbach’s alpha scores, indicating some items may not 
demonstrate good fit with the concept or construct of these dimensions, and suggesting 
there are problems regarding the internal consistency, highlighting the need to explore 
these dimensions more closely.   
 
 
 
 
 
 
  Number 
of items 
Valid N No. 
Missing 
Cronbach’s 
alpha 
Mean Median Standard 
Deviation 
OIQoL Being 
safe and 
careful 
dimension (0-
100) 
6 94 1 0.84 34.2 29.2 25.6 
OIQoL 
Reduced 
function 
dimension                  
(0-100) 
8 95 0 0.72 61.4 62.5 20.3 
OIQoL Pain 
dimension           
(0-100) 
6 95 0 0.75 74.3 79.2 20.7 
OIQoL Fear 
dimension           
(0-100) 
6 94 1 0.76 73.8 79.2 21.6 
OIQoL 
Independence 
dimension           
(0-100) 
7 93 2 0.49 68 67.9 15.6 
OIQoL 
Isolation 
dimension           
(0-100) 
6 93 2 0.56 56.5 54.2 19.6 
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Being safe and careful. 
 
The being safe and careful dimension contains six items, all which have Cronbach’s 
alpha score above the threshold of 0.70.  No improvement would be made to the 
internal consistency of this dimension if items were removed, and all item-total 
correlations are moderate indicating all items correlate well with the construct of this 
dimension (Table 9.14). 
 
Table 9.14.  Item-total statistics for 6 item dimension ‘Being safe and careful’  (n=94) 
 
 
  Scale 
Mean if 
Item 
Deleted 
Scale 
Variance 
if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q1 In the last week did someone give 
you extra help to keep you safe? 
11.8 28.0 0.57 0.39 0.82 
Q2 In the last week did you keep 
away from busy areas to keep safe? 
11.7 27.1 0.65 0.58 0.81 
Q3 In the last week did you keep 
away from crowds to keep safe? 
11.7 27.0 0.62 0.55 0.81 
Q4 In the last week did you try to 
keep safe to stop you breaking a 
bone? 
12.3 26.3 0.76 0.60 0.79 
Q5 In the last week did you keep 
away from some activities to stop you 
having a broken bone? 
11.7 27.4 0.56 0.43 0.82 
Q6 In the last week did you think 
before playing sports to avoid having 
a broken bone? 
11.9 27.2 0.55 0.41 0.83 
 
 
 
 
Reduced function 
 
The reduced function dimension has 8 items, and Cronbach’s alpha is 0.72.  No 
improvement would be made in this value by deleting any items, however items Q7-9 
which discuss aspects of tiredness, have very low item-total correlations <0.3 and are 
therefore not well correlated with the dimension (Table 9.15).  Removing Q7+8 
increases Cronbach’s alpha to 0.74, but Q9 still continues to have a low item-total 
correlation (Table 9.16).  However, choosing to eliminate item Q9 and leaving either 
item Q7 or Q8 has a less positive effect on Cronbach’s alpha and leaves a poorer item-
total correlation (Table 9.17).  It would be tempting statistically to remove all three 
items, but this would not provide good content validity as tiredness was described as 
an important theme within the focus groups.   
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Table 9.15.  Item-total statistics for 8 item dimension ‘Reduced function’  (n=95) 
 
 
  Scale 
Mean if 
Item 
Deleted 
Scale 
Variance 
if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q7 In the last week have you felt tired 
in the day? 
25.1 37.3 0.26 0.38 0.72 
Q8 In the last week have you felt tired 
by the end of the day? 
25.3 36.2 0.27 0.33 0.72 
Q9 In the last week did you have to 
take rests in the day? 
24.2 36.5 0.29 0.34 0.72 
Q10 In the last week has having a 
broken bone stopped you doing 
things? 
23.7 32.2 0.45 0.64 0.69 
Q11 In the last week has it been more 
difficult to move around because of a 
broken bone? 
23.5 31.3 0.61 0.78 0.66 
Q12 In the last week have you had to 
do things differently because of a 
broken bone? 
23.5 32.0 0.52 0.78 0.67 
Q13 In the last week did you use 
equipment to help you to move 
around? 
24.1 30.4 0.52 0.41 0.67 
Q14 In the last week did you have to 
use equipment to help at school or 
home? 
24.3 31.6 0.4 0.38 0.7 
 
 
 
 
Removal of items 7+8:  
  
Table 9.16.  Reliability Statistics following removal of items Q7 and Q8. 
 
 
Cronbach's Alpha N of Items 
0.74 6 
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Table 9.17.  Item-total statistics for dimension ‘Reduced function’, following removal of 
items Q7 and Q8  (n=95) 
 
 
 
  Scale 
Mean if 
Item 
Deleted 
Scale 
Variance if 
Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q9 In the last week did you have 
to take rests in the day? 
19.3 29.8 0.13 0.14 0.78 
Q10 In the last week has having a 
broken bone stopped you doing 
things? 
18.8 22.9 0.54 0.63 0.68 
Q11 In the last week has it been 
more difficult to move around 
because of a broken bone? 
18.5 22.4 0.70 0.78 0.64 
Q12 In the last week have you 
had to do things differently 
because of a broken bone? 
18.6 22.6 0.63 0.77 0.66 
Q13 In the last week did you use 
equipment to help you to move 
around? 
19.2 22.3 0.54 0.40 0.69 
Q14 In the last week did you have 
to use equipment to help at 
school or home? 
19.4 23.9 0.37 0.33 0.74 
 
 
 
Pain 
 
Table 9.18.  Item-total statistics for 6 item dimension ‘Pain’  (n=95) 
 
  Scale 
Mean if 
Item 
Deleted 
Scale 
Variance 
if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q15 In the last week have you had 
pain in your back? 
20.3 19.4 0.34 0.29 0.75 
Q16 In the last week have you had 
pain in your legs or arms? 
20.4 17.5 0.53 0.35 0.70 
Q17In the last week have you had 
to take medicine for pain? 
20.0 16.9 0.54 0.38 0.70 
Q18 In the last week have you had 
to take medicine because you 
broke a bone? 
19.2 19.4 0.46 0.63 0.72 
Q19 In the last week did you have 
pain because you had a broken 
bone? 
19.5 17.3 0.54 0.66 0.70 
Q20 In the last week have you 
missed meeting up with your 
friends because you had pain? 
19.7 17.5 0.53 0.31 0.70 
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The pain dimension includes six items with a Cronbach’s alpha score of 0.75.  Table 
9.18 demonstrates there is no improvement made by removing an item.  The item-total 
correlation for item Q15 is quite low, but is over the recommended 0.3.  Back pain is a 
theme which was discussed throughout the interview and focus group stages of 
concept elicitation and alongside the experience of the principle researcher, this is a 
complaint often described by patients.  For this reason and because of the initially low 
sample size, this item will not be removed at this stage. 
 
Fear 
 
Cronbach’s alpha for the six items within the fear dimension is 0.76 (see Table 9.13).  
Removal of item Q24 would increase the Cronbach’s alpha to 0.79, and as this item 
also demonstrates very poor correlation to other items within this dimension, with an 
ITC score of 0.28 (Table 9.19), its removal would improve the dimension’s internal 
consistency (Table 9.20). 
 
Table 9.19.  Item-total statistics for 6 item dimension ‘Fear’  (n=94) 
 
 
  Scale 
Mean if 
Item 
Deleted 
Scale 
Variance 
if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q21 In the last week have you 
been worried about breaking a 
bone? 
20.0 19.0 0.56 0.50 0.70 
Q22 In the last week did you 
get scared about doing 
something that might make 
you break a bone? 
19.9 17.9 0.70 0.60 0.67 
Q23 In the last week did you 
worry about coming into 
hospital? 
19.7 21.0 0.40 0.26 0.75 
Q24 In the last week did you 
get scared about needles? 
20.0 20.6 0.28 0.22 0.79 
Q25 In the last week did you 
worry that someone might 
move you wrong and cause a 
broken bone? 
19.5 19.2 0.65 0.59 0.69 
Q26 In the last week have you 
worried about new people 
handling you? 
19.6 20.3 0.50 0.37 0.72 
 
 
 
 
Removal of item Q24 increased Cronbach’s alpha to 0.79, but removing this item also 
highlighted the low ITC score for item Q23 (0.26), which is outside the suggested range 
of ITC>0.3.  However if this item was also provisionally removed, Cronbach’s alpha 
score for the dimension would increased to 0.84 as a result, yet content validity in 
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relation to item elicitation would decrease, as these items were discussed at length in 
focus group 1.  
 
Table 9.20.  Item-total statistics for the 5 item dimension ‘Fear’ following removal of 
item Q24  (n=94) 
  Scale 
Mean if 
Item 
Deleted 
Scale 
Variance 
if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q21 In the last week have you been 
worried about breaking a bone? 
16.3 12.8 0.62 0.49 0.73 
Q22 In the last week did you get 
scared about doing something that 
might make you break a bone? 
16.1 12.3 0.73 0.55 0.69 
Q23 In the last week did you worry 
about coming into hospital? 
15.9 16.3 0.26 0.11 0.84 
Q25 In the last week did you worry 
that someone might move you 
wrong and cause a broken bone? 
15.7 13.1 0.71 0.57 0.70 
Q26 In the last week have you 
worried about new people handling 
you? 
15.8 14.3 0.54 0.35 0.75 
 
 
Independence 
 
Table 9.21.  Item-total statistics for the 7 item dimension ‘Independence’  (n=93) 
 
  Scale 
Mean if 
Item 
Deleted 
Scale 
Variance 
if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q27 In the last week did you like 
to do things for yourself? 
21.9 16.9 0.14 0.10 0.48 
Q28 In the last week did your 
family encourage you to do 
things for yourself? 
22.3 14.7 0.26 0.17 0.43 
Q29 In the last week did you 
have as much freedom as your 
friends? 
22.7 13.8 0.36 0.19 0.38 
Q30 In the last week did your 
family let you make your own 
decision about what is safe? 
22.7 13.3 0.39 0.40 0.36 
Q31 In the last week did the 
teachers at school over protect 
you? 
22.5 17.3 -0.01 0.20 0.56 
Q32 In the last week did the 
teachers at school stop you 
doing things that you think are 
safe? 
22.0 16.2 0.15 0.20 0.48 
Q33 In the last week did your 
family let you choose your own 
activities? 
22.3 14.2 0.37 0.34 0.38 
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The independence dimension has an unsatisfactory Cronbach’s alpha score of 0.49; 
removal of any one item does not increase the Cronbach’s alpha score by any 
significant amount. The ITC scores are all quite low, demonstrating the items have very 
little correlation within the dimension at all (table 9.21). A similar pattern is seen in the 
final dimension ‘isolation’. 
 
 
Isolation  
 
Overall Cronbach’s alpha for the isolation dimension is 0.55 which is below the 
suggested accepted level of 0.70.  ITC scores for the items within this dimension are 
very low, with only two items (Q35+36) showing moderate correlation (table 9.22). For 
this reason we chose to examine the latter two dimensions as a singular dimension and 
look for any correlations between items. 
 
 
Table 9.22. Item-total statistics for the 6 item dimension ‘Isolation’ (n=93) 
 
 
  Scale 
Mean if 
Item 
Deleted 
Scale 
Variance if 
Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Q34 Did you see your 
friends outside of 
school? 
16.4 16.8 0.27 0.20 0.52 
Q35 Are you able to do 
everything your friends 
do? 
16.3 15.2 0.57 0.44 0.39 
Q36 Did you get to do 
lots of different 
activities? 
16.1 15.8 0.44 0.29 0.44 
Q37 Do you feel 
different because you 
have to be more careful 
than your friends? 
16.6 16.6 0.31 0.32 0.50 
Q38 Have people 
treated you differently 
because you have brittle 
bones? 
16.4 17.0 0.29 0.37 0.50 
Q39 Did you do PE at 
school? 
15.9 19.6 0.00 0.17 0.65 
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Table 9.23.   Reliability Statistics following the combination of dimensions 
independence and isolation. 
 
 
 
Cronbach's Alpha N of Items 
0.64 13 
 
 
Combining these two dimensions produced a dimension with thirteen items, with a 
Cronbach’s alpha of 0.64 (Table 9.23), but this may be due to the effect of the 
increased number of items reducing the variability.  It is easy to see that a couple of 
item have negative ITC demonstrating that they correlate poorly with this new 
combined dimension and are not measuring a similar construct (Items Q31 and Q39).   
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Table 9.24.  Item-total statistics for combined dimensions ‘Independence’ and 
‘Isolation’, now 13 items and entitled ‘Life skills’  n=93 
 
  Scale 
Mean if 
Item 
Deleted 
Scale 
Variance if 
Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Q27 In the last week did you 
like to do things for yourself? 
41.5 53.1 0.22 0.20 0.63 
Q28 In the last week did your 
family encourage you to do 
things for yourself? 
41.9 50.9 0.25 0.27 0.63 
Q29 In the last week did you 
have as much freedom as 
your friends? 
42.2 45.3 0.60 0.49 0.57 
Q30 In the last week did your 
family let you make your own 
decision about what is safe? 
42.3 49.2 0.33 0.47 0.62 
Q31 In the last week did the 
teachers at school over 
protect you? 
42.1 57.2 -0.08 0.28 0.68 
Q32 In the last week did the 
teachers at school stop you 
doing things that you think 
are safe? 
41.6 53.2 0.16 0.28 0.64 
Q33 In the last week did your 
family let you choose your 
own activities? 
41.9 49.9 0.35 0.40 0.61 
Q34 In the last week did you 
see your friends outside of 
school? 
42.5 51.1 0.19 0.23 0.64 
Q35 In the last week were 
you able to do everything 
your friends do? 
42.4 45.6 0.60 0.60 0.57 
Q36 In the last week did you 
get to do lots of different 
activities? 
42.2 48.4 0.38 0.40 0.61 
Q37 In the last week did you 
feel different because you 
have to be more careful than 
your friends? 
42.6 48.0 0.36 0.43 0.61 
Q38 In the last week have 
people treated you differently 
because you have brittle 
bones? 
42.5 46.7 0.46 0.55 0.59 
Q39 In a normal school week 
do you do PE? 
42.0 56.0 -0.05 0.26 0.69 
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Table 9.25.  Item-total statistics for combined dimension (Life skills) with item removal  
(n=93) 
 
 Scale 
Mean if 
Item 
Deleted 
Scale 
Variance 
if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q27 In the last week did you like 
to do things for yourself? 
34.3 50.5 0.24 0.16 0.72 
Q28 In the last week did your 
family encourage you to do things 
for yourself? 
34.7 48.4 0.26 0.26 0.72 
Q29 In the last week did you 
have as much freedom as your 
friends? 
35.0 43.0 0.61 0.48 0.67 
Q30 In the last week did your 
family let you make your own 
decision about what is safe? 
35.1 45.8 0.39 0.45 0.70 
Q32 In the last week did the 
teachers at school stop you doing 
things that you think are safe? 
34.4 52.0 0.10 0.18 0.74 
Q33 In the last week did your 
family let you choose your own 
activities? 
34.7 47.1 0.38 0.40 0.70 
Q34 In the last week did you see 
your friends outside of school? 
35.4 48.8 0.19 0.22 0.73 
Q35 In the last week were you 
able to do everything your friends 
do? 
35.3 42.8 0.65 0.58 0.66 
Q36 In the last week did you get 
to do lots of different activities? 
35.0 46.3 0.37 0.29 0.70 
Q37 In the last week did you feel 
different because you have to be 
more careful than your friends? 
35.5 45.2 0.40 0.43 0.70 
Q38 In the last week have people 
treated you differently because 
you have brittle bones? 
35.3 44.2 0.48 0.52 0.69 
 
 
Removal of items Q31 and Q39 with poor ITC values results in an eleven item 
dimension with a higher Cronbach’s alpha of 0.72, but still identifies some items with 
low ITC (Q32 and Q34), showing poor correlation with the other items (Table 9.25). 
 
Using the item removal strategy of Cronbach’s alpha >0.7 and ITC values>0.3, a 
further 4 items were removed (Q32, Q34, Q27, Q28), resulting in a 7 item dimension 
with a Cronbach’s alpha score of 0.76 (Table 9.27). 
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Table 9.26.  Reliability statistics of potential 7 item dimension Life skills.    
 
 
 
Cronbach's Alpha N of Items 
0.76 7 
 
 
  
Table 9.27.  Item-total statistics for combined 7 item dimension with removal of 6 items. 
 
 
 
 
 
 
 
 
 
 
  Scale 
Mean if 
Item 
Deleted 
Scale 
Variance 
if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Q29 In the last week did you 
have as much freedom as your 
friends? 
19.9 25.4 0.64 0.47 0.69 
Q35 In the last week were you 
able to do everything your friends 
do? 
20.2 26.4 0.58 0.48 0.70 
Q37 In the last week did you feel 
different because you have to be 
more careful than your friends? 
20.4 26.3 0.47 0.35 0.73 
Q38 In the last week have people 
treated you differently because 
you have brittle bones? 
20.2 27.0 0.45 0.44 0.73 
Q30 In the last week did your 
family let you make your own 
decision about what is safe? 
20.0 27.6 0.40 0.40 0.74 
Q33 In the last week did your 
family let you choose your own 
activities? 
19.6 28.9 0.38 0.36 0.74 
Q36 In the last week did you get 
to do lots of different activities? 
19.9 27.9 0.40 0.26 0.74 
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9.4.8 Possible questionnaire following item elimination 
Table 9.28.  Summary descriptive statistics for 29 item adapted OIQoL 
 
 
 Number of 
items 
Valid 
N 
No. 
Missing 
Cronbach’s 
alpha 
Mean Median SD 
OIQoL Being safe and careful 
dimension (0-100) 
6 
94 1 0.84 34.2 29.2 25.6 
OIQoL Reduced function 
dimension (0-100) 
6 
95 0 0.74 22.6 24.0 5.7 
OIQoL Pain dimension (0-100) 6 95 0 0.75 74.3 79.2 20.7 
OIQoL Fear dimension (0-100) 4 94 1 0.84 15.9 17 4.0 
OIQoL Life skills (0-100) 7 93 2 0.76 23.4 23 5.9 
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9.4.9      Test retest at one week 
 
Table 9.29.  Table to demonstrate item level stability of the OIQoL at one week test retest (max n=51) for those patients who reported no           
change in global rating of health change question at time 2. 
 
              Confidence Interval   
item N Mean t=1 SD t=1 
N  Mean t=2 SD t=2 Mean diff Lower Upper 
Sig. (2-
tailed 
Q1 In the last week did someone give you extra help to keep you safe? 
base 
51 2.4 1.3 51 3.0 1.3 -0.61 -0.99 -0.23 0.00 
Q2 In the last week did you keep away from busy areas to keep safe? 
base 
51 2.5 1.3 51 3.1 1.2 -0.55 -0.88 -0.21 0.00 
Q3 In the last week did you keep away from crowds to keep safe? base 51 2.6 1.4 51 3.2 1.4 -0.59 -0.97 -0.21 0.00 
Q4 In the last week did you try to keep safe to stop you breaking a 
bone? 
51 2.0 1.3 51 2.4 1.3 -0.35 -0.74 0.03 0.07 
Q5 In the last week did you keep away from some activities to stop you 
having a broken bone? 
51 2.7 1.5 51 3.0 1.2 -0.31 -0.67 0.04 0.08 
Q6 In the last week did you think before playing sports to avoid having a 
broken bone? 
50 2.3 1.4 50 2.6 1.5 -0.36 -0.83 0.11 0.13 
Q7 In the last week have you felt tired in the day? 50 2.4 1.0 50 2.9 1.2 -0.42 -0.68 -0.16 0.00 
Q8 In the last week have you felt tired by the end of the day? 50 2.4 1.2 50 2.4 1.1 0.00 -0.36 0.36 1.00 
Q9 Din the last week did you have to take rests in the day? 50 3.5 1.2 50 3.7 1.3 -0.18 -0.51 0.15 0.28 
Q10 In the last week has having a broken bone stopped you doing 
things? 
50 4.0 1.5 50 4.3 1.3 -0.32 -0.74 0.10 0.14 
Q11 In the last week has it been more difficult to move around because 
of a broken bone? 
50 4.3 1.2 50 4.4 1.3 -0.06 -0.37 0.25 0.70 
Q12 In the last week have you had to do things differently because of a 
broken bone? 
50 4.2 1.3 50 4.3 1.3 -0.14 -0.49 0.21 0.42 
Q13 In the last week did you use equipment help you to move around? 50 3.7 1.6 50 3.9 1.4 -0.22 -0.60 0.16 0.25 
Q14 Din the last week did you have to use equipment to help at school 
or home? 
50 3.7 1.6 50 3.5 1.6 0.22 -0.25 0.69 0.35 
Q15 In the last week have you had pain in your back? 51 3.4 1.3 51 3.5 1.3 -0.14 -0.47 0.19 0.40 
Q16 In the last week have you had pain in your legs or arms? 51 3.4 1.2 51 3.2 1.2 0.20 -0.12 0.51 0.22 
Q17 In the last week have you had to take medicine for pain? 51 4.0 1.3 51 4.1 1.4 -0.06 -0.47 0.35 0.77 
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Q18 In the last week have you had to take medicine because you broke 
a bone? 
51 4.7 1.0 51 4.9 .6 -0.22 -0.47 0.04 0.09 
Q19 In the last week did you have pain because you had a broken 
bone? 
51 4.3 1.3 51 4.7 .9 -0.41 -0.71 -0.11 0.01 
Q20 In the last week have you missed meeting up with your friends 
because you had pain? 
51 4.1 1.4 51 4.3 1.2 -0.12 -0.53 0.29 0.57 
Q21 In the last week have you been worried about breaking a bone? 51 3.5 1.4 51 3.7 1.3 -0.20 -0.52 0.13 0.24 
Q22 In the last week did you get scared about doing something that 
might make you break a bone? 
51 3.8 1.3 51 3.6 1.3 0.16 -0.13 0.44 0.27 
Q23 In the last week did you worry about coming into hospital? 51 4.2 1.2 51 4.2 1.1 -0.04 -0.36 0.28 0.81 
Q24 In the last week did you get scared about needles? 50 3.5 1.6 50 4.2 1.3 -0.68 -1.12 -0.24 0.00 
Q25 In the last week did you worry that someone might move you 
wrong and cause a broken bone? 
51 4.2 1.3 51 4.4 1.0 -0.22 -0.52 0.08 0.15 
Q26 In the last week have you worried about new people handling you? 51 4.2 1.1 51 4.4 1.1 -0.16 -0.46 0.14 0.30 
Q27 In the last week did you like to do things for yourself? 51 1.9 1.1 51 1.8 .9 0.16 -0.12 0.43 0.25 
Q28 In the last week did your family encourage you to do things for 
yourself? 
51 2.2 1.3 51 2.3 1.3 -0.12 -0.49 0.26 0.53 
Q29 In the last week did you have as much freedom as your friends? 51 2.7 1.2 51 2.7 1.2 0.02 -0.34 0.38 0.91 
Q30 In the last week did your family let you make your own decision 
about what is safe? 
50 2.8 1.4 50 2.5 1.2 0.36 -0.01 0.73 0.06 
Q31 In the last week did the teachers at school over protect you? 51 3.5 1.3 51 3.7 1.4 -0.14 -0.47 0.20 0.42 
Q32 In the last week did the teachers at school stop you doing things 
that you think are safe? 
51 3.9 1.1 51 4.0 1.3 -0.10 -0.45 0.26 0.58 
Q33 In the last week did your family let you choose your own activities? 51 2.3 1.2 51 2.2 1.2 0.14 -0.23 0.51 0.46 
Q34 In the last week did you see your friends outside of school? 50 2.9 1.5 50 3.0 1.4 -0.12 -0.49 0.25 0.51 
Q35 In the last week were you able to do everything your friends do? 50 2.9 1.2 50 2.8 1.2 0.08 -0.22 0.38 0.59 
Q36 In the last week did you get to do lots of different activities? 50 2.7 1.3 50 2.9 1.1 -0.22 -0.56 0.12 0.19 
Q37 In the last week did you feel different because you have to be more 
careful than your friends? 
50 2.9 1.4 50 3.4 1.4 -0.52 -0.84 -0.20 0.00 
Q38 In the last week have people treated you differently because you 
have brittle bones? 
50 3.1 1.4 50 3.3 1.3 -0.14 -0.57 0.29 0.52 
Q39 In a normal school week do you do PE?  50 2.2 1.5 50 2.3 1.5 -0.10 -0.42 0.22 0.53 
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Table 9.30.  Table to demonstrate dimensional stability of OIQoL at one week test retest (max n=50) for those patients who  
          reported no change in global rating of health change question at time 2. 
    
 
        95% CI diff    95% CI ICC 
 N 
Mean 
t=1 
SD 
t=1 
Mean 
t=2 
SD 
t=2 
Mean 
diff lower higher 
p 
value Correlation ICC Lower higher 
OIQoL Being 
safe and 
careful (0-100) 
49 33.5 23.6 43.8 26.6 11.7 -17.80 -5.50 0.00 0.66 0.70 0.56 0.83 
OIQoL 
Reduced 
function 
dimension (0-
100) 
49 58.3 19.1 65.3 21.7 3.5 -8.50 1.50 0.17 0.63 0.77 0.46 0.75 
OIQoL Pain 
dimension (0-
100) 
50 73.1 20.6 77.9 19.8 3.1 -7.80 1.60 0.19 0.68 0.75 0.58 0.85 
OIQoL Fear 
dimension (0-
100) 
49 69.5 24.3 76.1 22.4 4.7 -8.40 -1.00 0.01 0.82 0.67 0.49 0.80 
OIQoL 
Independence 
dimension (0-
100) 
49 68 15.1 69.6 15.8 3.2 -7.20 0.80 0.11 0.60 0.81 0.67 0.89 
OIQoL 
Isolation 
dimension (0-
100) 
49 55.7 20.2 57 21.9 1.3 -5.60 3.11 0.57 0.72 0.59 0.38 0.74 
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Table 9.31. 
 
Table to demonstrate stability of the PedsQL and EQ5D one week test retest.  (max n=50) for those patients who  
reported no change in global rating of health change question at time 2. 
 
 
 
 
 
 
 
 
 
 
              95% CI diff       95% CI ICC 
  
N 
Mean 
t=1 
SD 
t=1 
Mean 
t=2 
SD 
t=2 
Mean 
diff 
lower higher 
p 
value 
Correlation ICC Lower higher 
EQ-5D Overall Utility (VAS) 
50 71.1 21.0 73.6 22.3 -2.5 -5.60 0.61 0.11 0.88 0.87 0.78 0.92 
EQ-5D Overall Utility (Tariff) 
  
50 0.9 0.0 0.9 0.0 0.0 -0.01 0.02 0.69 0.16 0.16 -0.13 0.42 
PedsQL Physical Functioning  
(0-100)  
 
49 50.3 23.8 51.4 23.3 -1.1 -5.06 2.77 0.56 0.83 0.84 0.73 0.90 
PedsQL Emotional Functioning  
(0-100)  
 
48 67.8 21.3 73.3 23.1 -5.5 -10.40 -0.61 0.03 0.71 0.69 0.50 0.82 
PedsQL Social Functioning (0-100)   
 
49 69.2 18.9 71.6 19.5 -2.4 -5.77 0.87 0.14 0.82 0.82 0.70 0.89 
PedsQL School Functioning (0-100) 
49 61.9 19.8 61.7 16.9 0.2 -3.65 4.06 0.92 0.74 0.74 0.58 0.84 
PedsQL Psychological Health 
Summary Score (0-100)  
48 65.9 16.5 69.0 16.3 3.02 0.33 5.71 0.29 0.84 0.84 0.73 0.91 
 
 
235 
Test-retest at one week examines those participants who recorded their global health 
rating as static between baseline and one week completions.  From the above tables 
(9.30 and 9.31) it is noted that ‘Being safe and careful’ and ‘fear’ are two dimensions 
which report significant difference in mean scores at one week test-retest.  The mean 
difference (11.7) for the dimension ‘being safe and careful’ stands out as much greater 
than the ‘fear’ dimension (4.7).   This is again noted at the item-level (table 9.29) where 
items Q1, Q2 and Q3, all of which are in the ‘being safe and careful’ dimension, 
demonstrate a significant difference between mean scores at baseline and retest.  A 
significant difference is also seen at one week retest for items Q7, Q19, Q24 and Q37; 
item Q24 is present within the ‘fear’ dimension and may have lead to the significant 
difference at the dimension level (table 9.30).   This may also be reflected in the fact 
that the correlation between baseline (t=1) and one week retest (t=2) for the ‘fear’ 
dimension was high (r=0.82).  The correlation for test-retest within the ‘isolation’ 
dimension was also above the accepted level for reliable scale stability with a score of 
0.72.  All other dimensions demonstrate only moderate correlations between baseline 
(t=1) and one week (t=2) scores, ranging from 0.60 – 0.68.  When examining the test-
retest for the EQ5D and PedsQL with the OI cohort, it is noted that the mean difference 
scores between baseline (t=1) and one week (t=2) are quite small.  However, the 
emotional functioning dimension of the PedsQL also demonstrates significant 
difference between baseline and one week scores (mean difference 5.5, sig 0.03) and 
therefore has poor test-retest within this cohort.  Correlations between dimensions at 
baseline and one week retest are in the majority above the accepted level for reliable 
scale stability, with scores above 0.70.  However the EQ5D tariff score demonstrates 
low correlation with a score of 0.16.  The intra class correlation coefficient (ICC) also 
demonstrates the same low score. 
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9.4.10      Test retest at 3 months OIQoL 
 
Table 9.32.  Table to demonstrate dimensional stability of the OIQoL at three month test retest (max n=42) for those patients who  
          reported no change in global rating of health change question at time 3. 
 
 
 
       95% CI diff    95% CI ICC 
 N 
Mean 
t=1 
SD 
t=1 
Mean 
t=3 
SD 
t=3 
Mean 
diff lower higher 
p 
value Correlation ICC Lower higher 
OIQoL Being 
safe and careful 
(0-100) 
42 33.4 23.9 38.3 25.7 4.8 -2.03 11.73 0.16 0.59 0.59 0.35 0.75 
OIQoL 
Reduced 
function 
dimension     
(0-100) 
42 62.9 18.3 63.1 21.1 0.1 -4.20 4.49 0.95 0.75 0.75 0.58 0.86 
OIQoL Pain 
dimension     
(0-100) 
42 72.8 20.3 73.4 20.2 0.6 -4.63 5.79 0.82 0.65 0.66 0.45 0.80 
OIQoL Fear 
dimension     
(0-100) 
42 71.2 22.6 69.6 23.1 -1.6 -8.35 5.06 0.62 0.55 0.55 0.31 0.73 
OIQoL 
Independence 
dimension     
(0-100) 
40 66.9 16.6 71.8 15.4 5.6 -0.21 11.37 0.06 0.34 0.31 0.01 0.56 
OIQoL Isolation 
dimension     
(0-100) 
42 56.8 20.7 54.1 19.8 -2.7 -7.40 1.98 0.25 0.72 0.71 0.53 0.83 
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Table 9.33.  Table to demonstrate stability of the PedsQL and at EQ5D three month test retest (max n=42) for those patients who  
reported no change in global rating of health change question at time 3. 
 
 
 
 
 
 
 
              95% CI diff       95% CI ICC 
  
N 
Mean 
t=1 
SD 
t=1 
Mean 
t=3 
SD 
t=3 
Mean 
diff 
lower higher 
p 
value 
Correlation ICC Lower higher 
EQ-5D Overall Utility (VAS) 
41 0.9 0.04 0.9 0.4 0.09 -0.01 0.03 0.28 0.65 0.05 -0.26 0.34 
EQ-5D Overall Utility (Tariff)  
 
41 72.2 20.6 71.4 18.6 -0.29 -5.41 4.84 0.91 0.05 0.65 0.44 0.80 
PedsQL Physical Functioning         
(0-100)  
 
42 49.1 20.5 45.0 24.7 -3.73 -7.91 0.45 0.08 0.84 0.83 0.70 0.90 
PedsQL Emotional Functioning  
(0-100)  
 
42 67.1 21.0 67.5 22.0 0.95 -4.26 6.16 0.71 0.70 0.70 0.50 0.83 
PedsQL Social Functioning (0-100) 
 
42 68.0 16.1 66.3 20.4 -1.31 -6.64 4.02 0.62 0.58 0.57 0.32 0.74 
PedsQL School Functioning (0-100) 
41 63.4 18.3 60.6 20.7 -1.83 -7.19 3.53 0.49 0.58 0.62 0.39 0.78 
PedsQL psychosocial health 
summary score (0-100)  
41 66.2 14.8 64.8 18.2 -0.93 -5.19 3.32 0.66 0.68 0.67 0.46 0.81 
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Table 9.34.  Table to demonstrate item level responsiveness analysis of the OIQoL at 3 months. 
      95% Confidence Interval for Mean  
Item 
Health 
Change 
N 
Mean 
change 
SD Lower Bound Upper Bound   
Sig 
Value 
Q1 In the last week did someone give you extra help to keep you safe? BETTER 19 0.9 1.8 0.1 1.8  0.21 
  SAME 43 0.3 1.5 -0.2 0.7   
  WORSE 9 0.0 1.0 -0.8 0.8   
  Total 71 0.4 1.6 0.1 0.8   
Q2 In the last week did you keep away from busy areas to keep safe? BETTER 19 0.5 1.3 -0.2 1.1   0.12 
  SAME 43 0.0 1.2 -0.4 0.3   
  WORSE 9 -0.6 1.5 -1.7 0.6   
  Total 71 0.0 1.3 -0.3 0.3     
Q3 In the last week did you keep away from crowds to keep safe? BETTER 19 0.8 1.1 0.3 1.4  0.01 
  SAME 43 0.3 1.3 -0.2 0.7   
  WORSE 9 -0.9 1.3 -1.9 0.1   
  Total 71 0.3 1.4 -0.1 0.6   
Q4 In the last week did you try to keep safe to stop you breaking a  BETTER 19 0.5 1.2 -0.1 1.1   0.20 
      bone? SAME 43 0.3 1.2 -0.1 0.7   
  WORSE 9 -0.3 0.7 -0.9 0.2   
  Total 71 0.3 1.2 0 0.5     
Q5 In the last week did you keep away from some activities to stop you  BETTER 19 0.3 1.3 -0.4 0.9  0.03 
      having a broken bone? SAME 43 0.1 1.7 -0.4 0.6   
  WORSE 9 -1.3 1.3 -2.4 -0.3   
  Total 71 0.0 1.6 -0.4 0.4   
Q6 In the last week did you think before playing sports to avoid having  BETTER 19 0.5 1.6 -0.3 1.2   0.08 
      a broken bone? SAME 43 0.3 1.7 -0.3 0.8   
  WORSE 9 -1.0 1.4 -2.1 0.1   
  Total 71 0.2 1.7 -0.2 0.6     
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Q7 In the last week have you felt tired in the day? BETTER 19 0.8 1.0 0.3 1.3  0.13 
  SAME 43 0.2 1.1 -0.1 0.6   
  WORSE 9 0.6 0.5 0.2 1   
  Total 71 0.4 1.1 0.2 0.7   
Q8 In the last week have you felt tired by the end of the day? BETTER 19 0.4 1.6 -0.4 1.1   0.44 
  SAME 43 -0.1 1.2 -0.5 0.3   
  WORSE 9 0.0 1.2 -0.9 0.9   
  Total 71 0.0 1.3 -0.3 0.4     
Q9 In the last week did you have to take rests in the day? BETTER 19 0.2 1.1 -0.3 0.8  0.07 
  SAME 43 -0.2 1.0 -0.5 0.1   
  WORSE 9 0.7 1.4 -0.4 1.8   
  Total 71 0.0 1.1 -0.3 0.3   
Q10 In the last week has having a broken bone stopped you doing                             BETTER 19 0.9 1.4 0.3 1.6   0.02 
        things? SAME 43 0.2 1.1 -0.2 0.5   
  WORSE 9 -0.4 1.5 -1.6 0.7   
  Total 71 0.3 1.3 0 0.6     
Q11 In the last week has it been more difficult to move around because  BETTER 19 0.7 1.1 0.2 1.3  0.08 
        of a broken bone? SAME 43 0.1 0.8 -0.2 0.3   
  WORSE 9 0.0 1.9 -1.5 1.5   
  Total 71 0.2 1.1 0 0.5   
Q12 In the last week have you had to do things differently because of  BETTER 19 0.6 1.6 -0.1 1.4   0.23 
        a broken bone? SAME 43 0.1 1.1 -0.3 0.4   
  WORSE 9 0.0 1.1 -0.9 0.9   
  Total 71 0.2 1.3 -0.1 0.5     
Q13 In the last week did you use equipment help you to move around? BETTER 19 -0.3 0.8 -0.7 0.1  0.06 
  SAME 43 0.0 1.1 -0.4 0.3   
  WORSE 9 0.8 1.6 -0.4 2   
  Total 71 0.0 1.1 -0.2 0.3   
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Q14 In the last week did you have to use equipment to help at school or home? BETTER 19 -0.2 2.1 -1.2 0.8   0.66 
  SAME 43 -0.2 1.6 -0.7 0.3   
  WORSE 9 0.4 2.4 -1.4 2.3   
  Total 71 -0.1 1.8 -0.5 0.4     
Q15 In the last week have you had pain in your back? BETTER 19 -0.3 1.4 -0.9 0.4  0.75 
  SAME 43 0.0 1.3 -0.4 0.4   
  WORSE 9 -0.2 1.5 -1.4 0.9   
  Total 71 -0.1 1.3 -0.4 0.2   
Q16 In the last week have you had pain in your legs or arms? BETTER 19 -0.4 1.8 -1.2 0.5   0.80 
  SAME 43 -0.2 1.3 -0.6 0.2   
  WORSE 9 0.0 0.9 -0.7 0.7   
  Total 71 -0.2 1.4 -0.5 0.1     
Q17 In the last week have you had to take medicine for pain? BETTER 19 -0.5 1.8 -1.4 0.3  0.32 
  SAME 43 0.1 1.5 -0.3 0.6   
  WORSE 9 0.2 2.0 -1.4 1.8   
  Total 71 0.0 1.6 -0.4 0.3   
Q18 In the last week have you had to take medicine because you  BETTER 19 0.1 1.4 -0.6 0.8   0.46 
        broke a bone? SAME 43 -0.1 1.0 -0.4 0.2   
  WORSE 9 -0.6 2.2 -2.2 1.1   
  Total 71 -0.1 1.3 -0.4 0.2     
Q19 In the last week did you have pain because you had a broken bone? BETTER 19 0.3 1.4 -0.4 0.9  0.29 
  SAME 43 0.2 1.1 -0.1 0.5   
  WORSE 9 -0.4 1.3 -1.5 0.6   
  Total 71 0.1 1.2 -0.1 0.4   
Q20 In the last week have you missed meeting up with your friends  BETTER 19 0.0 1.4 -0.7 0.7   0.86 
        because you had pain? SAME 43 0.1 0.9 -0.2 0.4   
  WORSE 9 0.2 0.7 -0.3 0.7   
  Total 71 0.1 1.0 -0.2 0.3     
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Q21 In the last week have you been worried about breaking a bone? BETTER 19 -0.2 1.7 -1 0.6  0.93 
  SAME 43 -0.1 1.3 -0.5 0.3   
  WORSE 9 -0.3 1.5 -1.5 0.8   
  Total 71 -0.2 1.4 -0.5 0.1   
Q22 In the last week did you get scared about doing something that might  BETTER 19 -0.2 1.4 -0.9 0.5   0.57 
        make you break a bone? SAME 43 -0.2 1.3 -0.6 0.2   
  WORSE 9 0.3 1.5 -0.8 1.5   
  Total 71 -0.1 1.4 -0.5 0.2     
Q23 In the last week did you worry about coming into hospital? BETTER 19 -0.2 1.3 -0.8 0.4  0.26 
  SAME 43 0.1 1.4 -0.3 0.6   
  WORSE 9 -0.7 1.7 -2 0.7   
  Total 71 -0.1 1.4 -0.4 0.3   
Q24 In the last week did you get scared about needles? BETTER 19 0.5 1.1 -0.1 1   0.20 
  SAME 43 0.1 1.3 -0.3 0.5   
  WORSE 9 -0.4 1.3 -1.5 0.6   
  Total 71 0.2 1.3 -0.1 0.5     
Q25 In the last week did you worry that someone might move you wrong and  BETTER 19 -0.4 1.6 -1.2 0.4  0.11 
        cause a broken bone? SAME 43 -0.2 1.1 -0.6 0.1   
  WORSE 9 0.7 1.1 -0.2 1.5   
  Total 71 -0.2 1.3 -0.5 0.2   
Q26 In the last week have you worried about new people handling you? BETTER 19 0.2 0.6 -0.1 0.4   0.01 
  SAME 43 -0.1 1.2 -0.5 0.2   
  WORSE 9 1.0 0.9 0.3 1.7   
  Total 71 0.1 1.1 -0.2 0.3     
Q27 In the last week did you like to do things for yourself? BETTER 19 -0.2 1.0 -0.6 0.3  0.06 
  SAME 43 -0.1 0.9 -0.4 0.1   
  WORSE 9 0.7 1.0 -0.1 1.4   
  Total 71 0.0 1.0 -0.3 0.2   
 
 
242 
Q28 In the last week did your family encourage you to do things for yourself? BETTER 19 0.0 1.2 -0.6 0.6   0.76 
  SAME 43 0.0 1.4 -0.5 0.4   
  WORSE 9 0.3 1.3 -0.7 1.4   
  Total 71 0.0 1.3 -0.3 0.3     
Q29 In the last week did you have as much freedom as your friends? BETTER 19 -0.3 1.3 -0.9 0.4  0.30 
  SAME 43 0.0 1.2 -0.3 0.4   
  WORSE 9 0.6 1.7 -0.7 1.8   
  Total 71 0.0 1.3 -0.3 0.3   
Q30 In the last week did your family let you make your own  BETTER 19 0.1 1.6 -0.7 0.8   0.22 
        decision about what is safe? SAME 41 -0.5 1.6 -1 0   
  WORSE 9 0.2 1.0 -0.5 1   
  Total 69 -0.3 1.5 -0.6 0.1     
Q31 In the last week did the teachers at school over protect you? BETTER 19 0.2 1.9 -0.7 1.1  0.70 
  SAME 43 0.5 1.4 0.1 0.9   
  WORSE 9 0.1 1.1 -0.7 0.9   
  Total 71 0.4 1.5 0 0.7   
Q32 In the last week did the teachers at school stop you  BETTER 19 0.4 1.4 -0.3 1.1   0.90 
       doing things that you think are safe? SAME 43 0.2 1.4 -0.2 0.7   
  WORSE 9 0.3 0.7 -0.2 0.9   
  Total 71 0.3 1.4 -0.1 0.6     
Q33 In the last week did your family let you choose your own activities? BETTER 19 0.0 1.4 -0.7 0.7  0.47 
  SAME 43 -0.1 1.5 -0.6 0.3   
  WORSE 9 0.6 2.1 -1 2.1   
  Total 71 0.0 1.5 -0.4 0.3   
Q34 In the last week did you see your friends outside of school? BETTER 19 0.1 1.5 -0.7 0.8   0.97 
  SAME 43 0.0 1.5 -0.5 0.5   
  WORSE 9 -0.1 1.5 -1.3 1.1   
  Total 71 0.0 1.5 -0.4 0.4     
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Q35 In the last week were you able to do everything your friends do? BETTER 19 -0.4 1.5 -1.1 0.3  0.14 
  SAME 43 0.3 1.2 -0.1 0.6   
  WORSE 9 0.3 1.3 -0.7 1.4   
  Total 71 0.1 1.3 -0.2 0.4   
Q36 In the last week did you get to do lots of different activities? BETTER 19 -0.4 1.2 -1 0.2   0.20 
  SAME 43 0.2 1.2 -0.2 0.5   
  WORSE 8 0.3 1.2 -0.7 1.2   
  Total 70 0.0 1.2 -0.3 0.3     
Q37 In the last week did you feel different because you have  BETTER 19 0.9 1.4 0.2 1.6  0.09 
        to be more careful than your friends? SAME 43 0.0 1.4 -0.4 0.5   
  WORSE 9 0.2 1.1 -0.6 1.1   
  Total 71 0.3 1.4 0 0.6   
Q38 In the last week have people treated you differently because  BETTER 19 0.4 1.5 -0.3 1.2   0.11 
        you have brittle bones? SAME 43 -0.2 1.1 -0.6 0.1   
  WORSE 9 0.6 1.5 -0.6 1.7   
  Total 71 0.1 1.3 -0.3 0.4     
Q39 In a normal school week do you do PE? BETTER 19 0.3 1.3 -0.4 0.9  0.39 
  SAME 43 0.1 1.4 -0.3 0.5   
  WORSE 9 0.8 1.9 -0.6 2.2   
  Total 71 0.2 1.4 -0.1 0.5     
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Table 9.35.  Table to demonstrate dimensional level responsiveness analysis of the OIQoL at 3 months. 
 
 
  N Mean 
Std. 
Deviation 
95% Confidence Interval for 
Mean   
Lower Bound Upper Bound Sig. 
OI PROM Being safe and careful dimension (0-100) Change 
from baseline to week 12 
BETTER 19 14.7 25.4 2.5 26.9 0.00 
SAME 43 4.8 22.4 -2.0 11.7   
WORSE 9 -17.1 16.6 -29.9 -4.4   
Total 71 4.7 24.2 -1.0 10.4   
OI PROM Reduced function dimension (0-100) Change 
from baseline to week 12 
BETTER 19 10.2 12.7 4.1 16.3 0.03 
SAME 43 0.1 14.1 -4.2 4.5   
WORSE 9 6.3 15.5 -5.7 18.2   
Total 71 3.6 14.4 0.2 7.0   
OI PROM Pain dimension (0-100)  Change from baseline to 
week 12 
BETTER 19 -3.3 28.1 -16.9 10.3 0.75 
SAME 43 0.6 16.9 -4.6 5.8   
WORSE 9 -3.2 19.8 -18.5 12.0   
Total 71 -0.9 20.6 -5.8 3.9   
OI PROM Fear dimension (0-100) Change from baseline to 
week 12 
BETTER 19 -1.8 23.9 -13.3 9.8 0.88 
SAME 43 -1.6 21.8 -8.4 5.1   
WORSE 9 2.3 16.6 -10.4 15.0   
Total 71 -1.2 21.6 -6.3 3.9   
OI PROM Independence dimension (0-100) Change from 
baseline to week 12 
BETTER 19 3.4 17.3 -4.9 11.7 0.18 
SAME 41 5.6 18.4 -0.2 11.4   
WORSE 9 -6.7 16.8 -19.7 6.2   
Total 69 3.4 18.1 -1.0 7.7   
OI PROM Isolation dimension (0-100) Change from baseline 
to week 12 
BETTER 19 7.7 20.4 -2.1 17.5 0.09 
SAME 43 -2.7 15.2 -7.4 2.0   
WORSE 8 -1.6 17.7 -16.3 13.2   
Total 70 0.2 17.4 -3.9 4.4   
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At three months the mean differences between test-retest at baseline (t=1) and three 
months (t=3) for those patients who reported no change in their global health were low 
for four dimensions of the OIQoL (reduced function, pain, fear and isolation).  However 
the mean difference for dimensions being safe and careful and independence were a 
little higher (4.8 and 5.6 respectively), but only the independence dimension was close 
to demonstrating significant difference (0.06) in scores at baseline (t=1) and three 
months (t=3).  Correlations between baseline and three month retest for dimension 
reduced function and isolation demonstrated adequate score (>0.70) for reliable scale 
stability. The independence dimension had low correlation (r=0.34) highlighting poor 
scale stability, but all other dimensions had moderate correlations (range 0.55 – 0.65), 
although falling outside the acceptable levels for scale stability.   
Assessment of test retest between baseline and three month scores for individuals who 
reported no change in global health, demonstrated reliable scale stability for both the 
PedsQL and EQ5D. (table 9.33) mean differences between baseline and retest were 
low and no significant difference between test and retest scores were found.  Both the 
physical functioning and emotional functioning dimensions of the PedsQL had 
acceptable levels of correlation (>0.70) for test-retest at 3 months.  The other three 
dimensions within the PedsQL and EQ5D tariff scores demonstrated moderate 
correlation between baseline (t=1) and three month (t=3) retest scores.  However, the 
tariff score for the EQ5D demonstrated very low correlation (0.05) and therefore poor 
test-retest reliability at three months. 
 
Table 9.34 examines the item level responsiveness of the OIQoL at three month retest 
for those individuals who reported change (better, same, worse) on the global health 
question.  From the table it can be seen that numerous items demonstrate the 
expected directional mean change in line with their self-reported global health question 
(Q1, Q2, Q3, Q4, Q5, Q6, Q11, Q12, Q18, Q19, Q24, Q27, Q28, Q29, Q35, Q36).  For 
example, item Q2 has mean change values of 0.5 for those individuals who report 
feeling better at 3 month retest; 0.0 mean change value for those individuals who state 
they feel the same; -0.6 mean change for those who report they feel worse at three 
month retest.  A similar pattern is seen for item Q29 (better -0.3, same 0.0, worse 0.6), 
however this item is reverse scored, with ‘Always’ scoring 5 and ‘Never’ scoring 1, as a 
result the numerical direction changes, but the transformed QoL score follows the 
same configuration.  Other items follow a similar directional pattern, however fail to 
gain a 0.0 mean change score for those individuals who state they feel the same at 
three month retest.  For example item Q4 (better 0.5, same 0.3, worse -0.3).  However, 
although several items follow this expected directional pattern in relation to self-
reported health change, this is significant in only three items Q3, Q5 and Q10.  Table 
9.35 demonstrates the dimensional level responsiveness for the reported change 
between baseline and three months.  Only two dimensions demonstrate significant 
difference, however only the being safe and careful dimension has the expected 
directional change as mentioned above in the item level data. 
 
9.5 Discussion 
 
OI is a rare condition and those patients affected by the disease encounter fluctuating 
needs due to the incidence of fractures with minimal cause.  For this reason children 
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and their families are often fearful of or avoid activities or events which may lead to 
fracture.  Current treatment can involve inpatient hospital stays and the occurrence of a 
fracture and subsequent deformity may require surgical intervention.  Therefore, it is 
imperative to quantify a child’s QoL and currently there is no disease specific means of 
doing so (see Chapter 4). 
 
The aim of this chapter has been to field test the 39-item OIQoL on a larger sample to 
examine its feasibility, acceptability, validity, internal consistency reliability and test-
retest ability.  In turn, those items which did not ensure a robust questionnaire were 
examined with a view to elimination and questionnaire revision.  Although the content 
validity of the OIQoL had been ensured during its early development (Chapters 5 and 
6) and pre-tested soon after (Chapter 8), the need to maintain this validity in the event 
of revision and item reduction is vastly important.  Although some items have been 
examined with regards to elimination and questionnaire revision, the sample size within 
this psychometric evaluation was small, and therefore some less vital item exclusions 
will be postponed until the questionnaire could be examined more closely on a larger 
cohort. 
 
This has been the first attempt to develop an OI specific QoL questionnaire for the 
paediatric OI population using a conceptual framework elicited from the children and 
their parents/carers, alongside expert opinion and literature review.  The questionnaire 
was intended to be completed by children and adolescents; in the case of younger 
children (6 - 8 years) with the aid, if necessary, of their parents or carers. The early 
psychometric properties of the OIQoL were assessed on a sample which was varied for 
age (6-18 years), sex and severity of disease.  Ninety five children and adolescents 
undertook the baseline questionnaires, with only 20% and 23% of participants lost to 
follow up at one week and three months respectively.  The acceptability of the OIQoL 
was high, with minimal amounts of missing data; at most 2.2% of incomplete items and 
no complete missing forms.  There was no pattern to the missing data, and no 
requirement to revise or eliminate items on these grounds. 
 
To ensure a suitably robust questionnaire it is necessary to examine floor and ceiling 
effects.  The OIQoL has some items which are causal in nature, relating to symptoms 
such as pain or fractures, or the consequence of these symptoms and their treatment.  
Other items Q10, Q11, Q12, Q18, Q19 and Q20 in retrospect were not well written, 
asking the individual two questions at the same time.  Items such as Q10 (In the last 
week has having a broken bone stopped you doing things), forces all individuals who 
haven’t sustained a fracture in the last week to answer ‘never’, and therefore promotes 
a ceiling effect.  For this reason floor and ceiling effects were found in several items, 
some of which were related to symptoms and their management, some which were 
poorly constructed and some which affected only a small number of more severely 
affected individuals. These latter items, such as fear of handling in the severely 
affected participants, were deemed clinically important within the item generation and 
validation stages of questionnaire development.  For this reason no items were 
eliminated on the grounds of floor or ceiling effects, as suggested by Fayers et al 
(1998).  However those items which resulted in floor or ceiling effects, which with 
hindsight were asking two questions within the one item (Q10, Q11, Q12, Q18, Q19 
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and Q20), needed revision and further consideration prior to further testing.  See 
appendix 13, suggested version 3 OIQoL following revision. 
 
Similarly, Gorecki et al (2013) during psychometric analysis of the PU-QOL for 
pressure ulcers found  their questionnaire had good data span across the ranges for all 
items, but noted a large number of items with floor effects greater than 15% with 
notably skewed data.  
 
There was no initial evidence to highlight any item redundancy, with the majority of 
items demonstrating only low-moderate item-item correlation.  A small selection of 
items were more highly correlated, but no item-item correlation reached the value of 
0.90 suggested by Fayers and Machin (2007) for redundancy. 
 
9.5.1 Criterion Validity 
 
Criterion validity can be a difficult concept to assess or prove, particularly with disease 
specific QoL measures, where the impetus for development was the lack of a suitable 
alternative.  The PedsQL and EQ5D were chosen as ‘gold’ standard questionnaires, 
alongside which to assess and compare the newly developed OIQoL.  With hindsight, 
the EQ5D was more difficult for children with OI to complete.  It is an adult based 
questionnaire, and uses more adult terminology within its questions.  The older 
adolescents and young people were competent in its completion; however the younger 
children often needed the help of an adult to comprehend the questionnaire.  The terms 
anxious or depressed were often replaced by worried or sad to aid the understanding 
of the younger children, and the term usual activities often sparked discussion.  The 
correlations noted between the dimensions of the OIQoL and EQ5D are therefore only 
low to moderate.  The PedsQL was developed for children, but it a generic 
questionnaire and was previously deemed not sensitive enough to meet the needs of a 
QoL questionnaire for the paediatric OI population.  Its dimensions are more highly 
correlated with the dimensions of the OIQoL than that of the EQ5D, but the majority are 
still only moderately correlated.  Nevertheless, dimensions such as physical functioning 
(PedsQL) and reduced function (OIQoL), and social functioning (PedsQL) and isolation 
(OIQoL) demonstrated slightly higher correlations of 0.63 and 0.61 respectively, which 
do offer some evidence to support validity. With hindsight, the Healthy Pathways Chid 
Report scale may have been a suitable alternative to the EQ5D to examine criterion 
validity within the paediatric OI population.  It is a paediatric measure, was developed 
well using bottom up methodology and consists of a single questionnaire covering a 
wide age range.   
 
9.5.2 Known Groups Validity 
 
The initial hypothesis on which to examine known groups validity, was that those 
children and adolescents with more severe disease would report lower QoL as a result.  
Alternatively, those individuals who were more mildly affected would describe a higher 
level of QoL.  There is currently no evidence however to support this notion, but it may 
be sensible to consider that individuals who are more severely affected may report 
more pain, may have to be more careful to avoid fractures and may have poorer 
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function than their more mildly affected peers.  However when the data is examined at 
the dimension level the only statistical difference is noted within the reduced function 
dimension, where those individuals with more severe disease report lower dimension 
scores.  No difference is noted between the different severities across the other five 
dimensions of the OIQoL.  Moreover, a similar picture is seen with the PedsQL, where 
a difference between the severities of disease is only noted in the physical functioning 
dimension. 
 
Additionally, when the data is examined at the item level, some significant differences 
are noted to support this notion.  Items relating to receiving extra help to keep safe, 
having to do things differently due to fractures and using equipment, all highlighted 
differences between the severity groups, with the more severely affected individuals 
reporting the lower scores.  However a different picture related to severity is seen in the 
items related to fear of activities which may lead to fracture, with those more 
moderately affected reporting lower scores.  This may have been due to the to the fact 
that those moderately affected individuals are troubled more often by fractures than 
those more mildly affected, and are often more mobile, less reliant on wheelchairs for 
mobility than their more severely affected peers and therefore more readily at risk of 
fractures, resulting in more reported fear.   
QoL is often described as the difference between an individual’s actual performance or 
QoL and their expectation of how they would like life to be or feel it ought to be.  
Anecdotally, it is often the more mildly effected teenagers that express disharmony with 
their QoL, as they more readily compare themselves with their peers.  From experience 
on the other hand, our more severely affected patients seem less likely to do so.  
Perhaps this is due to the degree of functional difference between these groups, where 
those more mildly affected expect their functional activity and participation to be equal 
to that or their non-affected peers.  This may explain the lack of difference seen 
between the severities for some of the items and the majority of dimensions within both 
the OIQoL and the PedsQL. 
 
Examining the item level data to uncover any significant known groups difference 
related to treatment group highlighted only a small number of items.  The three items 
related to doing things differently because of a fracture and having to use equipment, 
all demonstrated those patients receiving no treatment to have the highest scores.  
This may however be related to the fact that those individuals receiving no treatment 
are often those who are more mildly affected and therefore be linked to severity of 
disease rather than just treatment or lack thereof.  It is interesting that two of these 
three items also demonstrated significant difference for severity groups.  Those 
individuals scoring significantly lower scores for the three items mentioned above were 
those individuals receiving Zoledronate.  This may be an effect of treatment, but could 
also be due to the fact that this group had the smallest number of participants (n=4).  
Further work to include a larger cohort of individuals treated with Zoledronate is 
required to further examine this effect. 
 
The items related to seeing friends outside of school highlighted a different significant 
picture between treatment groups.  Again those treated with Zoledronate reported the 
lowest QoL score, with ‘never’ the mean score documented at raw data level.  However 
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this item demonstrated those individuals receiving Risedronate as having the better 
QoL score and more frequently seeing their friends outside of school. 
 
As noted within the results section of this chapter, those individuals receiving 
Pamidronate therapy often report a cyclic up and down nature to their symptoms in 
relation to their treatment.  Parents of younger children and self-reporting older children 
state they feel immediate benefit from their Pamidronate infusion, and this benefit is 
noted to wear off towards the end of the three months, prior to their next infusion.  This 
was also described during the interview phase of this study.  The item level data at one 
week retest, immediately following Pamidronate infusion, and at three month follow up 
immediately prior to re-treatment demonstrated significant difference between only a 
few items.  Again those items related to using equipment highlighted significant 
difference between those individuals on Pamidronate and those receiving other 
treatment or nothing, however this difference was not in favour of Pamidronate at the 
one week retest, as suggested by the anecdotal evidence.   
 
However the item related to feeling different because of having to be more careful did 
demonstrate significant difference in favour of Pamidronate therapy at the one week 
retest.  Nevertheless this was not repeated at the three month follow up, and when this 
item is examined at baseline, one week retest and three month follow up; the 
suggested cyclic pattern is not present.  This may have been due to small numbers, but 
could highlight that these suggested ‘highs and lows’ of Pamidronate therapy is not 
repeatedly experienced across the paediatric cohort, or could be highlighting poor 
responsiveness in the OIQoL. 
 
9.5.3 Internal Consistency 
 
Cronbach’s alpha for the complete 39-item OIQoL is 0.86.  This score is reasonable 
and demonstrates good internal consistency.  However this value may be high as there 
are a large number of items within the current OIQoL, which as stated by Fayers and 
Machin (2007), would lead to increased reliability.  For this reason it was necessary to 
examine the internal consistency and item-total correlations for the items within each 
individual dimension, to aid the decision making process with regards to questionnaire 
revision and possible item elimination.   
 
‘Being safe and careful’ was a dimension which had the highest internal consistency 
with high Cronbach’s alpha score and reasonable item-total correlations.  The themes 
within this dimension were discussed at length within the interviews and focus groups 
and therefore good content validity is also ensured.  There was therefore no 
requirement to make alterations to the items within this dimension. 
The second dimension ‘reduced function’ also demonstrated reasonable internal 
consistency with a Cronbach’s alpha score of greater than 0.70; however three items 
relating to fatigue had low item-total correlations.  Removing all three of these items 
would benefit the internal consistency, but lead to reduced content validity.  
Alternatively, placing these three items within their own dimension may be a better 
option.  Fatigue was a theme mentioned within the interviews and discussed at length 
within the focus groups, removing all three items would therefore not allow the 
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questionnaire to stay true to the qualitative data.  The decision to wait until the 
questionnaire could be examined with a larger cohort prior to dimension revision or 
item elimination was therefore made. 
 
The pain dimension had a reasonable Cronbach’s alpha score above the threshold and 
all item-total correlations were moderate, demonstrating reasonable fit of the items 
within this dimension.  There was therefore no requirement to consider item reduction 
at this stage on the ground of internal consistency. 
The internal consistency of the fear dimension was above the required threshold, yet 
two items which related to being fearful of needles and hospital had very poor item-total 
correlation and therefore poor fit within this dimension.  Removal of these items was 
considered; this would have a positive effect on the internal consistency of this 
dimension but may reduce content validity.  However due to the small sample size, this 
item elimination was also postponed until evaluation with a larger cohort had taken 
place.  
The latter two dimensions however had both poor internal consistency and validity.  
The items within both dimensions demonstrated poor fit, and elimination of any item did 
not improve the psychometric properties.  For this reason combining the two 
dimensions was considered, to produce a five dimension questionnaire rather than the 
original six. Some items were eliminated to improve both internal consistency and 
validity and the resultant seven item dimension demonstrated reasonable internal 
consistency. 
 
The small sample size was the prominent concern surrounding early item elimination, 
particularly in dimensions where internal consistency (Cronbach’s alpha scores) were 
above the threshold (0.70).  However, dimensions five (Independence) and six 
(Isolation) within the newly developed OIQoL had low reliability with poorly correlated 
items, hence revisions to these latter dimensions were deemed important. The original 
OIQoL consisted of six dimensions (being safe and careful (6 items), reduced function 
(8 items), pain (6 items), fear (6 items), independence (7 items), and isolation (6 items).  
The potential adapted version is a five dimension questionnaire which includes the 
initial four dimensions, alongside a fifth dimension ‘life skills’ which includes seven 
items.  Although consideration was made regarding item elimination in the reduced 
function and fear dimensions, for reasons related to small sample size, this was 
postponed until the OIQoL was evaluated alongside a larger sample. 
Bevans et al (2010) developed the Healthy Pathways child-report scales from the 
previously developed Child health and illness profile (CHIP), in an attempt to develop a 
single questionnaire which allowed HRQoL to be monitored throughout childhood and 
into adolescence.  They too discovered issues with a particular domain (resilience) 
which had a strong conceptual link, but was difficult to operationalise with poor internal 
consistency reliability.  They chose however to revised this dimension, adding further 
items to improve reliability.   
 
9.5.4 Test-retest      
 
The test-retest at both one week and three months highlighted some areas of potential 
poor scale stability in the OIQoL.  The dimension being safe and careful at the one 
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week test-retest demonstrated significant difference between mean scores and only 
moderate correlation.  At the item level, three items within this dimension demonstrated 
significant difference between baseline and one week retest.  Although the fear 
dimension had a significant difference between mean scores at one week retest, it did 
demonstrate good correlation and is therefore less of a concern.  It was initially felt that 
the test-retest at one week may be affected by treatment; a proportion of OI patients 
attending Sheffield Children’s Hospital will have done so on an inpatient basis and this 
may have involved Pamidronate treatment.  This three monthly bisphosphonate 
treatment can improve symptoms such as pain, making patients feel better.  This may 
explain some of the differences noted at a dimensional level for the one week retest, 
particularly as all mean scores at one week were higher than those at baseline, and 
could be linked to patients feeling better, reporting less pain and therefore their QoL 
score increasing.  However this was only the case for a small amount of items when 
item-level data was examined, and can therefore not completely explain any poor 
stability.  Nevertheless, this improvement may not have been large enough to be 
apparent to the cohort, or may have been the normal improvement that OI patients feel 
following treatment and therefore this was not reflected in the global health question.    
 
Although there is no significant difference in mean dimensional scores between the 
test-retest at three months for those individuals who report no change, the poor 
correlation within the isolation dimension is a little concerning.  The mean differences 
for the isolation and fear dimensions at the three month retest were both negative 
scores, highlighting the reduction in QoL score.  This could also have been an effect of 
treatment, or the lack of it.  Anecdotal evidence from patients on three monthly 
bisphosphonate treatment supports the reduction in symptom suppression a few weeks 
prior to their next infusion.  This may have caused their reported QoL dimension scores 
to be lower immediately prior to treatment. However, the item level data doesn’t 
support this suggestion, and there appears to be no obvious pattern within the data.   
This reduction in QoL score is collaborated by the negative mean difference values for 
several dimensions within the PedsQL and the EQ5D tariff.   
 
Responsiveness at an item level is also examined by comparing baseline scores with 
the three month retest, against the outcome of the global health question, for the 
complete cohort.  Several items demonstrate the expected directional spread, where 
those individuals who state they had improved (better), report positive mean 
differences, for those items which are not reversed scored, minimal mean difference for 
those who report they feel the same, and negative mean difference for those 
individuals who report they are worse.  This expected directional spread is not 
replicated across all items, and only a small proportion demonstrate this with significant 
value.  A similar picture is seen at the dimensional level, where the expected directional 
spread is only significant within the being safe and careful dimension.  This may be due 
to poor responsive properties in some items, and this may perhaps improve following 
the necessary revisions, particularly relating to the ceiling effects of some items.  
Alternatively, it may be the effect of small sample size, as those individuals reporting 
worsening QoL were very low in number.  The global health question was also self 
reported, and this may have lead to some bias in its completion, with some individuals 
not feeling comfortable reporting their QoL as deteriorating, seeing this as failure or a 
weakness.   Filocamo et al (2010) used a clinician assigned score, based on their 
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assessment of disease severity, with which to assess the responsiveness of their newly 
developed HRQoL measure for paediatric rheumatic diseases; therefore removing the 
need for a self reporting global health question.  The addition of a clinician reporting 
health change, alongside the self reported global health question may be a useful 
adjunct to future studies. 
 
9.6 Questionnaire Revision 
 
Items which demonstrated ceiling effects, which were due to poor item construction, 
will be revised.  This will ensure that those items no longer ask two questions within the 
same item, and therefore reduce the chance of ceiling effects which were seen during 
both pilot phase and psychometric testing of the OIQoL. As a result of this change item 
Q18 will now be irrelevant as it replicates the content of item Q17. 
 
Items within dimensions ‘isolation’ and ‘independence’ demonstrated poor internal 
consistency, and the suggestion was made to combine these latter two dimensions.  
This would result in a seven item dimension, with better internal consistency, however 
this would eliminate items which demonstrated good known groups validity for both 
severity of disease and effect of treatment.  For this reason it is proposed that the two 
dimensions will be amalgamated, however items which demonstrated significant known 
groups validity would remain, resulting in an eight item dimension. 
 
The three items related to fatigue within the ‘reduced function’ dimension demonstrated 
poor item-total correlation; however they have high content validity and were reported 
at length during both the one-to-one interview and focus group phases of this research.  
For this reason they cannot be eliminated and will be placed within a separate 
dimension entitled ‘fatigue’. 
 
9.7 Strengths and limitations 
 
A strength of this field testing stage is that the preliminary psychometric testing of the 
revised questionnaire enabled missing data, floor and ceiling effects and overall 
acceptability to be examined.  Participants had completed the questionnaires in 
different locations; away from direct observation from the principle researcher, and 
therefore, less pressure was placed on the children and young people to fully complete 
the questionnaire, had they not wished to do so. 
Several of the items/questions again demonstrated floor or ceiling effects, and some 
were due to the nature of the item and/or its construction.  As previously mentioned in 
Chapter 8, those items which refer to both fractures and pain, or fractures and reduced 
function, have automatically provided an increased chance of floor or ceiling effects, 
and this is demonstrated in the data.  A limitation of this research was not having the 
confidence to revise these items, following pilot testing, prior to this psychometric 
stage.  This meant that poorly worded items were included in the psychometric testing 
stage of the study, which on a larger sample highlighted obvious ceiling effects.  In 
hindsight making revisions to these items prior to this larger scale testing (n=95) would 
have proved more useful.  As a result of this, these items will require revision or 
removal prior to further, multi-site research.  Discussing the options for revision or 
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removal alongside the target population might aid this process, and could be 
considered prior to further testing.  See appendix 13 for version 3 of the OIQoL with 
suggested revisions.  
A further limitation to this phase of the research was the decision to use the EQ5D as a 
QoL measure with which to examine criterion validity.  The EQ5D is an adult based 
measure and therefore not well received by the paediatric OI population, who had 
issues related to its completion.  With hindsight the Healthy Pathways Child Report 
scale would have proved a more suitable option; it is well developed for the paediatric 
population and involves the use of a single questionnaire encompassing a wide age 
range. 
The decision to use traditional methods to undertake psychometric analysis was made 
because of the size of the available sample (n=95 OI patients), the experience and 
understanding of the principle researcher and the time constraints set by the nature of 
the doctoral study; this was a limitation to this stage of the study.  The use of a larger 
sample would have enabled factor analysis and a more modern approach to 
psychometrics.  The use of item response theory or Rasch analysis would have 
allowed the questionnaire to be submitted to rigorous testing alongside a hypothesised 
model to inform the overall construct.  However, it would still be important to remain 
true to the initial qualitative process undertaken to uncover themes to inform item 
development and ensure high content validity.  Item reduction would still warrant 
careful consideration and a balance between excellent psychometric properties and 
high content validity would have to be sought. 
 
The newly developed OIQoL appears to include a number of causal items.  Causal 
items however do not necessarily measure the same single construct (QoL), but rather 
measure elements or symptoms that lead to changes within the construct.  As 
psychometric analysis often uses correlations to assess the validity of newly developed 
questionnaires, and causal items are often not well correlated with one another, this 
may not be the most suitable method to assess the validity of an instrument; 
particularly if it includes a large proportion of causal items and fewer effect or indicator 
items. These modern psychometric techniques could also have been used to identify 
the effect of causal items on the suitability of a summated total score, hence informing 
the researcher of the most appropriate method to ensure statistical robustness. 
Exploration of factor structure would have provided more information on the 
psychometric qualities of the newly developed OIQoL.  With additional knowledge and 
understanding the principle researcher plans to undertake factor analysis using the 95 
baseline questionnaires, to enhance the development process. 
 
As this was the first evaluation of the OIQoL and the sample size was small (n=95), 
modern techniques such as Rasch analysis and item response theory were not 
possible.  Further research on a larger sample would enable modern psychometric 
techniques and modelling of the construct.  
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9.8 Conclusion 
 
This chapter describes the process of psychometric testing the newly developed OIQoL 
on a small sample of the paediatric OI population.  Initial analysis demonstrates the 
OIQoL questionnaire has good acceptability across the age range (6 – 18 years), with 
minimal missing data and no missing forms.  However, the analysis revealed issues 
with regards to the internal consistency of dimensions five (independence) and six 
(isolation), which improved with preliminary revisions resulting in a five dimension 
questionnaire.  A few items within the ‘fear’ and ‘reduced function’ dimensions had poor 
item-total correlation, which would require further testing to inform possible item 
elimination, ensuring content validity is maintained, as informed by the initial stages of 
this research (Chapters 4 and 5). 
 
The test-retest reliability highlighted some areas of poor scale stability, alongside some 
possible positive effects of treatment at one week and the subsequent negative effect 
at three months.  Further test-retest reliability assessment is required on a larger 
sample, with particular attention paid to those participants who have received three 
monthly intravenous bisphosphonate therapy, compared with those on weekly oral 
treatment, six monthly therapy and those who are treatment naïve. 
Known groups validity demonstrated a difference between the severity of OI groups for 
only a small number of individual items and the reduced function dimension only, but 
this latter difference was replicated in the physical function domain of the PedsQOL, 
providing further evidence of construct validity. 
  
The relatively small sample used to field test the newly developed OIQoL prevented the 
use of the more modern psychometric techniques, such as Rasch analysis and Item 
response theory.  Following revision of some items, alongside elimination of others 
(see Appendix 13 for revised version 3 OIQoL), further testing on a larger sample of the 
paediatric OI population would enable more comprehensive analysis of the construct, 
reliability and responsiveness of the OIQoL.  The principle researcher plans to do this 
further analysis on a larger, multicentre UK cohort. 
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Chapter 10 
Conclusion and future research 
10.1 Aim of the thesis 
The overall aim of this study was to develop a disease specific quality of life (QoL) 
measure for children (aged 6-18 years) with Osteogenesis Imperfecta (OI).  OI is a 
disease that effects only a small proportion of the population, approximately 1 in 20,000 
(Glorieux, 2008) and has a wide range of severity.  The disease course is varied, with 
severely affected individuals sustaining many fractures throughout life leading to 
deformity, pain, lack of independent mobility and the potential for reduced QoL. 
This study has demonstrated how the initial 39-item OIQoL, a disease specific QoL 
measure for children with OI, was developed, pre-tested and finally psychometrically 
tested on a cohort of 95 children with varying severity of OI, resulting in a revised 33-
item questionnaire.  
10.2 Initial questions 
Prior to developing a QoL measure for the paediatric OI population it was important to 
ascertain whether there was a readily available generic QoL measure, or suitable 
disease specific questionnaire which was relevant to the OI population, thus negating 
the need to develop a disease specific version. 
The requirements of either, a suitable relevant generic QoL measure, or a newly 
developed OI specific QoL measure was described in Chapter 4.  Many children with 
OI attend both secondary and tertiary centres for their OI care.  They are monitored 
and where necessary treated medically, surgically and therapeutically from birth into 
adulthood.  Gaining an understanding and then quantifying a child’s QoL throughout 
childhood and transition onto adult care is essential.  Comprehending what 
interventions improve the QoL of these children allows services to provide the most 
suitable care at the best possible time and place.  For these reasons a QoL measure 
suitable for the paediatric OI population should: 
 Allow self completion by the child across a wide age range 6-18 years. 
 Encourage the use of one single measure across the age range, negating the 
need for age specific modules, allowing a child’s progress at whatever level to 
be monitored. 
 Have been rigorously developed alongside the paediatric population ensuring 
high content validity. 
 Include items relevant to the paediatric OI population. 
Self completion by children ensures that the child’s opinion is captured.  Parents or 
proxy respondents have been shown to provide accurate reports of functional ability 
and other external observable concepts, but do not impart accurate responses for more 
social or emotional aspects, particularly of their teenage children who may spend large 
amounts of time outside the family home (Eiser and Varni, 2013). 
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The development of a single questionnaire covering a wide age range will prevent the 
need for separate age related modules with differing questions.  The ability to monitor a 
child’s self reported QoL from age 6 to 18 years will ensure they can be reliably 
monitored throughout childhood and transition to adult care.  There will be no confusion 
as to which module is the most appropriate, particularly in the case of more mature 
children, who may not suit their age appropriate version.  Questionnaire development 
using bottom up methodology ensures high content validity for the target population, 
encouraging the inclusion of more relevant, specific and appropriate concepts for the 
paediatric OI population. 
The review of the literature surrounding generic and appropriate disease specific QoL 
measures (Chapter 4), alongside the initial conceptual framework (Figure 4.2, Chapter 
4) highlighted the need to develop a questionnaire which was specific for the paediatric 
OI population.    
Gaining an appreciation of what elements of a child’s life is important to the quality of 
that life and their well-being can only be uncovered by working with children and asking 
them how they feel.  This has been done previously in both children (Stevens, 2010) 
and adults (Gorecki et al, 2013) to elicit themes for a preference based measure and 
patient reported outcome measure (PROM) respectively.  The use of bottom up 
methodology, alongside literature review and expert opinion, encourages the 
development of a questionnaire or instrument which includes items that are relevant to 
the target population and therefore pursues good content validity (Patrick et al, 2011a) 
and improved acceptability. 
10.3 Key Findings 
This study used phenomenological based interviews with the OI population (children 
and parents) and those involved in their care (AHPs), to gain an awareness of this 
groups’ lived experience of their disease.  The initial sample size was relatively small 
(n=25) and therefore the need to validate the themes derived from these interviews 
was felt necessary, again adding to the depth of understanding and content validity. 
The themes uncovered (Chapter 5), later validated (Chapter 6) and revised to inform 
the development of the conceptual framework, included: 
 Being safe and careful. 
 Reduced function. 
 Pain. 
 Fear. 
 Independence.  
 Isolation. 
These themes, alongside sub themes, formed the basis of the conceptual framework 
on which the dimension headings within the newly developed OIQoL were written 
(Figure 6.1, Chapter 6).  The cyclic nature of the conceptual framework highlighted an 
interesting phenomenon which became apparent as concepts were uncovered and 
participants discussed their lived experience of OI.   
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The diagnosis of OI in your child or yourself appears to lead to a cyclic thought process 
of altered activity in an attempt to keep safe, avoid fractures and resultant pain.  Young 
people and parents described fractures in relation to the consequences which result.  
Fracture leads to pain, immobilisation and reduced function, subsequent loss of 
independence, isolation from activities and peers, and a resultant fear of a repeat 
event.  This fear leads to a further change in behaviour in an attempt to stay safe and 
remain fracture free.   This effort to stay safe and careful to avoid potential fractures, 
leads to an apparent choice to isolate oneself from activities which may result in 
fracture and also a subsequent isolation from the social interaction of such activity, 
often producing some further loss of independence.  Interview and focus group 
participants reported gradually reducing their guard following a period without fracture, 
but as soon as a further fracture occurs the cycle restarts.  Therefore, it is speculated 
that if the conceptual framework is an accurate and valid representation of QoL in OI, 
then an individual’s reported QoL will reduce as a consequence of a fracture. Further 
research on a larger cohort would enable validation and a deeper understanding of this 
potential phenomenon. 
10.4 Questionnaire development 
Effort was made throughout this study, to be transparent with regards to questionnaire 
development.  Within the literature this is not always the case, with large leaps being 
made between the stages of concept elicitation and questionnaire pre-testing (Brod et 
al, 2014; Bruce et al, 2010; Corona et al, 2011).  One of the strengths of this study is its 
transparency; Chapter 7 provides a large amount of detail describing how initial themes 
were transformed into items, and how, using the children’s language, the content 
validity, relevance and acceptability of the dimensions was ensured.  
Primary school teachers and a small convenience sample of younger children were 
used to assess readability and understanding of some more complex items and the 
Likert response scale.  To the best of the author’s knowledge this is not a method 
previously used in instrument development.  Nonetheless, working alongside children 
is a method that has been used to aid the development of the Likert scale, providing 
feedback regarding its content (Carlton, 2013), and the Likert scale levels themselves 
(Stevens, 2009). 
Patrick et al (2011b) describes the need to assess the understanding, acceptability and 
comfort of the newly developed QoL instrument or patient reported outcome measure 
prior to psychometrically testing the questionnaire on a larger sample.  The pilot or 
pretesting phase of this study (Chapter 8) proved to be very important in the 
development process, without which errors in understanding and logistical problems 
would not have come to light.  Changes within the question stem were deemed 
necessary; children could remember and report their activities within the last week with 
ease, but often forgot the recall time towards the end of the dimension, rushing ahead 
to complete the item.  For this reason each question stem was revised to include ‘In the 
last week…..’, to promote consistent accuracy in recall throughout each dimension. 
During pilot testing the questionnaire was reported as acceptable and this was 
reflected within the lack of any missing data, although this may have differed had 
participants not been observed during completion.  However one child did describe 
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some discomfort and upset when comparing herself to her peers.  This appeared to be 
in relation to what activities she was able to participate in, and how she felt she missed 
out and was isolated from her friends as a result of her OI.   
Pre-testing also highlighted some ceiling effects for several items; in hindsight revision 
and modification of these items at this stage would have enabled an improved version 
of the OIQoL undergoing psychometric testing within the latter stage of this study. 
10.5 Psychometric evaluation   
The largest discussion point and ongoing internal argument which has resulted from 
this study, is how best to measure or assess the validity, reliability and responsiveness 
of a newly developed PROM or QoL questionnaire.  This is discussed within the 
literature (Eiser and Morse, 2001; Cano and Hobart, 2011; Fayers and Machin, 2007) 
with authors expressing differing opinions as to what is the correct methodology.  Some 
researchers feel emphasis should be placed on content validity, staying close to the 
items uncovered during concept elicitation alongside the target population.  They report 
care should be taken when considering eliminating items on statistical reasons, 
particularly if the concepts were relevant to the patient population (Eiser, and Morse, 
2001; Fayers and Machin, 2007). 
Gaining a correct balance between ensuring content validity and relevance to the target 
population, alongside developing a psychometrically sound questionnaire appears to 
be a difficult undertaking.  One can choose to develop a questionnaire which 
statistically stands up; items may be eliminated on statistical grounds and grouped into 
dimensions on the basis of modern psychometric tests such as Rasch analysis or item 
response theory.  However, the outcome may clinically not meet the needs of the 
population and be deemed irrelevant.  Alternatively, developers can choose to 
concentrate on achieving high content validity, relevance and therefore acceptability 
within the target population, which may statistically not reach accepted levels of internal 
consistency or correlation of items within dimensions. 
Fayers and Machin (2007) express concern in relation to causal items; those which are 
reporting symptoms of a particular disease or the side effects of treatments.  These 
items do not necessarily statistically behave in the same way that effect items behave; 
therefore they may not be well suited to traditional psychometric techniques.   A 
number of items within the newly developed OIQoL appear on the face of it to be 
causal in nature, but without further assessment their exact meaning cannot be 
uncovered.  Further research to expose the behaviour of causal items within the 
OIQoL, would highlight which psychometric tests would prove most suitable to assess 
its validity, reliability and appropriateness.   This may be aided by the inclusion of 
Rasch theory, to examine the legitimacy of summing items to generate a total score 
and provide a greater understanding of the construct. 
From both a clinical and research prospective, it would appear necessary to develop a 
questionnaire or instrument that is reliable and stable over time.  For those patients 
whose global QoL does not change, this should be demonstrated as a stable QoL 
score on the newly developed instrument.  Test-retest scores at one week for those 
children who reported no change in global QoL score demonstrated stability in most 
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dimensions of the OIQoL.  However, this also highlighted significant positive change in 
the being safe and careful dimension, which initially was thought to have resulted from 
a treatment effect.  This is supported at the item level, where three items within this 
dimension demonstrated significant improvement in Qol scores from baseline to one 
week retest.  The anecdotal effect of Pamidronate has been discussed in chapter 9.  It 
was initially suggested that these reported ‘ups’ and ‘downs’ of Pamidronate therapy 
may be the cause of some of the stability issues.  However, when mean differences 
between treatment groups are examined at both baseline and retest, no noticeable 
difference is seen in favour of Pamidronate therapy at the one week retest in 
comparison with baseline scores. 
It would also be encouraging if the newly developed questionnaire demonstrated 
known groups or criterion validity, yet this again appears to be somewhat subjective.  
Without the presence of a suitable ‘gold standard’ measure with which to compare a 
newly developed instrument, ensuring criterion validity is very difficult, particularly when 
the driving force behind the development of a disease specific QoL measure is the lack 
of a suitable relevant alternative.  The Pedsql and the EQ5D were chosen as suitable 
questionnaires with which to assess criterion validity of the OIQoL , however with 
hindsight  these may not have been the most appropriate choice. 
Known groups validity at first glance would appear easier to assess.  However, this 
would demand that groups or factions within the target population behave as a 
particular hypothesis would suggest.  It appears common sense that children with more 
severe OI would report poorer QoL than their more mildly affected peers, but both this 
study and clinical experience highlights that this is not necessarily the case. 
This study has demonstrated that children and young people with severe OI report 
lower scores within the reduced function dimension of the OIQoL and the physical 
functioning dimension of the PedsQL respectively.   There is no other significant 
difference noted between the severity groups for any of the other dimensions within the 
OIQoL, PedsQL and EQ5D.  At the item level significant difference is noted between 
the severity groups for a handful of items, but this difference is not always related to 
those more severely affected patients reporting lower QoL scores.  This is not 
immediately explicable, however, it is postulated that those individuals within the 
paediatric OI population that are more mildly affected, may regularly compare 
themselves to their peers.  The nature of their disease and the need to be safe and 
careful to avoid fracture prevents participation in some activities, resulting in an amount 
of isolation from peers and an ensuing dissatisfaction with their QoL.  Alternatively, 
many children and young people who are more severely affected appear less likely to 
directly compare themselves with their peers, and therefore this may be reflected in the 
minimal difference noted between the severity groups across the other dimensions of 
the OIQoL.  Moreover, the fact that this is replicated within the PedsQL, does offer 
some evidence to support criterion validity.  Known groups validity in relation to 
treatment received demonstrated significant differences for only a small number of 
items.  This could be due to the small number of participants in some treatment groups 
validity of the OIQoL.  Perhaps examining a more suitable known groups validity would 
be beneficial; such as following fracture or surgical intervention. 
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The psychometric properties of the independence and isolation dimensions of the 
OIQoL were a little disappointing, highlighting a potential need for revision.  These 
dimensions do not appear to include a large number of causal items, and therefore this 
is unlikely to be the reason behind the poor internal consistency of the items within.  
Moreover, the three fatigue related items within the reduced function dimension, also 
demonstrate poor item-total correlation.  Tentative item elimination produced a seven 
item dimension entitles ‘life skills’, with improved internal consistency; a three item 
dimension entitled ‘fatigue’, and a resultant six dimension questionnaire.  Initial item 
elimination involved removal of one item which demonstrated significant known groups 
validity and was also discussed during both the interview and focus groups phases of 
this research.  For this reason, the decision was made at this stage not to remove this 
item until further testing had taken place.   
On reflection the sample size used for psychometric testing was quite small (n=95).  
This enabled a satisfactory assessment of questionnaire understanding and 
acceptability, alongside an appreciation of any floor or ceiling effects and the data span 
across the Likert scale options.  With minimal missing data and no complete missing 
forms, the newly developed OIQoL was deemed acceptable and understandable to the 
paediatric OI population aged 6-18 years old.  However, this field testing did highlight 
items which were more relevant to some minority groups within the cohort (the need for 
handling to aid transfers within the severely affected children); the presence of some 
causal alongside some items which were poorly worded and required revision.  The 
presence of these more extreme items did result in some more mildly affected children 
questioning the need to be handled, and thus demonstrated a difference between the 
severity groups. 
Nonetheless, the small sample size did prevent the use of more modern psychometric 
methods such as item response theory and Rasch analysis.  The latter method would 
have enabled assessment of the suitability of the items within the OI QoL to be 
summated to achieve a total score, alongside further assessment of the overall 
construct.  The decision to eliminate items from the latter two dimensions 
(independence and isolation) of the OIQoL was a difficult one, particularly when the 
small sample size dictated the use of more traditional psychometric techniques.  The 
items within the latter dimensions were not well correlated with each other and as a 
result the internal consistency of these dimensions was poor.   It would seem 
appropriate to consider item elimination and then re-test the OIQoL on a larger sample 
of children, enabling the use of Rasch or item response theory, to inform the overall 
structure, consider the effects of causal items and reassess further potential item 
elimination. 
10.6 Strengths and limitations   
This study has several strengths, particularly within its early stages.   
 The repeat review of the literature, following the reviews undertaken previously 
by Eiser and Morse (2001), McCabe (2003) and Stevens (2008) enabled 
clarification of the need to develop a paediatric OI specific QoL instrument, as 
there was no suitable alternative available which included items relevant to the 
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OI population.  It also uncovered information to facilitate the development of the 
conceptual framework surrounding QoL in children with OI.   
 The use of bottom up methodology working with children and their families, 
alongside health professionals experienced in caring for and treating children 
with OI, identified concepts and themes which were highly relevant to the 
paediatric OI population.  The subsequent development of a conceptual 
framework including these themes and how they interacted was used to inform 
the development of the OIQoL. 
 Transparency throughout all stages of questionnaire development has allowed 
the children’s own thematic based quotes to be used as items within the OIQoL, 
encouraging high content validity and acceptability of the newly developed 
questionnaire.  Its readability, understanding and scoring format was assessed 
and improved with the help of a small sample of young children, to ensure 
suitability, comprehension and comfort across the age range.   
 Observed pre-testing of the questionnaire with the addition of post completion 
interviews, allowed pauses and lack of understanding to be monitored, and 
questions to be asked.  This highlighted areas of concern and discomfort which 
were later used to inform changes and revision of the OIQoL, particularly with 
reference to the item stem, which following revision has improved accuracy. 
However, although this study demonstrated several strengths within the methodology, 
it is important to document its limitations.  
 In retrospect the inclusion criteria used for systematically reviewing the 
literature, when appraising previously developed generic and suitable disease 
specific QoL measure was very strict.  Had the criteria included only three of the 
four suggestions, questionnaires such as the Healthy Pathways Care scale may 
well have been appropriate and possibly a suitable alternative to the EQ5D for 
examination of criterion validity. 
 A further concern regarding the methodology of the item generation phases of 
this research was the effect of the primary researcher.  Acting as interviewer or 
focus group moderator alongside being a physiotherapist within the Metabolic 
Bone Disease Team may have effected the outcome.  Participants may have 
been more inclined to take part as they already knew the principle researcher 
as a physiotherapist in the team.  Alternatively they may have felt pressurised to 
enter into the study for the same reason.  The principle researcher’s previously 
relationship with the participants may however have put the children and young 
people at ease, enabling them to feel comfortable answering questions and 
talking about their QoL. Had the topic of the interviews or focus groups included 
questions about the provision of therapy or the treatment that the participants 
were receiving, then the relationship between the researcher and the children or 
young people may have had a very different effect on the outcome. 
 The use of the EQ5D was also a further limitation of the final psychometric 
testing phase of the study.  This adult based measure proved difficult for 
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younger children to complete, the wording was very adult in nature and many 
children didn’t grasp what the thermometer was asking them to do.  The use of 
an alternative, such as the Healthy Care Pathway scale may have proved 
beneficial and provided a better measure with which to assess criterion validity. 
 Preliminary psychometric testing of the revised questionnaire enabled missing 
data, floor and ceiling effects and overall acceptability to be examined.  Floor 
effects were uncovered in a couple of items related to being handled, which 
although these items effect only a small number of the more severely affected 
OI patients, the decision was made to keep these items within the OIQoL 
questionnaire.  Ceiling effects were identified in several items which when 
examined more closely, were found to be poorly worded and required revision.  
These latter ceiling effects were seen in both the pre-testing (chapter 8) and 
psychometric phases of this study, with hindsight the methodology would have 
been improved had revisions been made immediately following the pilot phase, 
enabling a better quality questionnaire being involved in the psychometric 
testing.  Delaying these revisions allowed the same ceiling effects to be 
demonstrated when the questionnaire was completed by 95 children and young 
people; further strengthening the evidence in favour of revision. 
 The small sample size, alongside the limited experience and understanding of 
the primary researcher prevented the use of modern psychometric techniques 
to inform the construct of the newly developed OIQoL.  These techniques could 
also have been used to identify the effect of causal items on the suitability of a 
summated total score, hence informing the researcher of the most appropriate 
method to ensure statistical robustness. 
 The data surrounding known groups validity is disappointing; with the reduced 
function dimension and only a handful of items demonstrating any significant 
difference between the severity types of OI (mild, moderate, severe).  A similar 
picture is seen when the potential known groups difference between treatment 
groups is examined, and any pattern uncovered between the treatment groups 
over the three month time period, is again only significant for a small number of 
items.  This may be due to the poor validity and responsiveness of the newly 
developed OIQoL, or due to the small number of participants within some 
groups, alternatively it could be due to the nature of the known groups under 
investigation.  With hindsight it may have been more sensible to initially 
examine known groups validity for those participants who had sustained a 
fracture or undergone surgical intervention compared to those who had not.  
This would have required a larger number of participants, and can therefore be 
investigated during further research. 
 The lack of any modern psychometric evaluation makes the decisions to 
eliminate items at this stage a difficult one.  The need to balance statistical 
robustness alongside high content validity and relevance to the target 
population can make item elimination a subjective process.  This reinforces the 
belief that further psychometric evaluation should take place to reassess and 
potentially strengthen the need for any further item elimination and 
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questionnaire revision, and that this should take place within several centres 
across the UK to gather a more diverse cohort. 
10.7 Future research  
It is therefore the opinion of the primary researcher, that further psychometric testing on 
a larger sample, enabling Rasch analysis or item response theory would help to inform 
the structure and internal consistency of the OIQoL.  A closer look at the presence and 
effect of causal items would also enhance the understanding of the newly developed 
OIQoL.  Triangulating the recent item revisions and eliminations within the OIQoL, 
alongside focus groups involving the paediatric OI populations would increase 
confidence in the newly developed OIQoL.  This would ensure no important items have 
been eliminated on statistical grounds and promote ongoing content validity.  
Subsequently, a multicentre study is proposed, involving several centres within the UK, 
to include a larger patient cohort, enabling the use of modern psychometric techniques 
to ensure further improved validity, reliability and responsiveness of the OIQoL.  Any 
future research should include wide diversity within the sample, enabling examination 
of any significant difference between groups such as; family background, parental 
employment status, ethnicity and family history of disease. 
The principle researcher is also in contact with several other multidisciplinary teams 
internationally.  Future long term plans involve translating the OIQoL into other 
languages (French, Spanish, German) and then further testing the psychometric 
properties of the OIQoL on different international cohorts (Canada, Spain, Australia, 
Portual, USA). 
It is also noted, that at several stages throughout this study, the opportunity was 
missed to develop a parent proxy measure alongside the child self-report.  This would 
not replace the child self-report, but would both supplement and complement it.  The 
principle researcher plans to revisit the interview data from the parent cohort and 
alongside focus groups involving parents of children with OI, the development of a 
proxy-report measure will be undertaken. 
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 Telephone: 0114 271 4011  
Facsimile: 0114 256 2469 
14 April 2010 
 
Mrs Claire Hill 
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Study Title: DEVELOPMENT OF AN OSTEOGENESIS IMPERFECTA 
QUALITY OF LIFE MEASURE AND VALIDATION AND 
RELIABILITY OF THE OSTEOGENESIS IMPERFECTA 
(OI) SPECIFIC ASSESSMENT TOOL 
REC reference number: 10/H1308/18 
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Thank you for your letter of 12 March 2010, responding to the Committee’s request for 
further information on the above research [and submitting revised documentation]. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation [as revised], subject to the conditions specified below. 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the 
start of the study (see “Conditions of the favourable opinion” below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start 
of the study. 
 
Management permission or approval must be obtained from each host organisation 
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prior to the start of the study at the site concerned. 
 
For NHS research sites only, management permission for research (“R&D approval”) 
should be obtained from the relevant care organisation(s) in accordance with NHS 
research governance arrangements.  Guidance on applying for NHS permission for 
research is available in the Integrated Research Application System or at 
http://www.rdforum.nhs.uk.  Where the only involvement of the NHS organisation is as 
a Participant Identification Centre, management permission for research is not required 
but the R&D office should be notified of the study. Guidance should be sought from the 
R&D office where necessary. 
 
Sponsors are not required to notify the Committee of approvals from host 
organisations. 
 
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site (as 
applicable). 
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Participant Information Sheet: Information sheet for young children 
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Questionnaire: PedsQL Young Child Report (age5-7) (48)  4  01 August 2007    
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Group 1 (22)  
3  12 March 2010    
Participant Information Sheet: Parent/Guardian child participation 
Phase 1 Focus Group 1 (23)  
3  12 March 2010    
Participant Information Sheet: Young people age 13-15 Phase 1 
Focus Group 2 (24)  
3  12 March 2010    
Participant Information Sheet: Young adult 16-18 Phase I Focus 
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Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National 
Research Ethics Service website > After Review 
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure.  If you wish to make 
your views known please use the feedback form available on the website. 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to improve 
our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk.  
 
10/H1308/18 Please quote this number on all correspondence 
 
Yours sincerely 
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Dr C A Moore 
Chair 
 
Email: april.dagnall@sth.nhs.uk 
 
Enclosures: “After ethical review – guidance for researchers” [SL-AR1 for CTIMPs, 
SL- AR2 for other studies]  
Copy to: Sheffield Children’s Hospital Research Department 
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Appendix 2 
 
Exhaustive list of items following interviews (Chapter 4) 
 
Safe/careful 
Being different 
Additional support 
Environment – access 
Environment – barrier 
Adaptation 
Tired 
Mobility 
Fear 
Equipment 
Hobbies 
Isolation 
Independence 
Acceptance 
Opportunities – more/less 
Positive thinking 
Effect of treatment 
Weakness 
Consequences 
Pain 
Aches 
Resilience 
Pride 
Being the same/normal 
Anger 
Coping strategies 
Endurance 
Made fun of 
Adapted psychologically 
Activity restriction 
Over protection 
Disappointment 
Upset/stress 
Reduced function 
Frustration 
Friendships/peer support 
Embarrassment 
Guilt 
Parental worry 
Medication/pain relief 
Fractures 
Additional attention 
Missed time from school 
Transport 
Needle phobia 
Stress on friendships 
Resentment 
Lack of support 
Control 
Lack of confidence 
Planning/organised 
Rebelling 
Extra effort/time 
Motivation/determination 
Proud 
Time off work 
Handling/bonding 
Feeling down/depressed 
Trust 
Letting go 
Achievement 
Stiffness/discomfort 
Fine motor/writing 
Orthotics 
Peer support 
Hospitalisation 
Financial impact 
Empowerment 
Parent ‘v’ child expectations and 
desires 
Sibling resentment 
Extra responsibility 
Handling 
Hypermobility 
Lack of exercise 
Appearance/deformity 
Uncertainty of fractures 
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Appendix 3 
 
Invitation letters and reply slips 
                                    Sheffield Children’s   
                                                                                                                     NHS Foundation Trust 
 
 
               Sheffield Children’s Hospital 
                                                                                                                                 Western Bank 
                                                                                                                                       Sheffield 
                                                                                                                                       S10 2TH 
                                                                                                        
                                                                                                          Telephone 0114 2717000 
<DATE> 
 
<NAME> 
<ADDRESS> 
 
Re: Development of an Osteogenesis Imperfecta quality of life measure and validation 
 and reliability of the Osteogenesis Imperfecta (OI) specific assessment tool. 
 
The Metabolic Bone Disease Team at Sheffield Children’s Hospital want to develop a quality of 
life measure to assess how children and young people feel about having Osteogenesis 
Imperfecta (Brittle Bone Disease).  Alongside this we wish to calculate the validity and reliability 
of the newly developed quality of life measure and the previously developed Osteogenesis 
Imperfecta functional assessment tool.   
 
We will be collecting views from a range of people, including patients, parents and health 
professionals, with regard to what should be included within this quality of life measure.  We will 
then develop the quality of life measure, again asking a range of people what they think to its 
suitability.   
 
We would like to invite you to take part in an interview to discuss quality of life in children and 
young people with Osteogenesis Imperfecta.  The interview would be held at Sheffield 
Children’s Hospital during your routine admission or out patient appointment and would take up 
to one hour. 
 
Please take time to read the enclosed information sheets, which explain the research, returning 
the reply slip, if you wish to take part in the research study.  Once you have returned the reply 
slip we will telephone you in a few days time to enquire about whether you are still willing to 
take part. 
 
This study is multifaceted, with several sections.  You can agree to take part in this section of 
the research alone if you prefer, or agree to take part in more than one section as they arise.  
Completing the reply slip enclosed will let the researchers know what you would like to be 
included in.  
 
May I take this opportunity to thank you in anticipation. 
 
Yours Sincerely 
 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s NHS Foundation Trust 
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                                    Sheffield Children’s   
                                                                                                                     NHS Foundation Trust 
 
 
               Sheffield Children’s Hospital 
                                                                                                                                 Western Bank 
                                                                                                                                       Sheffield 
                                                                                                                                       S10 2TH 
                                                                                                         
                                                                                                          Telephone 0114 2717000 
<DATE> 
 
<NAME> 
<ADDRESS> 
 
 
Re: Development of an Osteogenesis Imperfecta quality of life measure and validation and 
reliability of the Osteogenesis Imperfecta (OI) specific assessment tool. 
 
The Metabolic Bone Disease Team at Sheffield Children’s Hospital want to develop a quality of 
life measure to assess how children and young people feel about having Osteogenesis 
Imperfecta (Brittle Bone Disease).  Alongside this we wish to calculate the validity and reliability 
of the newly developed quality of life measure and the previously developed Osteogenesis 
Imperfecta functional assessment tool.   
 
We will be collecting views from a range of people, including patients, parents and health 
professionals, with regard to what should be included within this quality of life measure.  We will 
then develop the quality of life measure, again asking a range of people what they think to its 
suitability.   
 
We would like to invite your child to take part in an interview to discuss quality of life in children 
and young people with Osteogenesis Imperfecta.  The interview would be held at Sheffield 
Children’s Hospital during their routine admission or out patient appointment and would take up 
to one hour. 
 
Please take time to read the enclosed information sheets, which explain the research, returning 
the reply slip, if you wish to take part in the research study.  Once you have returned the reply 
slip we will telephone you in a few days time to enquire about whether you are still willing to 
take part. 
 
This study is multifaceted, with several sections.  You can agree to your child taking part in this 
section of the research alone if you prefer, or agree to them taking part in more than one section 
as they arise.  Completing the reply slip enclosed will let the researchers know what you would 
like them to be included in.  
 
May I take this opportunity to thank you in anticipation. 
 
Yours Sincerely 
 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s NHS Foundation Trust 
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          Sheffield Children’s   
                                                                                                        NHS Foundation Trust 
 
 
               Sheffield Children’s Hospital 
                                                                                                                                 Western Bank 
                                                                                                                                       Sheffield 
                                                                                                                                       S10 2TH 
                                                                                                         
                                                                                                          Telephone 0114 2717000 
 
<DATE> 
 
<NAME> 
<ADDRESS> 
 
 
 
 
 
 
Re: Development of an Osteogenesis Imperfecta quality of life measure and validation 
 and reliability of the Osteogenesis Imperfecta (OI) specific assessment tool. 
 
The Metabolic Bone Disease Team at Sheffield Children’s Hospital want to develop a quality of 
life measure to assess how children and young people feel about having Osteogenesis 
Imperfecta (Brittle Bone Disease).  Alongside this we wish to calculate the validity and reliability 
of the newly developed quality of life measure and the previously developed Osteogenesis 
Imperfecta functional assessment tool.   
 
We will be collecting views from a range of people, including patients, parents and health 
professionals, with regard to what should be included within this quality of life measure.  We will 
then develop the quality of life measure, again asking a range of people what they think to its 
suitability.   
 
We would like to invite you to take part in a focus group to discuss quality of life in children and 
young people with Osteogenesis Imperfecta.  The focus group would be held at Sheffield 
Children’s Hospital at a time convenient to you and would take up to one hour. 
Please take time to read the enclosed information sheet, which explains the research returning 
the reply slip, if you wish to take part in the research study.  Once you have returned the reply 
slip we will telephone you in a few days time to enquire about whether you are still willing to 
take part. 
 
This study is multifaceted, with several sections.  You can agree to take part in this section of 
the research alone if you prefer, or agree to take part in more than one section as they arise.  
Completing the reply slip enclosed will let the researchers know what you would like to be 
included in.  
 
May I take this opportunity to thank you in anticipation. 
 
Yours Sincerely 
 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s NHS Foundation Trust 
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          Sheffield Children’s   
                                                                                                                    NHS Foundation Trust 
 
 
               Sheffield Children’s Hospital 
                                                                                                                                 Western Bank 
                                                                                                                                       Sheffield 
                                                                                                                                       S10 2TH 
                                                                                                         
                                                                                                          Telephone 0114 2717000 
 
 
<DATE> 
 
<NAME> 
<ADDRESS> 
 
 
 
 
 
 
Re: Development of an Osteogenesis Imperfecta quality of life measure and validation 
 and reliability of the Osteogenesis Imperfecta (OI) specific assessment tool. 
 
The Metabolic Bone Disease Team at Sheffield Children’s Hospital want to develop a quality of 
life measure to assess how children and young people feel about having Osteogenesis 
Imperfecta (Brittle Bone Disease).  Alongside this we wish to calculate the validity and reliability 
of the newly developed quality of life measure and the previously developed Osteogenesis 
Imperfecta functional assessment tool.   
 
We will be collecting views from a range of people, including patients, parents and health 
professionals, with regard to what should be included within this quality of life measure.  We will 
then develop the quality of life measure, again asking a range of people what they think to its 
suitability.   
 
We would like to invite you to take part in a focus group to discuss quality of life in children and 
young people with Osteogenesis Imperfecta.  The focus group would be held at Sheffield 
Children’s Hospital at a time convenient to you and would take up to one hour. 
Please take time to read the enclosed information sheet, which explains the research returning 
the reply slip, if you wish to take part in the research study.  Once you have returned the reply 
slip we will telephone you in a few days time to enquire about whether you are still willing to 
take part. 
 
This study is multifaceted, with several sections.  You can agree to take part in this section of 
the research alone if you prefer, or agree to take part in more than one section as they arise.  
Completing the reply slip enclosed will let the researchers know what you would like to be 
included in.  
 
May I take this opportunity to thank you in anticipation. 
 
Yours Sincerely 
 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s NHS Foundation Trust 
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                      Sheffield Children’s   
                                                                                                                     NHS Foundation Trust 
 
 
               Sheffield Children’s Hospital 
                                                                                                                                 Western Bank 
                                                                                                                                       Sheffield 
                                                                                                                                       S10 2TH 
                                                                                                         
                                                                                                          Telephone 0114 2717000 
<DATE> 
 
<NAME> 
<ADDRESS> 
 
 
Re: Development of an Osteogenesis Imperfecta quality of life measure and validation and 
reliability of the Osteogenesis Imperfecta (OI) specific assessment tool. 
 
The Metabolic Bone Disease Team at Sheffield Children’s Hospital want to develop a quality of 
life measure to assess how children and young people feel about having Osteogenesis 
Imperfecta (Brittle Bone Disease).  Alongside this we wish to calculate the validity and reliability 
of the newly developed quality of life measure and the previously developed Osteogenesis 
Imperfecta functional assessment tool.   
 
We will be collecting views from a range of people, including patients, parents and health 
professionals, with regard to what should be included within this quality of life measure.  We will 
then develop the quality of life measure, again asking a range of people what they think to its 
suitability.   
 
We would like to invite your child to take part in a focus group to discuss quality of life in 
children and young people with Osteogenesis Imperfecta.  The focus group would be held at 
Sheffield Children’s Hospital at a time convenient to you and your child and would take up to 
one hour. 
 
Please take time to read the enclosed information sheet, which explains the research returning 
the reply slip, if you wish to take part in the research study.  Once you have returned the reply 
slip we will telephone you in a few days time to enquire about whether you are still willing to 
take part. 
 
This study is multifaceted, with several sections.  You can agree to your child taking part in this 
section of the research alone if you prefer, or agree to them taking part in more than one section 
as they arise.  Completing the reply slip enclosed will let the researchers know what you would 
like to be included in.  
 
May I take this opportunity to thank you in anticipation. 
 
Yours Sincerely 
 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s NHS Foundation Trust 
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                      Sheffield Children’s   
                                                                                                                    NHS Foundation Trust 
 
 
               Sheffield Children’s Hospital 
                                                                                                                                 Western Bank 
                                                                                                                                       Sheffield 
                                                                                                                                       S10 2TH 
                                                                                                         
                                                                                                          Telephone 0114 2717000 
<DATE> 
 
<NAME> 
<ADDRESS> 
 
 
 
Re: Development of an Osteogenesis Imperfecta quality of life measure and validation and 
reliability of the Osteogenesis Imperfecta (OI) specific assessment tool. 
 
The Metabolic Bone Disease Team at Sheffield Children’s Hospital want to develop a quality of 
life measure to assess how children and young people feel about having Osteogenesis 
Imperfecta (Brittle Bone Disease).  Alongside this we wish to calculate the validity and reliability 
of the newly developed quality of life measure and the previously developed Osteogenesis 
Imperfecta functional assessment tool.   
 
We have collected views from a range of people, including patients, parents and health 
professionals, with regard to what should be included within this quality of life measure.  We 
have developed the quality of life measure, and are now asking a range of people what they 
think to its suitability.   
 
We would like to invite you to take a look at the newly developed quality of life measure and 
then take part in an interview to find out what you think about it.  The interview would be held at 
Sheffield Children’s Hospital during your routine admission or out patient appointment and 
would take approximately 10 minutes. 
 
Please take time to read the enclosed information sheets, which explain the research, returning 
the reply slip, if you wish to take part in the research study.  Once you have returned the reply 
slip we will telephone you in a few days time to enquire about whether you are still willing to 
take part. 
 
This study is multifaceted, with several sections.  You can agree to take part in this section of 
the research alone if you prefer, or agree to take part in more than one section as they arise.  
Completing the reply slip enclosed will let the researchers know what you would like them to be 
included in.  
 
May I take this opportunity to thank you in anticipation. 
 
Yours Sincerely 
 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s NHS Foundation Trust 
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          Sheffield Children’s   
                                                                                                                    NHS Foundation Trust 
 
 
               Sheffield Children’s Hospital 
                                                                                                                                 Western Bank 
                                                                                                                                       Sheffield 
                                                                                                                                       S10 2TH 
                                                                                                         
                                                                                                          Telephone 0114 2717000 
<DATE> 
 
<NAME> 
<ADDRESS> 
 
 
 
Re: Development of an Osteogenesis Imperfecta quality of life measure and validation  
 and reliability of the Osteogenesis Imperfecta (OI) specific assessment tool. 
 
The Metabolic Bone Disease Team at Sheffield Children’s Hospital want to develop a quality of 
life measure to assess how children and young people feel about having Osteogenesis 
Imperfecta (Brittle Bone Disease).  Alongside this we wish to calculate the validity and reliability 
of the newly developed quality of life measure and the previously developed Osteogenesis 
Imperfecta functional assessment tool.   
 
We have collected views from a range of people, including patients, parents and health 
professionals, with regard to what should be included within this quality of life measure.  We 
have developed the quality of life measure, and are now asking a range of people what they 
think to its suitability.   
 
We would like to invite your child to take a look at the newly developed quality of life measure 
and then take part in an interview to find out what they think about it.  The interview would be 
held at Sheffield Children’s Hospital during their routine admission or out patient appointment 
and would take approximately 10 minutes. 
 
Please take time to read the enclosed information sheets, which explain the research, returning 
the reply slip, if you wish to take part in the research study.  Once you have returned the reply 
slip we will telephone you in a few days time to enquire about whether you are still willing to 
take part. 
 
This study is multifaceted, with several sections.  You can agree to your child taking part in this 
section of the research alone if you prefer, or agree to them taking part in more than one section 
as they arise.  Completing the reply slip enclosed will let the researchers know what you would 
like them to be included in.  
 
May I take this opportunity to thank you in anticipation. 
 
Yours Sincerely 
 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s NHS Foundation Trust 
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          Sheffield Children’s   
                                                                                                                     NHS Foundation Trust 
 
 
               Sheffield Children’s Hospital 
                                                                                                                                 Western Bank 
                                                                                                                                       Sheffield 
                                                                                                                                       S10 2TH 
                                                                                                         
                                                                                                          Telephone 0114 2717000 
 
 
 
Dear Researcher 
 
Re: Development of an Osteogenesis Imperfecta quality of life measure and validation 
 and reliability of the Osteogenesis Imperfecta (OI) specific assessment tool. 
 
 
 
I confirm that I would be willing to participate in the study.   YES/NO 
 
I confirm that I would be happy for my child to participate in the study.  YES/NO 
 
 
 
I consent to being contacted further and include my contact details below: 
 
 
 
 
 
  
 
 
I confirm that I would be willing to be contacted for participation  
in the other sections of this study      
 YES/NO 
 
 
I confirm that I would be happy for my child to be contacted for 
Participation in the other sections of this study     YES/NO 
 
 
Please return this slip in the envelop provided to: 
 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Physiotherapy Department 
Sheffield Children’s NHS Foundation Trust 
Western Bank 
Sheffield   
S10 2TH 
 
 
 
                                
 
 
NAME:   
    
TELEPHONE NUMBER:      
 
EMAIL:      
 
SIGNATURE:     
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PARTICIPANT INFORMATION SHEET 
FOR CHILDREN 
PHASE 1 INTERVIEW 
Age 6-12 
To be shown and read by parent/carer if required 
Study Title 
Development of a set of questions for children with Brittle Bone 
Disease. 
1. What is research? 
Research is what we do to find out the answer to an 
important question. 
2. What is Brittle Bone Disease? 
It means your bones can break easier and that your joints may 
be bendier than your friends or brothers and sisters. 
3. Why is this project being done? 
We want to develop a set of questions to help us work out how 
you feel about having Brittle Bone 
Disease. 
4. Why me? 
You have been chosen because you have 
Brittle Bones and you visit Sheffield 
Children’s Hospital for your treatment and care.  We are asking 
10 children, 10 parents and 5 doctors and nurses to take part in 
this section. 
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5. Do I have to take part? 
No you do not.  It is up to you.  We would like you to read this 
information sheet.  If you agree to take part, we would like you 
to write your name on two forms.  We will also ask your Mum, 
Dad or carer to write their name on the forms and give one back 
to us.  You can still change your mind later.  If you don’t want to 
take part, just say no.   You may be asked to take part again in a 
month or two.  If you don’t want to, just let your Mum, Dad or 
carer know.                   
6. What will happen? 
We would like to talk to you and ask you some questions.  The 
questions will be about what you think about having brittle 
bones.  This will be recorded on audio cassette. 
We will use the information to develop a set of questions to 
measure how children with brittle bones feel.  When the 
assessment is finished we will send you a copy so you can tell us 
what you think. 
We will talk to you about the research during your normal 
hospital visit.  There will be no extra blood tests or x-rays.  Your 
Mum, Dad or carer can stay with you during the interview. 
7. Will joining in help me? 
No, but it may help us to know more about how 
children with brittle bones feel.  We want to 
develop an assessment to measure how children 
with brittle bones feel so that we can improve 
our service. 
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8. What else might happen? 
We will only record the questions on tape.  Then we can write 
down what you said, by listening to the tape.  Once we have 
written it down we will give you a pretend name so that no one 
else will know what you have said.   
9. What happened when the research study stops? 
We will collect what everyone has said together and use the 
information to make a special assessment about how children 
with brittle bones feel. 
10. What if something goes wrong? 
Your Mum, Dad or carer will be able to talk to someone who will 
be able to tell them what they need to do about it. 
11. What if I don’t want to do the research anymore? 
Just tell your Mum, Dad, carer or doctor at any time.  They will 
not be cross with you.  You will still have the same care whilst 
you are at hospital.  
12. What if I wish to complain about the 
study? 
If you wish to complain you or your Mum, Dad or 
carer can talk to Claire Hill or Mrs Linda Towers 
at this hospital. 
13. Will anyone else know I am doing this? 
The people in our research team will know you are taking part.  
The doctor looking after you while you are in hospital will also 
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know.  No one else will know because we will not use your name or 
address.  You will get a pretend name instead. 
 
 
14. What happens to what the researchers find out? 
When we collect your information we will make sure it 
is stored in a safe place and only the people doing 
the research can look at it.  We will use the 
information to develop an assessment to measure 
how children with brittle bones feel and put it in medical 
magazines and on websites that doctors and therapists read. 
A short summary will also be on the hospital’s research website 
and the Brittle Bone Society website.  No one will know you were 
in the study. 
15. Did anyone else check the study is OK to do? 
The study has been checked by several 
people at the hospital and the university 
to make sure it is alright. 
16.  How can I find out more about the study? 
Your Mum, Dad, carer or other grown-up you trust may be able 
to answer your questions.  The doctors, nurses or therapists 
looking after you can also help you find out more about the 
study. 
Thank you for taking the time to read this – please ask any 
questions if you need to. 
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PARTICIPANT INFORMATION SHEET 
YOUNG PEOPLE (Aged 13 – 15) 
PHASE 1 INTERVIEW 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
We would like you to help us with our research study.  This is an educational 
study.  Please read this information carefully and talk to your Mum, Dad or carer 
about the study.  Ask us if there is anything that is not clear or if you want to 
know more. Take time to decide if you want to take part.  It is up to you if you 
want to do this.  If you don’t then that’s fine, you’ll be looked 
after at the hospital just the same. 
 
2. Why are we doing this research? 
We want to develop a Quality of Life measure to assess how 
children and young people feel about having Osteogenesis 
Imperfecta (Brittle Bone Disease). There are five sections in 
total (Phases 1a, 1b, 1c, 2 and 3), and by random selection you may be invited 
to take part in three of the five sections.  This is Phase 1 and you may also be 
invited to take part in Phase 1c and Phase 3.  This research is part of an 
educational qualification. 
3. Why have I been asked to take part? 
You have been chosen because you have Osteogenesis Imperfecta (Brittle 
Bone Disease).  We are asking 10 children and young people, 10 parents and 5 
health professionals to take part in this phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that your bones 
can break easier and that your joints may be bendier than your friends, brothers 
and sisters. 
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4. Do I have to take part? 
No it is entirely up to you.  If you do decide to take part: 
- You will be asked to sign a form to say that you agree to take part (a 
consent/assent form) 
- You will be given this information sheet and a copy of your signed 
consent/assent form to keep. 
You are free to stop taking part at any time during the research without giving a 
reason.  If you decide to stop, this will not affect the care you receive whilst in 
this hospital. 
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen to me if I take part? 
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital for interview.  You can do this during a 
clinic visit or when you are admitted for treatment.  
We would like to interview you and ask you some questions.  The questions will 
be about what you think about having Brittle Bone Disease (OI).  The interview 
will be recorded. 
We will use the information to develop a Quality of Life measure for children and 
young people with Brittle Bone Disease.  When the Quality of Life measure is 
developed we will send you a copy so you can tell us what you think. 
We will interview you during your normal hospital visit.  There will be no extra 
blood tests or x-rays.  You can choose to have someone stay with you during 
the interview, such as a parent/carer or friend. 
6. What will I be asked to do? 
We will ask you a few questions about how you feel about having Brittle Bone 
Disease.  We would like to get your opinion about what it is like to have Brittle 
Bone Disease, and how this affects your daily life.  We will record the interview, 
so that we can transcribe it to paper after the interview has finished.  We will 
anonymise the transcript by giving you a different name.  Once we have 
transcribed the interview to paper the tape recording will be destroyed. 
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7. Is there anything else to be worried about? 
No.  We want to develop a Quality of Life measure to enable us to assess how 
children and young people with Brittle Bone Disease feel about their daily life.  
We hope this new quality of life measure will help us provide better care for 
children and young people with OI. 
If we find out something that we think is important about your Brittle Bone 
Disease, we will talk to your Mum, Dad or carer and ask them if they want you 
to come back and have you checked again at the hospital. 
8. Will the study help me? 
No, but the information we get will help us to develop the quality of life measure.  
We hope the new quality of life measure will improve the care of other children 
and young people with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collect everyone’s opinions and use the information to develop a Quality 
of Life measure for children and young people with Brittle Bones disease. 
10. Contact for further information 
If you would like any further information about this study you 
could contact: 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
11. What if new information comes along? 
Sometimes during research, new things are found out about Brittle Bone 
Disease.  If this happens, someone from the research team will tell you about it 
and discuss whether you want to continue the study.  If you change your mind 
this will not affect any care you receive whilst in hospital.  If you decide to 
continue in the study you will be asked to sign an updated consent/assent form. 
12. What if I don’t want to do the research anymore? 
Just tell your Mum, Dad, carer, doctor or therapist at any time.  They will not be 
cross with you.  You will still have the same care whilst you are at hospital. 
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13. What if there is a problem or something goes wrong? 
Tell us if there is a problem and we will try to sort it out straight away.  You and 
your Mum, Dad or carer can either contact the project co-ordinator: 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Trust 
Tel: 01142717594 
 
14. Will anyone else know I’m doing this? 
The people in our research team will know you are taking part.  The doctor 
looking after you while you are in hospital will also know.   
Your medical notes may also be looked at by other people who work at the 
hospital to check that the study is being carried out correctly. 
All the information that is collected about you during the research will be kept 
strictly confidential.  Your transcript will be given a number; your name will be 
changed. 
Any information about you that leaves the hospital will have your name and 
address removed so that you cannot be recognised from it.  Once the study is 
complete all information will be destroyed or kept in your own confidential notes. 
 
15. What happens to the results of the researchers study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put an article in 
the hospital newsletter and on the Brittle Bone Society website.  The results will 
be anonymous, which means that you will not be identified from them. 
16. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Trust are organising the study.  They 
will not get any extra money for doing this. 
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17. Who has checked the study? 
Before any study goes ahead it has to be checked by a Research Ethics 
Committee. This is a group of people who make sure the research is OK to do.  
This study has been looked at by Sheffield Research Ethics Committee.   
It has also been checked by the research department at Sheffield Children’s 
NHS Foundation Trust. 
18.  How can I find out more about research? 
The Clinical Research Support Unit at this hospital has an information for 
families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PATIENT INFORMATION SHEET 
YOUNG ADULT AGED 16-18  
PHASE 1 INTERVIEW 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
You are being asked to take part in a research study.  This is an educational 
study.  Before you decide it is important for you to understand 
why the research is being done and what it will involve.  Please 
take time to read the following information carefully.  Talk to 
others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information (contact: Claire Hill on 01142267890).  Take 
time to decide whether or not you want to take part. 
2. What is the purpose of the study? 
We want to develop a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  This research involves several sections and you may be asked to 
take part in other sections of the research too.  There are five sections in total 
(Phases 1a, 1b, 1c, 2 and 3), and by random selection you may be invited to 
take part in three of the five sections.  This is Phase 1 and you may also be 
invited to take part in Phase 1c and Phase 3.  This research is part of an 
educational qualification. 
3. Why have I been chosen? 
You have been chosen because you have with Osteogenesis Imperfecta (Brittle 
Bone Disease).  Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It 
means that your bones can break easier and that your joints may be bendier 
than your friends, brothers and sisters. 
To develop a really useful quality of life measure for children and young people 
with Osteogenesis Imperfecta we need to find out what living with the condition 
is really like.  We are asking 10 children and young people, 10 parents and 5 
health professionals to take part in this phase. 
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4. Do I have to take part? 
No.  It is entirely up to you to decide whether or not to take part.  You are free to 
withdraw from the research at any time without giving a reason.  Your decisions 
about this will not affect the standard of care you will receive.   
If you are happy to take part, and are happy with the explanations from the 
research team, you will be asked to sign a consent form.  You will be given a 
copy of the information sheet and the signed consent/assent forms to keep for 
your records.  
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen if I agree to take part? 
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital for interview.  If preferred, you can do this 
during a clinic visit or when you are admitted for treatment.  
We would like to interview you and ask you some questions.  The questions will 
be about what you think about having Brittle Bone Disease (OI). What makes 
your life easier or more difficult?  The interview will be recorded. 
We will use the information to develop a Quality of Life measure for children and 
young people with Brittle Bone Disease.  When the Quality of Life measure is 
developed we will send you a copy so you can tell us what you think. 
6. What will I be asked to do? 
We will ask you a few questions about how you feel about having Brittle Bone 
Disease.  We would like to get your opinion about what it is like to have Brittle 
Bone Disease, and how this affects your daily life.  We will record the interview, 
so that we can transcribe it to paper after the interview has finished.  We will 
anonymise the transcript by giving you a different name.  Once we have 
transcribed the interview to paper and analysed the data, the tape recording will 
be destroyed. 
7. What are the possible disadvantages and risks of taking part? 
None.  We want to develop a Quality of Life measure to enable us to assess 
how children and young people with Brittle Bone Disease feel about their daily 
life.  We hope this new quality of life measure will help us provide better care for 
children and young people with OI. 
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8. What are the possible benefits of taking part? 
You will not benefit from being part of this study.  However, the information we 
collect will help us to develop the quality of life measure.  We hope the new 
quality of life measure will improve the care of other children and young people 
with Brittle Bone Disease (OI).   
9. What happens when the research study stops? 
We will collate everyone’s opinions and use the information to develop a Quality 
of Life measure for children and young people with Brittle Bones disease. 
10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  If you have any cause to 
complain about any aspect of the way in which you have been approached or 
treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you and you are not compromised in 
any way because you have taken part in a research study. 
11. Will my taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about you will 
be handled in confidence.  All information which is collected about you during 
the course of the research will be kept strictly confidential. Any information 
about you which leaves the hospital will have your name and address removed 
so that you cannot be recognised from it.  Once the study is complete all 
information will be destroyed. 
 
12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, someone from the 
research team will tell you about it and discuss whether you want to continue 
the study.  If you change your mind this will not affect any care you receive 
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whilst in hospital.  If you decide to continue in the study you will be asked to 
sign an updated consent form. 
14. What will happen if I don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your identifiable data, but we 
will need to use the data collected up to your withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you and you 
are not compromised in any way because you have taken part in a research 
study.  If you have any complaints or concerns please contact either the project 
co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Trust 
Tel: 01142717594 
 
Harm 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone else’s fault, 
then you may have grounds for a legal action – but you may have to pay for it. 
16. Will taking part in this study be kept confidential? 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it.  Once the study is complete all information will be destroyed. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your transcript will be given a number; your name will be changed.   
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17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that you will not be 
identified from them. 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Trust are organising the study.  They 
will not get any extra money for doing this. 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at Sheffield Children’s 
NHS Foundation Trust. 
20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PARENT/LEGAL GUARDIAN INFORMATION SHEET 
Child/young people participation                               
PHASE 1 INTERVIEW 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
Your child is being asked to take part in a research study.  This is an 
educational study.  Before you decide it is important for you to 
understand why the research is being done and what it will 
involve.  Please take time to read the following information 
carefully.  Talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information (contact: Claire Hill on 01142267890).   Take 
time to decide whether or not you want your child to take part. 
2. What is the purpose of the study? 
We want to develop a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  This research involves several sections and your child may be asked 
to take part in other stages of the research too.  There are five sections in total 
(1a, 1b, 1c, 2 and 3), and by random selection you or your child may be invited 
to take part in three of the five.  This is Phase 1 and you may also be invited to 
take part in Phase 1c and Phase 3.  This research is part of an educational 
qualification. 
3. Why has my child been chosen? 
Your child has been chosen because they have Osteogenesis Imperfecta 
(Brittle Bone Disease).  Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It 
means that their bones can break easier and that their joints may be bendier 
than their friends, brothers and sisters. 
To develop a useful quality of life measure for children and young people with 
Osteogenesis Imperfecta we need to find out what living with the condition is 
like.  We are asking 10 children and young people, 10 parents and 5 health 
professionals to take part in this phase. 
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4. Does my child have to take part? 
No.  It is entirely up to you and your child (wherever possible) to decide whether 
or not to take part.  You are both free to withdraw from the research at any time 
without giving a reason.  Your decisions about this will not affect the standard of 
care your child will receive.   
If you are happy to take part, and are happy with the explanations from the 
research team, you will be asked to sign a consent form.  If your child is able to 
understand the research and is happy to take part and can write their name, 
they will be asked to sign an assent form with you, if they want to.  You will be 
given a copy of the information sheet and the signed consent/assent forms to 
keep for your records. 
You can agree to your child taking part in this section of the research alone if 
you prefer, or agree to them taking part in more than one section as they arise.  
Completing the reply slip enclosed will let the researchers know what you would 
like your child to be included in.  
5. What will happen to my child if we agree to take part? 
If you agree to take part we will arrange a date and time convenient for your 
child to come to Sheffield Children’s Hospital for interview.  If preferred you can 
do this during a clinic visit or when they are admitted for treatment.  
We would like to interview your child and ask them some questions.  The 
questions will be about what they think about having Brittle Bone Disease (OI).  
The interview will be recorded. 
We will use the information to develop a Quality of Life measure for children and 
young people with Brittle Bone Disease.  When the Quality of Life measure is 
developed we will send them a copy so they can tell us what they think. 
We will interview them during your normal hospital visit.  There will be no extra 
blood tests or x-rays.  You can stay with them during the interview if they would 
prefer that. 
6. What will we be asked to do? 
We will ask your child a few questions about how they feel about having Brittle 
Bone Disease.  We would like to get their opinion about what it is like to have 
Brittle Bone Disease, and how this affects their daily life.  We will record the 
interview, so that we can transcribe it to paper after the interview has finished.  
We will anonymise the transcript by giving your child a different name.  Once we 
have transcribed the interview to paper and analysed the data, the tape 
recording will be destroyed. 
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7. What are the possible disadvantages and risks of taking part? 
None.  We want to develop a Quality of Life measure to enable us to assess 
how children and young people with Brittle Bone Disease feel about their daily 
life.  We hope this new quality of life measure will help us provide better care for 
children and young people with OI. 
If we find out something that we think is important about your child’s Brittle Bone 
Disease, we will talk to you and ask if you want to come back and have your 
child checked again at the hospital. 
8. What are the possible benefits of taking part? 
Your child will not benefit from being part of this study.  However, the 
information we collect will help us to develop the quality of life measure.  We 
hope the new quality of life measure will improve the care of other children and 
young people with Brittle Bone Disease (OI).   
9. What happens when the research study stops? 
We will collate everyone’s opinions and use the information to develop a Quality 
of Life measure for children and young people with Brittle Bone disease. 
10. What if there is a problem? 
Any complaint about the way you or your child have been dealt with during the 
study or any possible harm you or your child might suffer will be addressed.  If 
you have any cause to complain about any aspect of the way in which you have 
been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms are available to you and you are not 
compromised in any way because you have taken part in a research study. 
11. Will my child’s taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about your 
child will be handled in confidence.  All information which is collected about your 
child during the course of the research will be kept strictly confidential. Any 
information about your child which leaves the hospital will have their name and 
address removed so that you cannot be recognised from it.  Once the study is 
complete all information will either be destroyed or kept in your child’s 
confidential notes. 
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12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, someone from the 
research team will tell you and your child about it and discuss whether you want 
your child to continue the study.  If you change your mind this will not affect any 
care your child receives whilst in hospital.  If you decide to continue in the study 
you and your child will be asked to sign an updated consent/assent form. 
14. What will happen if we don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your child’s identifiable data if 
you wish, but we will need to use the data collected up to their withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you or 
your child has been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are available to you 
and you are not compromised in any way because you have taken part in a 
research study.  If you have any complaints or concerns please contact either 
the project co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Trust 
Tel: 01142717594 
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Harm 
If your child is harmed by taking part in this research project, there are no 
special compensation arrangements.  If your child is harmed due to someone 
else’s fault, then you may have grounds for a legal action – but you may have to 
pay for it. 
 
16. Will taking part in this study be kept confidential? 
All information which is collected about your child during the course of the 
research will be kept strictly confidential. Any information about your child which 
leaves the hospital will have their name and address removed so that your child 
cannot be recognised from it.  Once the study is complete all information will 
either be destroyed or kept in your child’s confidential notes. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your child’s transcript will be given a number; their name will be changed.  Your 
child’s medical notes may also be looked at by other people within the hospital 
involved in the running and supervision of the study to check that it is being 
carried out correctly. 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that your child will 
not be identified from them. 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at Sheffield Children’s 
NHS Foundation Trust. 
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20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PARENT/LEGAL GUARDIAN INFORMATION SHEET 
Parental Participation 
PHASE 1 INTERVIEW 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
You are being asked to take part in a research study.  This is an educational 
study.  Before you decide it is important for you to understand 
why the research is being done and what it will involve.  Please 
take time to read the following information carefully.  Talk to 
others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information (contact: Claire Hill on 01142267890).  Take 
time to decide whether or not you want to take part. 
2. What is the purpose of the study? 
We want to develop a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  This research involves several sections and you may be asked to 
take part in other sections of the research too.  There are five sections in total 
(Phases 1a, 1b, 1c, 2 and 3), and by random selection you may be invited to 
take part in three of the five sections.  This is Phase 1 and you may also be 
invited to take part in Phase 1c and Phase 3.  This research is part of an 
educational qualification. 
3. Why have I been chosen? 
You have been chosen because you have a child/children with Osteogenesis 
Imperfecta (Brittle Bone Disease).  Osteogenesis Imperfecta (OI) is Brittle Bone 
Disease.  It means that your child’s bones can break easier and that their joints 
may be bendier than their friends, brothers and sisters. 
To develop a really useful quality of life measure for children and young people 
with Osteogenesis Imperfecta we need to find out what living with the condition 
is really like.  We are asking 10 children and young people, 10 parents and 5 
health professionals to take part in this phase. 
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4. Do I have to take part? 
No.  It is entirely up to you to decide whether or not to take part.  You are free to 
withdraw from the research at any time without giving a reason.  Your decisions 
about this will not affect the standard of care your child will receive.   
If you are happy to take part, and are happy with the explanations from the 
research team, you will be asked to sign a consent form.  You will be given a 
copy of the information sheet and the signed consent/assent forms to keep for 
your records.  
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen if I agree to take part? 
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital for interview.  If preferred, you can do this 
during a clinic visit or when your child/children are admitted for treatment.  
We would like to interview you and ask you some questions.  The questions will 
be about what you think about looking after a child who has Brittle Bone 
Disease (OI). What makes their life easier or more difficult?  The interview will 
be recorded. 
We will use the information to develop a Quality of Life measure for children and 
young people with Brittle Bone Disease.  When the Quality of Life measure is 
developed we will send you a copy so you can tell us what you think. 
6. What will I be asked to do? 
We will ask you a few questions about parenting a child/children with Brittle 
Bone Disease.  We would like to get your opinion about what it is like to have a 
child with Brittle Bone Disease, and how this affects their daily life.  We will 
record the interview, so that we can transcribe it to paper after the interview has 
finished.  We will anonymise the transcript by giving you a different name.  
Once we have transcribed the interview to paper and analysed the data, the 
tape recording will be destroyed. 
7. What are the possible disadvantages and risks of taking part? 
None.  We want to develop a Quality of Life measure to enable us to assess 
how children and young people with Brittle Bone Disease feel about their daily 
life.  We hope this new quality of life measure will help us provide better care for 
children and young people with OI. 
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8. What are the possible benefits of taking part? 
You will not benefit from being part of this study.  However, the information we 
collect will help us to develop the quality of life measure.  We hope the new 
quality of life measure will improve the care of other children and young people 
with Brittle Bone Disease (OI).   
9. What happens when the research study stops? 
We will collate everyone’s opinions and use the information to develop a Quality 
of Life measure for children and young people with Brittle Bones disease. 
10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  If you have any cause to 
complain about any aspect of the way in which you have been approached or 
treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you and you are not compromised in 
any way because you have taken part in a research study. 
11. Will my taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about you will 
be handled in confidence.  All information which is collected about you during 
the course of the research will be kept strictly confidential. Any information 
about you which leaves the hospital will have your name and address removed 
so that you cannot be recognised from it.  Once the study is complete all 
information will be destroyed. 
12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, someone from the 
research team will tell you about it and discuss whether you want to continue 
the study.  If you change your mind this will not affect any care your child 
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receives whilst in hospital.  If you decide to continue in the study you will be 
asked to sign an updated consent form. 
14. What will happen if I don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your identifiable data, but we 
will need to use the data collected up to your withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you and you 
are not compromised in any way because you have taken part in a research 
study.  If you have any complaints or concerns please contact either the project 
co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Trust 
Tel: 01142717594 
 
Harm 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone else’s fault, 
then you may have grounds for a legal action – but you may have to pay for it. 
 
16. Will taking part in this study be kept confidential? 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it.  Once the study is complete all information will be destroyed. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
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Your transcript will be given a number; your name will be changed.   
 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that you or your 
child will not be identified from them. 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at Sheffield Children’s 
NHS Foundation Trust. 
20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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HEALTH PROFESSIONALS INFORMATION SHEET 
PHASE 1 INTERVIEW 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
You are being asked to take part in a research study.  This is an educational 
study.  Before you decide it is important for you to understand why the research 
is being done and what it will involve.  Please take time to read the following 
information carefully.  Talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like more information 
(contact: Claire Hill on 01142267890).   Take time to decide whether or not you 
want to take part. 
2. What is the purpose of the study? 
We want to develop a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone Disease) 
and how it affects their daily life.  This research is part of an educational 
qualification. 
3. Why have I been chosen? 
You have been chosen because you work with children and young people who 
have   Osteogenesis Imperfecta (Brittle Bone Disease). We feel it is very 
important to gain a professional perspective of quality of life in your patients. 
To develop a really useful quality of life measure for children and young people 
with Osteogenesis Imperfecta we need to find out what living with the condition 
is really like.  We are asking 10 children and young people, 10 parents and 5 
health professionals to take part in this phase.   
4. Do I have to take part? 
No.  It is entirely up to you to decide whether or not to take part.  You are free to 
withdraw from the research at any time without giving a reason.  If you are 
happy to take part, and are happy with the explanations from the research 
team, you will be asked to sign a consent form.  You will be given a copy of the 
information sheet and the signed consent form to keep for your records. 
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5. What will happen if I agree to take part? 
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital for interview.  You can do this during 
normal working hours, at lunch time or at the end of the working day.  
We would like to interview you and ask you some questions.  The questions will 
ask; how you think having Osteogenesis Imperfecta affects a child’s quality of 
life and the life of their family.  The interview will be recorded. 
We will use the information to develop a Quality of Life measure for children and 
young people with Osteogenesis Imperfecta.  When the Quality of Life measure 
is developed we will send you a copy so you can tell us what you think. 
6. What will I be asked to do? 
We will ask you a few questions about treating children with Osteogenesis 
Imperfecta.  We would like to get your opinion about how Osteogenesis 
Imperfecta affects your patients’ daily life.  We will record the interview, so that 
we can transcribe it to paper after the interview has finished.  We will 
anonymise the transcript by giving you a different name.  Once we have 
transcribed the interview to paper and analysed the data, the tape recording will 
be destroyed. 
7. What are the possible disadvantages and risks of taking part? 
None.  We want to develop a Quality of Life measure to enable us to assess 
how children and young people with Osteogenesis Imperfecta feel about their 
daily life.  We hope this new quality of life measure will help us provide better 
care for children and young people with OI. 
8. What are the possible benefits of taking part? 
You will not benefit from being part of this study.  However, the information we 
collect will help us to develop the quality of life measure.  We hope the new 
quality of life measure will improve the care of other children and young people 
with Osteogenesis Imperfecta (OI).   
9. What happens when the research study stops? 
We will collate everyone’s opinions and use the information to develop a Quality 
of Life measure for children and young people with Osteogenesis Imperfecta. 
10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  If you have any cause to 
complain about any aspect of the way in which you have been approached or 
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treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you and you are not compromised in 
any way because you have taken part in a research study. 
11. Will my taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about you will 
be handled in confidence.  All information which is collected about you during 
the course of the research will be kept strictly confidential. Any information 
about you which leaves the hospital will have your name and address removed 
so that you cannot be recognised from it.  Once the study is complete all 
information will be destroyed. 
12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, someone from the 
research team will tell you about it and discuss whether you want to continue 
the study.  If you decide to continue in the study you will be asked to sign an 
updated consent form. 
14. What will happen if I don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your identifiable data if you 
wish, but we will need to use the data collected up to your withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you and you 
are not compromised in any way because you have taken part in a research 
study.  If you have any complaints or concerns please contact either the project 
co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
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Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Trust 
Tel: 01142717594 
 
Harm 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone else’s fault, 
then you may have grounds for a legal action – but you may have to pay for it. 
 
16. Will taking part in this study be kept confidential? 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it.  Once the study is complete all information will be destroyed. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your transcript will be given a number; your name will be changed.   
 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website.  This will be available at the end of 
the study, on www.sheffieldchildrenscrf.nhs.uk.  The results will also be 
included as part of the chief investigators educational qualification.  The results 
will be anonymous, which means that you will not be identified from them. 
 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
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19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the Research and Development department at the 
hospital. 
20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PARTICIPANT INFORMATION SHEET 
FOR YOUNG PEOPLE (Age 13-15) 
PHASE 1 FOCUS GROUP 1 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
We would like you to help us with our research study.  This is an 
educational study.  Please read this information carefully and 
talk to your Mum, Dad or carer about the study.  Ask us if there 
is anything that is not clear or if you want to know more.  Take 
time to decide if you want to take part.  It is up to you if you want 
to do this.  If you don’t then that’s fine, you’ll be looked after at 
the hospital just the same. 
2. Why are we doing this research? 
We want to develop a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), and by 
random selection you may be invited to take part in three of the five sections.  
This is Phase 1b and you may also be invited to take part in Phase 1a and 
Phase 3.  This research is part of an educational qualification. 
3. Why have I been asked to take part? 
You have been chosen because you have Osteogenesis Imperfecta (Brittle 
Bone Disease).  We are asking 5 - 10 children and young people to take part in 
this phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that your bones 
can break easier and that your joints may be bendier than your friends, brothers 
and sisters. 
4. Do I have to take part? 
No it is entirely up to you.  If you do decide to take part: 
- You will be asked to sign a form to say that you agree to take part (a 
consent/assent form) 
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- You will be given this information sheet and a copy of your signed 
consent/assent form to keep. 
You are free to stop taking part at any time during the research without giving a 
reason.  If you decide to stop, this will not affect the care you receive whilst in 
this hospital. 
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen to me if I take part? 
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital.  We would like to chat to you and some 
other children and young people in a group.  This is called a focus group.   
We would like to ask you some questions.  The questions will be about what 
you think about having Brittle Bone Disease (OI).  We will ask you about some 
of the ideas we have found out about quality of life and Brittle Bone Disease so 
far.  The focus group will be recorded on DVD.  If you do not wish to be 
identified on the DVD your face can be pixellated/obscured. 
We will use the information to develop a Quality of Life measure for children and 
young people with Brittle Bone Disease.  When the Quality of Life measure is 
developed we will send you a copy so you can tell us what you think. 
There will be no extra blood tests or x-rays.   
6. What will I be asked to do? 
We will ask you a few questions about how you feel about having Brittle Bone 
Disease.  We will ask you to look at some of the ideas and information that has 
been suggested so far.  We will record the focus group, so that we can 
transcribe it to paper after the interview has finished.  We will anonymise the 
transcript by giving you a different name.  Once we have transcribed the focus 
group to paper and completed the research the DVD recording will be 
destroyed. 
7. Is there anything else to be worried about? 
No.  We want to develop a Quality of Life measure to enable us to assess how 
children and young people with Brittle Bone Disease feel about their daily life.  
We hope this new quality of life measure will help us provide better care for 
children and young people with OI. 
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If we find out something that we think is important about your Brittle Bone 
Disease, we will talk to your Mum, Dad or carer and ask them if they want you 
to come back and have you checked again at the hospital. 
8. Will the study help me? 
No, but the information we get will help us to develop the quality of life measure.  
We hope the new quality of life measure will improve the care of other children 
and young people with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collect everyone’s opinions and use the information to develop a Quality 
of Life measure for children and young people with Brittle Bone Disease. 
10. Contact for further information 
If you would like any further information about this study you 
could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
11. What if new information comes along? 
Sometimes during research, new things are found out about Brittle Bone 
Disease.  If this happens, someone from the research team will tell you about it 
and discuss whether you want to continue the study.  If you change your mind 
this will not affect any care you receive whilst in hospital.  If you decide to 
continue in the study you will be asked to sign an updated consent/assent form. 
12. What if I don’t want to do the research anymore? 
Just tell your Mum, Dad, carer, doctor or therapist at any time.  They will not be 
cross with you.  You will still have the same care whilst you are at hospital. 
13. What if there is a problem or something goes wrong? 
Tell us if there is a problem and we will try to sort it out straight away.  You and 
your Mum, Dad or carer can either contact the project co-
ordinator: 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
 
 
316 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
14. Will anyone else know I’m doing this? 
The people in our research team will know you are taking part.  The doctor 
looking after you while you are in hospital will also know.   
Your medical notes may also be looked at by other people who work at the 
hospital to check that the study is being carried out correctly. 
All the information that is collected about you during the research will be kept 
strictly confidential.  Your transcript will be given a number; your name will be 
changed.   
Any information about you that leaves the hospital will have your name and 
address removed so that you cannot be recognised from it.  Once the study is 
complete all information will be destroyed or kept in your own confidential notes. 
15. What happens to the results of the researchers study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put an article in 
the hospital newsletter and on the Brittle Bone Society website.  The results will 
be anonymous, which means that you will not be identified from them. 
16. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Trust are organising the study.  They 
will not get any extra money for doing this. 
17. Who has checked the study? 
Before any study goes ahead it has to be checked by a Research Ethics 
Committee. This is a group of people who make sure the research is OK to do.  
This study has been looked at by Sheffield Research Ethics Committee.   
It has also been checked by the research department at Sheffield Children’s 
NHS Foundation Trust. 
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18.  How can I find out more about research? 
The Clinical Research Support Unit at this hospital has an information for 
families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PATIENT INFORMATION SHEET  
YOUNG ADULT AGED 16-18  
PHASE 1 FOCUS GROUP 1 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
You are being asked to take part in a research study.  This is an educational 
study.  Before you decided it is important for you to understand 
why the research is being done and what it will involve.  Please 
take time to read the following information carefully.  Talk to 
others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information (contact: Claire Hill on 01142267890).  Take 
time to decide whether or not you want to take part. 
2. What is the purpose of the study? 
We want to develop a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), and by 
random selection you may be invited to take part in three of the five sections.  
This is Phase 1b and you may also be invited to take part in Phase 3. This 
research is part of an educational qualification. 
3. Why have I been chosen? 
You have been chosen because you have Osteogenesis Imperfecta (Brittle 
Bone Disease). We are asking 5 - 10 children and young people to take part in 
this phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that your bones 
can break easier and that your joints may be bendier than your friends, brothers 
and sisters. 
To develop a useful quality of life measure for children and young people with 
Osteogenesis Imperfecta we need to find out what living with the condition is 
really like.  We have already asked 10 children and young people, 10 parents 
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and 5 health professionals about their views.  We would now like to validate 
these views by asking you what you think to the items already suggested. 
4. Do I have to take part? 
No.  It is entirely up to you to decide whether or not to take part.  You are free to 
withdraw from the research at any time without giving a reason.  Your decisions 
about this will not affect the standard of care you will receive.   
If you are happy to take part, and are happy with the explanations from the 
research team, you will be asked to sign a consent form.  You will be given a 
copy of the information sheet and the signed consent form to keep for your 
records. 
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen if I agree to take part?  
If you agree to take part we will arrange a date and time convenient for your 
child to come to Sheffield Children’s Hospital for the focus group.  We will try to 
do this during a clinic visit or when you are admitted for treatment where 
possible.  
We would like you to take part in a focus group.  We would like to ask the focus 
group some questions about the items we have already generated (from 
previous interviews).  The questions will be about what they think of the newly 
generated items, and their relevance to living with Brittle Bone Disease (OI).  
The focus group will be recorded on DVD.  If you do not wish to be identified on 
the DVD your face can be pixellated/obscured. 
We will use the information to further develop a Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed we will send you a copy so you can tell us what you 
think. 
There will be no extra blood tests or x-rays.   
6. What will we be asked to do? 
We will ask you a few questions about what you feel about the newly generated 
quality of life items.  We would like to get your opinion about their suitability for 
inclusion in the newly developed quality of life measure.  We will record the 
focus group on DVD, so that we can transcribe it to paper.  We will anonymise 
the transcript by giving you a different name.  Once we have transcribed the 
focus group to paper and the research complete the DVD recording will be 
destroyed. 
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7. What are the possible disadvantages and risks of taking part? 
None.  We want to develop a Quality of Life measure to enable us to assess 
how children and young people with Brittle Bone Disease feel about their daily 
life.  We hope this new quality of life measure will help us provide better care for 
children and young people with OI. 
If we find out something that we think is important about your Brittle Bone 
Disease, we will talk to you and ask if you want to come back and be checked 
again at the hospital. 
8. What are the possible benefits of taking part? 
You will not benefit from being part of this study.  However, the information we 
collect will help us to develop the quality of life measure.  We hope the new 
quality of life measure will improve the care of other children and young people 
with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collate everyone’s opinions and use the information to develop a Quality 
of Life measure for children and young people with Brittle Bone Disease. 
10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  If you have any cause to 
complain about any aspect of the way in which you have been 
approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are 
available to you and you are not compromised in any way 
because you have taken part in a research study.  
11. Will my taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about you will 
be handled in confidence.  All information which is collected about you during 
the course of the research will be kept strictly confidential. Any information 
about you which leaves the hospital will have your name and address removed 
so that you cannot be recognised from it.  Once the study is complete all 
information will either be destroyed. 
12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
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Sheffield Children’s Hospital 
01142267890 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new 
information becomes available about Osteogenesis 
Imperfecta.  If this happens, someone from the research 
team will tell you about it and discuss whether you want to 
continue the study.  If you change your mind this will not 
affect any care you receive whilst in hospital.  If you decide to 
continue in the study you will be asked to sign an updated consent form. 
14. What will happen if we don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your identifiable samples if you 
wish, but we will need to use the data collected up to your withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you and you 
are not compromised in any way because you have taken part in a research 
study.  If you have any complaints or concerns please contact either the project 
co-ordinator: 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
 
Harm 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone else’s fault, 
then you may have grounds for a legal action – but you may have to pay for it. 
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16. Will taking part in this study be kept confidential? 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it.  Once the study is complete all information will either be 
destroyed or kept in your confidential notes. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your transcript will be given a number; your name will be changed.  Your 
medical notes may also be looked at by other people within the hospital 
involved in the running and supervision of the study to check that it is being 
carried out correctly. 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that you will not be 
identified from them. 
 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
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20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PARENT/LEGAL GUARDIAN INFORMATION SHEET  
Child/young people participation                             
PHASE 1 FOCUS GROUP 1 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
Your child is being asked to take part in a research study.  This is an 
educational study.  Before you decided it is important for you to 
understand why the research is being done and what it will 
involve.  Please take time to read the following information 
carefully.  Talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information (contact: Claire Hill on 01142267890).  Take 
time to decide whether or not you want your child to take part. 
2. What is the purpose of the study? 
We want to develop a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), and by 
random selection you or your child may be invited to take part in three of the 
five sections.  This is Phase 1b and you may also be invited to take part in 
Phase 3. This research is part of an educational qualification. 
3. Why has my child been chosen? 
Your child has been chosen because they have Osteogenesis Imperfecta 
(Brittle Bone Disease). We are asking 5 - 10 children and young people to take 
part in this phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that their bones 
can break easier and that their joints may be bendier than their friends, brothers 
and sisters. 
To develop a really useful quality of life measure for children and young people 
with Osteogenesis Imperfecta we need to find out what living with the condition 
is really like.  We have already asked 10 children and young people, 10 parents 
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and 5 health professionals about their views.  We would now like to validate 
these views by asking your child what they think to the items already suggested. 
4. Does my child have to take part? 
No.  It is entirely up to you and your child (wherever possible) to decided 
whether or not to take part.  You are both free to withdraw from the research at 
any time without giving a reason.  Your decisions about this will not affect the 
standard of care your child will receive.   
If you are happy for your child to take part, and are happy with the explanations 
from the research team, you will be asked to sign a consent form.  If your child 
is able to understand the research and is happy to take part and can write their 
name, they will be asked to sign an assent form with you, if they want to.  You 
will be given a copy of the information sheet and the signed consent/assent 
forms to keep for your records. 
You can agree to your child taking part in this section of the research alone if 
you prefer, or agree to them taking part in more than one section as they arise.  
Completing the reply slip enclosed will let the researchers know what you would 
like your child to be included in.  
5. What will happen to my child if we agree to take part?  
If you agree to take part we will arrange a date and time convenient for your 
child to come to Sheffield Children’s Hospital for the focus group.  We will try to 
do this during a clinic visit or when they are admitted for treatment where 
possible.  
We would like your child to take part in a focus group.  We would like to ask the 
focus group some questions about the items we have already generated (from 
previous interviews).  The questions will be about what they think of the newly 
generated items, and their relevance to living with Brittle Bone Disease (OI).  
The focus group will be recorded on DVD.  If you do not wish to be identified on 
the DVD your face can be pixellated/obsured. 
We will use the information to further develop a Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed we will send them a copy so they can tell us what they 
think. 
There will be no extra blood tests or x-rays.   
6. What will we be asked to do? 
We will ask your child a few questions about what they feel about the newly 
generated quality of life items.  We would like to get their opinion about their 
suitability for inclusion in the newly developed Quality of life measure.  We will 
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record the focus group on DVD, so that we can transcribe it to paper.  We will 
anonymise the transcript by giving your child a different name.  Once we have 
transcribed the focus group to paper and the research complete the DVD 
recording will be destroyed. 
7. What are the possible disadvantages and risks of taking part? 
None.  We want to develop a Quality of Life measure to enable us to assess 
how children and young people with Brittle Bone Disease feel about their daily 
life.  We hope this new quality of life measure will help us provide better care for 
children and young people with OI. 
If we find out something that we think is important about your child’s Brittle Bone 
Disease, we will talk to you and ask if you want to come back and have your 
child checked again at the hospital. 
8. What are the possible benefits of taking part? 
Your child will not benefit from being part of this study.  However, the 
information we collect will help us to develop the quality of life measure.  We 
hope the new quality of life measure will improve the care of other children and 
young people with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collate everyone’s opinions and use the information to develop a Quality 
of Life measure for children and young people with Brittle Bones disease. 
10. What if there is a problem? 
Any complaint about the way you or your child have been dealt with during the 
study or any possible harm you or your child might suffer will be addressed.  If 
you have any cause to complain about any aspect of the way in 
which you have been approached or treated during the course 
of this study, the normal National Health Service complaints 
mechanisms are available to you and you are not compromised 
in any way because you have taken part in a research study.  
11. Will my child’s taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about your 
child will be handled in confidence.  All information which is collected about your 
child during the course of the research will be kept strictly confidential. Any 
information about your child which leaves the hospital will have their name and 
address removed so that they cannot be recognised from it.  Once the study is 
complete all information will either be destroyed or kept in your child’s 
confidential notes. 
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12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, someone from the 
research team will tell you and your child about it and discuss 
whether you want your child to continue the study.  If you 
change your mind this will not affect any care your child 
receives whilst in hospital.  If you decide to continue in the 
study you and your child will be asked to sign an updated 
consent/assent form. 
14. What will happen if we don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your child’s identifiable 
samples if you wish, but we will need to use the data collected up to their 
withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you or 
your child has been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are available to you 
and you are not compromised in any way because you have taken part in a 
research study.  If you have any complaints or concerns please contact either 
the project co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
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Tel: 01142717594 
 
Harm 
If your child is harmed by taking part in this research project, there are no 
special compensation arrangements.  If your child is harmed due to someone 
else’s fault, then you may have grounds for a legal action – but you may have to 
pay for it. 
 
16. Will taking part in this study be kept confidential? 
All information which is collected about your child during the course of the 
research will be kept strictly confidential. Any information about your child which 
leaves the hospital will have their name and address removed so that your child 
cannot be recognised from it.  Once the study is complete all information will 
either be destroyed or kept in your child’s confidential notes. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your child’s transcript will be given a number; their name will be changed.  Your 
child’s medical notes may also be looked at by other people within the hospital 
involved in the running and supervision of the study to check that it is being 
carried out correctly. 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that your child will 
not be identified from them. 
 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
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19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PARTICIPANT INFORMATION SHEET 
FOR YOUNG PEOPLE (Age 13-15) 
PHASE 1 FOCUS GROUP 2 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
We would like you to help us with our research study.  This is an educational 
study.  Please read this information carefully and talk to your Mum, Dad or carer 
about the study.  Ask us if there is anything that is not clear or if 
you want to know more.  Take time to decide if you want to take 
part.  It is up to you if you want to do this.  If you don’t then that’s 
fine, you’ll be looked after at the hospital just the same. 
 
2. Why are we doing this research? 
We have developed a Quality of Life measure to assess how 
children and young people feel about having Osteogenesis Imperfecta (Brittle 
Bone Disease).  We now want to assess the suitability and usefulness of the 
items/questions.  There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), 
and by random selection you may be invited to take part in three of the five 
sections.  This is Phase 1c and you may also be invited to take part in Phase 1a 
and Phase 3. This research is part of an educational qualification. 
3. Why have I been asked to take part? 
You have been chosen because you have Osteogenesis Imperfecta (Brittle 
Bone Disease), and you participated in the previous interviews to generate 
items.  We are asking 5 - 10 young people and parents to take part in this 
phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that your bones 
can break easier and that your joints may be bendier than your friends, brothers 
and sisters. 
4. Do I have to take part? 
No it is entirely up to you.  If you do decide to take part: 
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- You will be asked to sign a form to say that you agree to take part (a 
consent/assent form) 
- You will be given this information sheet and a copy of your signed 
consent/assent form to keep. 
You are free to stop taking part at any time during the research without giving a 
reason.  If you decide to stop, this will not affect the care you receive whilst in 
this hospital. 
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
 
5. What will happen to me if I take part? 
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital.  We will show you a copy of the newly 
developed quality of life measure.  We would like to chat to you and some other 
young people in a group.  This is called a focus group.   
We would like to ask you some questions.  We would like to ask you what you 
think about the suitability of the new quality of life measure.  The focus group 
will be recorded on DVD.  If you do not wish to be identified on the DVD your 
face can be pixellated/obscured. 
We will use the information to further develop the new Quality of Life measure 
for children and young people with Brittle Bone Disease.  When the final Quality 
of Life measure is developed we will send you a copy. 
There will be no extra blood tests or x-rays.   
6. What will I be asked to do? 
We would like you to discuss the new Quality of Life measure within a focus 
group.  We will record the focus group, so that we can transcribe it to paper 
after the interview has finished.  We will anonymise the transcript by giving you 
a different name.  Once we have transcribed the interview to paper and 
completed the research the DVD recording will be destroyed. 
7. Is there anything else to be worried about? 
No.  We want to further develop a Quality of Life measure to enable us to 
assess how children and young people with Brittle Bone Disease feel about 
their daily life.  We hope this new Quality of Life measure will help us provide 
better care for children and young people with OI. 
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If we find out something that we think is important about your Brittle Bone 
Disease, we will talk to your Mum, Dad or carer and ask them if they want to 
come back and have you checked again at the hospital. 
8. Will the study help me? 
No, but the information we get will help us to develop the quality of life measure.  
We hope the new quality of life measure will improve the care of other children 
and young people with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collect everyone’s opinions and use the information to further develop a 
Quality of Life measure for children and young people with Brittle Bones 
disease. 
10. Contact for further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
11. What if new information comes along? 
Sometimes during research, new things are found out about Brittle Bone 
Disease.  If this happens, someone from the research team will tell you about it 
and discuss whether you want to continue the study.  If you change your mind 
this will not affect any care you receive whilst in hospital.  If you decide to 
continue in the study you will be asked to sign an updated consent/assent form. 
12. What if I don’t want to do the research anymore? 
Just tell your Mum, Dad, carer, doctor or therapist at any time.  They will not be 
cross with you.  You will still have the same care whilst you are at hospital. 
13. What if there is a problem or something goes wrong? 
Tell us if there is a problem and we will try to sort it out straight away.  You and 
your Mum, Dad or carer can either contact the project co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
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Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
14. Will anyone else know I’m doing this? 
The people in our research team will know you are taking part.  The doctor 
looking after you while you are in hospital will also know.   
Your medical notes may also be looked at by other people who work at the 
hospital to check that the study is being carried out correctly. 
All the information that is collected about you during the research will be kept 
strictly confidential.  Your transcript will be given a number; your name will be 
changed.  Any information about you that leaves the hospital will have your 
name and address removed so that you cannot be recognised from it.  Once the 
study is complete all information will be destroyed or kept in your own 
confidential notes. 
15. What happens to the results of the researchers study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put an article in 
the hospital newsletter and on the Brittle Bone Society website.  The results will 
be anonymous, which means that you will not be identified from them. 
16. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
17. Who has checked the study? 
Before any study goes ahead it has to be checked by a Research Ethics 
Committee. This is a group of people who make sure the research is OK to do.  
This study has been looked at by Sheffield Research Ethics Committee.   
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
18.  How can I find out more about research? 
The Clinical Research Support Unit at this hospital has an information for 
families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
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Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PATIENT INFORMATION SHEET  
YOUNG ADULT AGED 16-18  
PHASE 1 FOCUS GROUP 2 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
You are being asked to take part in a research study.  This is an educational 
study.  Before you decide it is important for you to understand 
why the research is being done and what it will involve.  Please 
take time to read the following information carefully.  Talk to 
others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information (contact: Claire Hill on 01142267890).  Take 
time to decide whether or not you want to take part. 
2. What is the purpose of the study? 
We want to develop a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), and by 
random selection you may be invited to take part in three of the five sections.  
This is Phase 1c and you may also be invited to take part in Phase 1a and 
Phase 3.  This research is part of an educational qualification. 
3. Why have I been chosen? 
You have been chosen because you have Osteogenesis Imperfecta (Brittle 
Bone Disease).  Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It 
means that your bones can break easier and that their joints may be bendier 
than your friends, brothers and sisters. 
We are asking 5 - 10 young people and parents to take part in this phase. 
To develop a useful quality of life measure for children and young people with 
Osteogenesis Imperfecta we need to find out what living with the condition is 
really like.  We have already asked 10 children and young people, 10 parents 
and 5 health professionals about their views.  We would now like to validate 
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these views by asking you what you think to the newly developed Quality of Life 
(QoL) measure. 
4. Do I have to take part? 
No.  It is entirely up to you to decide whether or not to take part.  You are free to 
withdraw from the research at any time without giving a reason.  Your decisions 
about this will not affect the standard of care you will receive.   
If you are happy to take part, and are happy with the explanations from the 
research team, you will be asked to sign a consent form.  You will be given a 
copy of the information sheet and the signed consent form to keep for your 
records. 
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen if I agree to take part?  
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital for the focus group.  We will try to do this 
during a clinic visit or when you are admitted for treatment where possible.  
We would like to show you a copy of the newly developed Quality of Life 
measure.  We would then like you to take part in a focus group.  We would like 
to ask the focus group some questions about the suitability of the new quality of 
life measure.  The focus group will be recorded on DVD.  If you do not wish to 
be identified on the DVD your face can be pixellated/obscured. 
We will use the information to further develop a Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed we will send you a copy so you can tell us what you 
think. 
6. What will I be asked to do? 
We would like you to discuss the new Quality of Life measure within a focus 
group.  We will record the focus group on DVD, so that we can transcribe it to 
paper after the interview has finished.  We will anonymise the transcript by 
giving you a different name.  Once we have transcribed the interview to paper 
and completed the research the DVD recording will be destroyed. 
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7. What are the possible disadvantages and risks of taking part? 
None.  We want to develop a Quality of Life measure to enable us to assess 
how children and young people with Brittle Bone Disease feel about their daily 
life.  We hope this new quality of life measure will help us provide better care for 
children and young people with OI. 
If we find out something that we think is important about your Brittle Bone 
Disease, we will talk to you and ask if you want to come back to be checked 
again at the hospital. 
8. What are the possible benefits of taking part? 
You will not benefit from being part of this study.  However, the information we 
collect will help us to develop the Quality of Life measure.  We hope the new 
Quality of Life measure will improve the care of other children and young people 
with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collate everyone’s opinions and use the information to further develop a 
Quality of Life measure for children and young people with Brittle Bone Disease. 
10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  If you have any cause to 
complain about any aspect of the way in which you have been 
approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are 
available to you and you are not compromised in any way 
because you have taken part in a research study.  
11. Will my taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about you will 
be handled in confidence.  All information which is collected about you during 
the course of the research will be kept strictly confidential. Any information 
about you which leaves the hospital will have your name and address removed 
so that you cannot be recognised from it.  Once the study is complete all 
information will be destroyed. 
12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
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Sheffield Children’s Hospital 
01142267890 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new 
information becomes available about Osteogenesis Imperfecta.  
If this happens, someone from the research team will tell you 
about it and discuss whether you want to continue the study.  If 
you change your mind this will not affect any care you receive 
whilst in hospital.  If you decide to continue in the study you will 
be asked to sign an updated consent form. 
14. What will happen if I don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your identifiable data if you 
wish, but we will need to use the data collected up to your withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you and you 
are not compromised in any way because you have taken part in a research 
study.  If you have any complaints or concerns please contact either the project 
co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
Harm 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone else’s fault, 
then you may have grounds for a legal action – but you may have to pay for it. 
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16. Will taking part in this study be kept confidential? 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it.  Once the study is complete all information will either be 
destroyed or kept in your confidential notes. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your transcript will be given a number; your name will be changed.  Your 
medical notes may also be looked at by other people within the hospital 
involved in the running and supervision of the study to check that it is being 
carried out correctly. 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that you will not be 
identified from them. 
 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
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20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PARENT/LEGAL GUARDIAN INFORMATION SHEET  
Child/young people participation                              
PHASE 1 FOCUS GROUP 2 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
Your child is being asked to take part in a research study.  This 
is an educational study.  Before you decide it is important for 
you to understand why the research is being done and what it 
will involve.  Please take time to read the following information 
carefully.  Talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information (contact: Claire Hill on 01142267890).  Take 
time to decide whether or not you want your child to take part. 
2. What is the purpose of the study? 
We want to develop a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), and by 
random selection you or your child may be invited to take part in three of the 
five sections.  This is Phase 1c and you may also be invited to take part in 
Phase 1a and Phase 3. This research is part of an educational qualification.  
3. Why has my child been chosen? 
Your child has been chosen because they have Osteogenesis Imperfecta 
(Brittle Bone Disease). We are asking 5 - 10 children and young people to take 
part in this phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that their bones 
can break easier and that their joints may be bendier than their friends, brothers 
and sisters. 
To develop a really useful quality of life measure for children and young people 
with Osteogenesis Imperfecta we need to find out what living with the condition 
is really like.  We have already asked 10 children and young people, 10 parents 
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and 5 health professionals about their views.  We would now like to validate 
these views by asking your child what they think to the newly developed quality 
of life measure. 
4. Does my child have to take part? 
No.  It is entirely up to you and your child (wherever possible) to decide whether 
or not to take part.  You are both free to withdraw from the research at any time 
without giving a reason.  Your decisions about this will not affect the standard of 
care your child will receive.   
If you are happy for your child to take part, and are happy with the explanations 
from the research team, you will be asked to sign a consent form.  If your child 
is able to understand the research and is happy to take part and can write their 
name, they will be asked to sign an assent form with you, if they want to.  You 
will be given a copy of the information sheet and the signed consent/assent 
forms to keep for your records. 
You can agree to your child taking part in this section of the research alone if 
you prefer, or agree to them taking part in more than one section as they arise.  
Completing the reply slip enclosed will let the researchers know what you would 
like your child to be included in.  
5. What will happen to my child if we agree to take part?  
If you agree to take part we will arrange a date and time convenient for your 
child to come to Sheffield Children’s Hospital for the focus group.  We will try to 
do this during a clinic visit or when they are admitted for treatment where 
possible.  
We would like to show your child a copy of the newly developed Quality of Life 
measure.  We would then like them to take part in a focus group.  We would like 
to ask the focus group some questions about the suitability of the new Quality of 
Life measure.  The focus group will be recorded on DVD.  If you do not wish to 
be identified on the DVD your face can be pixellated/obscured. 
We will use the information to further develop a Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed we will send them a copy so they can tell us what they 
think. 
There will be no extra blood tests or x-rays.   
6. What will we be asked to do? 
We would like your child to discuss the new Quality of Life measure within a 
focus group.  We will record the focus group, so that we can transcribe it to 
paper after the interview has finished.  We will anonymise the transcript by 
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giving them a different name.  Once we have transcribed the interview to paper 
and completed the research the DVD recording will be destroyed. 
7. What are the possible disadvantages and risks of taking part? 
None.  We want to develop a Quality of Life measure to enable us to assess 
how children and young people with Brittle Bone Disease feel about their daily 
life.  We hope this new quality of life measure will help us provide better care for 
children and young people with OI. 
If we find out something that we think is important about your child’s Brittle Bone 
Disease, we will talk to you and ask if you want to come back and have your 
child checked again at the hospital. 
8. What are the possible benefits of taking part? 
Your child will not benefit from being part of this study.  However, the 
information we collect will help us to develop the quality of life measure.  We 
hope the new quality of life measure will improve the care of other children and 
young people with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collate everyone’s opinions and use the information to further develop a 
Quality of Life measure for children and young people with Brittle Bone Disease. 
10. What if there is a problem? 
Any complaint about the way you or your child have been dealt with during the 
study or any possible harm you or your child might suffer will be addressed.  If 
you have any cause to complain about any aspect of the way in 
which you have been approached or treated during the 
course of this study, the normal National Health Service 
complaints mechanisms are available to you and you are not 
compromised in any way because you have taken part in a 
research study.  
11. Will my child’s taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about your 
child will be handled in confidence.  All information which is collected about your 
child during the course of the research will be kept strictly confidential. Any 
information about your child which leaves the hospital will have their name and 
address removed so that you cannot be recognised from it.  Once the study is 
complete all information will either be destroyed. 
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12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, 
someone from the research team will tell you and your child 
about it and discuss whether you want your child to continue 
the study.  If you change your mind this will not affect any 
care your child receives whilst in hospital.  If you decide to 
continue in the study you and your child will be asked to sign 
an updated consent/assent form. 
 
14. What will happen if we don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your child’s identifiable data if 
you wish, but we will need to use the data collected up to their withdrawal. 
 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you or 
your child has been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are available to you 
and you are not compromised in any way because you have taken part in a 
research study.  If you have any complaints or concerns please contact either 
the project co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
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Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
Harm 
If your child is harmed by taking part in this research project, there are no 
special compensation arrangements.  If your child is harmed due to someone 
else’s fault, then you may have grounds for a legal action – but you may have to 
pay for it. 
16. Will taking part in this study be kept confidential? 
All information which is collected about your child during the course of the 
research will be kept strictly confidential. Any information about your child which 
leaves the hospital will have their name and address removed so that your child 
cannot be recognised from it.  Once the study is complete all information will 
either be destroyed or kept in your child’s confidential notes. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your child’s transcript will be given a number; their name will be changed.  Your 
child’s medical notes may also be looked at by other people within the hospital 
involved in the running and supervision of the study to check that it is being 
carried out correctly. 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that your child will 
not be identified from them. 
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18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PARENT/LEGAL GUARDIAN INFORMATION SHEET  
(Parental participation) 
PHASE 1 FOCUS GROUP 2 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
You are being asked to take part in a research study.  This is an educational 
study.  Before you decide it is important for you to understand why the research 
is being done and what it will involve.  Please take time to 
read the following information carefully.  Talk to others 
about the study if you wish. 
Ask us if there is anything that is not clear or if you would 
like more information (contact: Claire Hill on 01142267890).  
Take time to decide whether or not you want to take part. 
2. What is the purpose of the study? 
We want to develop a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), and by 
random selection you or your child may be invited to take part in three of the 
five sections.  This is Phase 1c and you may also be invited to take part in 
Phase 1a and Phase 3.  This research is part of an educational qualification. 
3. Why have I been chosen? 
You have been chosen because you have a child/children with Osteogenesis 
Imperfecta (Brittle Bone Disease).  Osteogenesis Imperfecta (OI) is Brittle Bone 
Disease.  It means that your child’s bones can break easier and that their joints 
may be bendier than their friends, brothers and sisters. 
We are asking 5 - 10 young people and parents to take part in this phase. 
To develop a really useful quality of life measure for children and young people 
with Osteogenesis Imperfecta we need to find out what living with the condition 
is really like.  We have already asked 10 children and young people, 10 parents 
and 5 health professionals about their views.  We would now like to validate 
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these views by asking you what you think to the newly developed quality of life 
(QoL) measure. 
4. Do I have to take part? 
No.  It is entirely up to you to decide whether or not to take part.  You are free to 
withdraw from the research at any time without giving a reason.  Your decisions 
about this will not affect the standard of care your child will receive.   
If you are happy to take part, and are happy with the explanations from the 
research team, you will be asked to sign a consent form.  You will be given a 
copy of the information sheet and the signed consent form to keep for your 
records. 
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen if I agree to take part?  
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital for the focus group.  We will try to do this 
during a clinic visit or when your child is admitted for treatment where possible.  
We would like to show you a copy of the newly developed Quality of Life 
measure.  We would then like you to take part in a focus group.  We would like 
to ask the focus group some questions about the suitability of the new Quality of 
Life measure.  The focus group will be recorded on DVD.  If you do not wish to 
be identified on the DVD your face can be pixellated/obscured. 
We will use the information to further develop a Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed we will send you a copy so you can tell us what you 
think. 
6. What will we be asked to do? 
We would like you to discuss the new Quality of Life measure within a focus 
group.  We will record the focus group, so that we can transcribe it to paper 
after the interview has finished.  We will anonymise the transcript by giving you 
a different name.  Once we have transcribed the focus group to paper and 
completed the research the DVD recording will be destroyed. 
7. What are the possible disadvantages and risks of taking part? 
None.  We want to develop a Quality of Life measure to enable us to assess 
how children and young people with Brittle Bone Disease feel about their daily 
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life.  We hope this new Quality of Life measure will help us provide better care 
for children and young people with OI. 
If we find out something that we think is important about your child’s Brittle Bone 
Disease, we will talk to you and ask if you want to come back and have your 
child checked again at the hospital. 
8. What are the possible benefits of taking part? 
You will not benefit from being part of this study.  However, the information we 
collect will help us to develop the quality of life measure.  We hope the new 
quality of life measure will improve the care of other children and young people 
with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collate everyone’s opinions and use the information to further develop a 
Quality of Life measure for children and young people with Brittle Bone Disease. 
10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  If you have any cause to 
complain about any aspect of the way in which you have been 
approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are 
available to you and you are not compromised in any way 
because you have taken part in a research study.  
11. Will my taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about you will 
be handled in confidence.  All information which is collected about you during 
the course of the research will be kept strictly confidential. Any information 
about you which leaves the hospital will have your name and address removed 
so that you cannot be recognised from it.  Once the study is complete all 
information will either be destroyed. 
12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
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13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, 
someone from the research team will tell you about it and 
discuss whether you want to continue the study.  If you change 
your mind this will not affect any care your child receives whilst 
in hospital.  If you decide to continue in the study you will be 
asked to sign an updated consent form. 
 
14. What will happen if I don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your identifiable data if you 
wish, but we will need to use the data collected up to your withdrawal. 
 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you or 
your child has been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are available to you 
and you are not compromised in any way because you have taken part in a 
research study.  If you have any complaints or concerns please contact either 
the project co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
Harm 
If you or your child is harmed by taking part in this research project, there are no 
special compensation arrangements.  If your child is harmed due to someone 
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else’s fault, then you may have grounds for a legal action – but you may have to 
pay for it. 
16. Will taking part in this study be kept confidential? 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital will have their name and address removed so that you cannot be 
recognised from it.  Once the study is complete all information will either be 
destroyed or kept in your child’s confidential notes. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your transcript will be given a number; your name will be changed.  Your child’s 
medical notes may also be looked at by other people within the hospital 
involved in the running and supervision of the study to check that it is being 
carried out correctly. 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that you or your 
child will not be identified from them. 
 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
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20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PARTICIPANT INFORMATION SHEET 
FOR CHILDREN 
PHASE 2 PILOT STUDY 
Age 6-12 
To be shown and read by parent/carer if required 
Study Title 
Development of a set of questions for children with Brittle Bone 
Disease 
1. What is research? 
Research is what we do to find out the answer to an 
important question. 
2. What is Brittle Bone Disease? 
It means your bones can break easier and that your joints may 
be bendier than your friends or brothers and sisters. 
3. Why is this project being done? 
We have developed an assessment to help us work out how you 
feel about having Brittle Bone Disease.  Now we want to know 
what you think about it. 
4. Why me? 
You have been chosen because you have Brittle 
Bones and you visit Sheffield Children’s 
Hospital for your treatment and care.  We are 
asking 30 children to take part in this section.   
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5. Do I have to take part? 
No you do not.  It is up to you.  We would like you to read this 
information sheet.  If you agree to take part, we would like you 
to write your name on two forms.  We will also ask your Mum, 
Dad or carer to write their name on the forms and give one back 
to us.  You can still change your mind later.  If you don’t want to 
take part, just say no.   You may be asked to take part again in a 
month or two.  If you don’t want to, just let your Mum, Dad or 
carer know.                  
6. What will happen? 
We would like you to answer some questions about our new 
assessment.  Your Mum, Dad or carer can help you. We would 
then like to ask you what you think to the new assessment.  This 
will be recorded on audio cassette. 
We will use the information to further develop the assessment 
to measure how children with brittle bones feel.  When the 
assessment is finished we will send you a copy. 
We will talk to you during your normal hospital visit.  There will 
be no extra blood tests or x-rays.  Your Mum, Dad or carer can 
stay with you during the interview. 
7. Will joining in help me? 
No, but it may help us to know more about how 
children with brittle bones feel.  We want to 
develop an assessment to measure how children 
with brittle bones feel so that we can improve 
our service.  
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8. What else might happen? 
We will only record your interview on tape.  Then we can write 
down what you say by listening to the tape.  Once we have 
written it down we will give you a pretend name so that no one 
else will know what you have said.     
9. What happened when the research study stops? 
We will collect what everyone has said together and use the 
information to make improvements to the special assessment 
about how children with brittle bones feel. 
10. What if something goes wrong? 
Your Mum, Dad or carer will be able to talk to someone who will 
be able to tell them what they need to do about it. 
11. What if I don’t want to do the research anymore? 
Just tell your Mum, Dad, carer, doctor or physiotherapist at any 
time.  They will not be cross with you.  You will still have the 
same care whilst you are at hospital.  
12. What if I wish to complain about the study? 
If you wish to complain you or your Mum, Dad or 
carer can talk to Claire Hill or Mrs Linda Towers 
at This hospital. 
13. Will anyone else know I am doing this? 
The people in our research team will know you are taking part.  
The doctor looking after you while you are in hospital will also 
know.  No one else will know because we will not use your name or 
address.  You will get a pretend name instead. 
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14. What happens to what the researchers find out? 
When we collect your information we will make sure it is stored 
in a safe place and only the people doing the research can look at 
it.  We will use the information to develop an assessment to 
measure how children with brittle bones feel and put it in 
medical magazines and on websites that doctors and therapists 
read. 
A short summary will also be on the hospital’s research website 
and the Brittle Bone Society website.  No one will know you were 
in the study. 
15. Did anyone else check the study is OK to do? 
The study has been checked by several people 
at the hospital and the university to make 
sure it is alright. 
16.  How can I find out more about the 
study? 
Your Mum, Dad, carer or other grown-up you trust may be able 
to answer your questions.  The doctors, nurses or therapists 
looking after you can also help you find out more about the 
study. 
Thank you for taking the time to read this – please ask any 
questions if you need to. 
 
 
 
 
 
 
357 
 
 
 
PARTICIPANT INFORMATION SHEET 
YOUNG PEOPLE (Aged 13 – 15) 
PHASE 2 PILOT STUDY 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
We would like you to help us with our research study.  This is an 
educational study.  Please read this information carefully and 
talk to your Mum, Dad or carer about the study.  Ask us if there 
is anything that is not clear or if you want to know more.  Take 
time to decide if you want to take part.  It is up to you if you want 
to do this.  If you don’t then that’s fine, you’ll be looked after at 
the hospital just the same. 
2. Why are we doing this research? 
We want to further develop a Quality of Life measure to assess how children 
and young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), and by 
random selection you may be invited to take part in three of the five sections.  
This is Phase 2 and you may also be invited to take part in Phase 3. This 
research is part of an educational qualification. 
3. Why have I been asked to take part? 
You have been chosen because you have Osteogenesis Imperfecta (Brittle 
Bone Disease).  We are asking 30 children and young people to take part in this 
phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that your bones 
can break easier and that your joints may be bendier than your friends, brothers 
and sisters. 
4. Do I have to take part? 
No it is entirely up to you.  If you do decide to take part: 
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- You will be asked to sign a form to say that you agree to take part (a 
consent/assent form) 
- You will be given this information sheet and a copy of your signed 
consent/assent form to keep. 
You are free to stop taking part at any time during the research without giving a 
reason.  If you decide to stop, this will not affect the care you receive whilst in 
this hospital. 
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen to me if I take part? 
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital for interview.  You can do this during a 
clinic visit or when you are admitted for treatment.  
We would like you to undertake the newly developed Quality of Life 
assessment.  We would then like to interview you and ask you some questions.  
The questions will be about the suitability of the new assessment and what you 
think about the feel of the questions.  The interview will be recorded on audio 
cassette. 
We will use the information to further develop a Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed further we will send you a copy so you can tell us what 
you think. 
We will interview you during your normal hospital visit.  There will be no extra 
blood tests or x-rays.  You can choose to have someone stay with you during 
the interview, such as a parent/carer or friend. 
 
6. What will I be asked to do? 
We will ask you to complete the newly developed Quality of Life assessment.  
We will ask you a few questions about how the assessment feels and what you 
thought about the questions.   We would like to find out if you think the 
assessment is suitable for children and young people with Brittle Bone disease.   
We will record the interview, so that we can transcribe it to paper after the 
interview has finished.  We will anonymise the transcript by giving you a 
different name.  Once we have transcribed the interview to paper and the 
research is completed the tape recording will be destroyed. 
 
 
 
359 
7. Is there anything else to be worried about? 
No.  We want to further develop a Quality of Life measure to enable us to 
assess how children and young people with Brittle Bone Disease feel about 
their daily life.  We hope this new quality of life measure will help us provide 
better care for children and young people with OI. 
If we find out something that we think is important about your Brittle Bone 
Disease, we will talk to your Mum, Dad or carer and ask them if they want you 
to come back and have you checked again at the hospital. 
8. Will the study help me? 
No, but the information we get will help us to develop the Quality of Life 
measure.  We hope the new Quality of Life measure will improve the care of 
other children and young people with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collect everyone’s opinions and use the information to further develop a 
Quality of Life measure for children and young people with Brittle Bones 
disease. 
10. Contact for further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
11. What if new information comes along? 
Sometimes during research, new things are found out about Brittle Bone 
Disease.  If this happens, someone from the research team will tell you about it 
and discuss whether you want to continue the study.  If you change your mind 
this will not affect any care you receive whilst in hospital.  If you decide to 
continue in the study you will be asked to sign an updated consent/assent form. 
12. What if I don’t want to do the research anymore? 
Just tell your Mum, Dad, carer, doctor or therapist at any time.  They will not be 
cross with you.  You will still have the same care whilst you are at hospital. 
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13. What if there is a problem or something goes wrong? 
Tell us if there is a problem and we will try to sort it out straight away.  You and 
your Mum, Dad or carer can either contact the project co-ordinator: 
 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
14. Will anyone else know I’m doing this? 
The people in our research team will know you are taking part.  The doctor 
looking after you while you are in hospital will also know.   
Your medical notes may also be looked at by other people who work at the 
hospital to check that the study is being carried out correctly. 
All the information that is collected about you during the research will be kept 
strictly confidential.  Your transcript will be given a number; your name will be 
changed. 
Any information about you that leaves the hospital will have your name and 
address removed so that you cannot be recognised from it.  Once the study is 
complete all information will be destroyed or kept in your own confidential notes. 
15. What happens to the results of the researchers study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put an article in 
the hospital newsletter and on the Brittle Bone Society website.    The results 
will be anonymous, which means that you will not be identified from them. 
16. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
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17. Who has checked the study? 
Before any study goes ahead it has to be checked by a Research Ethics 
Committee. This is a group of people who make sure the research is OK to do.  
This study has been looked at by Sheffield Research Ethics Committee.   
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
18.  How can I find out more about research? 
The Clinical Research Support Unit at this hospital has an information for 
families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PATIENT INFORMATION SHEET 
YOUNG ADULT AGED 16-18  
PHASE 2 PILOT STUDY 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
You are being asked to take part in a research study.  This is an educational 
study.  Before you decide it is important for you to understand why the research 
is being done and what it will involve.  Please take time to read 
the following information carefully.  Talk to others about the 
study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information (contact: Claire Hill on 01142267890).   Take 
time to decide whether or not you want to take part. 
2. What is the purpose of the study? 
We want to further develop a Quality of Life measure to assess how children 
and young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), and by 
random selection you may be invited to take part in three of the five sections.  
This is Phase 2 and you may also be invited to take part in Phase 3. This 
research is part of an educational qualification. 
3. Why have I been chosen? 
You have been chosen because you have Osteogenesis Imperfecta (Brittle 
Bone Disease) and attend Sheffield Children’s Hospital for treatment or review. 
We are asking 30 children and young people to take part in this phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that your bones 
can break easier and that your joints may be bendier than your friends, brothers 
and sisters. 
To develop a really useful quality of life measure for children and young people 
with Osteogenesis Imperfecta we need to find out what living with the condition 
is really like.  We have already developed the Quality of Life measure by asking 
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children, young people with OI and their parents/carers what they think should 
be included in the Quality of Life measure. We would now like to validate these 
views by asking you what you think to the newly developed Quality of Life 
measure.  Whether you think the items are suitable, understandable and feel ok 
to answer. 
4. Do I have to take part? 
No.  It is entirely up to you to decide whether or not to take part.  You are free to 
withdraw from the research at any time without giving a reason.  Your decisions 
about this will not affect the standard of care you will receive.   
If you are happy to take part, and are happy with the explanations from the 
research team, you will be asked to sign a consent form.  You will be given a 
copy of the information sheet and the signed consent form to keep for your 
records.  
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen if I agree to take part? 
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital for interview.  You can do this during a 
clinic visit or when you are admitted for treatment.  
We would like you to undertake the newly developed Quality of Life 
assessment.  We would then like to interview you and ask them some 
questions.  The questions will be about the suitability of the new assessment 
and what you think about the feel of the questions.  The interview will be 
recorded on audio cassette. 
We will use the information to further develop a Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed we will send you a copy so you can tell us what you 
think. 
We will interview you during your normal hospital visit.   
6. What will I be asked to do? 
We will ask you a few questions about what you think about the newly 
developed Quality of Life measure.  We would like to get your opinion about the 
suitability of the newly developed Quality of Life measure.  We will tape record 
the interview, so that we can transcribe it to paper.  We will anonymise the 
transcript by giving you a different name.  Once we have transcribed the 
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interviews to paper and completed the research, the tape recording will be 
destroyed. 
7. What are the possible disadvantages and risks of taking part? 
None.  We want to further develop a Quality of Life measure to enable us to 
assess how children and young people with Brittle Bone Disease feel about 
their daily life.  We hope this new quality of life measure will help us provide 
better care for children and young people with OI. 
8. What are the possible benefits of taking part? 
You will not benefit from being part of this study.  However, the information we 
collect will help us to develop the Quality of Life measure.  We hope the new 
Quality of Life measure will improve the care of other children and young people 
with Brittle Bone Disease (OI).   
9. What happens when the research study stops? 
We will collate everyone’s opinions and use the information to further develop a 
Quality of Life measure for children and young people with Brittle Bone Disease. 
10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  If you have any cause to 
complain about any aspect of the way in which you have been approached or 
treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you and you are not compromised in 
any way because you have taken part in a research study. 
11. Will my taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about you will 
be handled in confidence.  All information which is collected about you during 
the course of the research will be kept strictly confidential. Any information 
about you which leaves the hospital will have your name and address removed 
so that you cannot be recognised from it.  Once the study is complete all 
information will either be destroyed. 
12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
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13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, someone from the 
research team will tell you about it and discuss whether you want to continue 
the study.  If you change your mind this will not affect any care you receive 
whilst in hospital.  If you decide to continue in the study you will be asked to 
sign an updated consent form. 
14. What will happen if I don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your identifiable samples if you 
wish, but we will need to use the data collected up to your withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you and you 
are not compromised in any way because you have taken part in a research 
study.  If you have any complaints or concerns please contact either the project 
co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
 
Harm 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone else’s fault, 
then you may have grounds for a legal action – but you may have to pay for it. 
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16. Will taking part in this study be kept confidential? 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it.  Once the study is complete all information will either be 
destroyed. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your transcript will be given a number; your name will be changed.   
 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that you or your 
child will not be identified from them. 
 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
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20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill  01142267890 
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PARENT/LEGAL GUARDIAN INFORMATION SHEET 
Child/young people participation                             
PHASE 2 PILOT STUDY 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
Your child is being asked to take part in a research study.  This is an 
educational study.  Before you decide it is important for you to 
understand why the research is being done and what it will involve.  
Please take time to read the following information carefully.  Talk to 
others about the study if you wish.   
Ask us if there is anything that is not clear or if you would like more 
information (contact: Claire Hill on 01142267890).  Take time to 
decide whether or not you want your child to take part. 
2. What is the purpose of the study? 
We have developed a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  We now want to assess the suitability, acceptability and feel of the 
items/questions. There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), 
and by random selection you or your child may be invited to take part in three of 
the five sections.  This is Phase 2 and you may also be invited to take part in 
Phase 3. This research is part of an educational qualification. 
3. Why has my child been chosen? 
Your child has been chosen because they have Osteogenesis Imperfecta 
(Brittle Bone Disease), and they attend Sheffield Children’s Hospital for 
treatment or review.  We are asking 30 children and young people to take part 
in this phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that their bones 
can break easier and that their joints may be bendier than their friends, brothers 
and sisters. 
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To further develop a really useful Quality of Life measure for children and young 
people with Osteogenesis Imperfecta we need to find out what living with the 
condition is really like.  We have already developed the Quality of Life measure 
by asking children, young people with OI and their parents/carers what they 
think should be included in the Quality of Life measure. We would now like to 
validate these views by asking your child what they think to the newly 
developed Quality of Life measure.  Whether they think the items are suitable, 
understandable and feel ok to answer. 
4. Does my child have to take part? 
No.  It is entirely up to you and your child (wherever possible) to decide whether 
or not to take part.  You are free to withdraw from the research at any time 
without giving a reason.  Your decisions about this will not affect the standard of 
care your child will receive.   
If you are happy for your child to take part, and are happy with the explanations 
from the research team, you will be asked to sign a consent form.  If your child 
is able to understand the research and is happy to take part and can write their 
name, they will be asked to sign an assent form with you, if they want to.  You 
will be given a copy of the information sheet and the signed consent/assent 
forms to keep for your records. 
You can agree to your child taking part in this section of the research alone if 
you prefer, or agree to them taking part in more than one section as they arise.  
Completing the reply slip enclosed will let the researchers know what you would 
like your child to be included in.  
5. What will happen to my child if we agree to take part?  
If you agree to take part we will arrange a date and time convenient for your 
child to come to Sheffield Children’s Hospital to coincide with your routine 
appointment or inpatient admission.   
We would like your child to undertake the newly developed Quality of Life 
assessment.  We would then like to interview your child and ask them some 
questions.  The questions will be about the suitability of the new assessment 
and what they think about the feel of the questions.  The interview will be 
recorded on audio cassette. 
We will use the information to further develop the Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed we will send you a copy. 
There will be no extra blood tests or x-rays.  You can stay with them during the 
interview if they would prefer that. 
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6. What will we be asked to do? 
We will ask your child a few questions about what they think about the newly 
developed Quality of Life measure.  We would like to get their opinion about the 
suitability of the newly developed Quality of Life measure.  We will tape record 
the interview, so that we can transcribe it to paper.  We will anonymise the 
transcript by giving your child a different name.  Once we have transcribed the 
interviews to paper and completed the research, the tape recording will be 
destroyed. 
7. What are the possible disadvantages and risks of taking part? 
None.  We want to further develop a Quality of Life measure to enable us to 
assess how children and young people with Brittle Bone Disease feel about 
their daily life.  We hope this new quality of life measure will help us provide 
better care for children and young people with OI. 
If we find out something that we think is important about your child’s Brittle Bone 
Disease, we will talk to you and ask if you want to come back and have your 
child checked again at the hospital. 
8. What are the possible benefits of taking part? 
Your child will not benefit from being part of this study.  However, the 
information we collect will help us to further develop the Quality of Life measure.  
We hope the new Quality of Life measure will improve the care of other children 
and young people with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collate everyone’s opinions and use the information to further develop a 
Quality of Life measure for children and young people with Brittle Bone Disease. 
10. What if there is a problem? 
Any complaint about the way you or your child have been dealt with during the 
study or any possible harm your child might suffer will be addressed.  If you 
have any cause to complain about any aspect of the way in 
which you have been approached or treated during the course 
of this study, the normal National Health Service complaints 
mechanisms are available to you and you are not 
compromised in any way because you have taken part in a 
research study. 
 
 
 
 
371 
11. Will my child’s taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about your 
child will be handled in confidence.  All information which is collected about your 
child during the course of the research will be kept strictly confidential. Any 
information about your child which leaves the hospital will have their name and 
address removed so that you cannot be recognised from it.  Once the study is 
complete all information will either be destroyed. 
12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, 
someone from the research team will tell you and your child 
about it and discuss whether you want your child to continue the 
study.  If you change your mind this will not affect any care your 
child receives whilst in hospital.  If you decide to continue in the 
study you and your child will be asked to sign an updated 
consent/assent form. 
14. What will happen if we don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your child’s identifiable 
samples if you wish, but we will need to use the data collected up to their 
withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you or 
your child has been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are available to you 
and you are not compromised in any way because you have taken part in a 
research study.  If you have any complaints or concerns please contact either 
the project co-ordinator: 
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Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
 
Harm 
If your child is harmed by taking part in this research project, there are no 
special compensation arrangements.  If your child is harmed due to someone 
else’s fault, then you may have grounds for a legal action – but you may have to 
pay for it. 
 
16. Will taking part in this study be kept confidential? 
All information which is collected about your child during the course of the 
research will be kept strictly confidential. Any information about your child which 
leaves the hospital will have their name and address removed so that your child 
cannot be recognised from it.  Once the study is complete all information will 
either be destroyed or kept in your child’s confidential notes. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your child’s transcript will be given a number; their name will be changed.  Your 
child’s medical notes may also be looked at by other people within the hospital 
involved in the running and supervision of the study to check that it is being 
carried out correctly. 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
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qualification.  The results will be anonymous, which means that your child will 
not be identified from them. 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PARTICIPANT INFORMATION SHEET 
FOR CHILDREN 
Age 6-12 
PHASE 3 QOL 
 
To be shown and read by parent/carer if required 
Study Title 
Development of a set of questions for children with Brittle Bone 
Disease 
1. What is research? 
Research is what we do to find out the answer to an 
important question. 
2. What is Osteogenesis Imperfecta? 
It means your bones can break easier and that your joints may 
be bendier than your friends or brothers and sisters. 
3. Why is this project being done? 
We have developed a set of questions to help us work out how 
you feel about having Brittle Bone Disease.  Now we want to find 
out if it works well. 
4. Why me? 
You have been chosen because you have 
Brittle Bones and you visit Sheffield 
Children’s Hospital for your treatment and 
care.  We are asking up to 150 patients to take part in this 
section.   
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5. Do I have to take part? 
No you do not.  It is up to you.  We would like you to read this 
information sheet.  If you agree to take part, we would like you 
to write your name on two forms.  We will also ask your Mum, 
Dad or carer to write their name on the forms and give one back 
to us.  You can still change your mind later.  If you don’t want to 
take part, just say no.   You may be asked to take part again in a 
month or two.  If you don’t want to, just let your Mum, Dad or 
carer know.                  
6. What will happen? 
We would like you to answer some questions in our new 
assessment.  Your Mum, Dad or carer can help you. We would 
then like to send you another copy (in the post) for you to do 
again at home a week later, and then 3 months later when you 
come back to Sheffield for your review or treatment.  
We will use the information to further develop the assessment 
to measure how children with brittle bones feel.  When the 
assessment is finished we will send you a copy. 
We will talk to you during your normal hospital visit.  There will 
be no extra blood tests or x-rays.   
7. Will joining in help me? 
No, but it may help us to know more about how 
children with brittle bones feel.  We want to 
further develop the assessment to measure how 
children with brittle bones feel. 
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8. What else might happen? 
Nothing else will happen to you.  You will just be asked a few 
questions in an assessment about how you feel about having 
Brittle Bones. 
9. What happened when the research study stops? 
We will collect what everyone has said together and use the 
information to make improvements to the new assessment about 
how children with brittle bones feel. 
10. What if something goes wrong? 
Your Mum, Dad or carer will be able to talk to someone who will 
be able to tell them what they need to do about it. 
11. What if I don’t want to do the research anymore? 
Just tell your Mum, Dad, carer, doctor or physiotherapist at any 
time.  They will not be cross with you.  You will still have the 
same care whilst you are at hospital.  
12. What if I wish to complain about the study? 
If you wish to complain you or your Mum, Dad or 
carer can talk to Claire Hill or Mrs Linda Towers 
at This hospital. 
13. Will anyone else know I am doing this? 
The people in our research team will know you are taking part.  
The doctor looking after you while you are in hospital will also 
know.  No one else will know because we will not use your name or 
address.  You will get a pretend name instead. 
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14. What happens to what the researchers find out? 
When we collect your information we will make sure it is stored 
in a safe place and only the people doing the research can look at 
it.  We will use the information to develop an assessment to 
measure how children with brittle bones feel and put it in 
medical magazines and on websites that doctors and therapists 
read. 
A short summary will also be on the hospital’s research website 
and on the Brittle Bone Society website.  No one will know you 
were in the study. 
15. Did anyone else check the study is OK to do? 
The study has been checked by several people 
at the hospital and the university to make sure 
it is alright. 
16.  How can I find out more about the 
study? 
Your Mum, Dad, carer or other grown-up you trust may be able 
to answer your questions.  The doctors, nurses or therapists 
looking after you can also help you find out more about the 
study. 
 
Thank you for taking the time to read this – please ask any 
questions if you need to. 
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PARTICIPANT INFORMATION SHEET 
YOUNG PEOPLE (Aged 13 – 15) 
PHASE 3 QOL 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
We would like you to help us with our research study.  This is an educational 
study.  Please read this information carefully and talk to your 
Mum, Dad or carer about the study.  Ask us if there is anything 
that is not clear or if you want to know more.   Take time to 
decide if you want to take part.  It is up to you if you want to do 
this.  If you don’t then that’s fine, you’ll be looked after at the 
hospital just the same. 
2. Why are we doing this research? 
We want to further develop a Quality of Life measure to assess how children 
and young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  Now we want to find out if it works well.  There are five sections in 
total (Phases 1a, 1b, 1c, 2 and 3), and by random selection you may be invited 
to take part in three of the five sections.  This is Phase 3 and you may also have 
been invited to take part in Phase 1 or 2. This research is part of an educational 
qualification. 
3. Why have I been asked to take part? 
You have been chosen because you have Osteogenesis Imperfecta (Brittle 
Bone Disease).  We are asking up to 150 children and young people take part 
in this phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that your bones 
can break easier and that your joints may be bendier than your friends, brothers 
and sisters. 
4. Do I have to take part? 
No it is entirely up to you.  If you do decide to take part: 
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- You will be asked to sign a form to say that you agree to take part (a 
consent/assent form) 
- You will be given this information sheet and a copy of your signed 
consent/assent form to keep. 
You are free to stop taking part at any time during the research without giving a 
reason.  If you decide to stop, this will not affect the care you receive whilst in 
this hospital. 
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen to me if I take part? 
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital.  You can do this during a clinic visit or 
when you are admitted for treatment.  
We would like you to undertake the newly developed Quality of Life assessment 
and two other well known assessments that measure Quality of Life.  We will 
then contact you one week later by post, and 3 months later during a routine 
hospital visit, and ask you to repeat the assessments. 
We will use the information to further develop a Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed we will send you a copy. 
We will see you during your normal hospital visit.  There will be no extra blood 
tests or x-rays.  You can choose to have someone stay with you during the 
interview, such as a parent/carer or friend. 
6. What will I be asked to do? 
You will be asked to repeat three Quality of Life assessments on three separate 
occasions. 
 Firstly, we would like you to undertake the newly developed Quality of 
Life assessment and two other well known assessments that measure 
Quality of Life, during a routine visit to Sheffield Children’s Hospital.  
 We will then contact you by post one week later and ask you to repeat 
the three Quality of Life assessments at home.  We will also ask you if 
your health has changed over the last week.   
 Three months later during a routine visit to Sheffield Children’s Hospital 
we will then ask you to repeat the three assessments again.  
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You can choose to have someone stay with you during the interview, such as a 
parent/carer or friend.  
7. Is there anything else to be worried about? 
No.  We want to further develop a Quality of Life measure to enable us to 
assess how children and young people with Brittle Bone Disease feel about 
their daily life.  We hope this new quality of life measure will help us provide 
better care for children and young people with OI. 
If we find out something that we think is important about your Brittle Bone 
Disease, we will talk to your Mum, Dad or carer and ask them if they want you 
to come back and have you checked again at the hospital. 
8. Will the study help me? 
No, but the information we get will help us to develop the quality of life measure.  
We hope the new quality of life measure will improve the care of other children 
and young people with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collect everyone’s assessments and use the information to work out 
how useful the newly developed Quality of Life measure is for children and 
young people with Brittle Bone Disease.  If you have also taken part in the 
functional assessment tool section of this study, we will compare the scores to 
give us more information about assessing children and young people with Brittle 
Bones.   
10. Contact for further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
11. What if new information comes along? 
Sometimes during research, new things are found out about Brittle Bone 
Disease.  If this happens, someone from the research team will tell you about it 
and discuss whether you want to continue the study.  If you change your mind 
this will not affect any care you receive whilst in hospital.  If you decide to 
continue in the study you will be asked to sign an updated consent/assent form. 
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12. What if I don’t want to do the research anymore? 
Just tell your Mum, Dad, carer, doctor or therapist at any time.  They will not be 
cross with you.  You will still have the same care whilst you are at hospital. 
13. What if there is a problem or something goes wrong? 
Tell us if there is a problem and we will try to sort it out straight away.  You and 
your Mum, Dad or carer can either contact the project co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
14. Will anyone else know I’m doing this? 
The people in our research team will know you are taking part.  The doctor 
looking after you while you are in hospital will also know.   
Your medical notes may also be looked at by other people who work at the 
hospital to check that the study is being carried out correctly. 
All the information that is collected about you during the research will be kept 
strictly confidential.  Your transcript will be given a number; your name will be 
changed. 
Any information about you that leaves the hospital will have your name and 
address removed so that you cannot be recognised from it.  Once the study is 
complete all information will be destroyed or kept in your own confidential notes. 
17. What happens to the results of the researchers study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put an article in 
the hospital newsletter and on the Brittle Bone Society website.  The results will 
be anonymous, which means that you will not be identified from them. 
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18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
19. Who has checked the study? 
Before any study goes ahead it has to be checked by a Research Ethics 
Committee. This is a group of people who make sure the research is OK to do.  
This study has been looked at by Sheffield Research Ethics Committee.   
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
20.  How can I find out more about research? 
The Clinical Research Support Unit at this hospital has an information for 
families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill  01142267890 
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PATIENT INFORMATION SHEET 
YOUNG ADULT (AGED 16-18) 
PHASE 3 QOL 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
You are being asked to take part in a research study. This is an educational 
study.   Before you decide it is important for you to understand why the research 
is being done and what it will involve.  Please take time to read 
the following information carefully.  Talk to others about the 
study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information (contact: Claire Hill on 01142267890).  Take 
time to decide whether or not you want to take part. 
2. What is the purpose of the study? 
We want to further develop a Quality of Life measure to assess how children 
and young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  We now want to work out if it is a valid, reliable and useful tool.  
There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), and by random 
selection you or your child may be invited to take part in three of the five 
sections.  This is Phase 3 and you may also have been invited to take part in 
Phase 1 or 2. This research is part of an educational qualification. 
3. Why have I been chosen? 
You have been chosen because you have Osteogenesis Imperfecta (Brittle 
Bone Disease) and you attend Sheffield Children’s Hospital for treatment or 
review. We are asking 150 children and young people to take part in this phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that your bones 
can break easier and that your joints may be bendier than your friends, brothers 
and sisters. 
To develop a really useful quality of life measure for children and young people 
with Osteogenesis Imperfecta we need to find out what living with the condition 
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is really like.  We have already developed the Quality of Life measure by asking 
children, young people with OI and their parents/carers what they think should 
be included in the Quality of Life measure. This stage of the research will tell us 
if the newly developed Quality of Life measure is valid, reliable and useful.   We 
would now like to validate these views by asking you to complete the Quality of 
Life measure. 
4. Do I have to take part? 
No.  It is entirely up to you to decide whether or not to take part.  You are free to 
withdraw from the research at any time without giving a reason.  Your decisions 
about this will not affect the standard of care you will receive.   
If you are happy to take part, and are happy with the explanations from the 
research team, you will be asked to sign a consent form.  You will be given a 
copy of the information sheet and the signed consent form to keep for your 
records.  
You can agree to take part in this section of the research alone if you prefer, or 
agree to take part in more than one section as they arise.  Completing the reply 
slip enclosed will let the researchers know what you would like to be included in.  
5. What will happen if I agree to take part? 
If you agree to take part we will arrange a date and time convenient for you to 
come to Sheffield Children’s Hospital to coincide with your routine appointment 
or inpatient admission.   
We would like you to undertake the newly developed Quality of Life assessment 
and two other well known assessments that measure Quality of Life.  We will 
then contact you one week later by post, and 3 months later during a routine 
visit to Sheffield, to repeat the assessments. 
We will use the information to further develop a Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed we will send you a copy.   
6. What will I be asked to do? 
We would like you to repeat three quality of life assessments on three separate 
occasions. 
 Firstly, we would like you to undertake the newly developed Quality of 
Life assessment and two other well known assessments that measure 
Quality of Life, during a routine visit to Sheffield Children’s Hospital.  
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 We would then like to contact you by post one week later and ask you to 
repeat the three Quality of Life assessments at home.  We will also ask 
you if your health has changed over the last week.   
 Three months later during a routine visit to Sheffield Children’s Hospital 
we will then ask you to repeat the three assessments again.  
7. What are the possible disadvantages and risks of taking part? 
None.  We want to further develop a Quality of Life measure to enable us to 
assess how children and young people with Brittle Bone Disease feel about 
their daily life.  We hope this new quality of life measure will help us provide 
better care for children and young people with OI. 
8. What are the possible benefits of taking part? 
You will not benefit from being part of this study.  However, the information we 
collect will help us to develop the quality of life measure.  We hope the new 
Quality of Life measure will improve the care of other children and young people 
with Brittle Bone Disease (OI).   
9. What happens when the research study stops? 
We will collate everyone’s opinions and use the information to further develop a 
Quality of Life measure for children and young people with Brittle Bone Disease.  
If you have also taken part in the functional assessment tool section of this 
study we will compare the scores to give us more information about assessing 
children and young people with Brittle Bones.   
10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  If you have any cause to 
complain about any aspect of the way in which you have been approached or 
treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you and you are not compromised in 
any way because you have taken part in a research study. 
11. Will my taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about you will 
be handled in confidence.  All information which is collected about you during 
the course of the research will be kept strictly confidential. Any information 
about you which leaves the hospital will have your name and address removed 
so that you cannot be recognised from it.  Once the study is complete all 
information will be destroyed or filed in your confidential notes. 
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12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, someone from the 
research team will tell you about it and discuss whether you want to continue 
the study.  If you change your mind this will not affect any care you receive 
whilst in hospital.  If you decide to continue in the study you will be asked to 
sign an updated consent form. 
14. What will happen if I don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your identifiable samples if you 
wish, but we will need to use the data collected up to your withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you and you 
are not compromised in any way because you have taken part in a research 
study.  If you have any complaints or concerns please contact either the project 
co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
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Harm 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone else’s fault, 
then you may have grounds for a legal action – but you may have to pay for it. 
16. Will taking part in this study be kept confidential? 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it.  Once the study is complete all information will either be 
destroyed or kept in your confidential notes. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your transcript will be given a number; your name will be changed.   
 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that you will not be 
identified from them. 
 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
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20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill 01142267890 
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PARENT/LEGAL GUARDIAN INFORMATION SHEET 
Child/young people participation                             
PHASE 3 QOL 
Study Title 
Development of a Quality of Life measure for children with Osteogenesis 
Imperfecta (OI) 
1. Invitation paragraph 
Your child is being asked to take part in a research study.  This is an 
educational study.  Before you decide it is important for you to 
understand why the research is being done and what it will 
involve.  Please take time to read the following information 
carefully.  Talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like more 
information (contact: Claire Hill on 01142267890).  Take time to 
decide whether or not you want your child to take part. 
2. What is the purpose of the study? 
We have developed a Quality of Life measure to assess how children and 
young people feel about having Osteogenesis Imperfecta (Brittle Bone 
Disease).  We now want to work out if it is a valid, reliable and useful tool.  
There are five sections in total (Phases 1a, 1b, 1c, 2 and 3), and by random 
selection you or your child may be invited to take part in three of the five 
sections.  This is Phase 3 and you may also have been invited to take part in 
Phase 1 or 2. This research is part of an educational qualification. 
3. Why has my child been chosen? 
Your child has been chosen because they have Osteogenesis Imperfecta 
(Brittle Bone Disease), and they attend Sheffield Children’s Hospital for 
treatment or review.  We are asking up to 150 children and young people to 
take part in this phase. 
Osteogenesis Imperfecta (OI) is Brittle Bone Disease.  It means that their bones 
can break easier and that their joints may be bendier than their friends, brothers 
and sisters. 
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To further develop a useful quality of life measure for children and young people 
with Osteogenesis Imperfecta we need to find out what living with the condition 
is really like.  We have already developed the Quality of Life measure by asking 
children, young people with OI and their parents/carers what they think should 
be included.  This stage of the research will tell us if the newly developed 
Quality of Life measure is valid, reliable and useful.    
4. Does my child have to take part? 
No.  It is entirely up to you and your child (wherever possible) to decide whether 
or not to take part.  You are both free to withdraw from the research at any time 
without giving a reason.  Your decisions about this will not affect the standard of 
care your child will receive.   
If you are happy for your child to take part, and are happy with the explanations 
from the research team, you will be asked to sign a consent form.  If your child 
is able to understand the research and is happy to take part and can write their 
name, they will be asked to sign an assent form with you, if they want to.  You 
will be given a copy of the information sheet and the signed consent/assent 
forms to keep for your records. 
You can agree to your child taking part in this section of the research alone if 
you prefer, or agree to them taking part in more than one section as they arise.  
Completing the reply slip enclosed will let the researchers know what you would 
like your child to be included in.  
5. What will happen to my child if we agree to take part?  
If you agree to take part we will arrange a date and time convenient for your 
child to come to Sheffield Children’s Hospital to coincide with their routine 
appointment or inpatient admission.   
We would like your child, with your help if necessary, to undertake the newly 
developed Quality of Life assessment and two other well known assessments 
that measure Quality of Life.  We will then contact them one week later by post, 
and 3 months later during a routine visit to Sheffield, to repeat the assessments. 
We will use the information to further develop the Quality of Life measure for 
children and young people with Brittle Bone Disease.  When the Quality of Life 
measure is developed we will send them a copy. 
There will be no extra blood tests or x-rays.  You can stay with them during the 
assessment if they would prefer that. 
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6. What will we be asked to do? 
We would like your child, with your help if necessary, to repeat three Quality of 
Life assessments on three separate occasions. 
 Firstly, we would like them (with your help if necessary) to undertake the 
newly developed Quality of Life assessment and two other well known 
assessments that measure Quality of Life, during a routine visit to 
Sheffield Children’s Hospital.  
 We would then like to contact them by post one week later and ask them 
(with your help if necessary) to repeat the three Quality of Life 
assessments at home.  We will also ask them if their health has changed 
over the last week.   
 Three months later during a routine visit to Sheffield Children’s Hospital 
we will then ask them (with your help if necessary) to repeat the three 
assessments again.  
7. What are the possible disadvantages and risks of taking part? 
None.  We want to further develop a Quality of Life measure to enable us to 
assess how children and young people with Brittle Bone Disease feel about 
their daily life.  We hope this new quality of life measure will help us care for 
children and young people better. 
If we find out something that we think is important about your child’s Brittle Bone 
Disease, we will talk to you and ask if you want to come back and have your 
child checked again at the hospital. 
8. What are the possible benefits of taking part? 
Your child will not benefit from being part of this study.  However, the 
information we collect will help us to further develop the Quality of Life measure.  
We hope the new Quality of Life measure will improve the care of other children 
and young people with Brittle Bone Disease (OI).   
9. What happened when the research study stops? 
We will collate everyone’s assessments and use the information to calculate 
how valid and reliable the newly developed Quality of Life measure is for 
children and young people with Brittle Bone Disease.  If your child has also 
taken part in the functional assessment tool section of this study we will 
compare the scores to give us more information about assessing children and 
young people with Brittle Bones.   
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10. What if there is a problem? 
Any complaint about the way you or your child have been dealt with during the 
study or any possible harm you or your child might suffer will be addressed. If 
you have any cause to complain about any aspect of the way in which you have 
been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms are available to you and you are not 
compromised in any way because you have taken part in a research study. 
11. Will my child’s taking part in the research project be confidential? 
Yes.  We will follow ethical and legal practice and all information about your 
child will be handled in confidence.  All information which is collected about your 
child during the course of the research will be kept strictly confidential. Any 
information about your child which leaves the hospital will have their name and 
address removed so that they cannot be recognised from it.  Once the study is 
complete all information will be destroyed. 
12. Contact for any further information 
If you would like any further information about this study you could contact: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
01142267890 
 
13. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about Osteogenesis Imperfecta.  If this happens, someone from the 
research team will tell you and your child about it and discuss whether you want 
your child to continue the study.  If you change your mind this will not affect any 
care your child receives whilst in hospital.  If you decide to continue in the study 
you and your child will be asked to sign an updated consent/assent form. 
14. What will happen if we don’t want to carry on with the research? 
If you withdraw from the study we will destroy all your child’s identifiable 
samples if you wish, but we will need to use the data collected up to their 
withdrawal. 
15. What if there is a problem? 
Complaints  
If you have any cause to complain about any aspect of the way in which you or 
your child has been approached or treated during the course of this study, the 
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normal National Health Service complaints mechanisms are available to you 
and you are not compromised in any way because you have taken part in a 
research study.  If you have any complaints or concerns please contact either 
the project co-ordinator: 
Claire Hill 
Clinical Specialist Physiotherapist 
Metabolic Bone Disease Team 
Sheffield Children’s Hospital 
Tel: 01142267890 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice and Liaison Co-ordinator 
Sheffield Children’s Hospital NHS Foundation Trust 
Tel: 01142717594 
 
Harm 
If your child is harmed by taking part in this research project, there are no 
special compensation arrangements.  If your child is harmed due to someone 
else’s fault, then you may have grounds for a legal action – but you may have to 
pay for it. 
 
16. Will taking part in this study be kept confidential? 
All information which is collected about your child during the course of the 
research will be kept strictly confidential. Any information about your child which 
leaves the hospital will have their name and address removed so that your child 
cannot be recognised from it.  Once the study is complete all information will 
either be destroyed or kept in your child’s confidential notes. 
Our procedures for handling, processing, storage and destruction of data are 
compliant with the Data Protection Act 1998. 
Your child’s transcript will be given a number; their name will be changed.  Your 
child’s medical notes may also be looked at by other people within the hospital 
involved in the running and supervision of the study to check that it is being 
carried out correctly. 
17. What happens to the results of the research study? 
When the study has finished we will present our findings to other doctors, 
nurses and therapists and we will put the results in medical magazines and 
websites that health professionals use.  We would also like to put a brief 
summary on the hospital research website and on the Brittle Bone Society 
website, so that you will be able to read about our results too.  This will be 
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available at the end of the study, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigators educational 
qualification.  The results will be anonymous, which means that your child will 
not be identified from them. 
18. Who is organising and funding the research? 
Researchers at Sheffield Children’s NHS Foundation Trust are organising the 
study.  They will not get any extra money for doing this. 
19. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
Sheffield Research Ethics Committee.     
It has also been checked by the research department at the Sheffield Children’s 
NHS Foundation Trust. 
20.  How can we find out more about research? 
The Clinical Research Support Unit at this hospital has an Information for 
Families section on its website www.sheffieldchildrenscrf.nhs.uk or you could 
contact the hospital Clinical Research Support Unit: 
Mrs Tracy N’Diaye 
Directorate Manager of Research 
Sheffield Children’s NHS Foundation Trust 
Tel: 01142267904 
 
Thank you for taking the time to read this – please ask any questions if 
you need to. 
Contact Claire Hill  01142267890 
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Appendix 5 
 
Consent forms 
 
 
ASSENT FORM FOR CHILDREN & YOUNG PEOPLE 
(to be completed by the child/young person and their parent/carer) 
 
Title of project: Development of an Osteogenesis Imperfecta (OI) quality of life measure and 
    validation and reliability of the OI specific  assessment tool.  
 
Phase (delete as appropriate) 
 Phase 1 – Interview 
 Phase 1 – Focus Group 1 
 Phase 1 – Focus Group 2 
 Phase 2 – Pilot Study 
 Phase 3 – Quality of life section 
 
Participant study number: 
 
Child (or if unable, parent on their behalf)/young person to circle all they agree with please: 
 
Have you read (or had read to you) about this project?        Yes / No 
 
Has somebody else explained this project to you?           Yes / No 
 
Do you understand what this project is about?                   Yes / No 
 
Have you asked all the questions you want?          Yes / No 
 
Have you had your questions answered in a way you understand?   Yes / No 
 
Do you understand it’s OK to stop taking part at any time?    Yes / No 
 
Are you happy to take part?                    Yes / No 
 
 
If any answers are ‘No’ or you don’t want to take part, don’t sign your name! 
 
If you do want to take part, please write your name and today’s date  
 
 
Your name   ________________________________ Date   ______________________ 
 
 
Your parent or carer must write their name here too if they are happy for you to do the project 
 
________________________ ________________   __________________________ 
Name of Parent/Carer Date Signature 
 
The person who explained this project to you needs to sign too: 
 
________________________ ________________   __________________________ 
Name of Researcher Date Signature 
 
Thank you for your help. 
 
 
1 copy for participant; 1 copy for researcher; 1 copy to be kept with hospital notes 
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Patient study number: 
 
CONSENT FORM FOR YOUNG ADULTS 16-18 YEARS  
 
Title of project: Development of an Osteogenesis Imperfecta (OI) quality of life measure and  
        validation and reliability of the OI specific assessment tool. 
 
Phase (delete as appropriate) 
 Phase 1 – Interview 
 Phase 1 – Focus Group 1 
 Phase 1 – Focus Group 2 
 Phase 2 – Pilot Study 
 Phase 3 – Quality of life section 
 
 
Names of researchers:  
 
          Please initial 
box 
 
1. I confirm that I have read and understand the information sheet 
 dated 12/03/10 (version 3.0) for the above study and have had the 
 opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
 withdraw at any time, without giving any reason, without my 
 medical care or legal rights being affected. 
 
              3.    I understand that my interview/focus group/assessment will be recorded  
                     and I give my permission for this. 
 
4.    I understand that sections of any of my clinical record may be looked 
 at by researchers and those involved in the running and supervision of the 
 study from Sheffield Children’s NHS Foundation Trust where it is relevant 
 to my taking part in research.  I give permission for these individuals 
 to have access to my records. 
       
        5.   I understand that relevant sections of my data collected during the study, may be 
looked at by individuals from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research.  I give my permission for these individuals 
to have access to my records. 
 
6. I agree to take part in the above study. 
 
 
 
__________________                                     ______________                           ____________________ 
Name of Patient Date Signature 
 
 
__________________ ________________                        ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________                        ____________________ 
Researcher Date Signature 
 
1 copy for patient; 1 copy for researcher; 1 copy to be kept with hospital notes 
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Patient study number: 
 
PARENT/LEGAL GUARDIAN/HEALTH PROFESSIONAL CONSENT FORM 
 
Title of project: Development of an Osteogenesis Imperfecta (OI) quality of life measure and  
        validation and reliability of the OI specific assessment tool. 
 
Phase (delete as appropriate) 
 Phase 1 – Interview 
 Phase 1 – Focus Group 1 
 Phase 1 – Focus Group 2 
 Phase 2 – Pilot Study 
 Phase 3 – Quality of life section 
 
Names of researchers:  
 
          Please initial 
box 
 
1. I confirm that I have read and understand the information sheet 
 dated 12/03/10 (version 3.0) for the above study and have had the 
 opportunity to ask questions. 
 
3. I understand that my/my child’s participation is voluntary and that I am free to 
 withdraw myself/my child at any time, without giving any reason, without my  
 child’s medical care or legal rights being affected.  
  
 3.    I understand that my/my child’s interview/focus group/assessment will be recorded  
                    and I give my permission for this. 
 
4.    I understand that sections of any of my child’s clinical record may be looked 
 at by researchers and those involved in the running and supervision of the 
 study from Sheffield Children’s NHS Foundation Trust where it is relevant 
 to my child taking part in research.  I give permission for these individuals 
 to have access to my child’s records. 
 
       5.   I understand that relevant sections of my/my child’s data collected during the study, 
may be looked at by individuals from regulatory authorities or from the NHS Trust, 
where it is relevant to my/my child taking part in this research.  I give my permission 
for these individuals to have access to my/my child’s records. 
 
6. I agree to my/my child taking part in the above study. 
 
 
 
________________________ ________________                        ____________________ 
Name of Parent/Guardian/AHP Date Signature 
 
 
_________________________ ________________                        ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________                        ____________________ 
Researcher Date Signature 
 
1 copy for parent/AHP; 1 copy for researcher; 1 copy to be kept with hospital notes 
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Appendix 6 
 
Interview Schedule 
 
 Interview Schedule 
Introduction 
This study is being performed to find out about the quality of life of children and 
adolescents with Osteogenesis Imperfecta (OI). 
We will be doing interviews and also some focus groups with parents, children, young 
people and health professionals. 
The study is for an educational qualification and no funding has been sought for this 
section of the study.  We have been given a small amount of funding for the later 
sections of this study which incorporates an assessment tool, and you might find you 
are invited to that at some point, but you don’t have to take part in part 2. 
The aim of today is to have an informal chat/discussion to get an idea about your views 
and opinions of what it is like to parent a child with OI, and how it affects their health 
and quality of life. 
There are no right or wrong answers, we just want your views and experience. 
If any questions arise during the interview about your child’s’ health or care, we can 
disucss them at the end of the interview.  If we discuss anything during the interview 
which could put in place to improve your child’s care or well being, we will again chat 
about this after the interview has finished. 
I know you know me as a Physiotherapist in the Metabolic Bone Disease Team here in 
Sheffield, but for the purpose of this interview I will be just a researcher.  I may ask 
some questions that you think I should already know the answers to, but this 
information is for the tape, and will help me with the analysis. 
I would like to make you aware that I will be using a Dictaphone to record the interview 
to help the analysis.  The information will remain anonymous and any reports will have 
names altered, this will prevent you being identified from your comments and opinions. 
Have you had a copy of the information sheet and do you have any questions before 
we start?   
Have you had a chance to sign the consent form? 
I know we already know each other, but could you tell me about yourself:  
your age 
where you live 
whose in your family 
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do you work 
do you have hobbies or interests outside of the family 
holidays etc 
Does OI impact on any of these? 
Could you describe yours and your child’s day from getting up to going to bed 
Who helps 
What do you have to do differently? 
What is it like to have a child with OI? 
How do you think having a child with OI compares to parenting a child with 
another condition? 
What are the positives or negatives? 
If you have other children, how does parenting them differ, or doesn’t it? 
Do you think your child has the same opportunities as their siblings or peers? 
Why do you think it differs 
Can they access the same hobbies, schools, extra curricular stuff? 
How does this make them/you feel? 
Your child is doing well at the minute….. 
Why do you think that is? 
How does that make them feel? 
How does it make you feel? 
What does the rest of the family think? 
How do their friends act about it? 
Your child has had a run of fractures recently…… 
Why do you think that is? 
How does that make them feel? 
How does it make you feel? 
What does the rest of the family think? 
How do their friends act about it? 
What is it like when your child has a fracture? 
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How do they feel? 
How do you feel? 
How does it affect their life? 
Does it affect family life? 
Do you have to do things differently? 
What do you think about coming into hospital? 
Is it easy? 
What could be better? 
LAST QUESTION 
We can’t get rid of your child’s OI, but if there was one thing we could change or 
improve, what would it be? 
 
SUMMERISE THE DISCUSSION 
DURING THIS INTERVIEW I THINK WE TALKED ABOUT…….. 
THANKS ETC……… 
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Interview Schedule small children 
Introduction 
This study is being done to see what children think about having Brittle Bones.   
We will be doing interviews and some group chats with parents, children, and medical 
people.  You might find you are invited to other sections of the study at some point, but 
you don’t have to take part if you don’t want to. 
The aim of today is to have a chat to find out what you think about having brittle bones, 
and if you have to do things differently because of it.     
There are no right or wrong answers, we just want to find out what you think.   
If you have any questions about your brittle bones or your care we can chat about 
those once the interview has finished.     
I know you know me as a Physiotherapist, but during this interview I will be a 
researcher.  I may ask some questions that you think I should already know the 
answers to, but this information is for the tape, and will help me write it up. 
I would like to let you know that I am recording this interview, so that I can type it up 
later.  I will give you a different name when I type it up, so you cannot be identified from 
what you say.   
Have you read the information sheet and do you have any questions before we start?   
Have you had a chance to sign the assent form? 
Has your mummy/daddy/carer signed the consent form? 
I know we already know each other, but could you tell me about yourself:  
your age 
where you live 
whose in your family 
do you work 
do you have hobbies or interests outside of the family 
holidays etc 
Does your brittle bones mean you have to do things differently? 
 
Could you describe your day from getting up to going to bed 
Who helps 
What do you have to do differently? 
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What is it like to have brittle bones? 
What are the good and bad parts of having brittle bones? 
Can you do the same things your friends and brothers/sister do?   
Why do you think it’s different? 
Can you do the same hobbies, schools, extra curricular stuff? 
How does this make you feel? 
 
You are doing well at the minute….. 
Why do you think that is? 
How does that make you feel? 
What does the rest of the family think? 
How do your friends act about it? 
You have had a run of fractures recently…… 
Why do you think that is? 
How does that make you feel? 
What does the rest of the family think? 
How do your friends act about it? 
What is it like when you have a fracture? 
How do you feel? 
How does it affect your life? 
Do you have to do things differently? 
What do you think about coming into hospital? 
Is it easy? 
What could be better? 
LAST QUESTION 
We can’t get rid of your brittle bones, but if there was one thing we could change or 
improve, what would it be? 
SUMMERISE THE DISCUSSION 
DURING THIS INTERVIEW I THINK WE TALKED ABOUT……..Thanks etc. 
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Interview Schedule CHILDREN/ADOLESCENTS 
Introduction 
This study is being performed to find out about the quality of life of children and 
adolescents with Osteogenesis Imperfecta (OI). 
We will be doing interviews and also some focus groups with parents, children, young 
people and health professionals. 
The study is for an educational qualification and no funding has been sought for this 
section of the study.  We have been given a small amount of funding for the later 
sections of this study which incorporates an assessment tool, and you might find you 
are invited to that at some point, but you don’t have to take part in part 2. 
The aim of today is to have an informal chat/discussion to get an idea about your views 
and opinions of what it is like to have OI, and how it affects your health and quality of 
life. 
There are no right or wrong answers, we just want your views and experience. 
If any questions arise during the interview about your health or care, we can disucss 
them at the end of the interview.  If we discuss anything during the interview which 
could put in place to improve your care or well being, we will again chat about this after 
the interview has finished. 
I know you know me as a Physiotherapist in the Metabolic Bone Disease Team here in 
Sheffield, but for the purpose of this interview I will be just a researcher.  I may ask 
some questions that you think I should already know the answers to, but this 
information is for the tape, and will help me with the analysis. 
I would like to make you aware that I will be using a Dictaphone to record the interview 
to help the analysis.  The information will remain anonymous and any reports will have 
names altered, this will prevent you being identified from your comments and opinions. 
Have you had a copy of the information sheet and do you have any questions before 
we start?   
Have you had a chance to sign the consent form? 
I know we already know each other, but could you tell me about yourself:  
your age 
where you live 
whose in your family 
do you go to school or work 
do you have hobbies or interests outside of the family 
holidays etc 
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Does having OI effect any of these? 
 
Could you describe your day from getting up to going to bed? 
Who helps 
What do you have to do differently? 
What is it like to have OI? 
How do you think having OI compares to your friends or siblings who don’t have 
it? 
What are the positives or negatives? 
Do you think you have had the same opportunities as your siblings or peers? 
Can you access the same hobbies, schools, extra curricular stuff? 
How does this make you feel? 
You are doing well at the minute….. 
Why do you think that is? 
How does that make you feel? 
What does the rest of the family think? 
How do your friends act about it? 
You have had a run of fractures recently…… 
Why do you think that is? 
How does that make you feel? 
What does the rest of the family think? 
How do your friends act about it? 
What is it like when you have a fracture? 
How do you feel? 
How does it affect your life? 
Does it affect family life? 
Do you have to do things differently? 
What do you think about coming into hospital? 
Is it easy? 
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What could be better? 
LAST QUESTION 
We can’t get rid of your OI, but if there was one thing we could change or improve, 
what would it be? 
 
SUMMERISE THE DISCUSSION 
DURING THIS INTERVIEW I THINK WE TALKED ABOUT…….. 
THANKS ETC……… 
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Interview Schedule  HP 
Introduction 
This study is being performed to find out about the quality of life of children and 
adolescents with Osteogenesis Imperfecta (OI). 
We will be doing interviews and also some focus groups with parents, children, young 
people and health professionals. 
The study is for an educational qualification and no funding has been sought for this 
section of the study.  We have been given a small amount of funding for the later 
sections of this study which incorporates an assessment tool, and you might find you 
are invited to that at some point, but you don’t have to take part in part 2. 
The aim of today is to have an informal chat/discussion to get an idea about your views 
and opinions of what it is like to work with children with OI, and how OI affects their 
health and quality of life. 
There are no right or wrong answers, we just want your views and experience. 
I know you know me as a Physiotherapist in the Metabolic Bone Disease Team here in 
Sheffield, but for the purpose of this interview I will be just a researcher.  I may ask 
some questions that you think I should already know the answers to, but this 
information is for the tape, and will help me with the analysis. 
I would like to make you aware that I will be using a Dictaphone to record the interview 
to help the analysis.  The information will remain anonymous and any reports will have 
names altered, this will prevent you being identified from your comments and opinions. 
Have you had a copy of the information sheet and do you have any questions before 
we start?   
Have you had a chance to sign the consent form? 
I know we already know each other, but could you tell me about yourself:  
your age 
Where you work and for how long have you worked there 
What is your experience of children with OI 
What does your job entail? 
How do you think your job helps the child and their family with OI? 
What in your view are the main problems that arise for children with OI and their 
families? 
How do you think OI impacts on the life of a child with OI? 
How do you think fractures impact on the life of a child with OI and their family? 
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What are the positives and negatives for a child with OI and their family? 
Do you think a child with OI has the same opportunities as their siblings or peers? 
Why do you think it differs? 
Can they access the same hobbies, schools, extra curricular stuff? 
How does this make them/you feel? 
What do you understand by quality of life? 
What do think quality of life means to children and families with OI? 
 
LAST QUESTION 
If there is one thing we could change or improve for a child with OI what would it be?       
 
 
SUMMERISE THE DISCUSSION 
DURING THIS INTERVIEW I THINK WE TALKED ABOUT…….. 
THANKS ETC……… 
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Interview Schedule 
 
Phase 2 
 
Pilot Study 
 
Young People/Young Adults 
 
This study is being performed to find out about the quality of life of children and 
adolescents with Osteogenesis Imperfecta (OI). 
 
Thank you for agreeing to take part and completing the Quality of Life questionnaire.  
We now want to get some information from you regarding what you thought of the 
questionnaire.  We will be interviewing 30 children and young people in total, to find out 
what they thought about the questionnaire. 
 
There are no right or wrong answers, we just want your thoughts and opinions. 
 
If any questions arise during the interview about your health or care, we can discuss 
them at the end of the interview.  If we discuss anything during the interview which 
could put in place to improve your care or well being, we will again chat about this after 
the interview has finished. 
 
I know you know me as a Physiotherapist in the Metabolic Bone Disease Team here in 
Sheffield, but for the purpose of this interview I will be just a researcher.  I may ask 
some questions that you think I should already know the answers to, but this 
information is for the tape, and will help me with the analysis. 
 
I would like to make you aware that I will be using a Dictaphone to record the interview 
to help the analysis.  The information will remain anonymous and any reports will have 
names altered, this will prevent you being identified from your comments and opinions. 
 
Have you had a copy of the information sheet and do you have any questions before 
we start?   
 
Have you had a chance to sign the consent form? 
 
 
 
Could you tell me your name and age for the tape? 
 
 
 
What did you think about the questionnaire? 
 
Was it easy to answer? 
 
Were there any questions that you didn’t understand? 
 
Were there any questions that didn’t make sense? 
 
Were there any questions that you didn’t like or didn’t want to answer? 
 
Did any questions upset you? 
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What did you think to the scoring? 
 
Always Most of the time Sometimes       Not much Never 
 
Did you understand all of the words? 
 
Such as: Freedom 
  Handling 
  The need for equipment 
 
 
 
Did you like that format? 
 
 
 
And the last question…. 
 
Could we make it better? 
 
 
 
 
Ok, to sum up……. 
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Appendix 7 
 
Early versions and thoughts around item development 
 
 
Themes – Dimensions   
 
Dimension 1 
 
Being safe and careful 
 
Items  validated from FG 
 
Thinking about your last week….. 
 
Does someone give you extra help at school to keep you safe? 
 
Always Almost Always Sometimes Almost Never Never 
 
Or 
 
Always   Sometimes   Never 
 
Do you avoid busy areas to keep safe? Focus group 1 
 
Do you keep away from busy areas to keep safe? 
 
Do you keep away from crowds to keep safe? 
 
Do you leave lessons early to avoid crowds at school?   Focus group 1  
 
 
 
Do you try to keep safe to avoid breaking a bone? 
 
Do you avoid some activities to stop you having a broken bone? 
 
Do you keep away from some activities to avoid having a broken bone? 
 
Do you keep away from some activities to stop you having a fracture? 
 
 
 
Do you think before playing sports to avoid having a fracture? 
 
Do you think before playing with your friends to stop you having a broken bone? 
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Dimension 2 
 
Reduced Function 
 
Items 
 
Thinking about your last week….. 
 
 
Are you tired in the day? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
Or 
 
Always   Sometimes   Never 
 
 
Have you felt tired in the day?  Focus group 2 
 
Have you felt tired by the end of the day? 
 
Do you have to rest in the day?  Focus group 2  
 
Do you have to take rests in the day? 
 
Do you find it hard to get out of bed in the morning?  Focus group 1 
 
 
 
Has having a broken bone stopped you doing things? 
 
Does having a fracture stop you doing things? 
 
Are things more difficult because you have had a fracture? 
 
Is it more difficult to move around because of a fracture? 
 
Have you had to do things differently because of a fracture? 
 
Have you had to do things differently because of a broken bone?  Focus group 1 
 
Has having a fracture stopped you going to school? 
 
Has having a broken bone stopped you going to school? 
 
 
 
Do you have to use equipment to move around?    “Did” or “Do”? 
 
Does equipment help you to move around? 
 
Do you have to use equipment to help at school? 
 
Do you have to use equipment to help at home? 
 
Do you have extra help from someone at home? 
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Dimension 3 
 
Pain 
 
Items 
 
Thinking about your last week….. 
 
 
Did you feel pain in your back? 
 
 
Always     Almost Always      Sometimes Almost Never Never 
 
Or 
 
Always   Sometimes    Never 
 
 
Did you get pain in your back? 
 
Have you had pain in your back? 
 
Have you had pain in your legs or arms? 
 
Did you get pain in your legs or arms? 
 
 
Did you have to take medicine for pain? 
 
Have you had to take medicine for pain? 
 
Have you had to take medicine because you had achy arms or legs? Focus 
group 1/2 
 
Have you had to take medicine because you broke a bone? 
 
Did you have pain because you had a broken bone? 
 
Did you miss playing with your friends because you had pain?  
 
Have you missed socialising with your friends because you had pain? 
 
Have you missed meeting up with your friends because you had pain? 
 
 
 
 
 
 
 
413 
Dimension 4 
 
Fear 
 
Items 
 
Thinking about your last week….. 
 
 
Have you been worried about breaking a bone? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
Or 
 
Always   Sometimes   Never 
 
 
Are you worried about breaking a bone? 
 
Do you get scared about breaking a bone? 
 
Did you get scared you might have broken a bone when you heard a click?  FG 
1 
 
Do you get scared about doing activities which might lead to fracture? 
 
Do you get scared about doing something that might make you break a bone? 
 
Did you get scared about what would happen if you did break a bone?  Bit 
vague, from FG 1/2 
 
 
Are you worried about coming into hospital? 
 
Do you worry about coming into hospital? 
 
Do you get scared about needles? 
 
Are you scared about needles? 
 
Do you get scared about having a blood test? 
 
 
Struggling with wording around this one…. 
Did you trust people to handle you well?  
I worry about new people handling me? 
Did you worry someone would handle you wrong and cause a fracture? 
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Dimension 5 
 
Isolation Note scoring system reversed…….always is good! 
 
Items 
 
Thinking about your last week….. 
 
Do you see your friends outside of school? 
 
Always Almost Always Sometimes Almost Never Never 
 
Or 
 
Always   Sometimes   Never 
 
 
 
Are you able to do everything your friends do? 
 
Do you get to do lots of different activities? 
 
Do you get to do lots of sports and extra curricular activities? 
 
Do you do PE at school? 
 
Do you play out with your friends at school? 
 
Do you think you are different because you have to be safe all the time? FG 2 
p3/4 
 
Do you feel different because you are trying to stay safe? 
 
Do you feel different because you have to be more careful than your friends? 
 
Have people treated you differently because you have brittle bones? FG2         
 
? understanding for younger children 
 
Question around being different, difficult to word as disliked the use of term 
“being different” in focus group 1. 
 
 
 
 
 
 
 
 
 
 
 
415 
Dimension 6 
 
Independence  
 
Items 
 
Thinking about your last week….. 
 
Do you like to do things for yourself? 
 
Did you like to do things for yourself? 
 
Always   Almost Always       Sometimes Almost Never             Never 
 
Or 
 
Always   Sometimes   Never 
 
 
 
Do you like to be independent? 
 
Were you independent? 
 
Do your family encourage you to do things for yourself? 
 
Did your family encourage you to do things for yourself? 
 
Have you as much independence as your friends? 
 
Are you as independent as your friends? 
 
Do you have as much freedom as your friends? 
 
Do you have as much freedom as your friends at school? 
 
Do your family let you make your own decision about what is safe? 
 
Do your family over protect you? Do young children understand over protection  
 
Do the teachers at school over protect you?  FG1 
 
Do the staff at school over protect you? FG1 
 
Do your family let you choose your own activities? 
 
Do your family allow you to decide what is safe? Lola FG 1 
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Early version 
 
 
Being safe and careful 
 
Thinking about your last week….. 
 
 
Does someone give you extra help to keep you safe? 
 
 
Always Almost Always Sometimes Almost Never Never 
Always Most of the time Sometimes     Not much  Never 
 
 
 
Do you keep away from busy areas to keep safe? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Do you keep away from crowds to keep safe? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Do you try to keep safe to stop you breaking a bone? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Do you keep away from some activities to stop you having a broken bone? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Do you think before playing sports to avoid having a broken bone? 
 
 
Always Almost Always Sometimes Almost Never Never 
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Amelia’s suggestion on new 5 pt scale  
 
Reduced Function 
 
 
Thinking about your last week….. 
 
 
Have you felt tired in the day? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
  
 
Have you felt tired by the end of the day? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
 
Do you have to take rests in the day? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
 
Has having a broken bone stopped you doing things? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
 
Has it been more difficult to move around because of a broken bone? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
 
Have you had to do things differently because of a broken bone?  
 
Always Almost Always Sometimes Almost Never Never 
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Do you use equipment to help you move around? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
 
Do you have to use special equipment to help at school or home? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
 
Pain 
 
 
Thinking about your last week….. 
 
 
Have you had pain in your back? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Have you had pain in your legs or arms? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Have you had to take medicine for pain? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Have you had to take medicine because you broke a bone? 
 
 
Always Almost Always Sometimes Almost Never Never 
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Did you have pain because you had a broken bone? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Have you missed meeting up with your friends because you had pain? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
 
 
Fear 
 
 
Thinking about your last week….. 
 
 
Have you been worried about breaking a bone? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Do you get scared about doing something that might make you break a bone? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Do you worry about coming into hospital? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Do you get scared about needles? 
 
 
Always Almost Always Sometimes Almost Never Never 
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Did you worry that someone might move you wrong and cause a broken bone? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Have you worried about new people handling you? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
 
Isolation Note scoring system reversed…….always is good! 
 
 
Thinking about your last week….. 
 
 
 
Did you see your friends outside of school? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Are you able to do everything your friends do? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Did you get to do lots of different activities? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Did you do PE at school? 
 
 
Always Almost Always Sometimes Almost Never Never 
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Do you feel different because you have to be more careful than your friends? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Have people treated you differently because you have brittle bones?  
 
 
Always Almost Always Sometimes Almost Never Never 
   
 
 
Independence Note scoring system reversed…….always is good!  
 
 
Thinking about your last week….. 
 
 
Did you like to do things for yourself? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Did your family encourage you to do things for yourself? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Do you have as much freedom as your friends? 
 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Do your family let you make your own decision about what is safe? 
 
 
Always Almost Always Sometimes Almost Never Never 
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Do the teachers at school over protect you?   
Do the teachers at school allow you as much freedom as you would like? 
 
Always Almost Always Sometimes Almost Never Never 
 
 
 
Do your family let you choose your own activities? 
 
 
Always Almost Always Sometimes Almost Never Never 
  
 
 
 New suggestion by Primary school teacher LJ. 
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Appendix 8 
PedsQL 
 
PedsQL
TM
 
Paediatric Quality of Life 
Inventory 
 
Version 4.0 – UK English 
 
 
YOUNG CHILD REPORT (ages 5-7) 
 
Instructions for interviewer: 
 
I am going to ask you some questions about things that might be a 
problem for some children.  I want to know how much of a problem any of 
these things might be for you. 
  
Show the child the template and point to the responses as you read. 
 
If it is not at all a problem for you, point to the smiling face. 
 
If it is sometimes a problem for you, point to the middle face. 
 
If it is a problem for you a lot, point to the frowning face.  
 
I will read each question. Point to the pictures to show me how much of a 
problem it is for you. Let’s try a practice one first. 
 
 Not at all Sometimes  A lot  
Is it hard for you to click your fingers?    
 
Ask the child to demonstrate clicking his or her fingers to determine whether or 
not the question was answered correctly. Repeat the question if the child 
demonstrates a response that is different from his or her action. 
 
Think about how you have been doing for the last few weeks. Please listen 
carefully to each sentence and tell me how much of a problem this is for 
you. 
 
After reading the item, gesture to the template. If the child hesitates or does not seem 
to understand how to answer, read the response options while pointing at the faces. 
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PHYSICAL FUNCTIONING (problems with…) Not  
at all 
Some-
times  
A lot 
1.  Is it hard for you to walk? 0 2 4 
2.  Is it hard for you to run? 0 2 4 
3.  Is it hard for you to play sports or exercise? 0 2 4 
4.  Is it hard for you to lift big things? 0 2 4 
5.  Is it hard for you to have a bath or shower? 0 2 4 
6.  Is it hard for you to help in the home (like picking up 
your toys)? 
0 2 4 
7.  Do you have aches and pains? 
(Where?___________) 
0 2 4 
8.  Do you ever feel too tired to play? 0 2 4 
 
Remember, tell me how much of a problem this has been for you for the last few 
weeks. 
EMOTIONAL FUNCTIONING (problems with…) Not  
at all 
Some-
times  
A lot 
1.  Do you feel scared? 0 2 4 
2.  Do you feel sad? 0 2 4 
3.  Do you feel angry? 0 2 4 
4.  Do you have trouble sleeping? 0 2 4 
5.  Do you worry about what will happen to you? 0 2 4 
 
SOCIAL FUNCTIONING (problems with…) Not  
at all 
Some-
times  
A lot 
1.  Do you have trouble getting on with other children? 0 2 4 
2.  Do other children say they do not want to play with 
you? 
0 2 4 
3.  Do other children tease you?  0 2 4 
4.  Can other children do things you cannot do? 0 2 4 
5.  Is it hard for you to keep up when you play with other 
children? 
0 2 4 
 
SCHOOL FUNCTIONING (problems with…) Not  
at all 
Some-
times  
A lot 
1.  Is it hard for you to pay attention in school?  0 2 4 
2.  Do you forget things?  0 2 4 
3.  Do you have trouble keeping up with schoolwork?  0 2 4 
4.  Do you miss school because of not feeling well? 0 2 4 
5.  Do you miss school to go to the doctor or hospital? 0 2 4 
How much of a problem is this for you? 
Not at all          Sometimes A lot 
  
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PedsQL
TM
 
Paediatric Quality of Life 
Inventory 
 
Version 4.0 – UK English 
 
CHILD REPORT (ages 8-12) 
 
 
 
 
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for you. 
     Please tell us how much of a problem each one has been for you 
     during the PAST MONTH by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
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In the PAST MONTH, how much of a problem has this been for you … 
 
 
ABOUT MY HEALTH AND ACTIVITIES (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  It is hard for me to walk more than a couple of streets 
(about 100 metres)  
0 1 2 3 4 
2.  It is hard for me to run 0 1 2 3 4 
3.  It is hard for me to do sports activities or exercise 0 1 2 3 4 
4.  It is hard for me to lift heavy things 0 1 2 3 4 
5.  It is hard for me to have a bath or shower by myself 0 1 2 3 4 
6.  It is hard for me to do chores around the house 0 1 2 3 4 
7.  I have aches and pains 0 1 2 3 4 
8.  I feel tired 0 1 2 3 4 
 
 
 
ABOUT MY FEELINGS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  I feel afraid or scared 0 1 2 3 4 
2.  I feel sad 0 1 2 3 4 
3.  I feel angry 0 1 2 3 4 
4.  I have trouble sleeping 0 1 2 3 4 
5.  I worry about what will happen to me 0 1 2 3 4 
 
 
 
HOW I GET ON WITH OTHERS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  I have trouble getting on with other children 0 1 2 3 4 
2.  Other children do not want to be my friend 0 1 2 3 4 
3.  Other children tease me 0 1 2 3 4 
4.  I cannot do things that other children my age can do 0 1 2 3 4 
5.  It is hard to keep up when I play with other children  0 1 2 3 4 
 
 
ABOUT SCHOOL (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  It is hard to pay attention in class 0 1 2 3 4 
2.  I forget things 0 1 2 3 4 
3.  I have trouble keeping up with my schoolwork 0 1 2 3 4 
4.  I miss school because of not feeling well 0 1 2 3 4 
5.  I miss school to go to the doctor or hospital 0 1 2 3 4 
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PedsQL
TM
 
Paediatric Quality of Life 
Inventory 
 
Version 4.0 – UK English 
 
TEENAGER REPORT (ages 13-18) 
 
 
 
   
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for you. 
     Please tell us how much of a problem each one has been for you 
     during the PAST MONTH by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
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In the PAST MONTH, how much of a problem has this been for you … 
 
ABOUT MY HEALTH AND ACTIVITIES (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  It is hard for me to walk more than a couple of streets 
(about 100 metres) 
0 1 2 3 4 
2.  It is hard for me to run 0 1 2 3 4 
3.  It is hard for me to do sports activities or exercise 0 1 2 3 4 
4.  It is hard for me to lift heavy things 0 1 2 3 4 
5.  It is hard for me to have a bath or shower by myself 0 1 2 3 4 
6.  It is hard for me to do chores around the house 0 1 2 3 4 
7.  I have aches and pains 0 1 2 3 4 
8.  I feel tired 0 1 2 3 4 
 
 
ABOUT MY FEELINGS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  I feel afraid or scared 0 1 2 3 4 
2.  I feel sad  0 1 2 3 4 
3.  I feel angry  0 1 2 3 4 
4.  I have trouble sleeping  0 1 2 3 4 
5.  I worry about what will happen to me 0 1 2 3 4 
 
 
HOW I GET ON WITH OTHERS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  I have trouble getting on with other teenagers 0 1 2 3 4 
2.  Other teenagers do not want to be my friend 0 1 2 3 4 
3.  Other teenagers tease me 0 1 2 3 4 
4.  I cannot do things that other teenagers my age can do 0 1 2 3 4 
5.  It is hard to keep up with other teenagers my age  0 1 2 3 4 
 
 
ABOUT SCHOOL / COLLEGE (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  It is hard to pay attention in class 0 1 2 3 4 
2.  I forget things 0 1 2 3 4 
3.  I have trouble keeping up with my school / college work 0 1 2 3 4 
4.  I miss school / college because of not feeling well 0 1 2 3 4 
5.  I miss school / college to go to the doctor or hospital 0 1 2 3 4 
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Appendix 9 
EQ5D 
 
Health Questionnaire  
 
English version for the UK  
(validated for Ireland) 
 
By placing a tick in one box in each group below, please indicate which 
statements best describe your own health state today. 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
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Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
 
 
To help people say how good or bad a health state is,  
we have drawn a scale (rather like a thermometer) on 
which the best health state you can imagine is marked 100 
and the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. 
Please do this by drawing a line from the box below to  
whichever point on the scale indicates how good or bad 
your health state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
   Worst 
    imaginable 
     health state 
0 
Best  
imaginable 
health state 
Your own 
health state 
today 
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Appendix 10 
Global rating of health at 1 week and 3 months. 
 
Has your health changed? 
 
Since last week, has there been any change in your health or 
quality of life?  
 
 
 
Has your health been: 
 
(Please circle one only) 
 
      
     Worse   About the same   Better  
  
 
 
 
 
Now please complete the questions on the 
next page. 
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Has your health changed? 
 
Since your last visit to Sheffield, has there been any change in 
your health or quality of life?  
 
 
 
Has your health been: 
 
(Please circle one only) 
 
      
     Worse   About the same   Better  
  
 
 
 
 
Now please complete the questions on the 
next page. 
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Appendix 11 
SPSS Syntax for Being safe and careful dimension  
Transforming to 0-100 scores 
 
* Being safe and careful dimension. 
* Six items. 
* No recoding required. 
* A higher score is good and means less worry about being safe and careful. 
 
* Computing scale scores by summing across items in the same scale. 
* Calculating raw scale scores. 
COMPUTE raw_safe=roiQ1+ roiQ2+ roiQ3+ roiQ4+ roiQ5+ roiQ6 . 
 
* Transforming raw scale scores to a 0-100 scale. 
* Transformed Scale = [(Actual raw score-lowest possible raw score)/Possible raw score 
range]*100. 
* Calculating transformed scale scores. 
COMPUTE Tsafe=((raw_safe-6)/24)*100. 
 
VARIABLE LABELS  raw_safe 'Raw OI PROM Being safe and careful dimension score'/ 
              tsafe 'OI Being safe and careful dimension (0-100)'.   
Execute. 
     
FREQUENCIES VARIABLES=Tsafe  
  /ORDER=ANALYSIS
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Appendix 12 
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Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23 Q24 Q25 Q26 Q27 Q28 Q29 Q30 Q31 Q32 Q33 Q34 Q35 Q36 Q37 Q38 Q39
Q1 1.00
Q2 0.42
** 1.00
Q3 0.40
**
0.72
** 1.00
Q4 0.60
**
0.62
**
0.58
** 1.00
Q5 0.33
**
0.38
**
0.32
**
0.51
** 1.00
Q6 0.42
**
0.32
**
0.32
**
0.46
**
0.59
** 1.00
Q7 0.01 0.14 0.11 0.13 0.16 0.13 1.00
Q8 0.07 0.12 0.12 0.04 0.22
*
0.22
*
0.49
** 1.00
Q9 0.17 0.06 0.12 0.15 0.27
** 0.20 0.45
**
0.42
** 1.00
Q10 0.19 0.32
** 0.17 0.25
* 0.19 0.23
* -0.05 0.02 -0.11 1.00
Q11 0.19 0.27
** 0.19 0.15 0.26
*
0.24
* -0.04 0.10 0.10 0.73
** 1.00
Q12 0.28
**
0.34
**
0.26
** 0.20 0.20
*
0.27
** -0.07 0.01 0.05 0.75
**
0.86
** 1.00
Q13 0.12 0.31
** 0.18 0.18 0.08 -0.05 0.11 0.16 0.19 0.34
**
0.35
**
0.29
** 1.00
Q14 0.18 0.41
**
0.29
**
0.38
**
0.24
* 0.10 0.27
** 0.09 0.22
* 0.12 0.21
* 0.15 0.56
** 1.00
Q15 -0.06 0.00 0.04 0.12 0.08 0.11 0.37
**
0.34
**
0.42
** -0.07 0.03 0.01 0.06 0.15 1.00
Q16 0.13 0.18 0.26
** 0.11 0.08 0.22
*
0.34
**
0.36
**
0.46
** -0.01 0.16 0.13 0.18 0.24
*
0.41
** 1.00
Q17 0.08 0.27
**
0.25
* 0.18 0.21
*
0.27
**
0.30
** 0.15 0.37
** -0.01 0.16 0.09 0.20 0.36
**
0.42
**
0.53
** 1.00
Q18 0.09 0.30
**
0.33
** 0.07 0.07 0.08 -0.05 0.01 0.04 0.56
**
0.52
**
0.66
**
0.29
** 0.17 -0.04 0.23
*
0.23
* 1.00
Q19 0.13 0.25
*
0.25
* 0.09 0.05 0.13 0.04 0.06 0.14 0.54
**
0.59
**
0.71
**
0.26
** 0.11 0.12 0.29
**
.248
*
0.78
** 1.00
Q20 0.02 0.26
* 0.09 0.06 0.20 0.10 0.13 0.14 0.14 0.37
**
0.34
**
0.33
**
0.33
**
0.31
**
0.24
*
0.31
**
0.39
**
0.38
**
0.47
** 1.00
Q21 0.29
**
0.22
* 0.18 0.33
**
0.34
**
0.36
** 0.13 0.27
**
0.31
**
0.27
**
0.36
**
0.26
* 0.16 0.15 0.29
**
0.24
* 0.16 0.17 0.29
**
0.28
** 1.00
Q22 0.14 0.14 0.04 0.14 0.34
**
0.32
**
0.21
*
0.29
**
0.25
*
0.20
*
0.33
**
0.30
** 0.14 0.17 0.25
*
0.29
**
0.25
* 0.11 0.21
*
0.34
**
0.64
** 1.00
Q23 0.01 0.01 0.01 0.15 0.27
** 0.02 0.16 0.00 0.23
* -0.09 -0.01 -0.03 0.10 0.12 0.22
* 0.11 0.11 -0.07 -0.06 0.18 0.17 0.32
** 1.00
Q24 -0.05 -0.05 -0.17 -0.05 0.15 -0.11 0.16 -0.10 0.11 -0.08 -0.14 -0.10 0.15 0.10 0.09 -0.11 0.00 -0.15 -0.26
* 0.12 0.09 0.22
*
0.46
** 1.00
Q25 0.15 0.05 -0.02 0.13 0.31
**
0.27
** 0.08 0.14 0.24
*
0.28
**
0.39
**
0.34
** 0.11 0.08 0.19 0.16 0.13 0.09 0.27
**
0.29
**
0.63
**
0.65
** 0.20 0.13 1.00
Q26 0.29
** 0.19 0.27
**
022
*
0.21
* 0.12 -0.04 0.08 0.18 0.37
**
0.47
**
0.49
** 0.15 0.17 0.07 0.17 0.03 0.31
**
0.29
** 0.20 0.41
**
0.48
** 0.18 0.12 0.57
** 1.00
Q27 0.14 0.17 0.26
**
0.20
*
0.25
*
0.22
* 0.04 -0.09 0.09 0.06 0.12 0.13 0.00 0.05 0.14 0.01 0.14 0.02 0.12 0.08 0.06 0.00 0.05 0.00 -0.01 0.02 1.00
Q28 -0.21
* -0.08 -0.04 -0.19 -0.15 0.01 -0.10 -0.05 0.02 0.05 0.05 0.08 -0.15 -0.30
** 0.15 0.12 0.06 0.10 0.16 -0.06 -0.14 -0.07 -0.12 -0.11 -0.01 -0.06 0.17 1.00
Q29 0.08 0.25
*
0.22
* 0.15 0.33
**
0.26
* 0.13 0.23
* 0.20 0.21
*
0.31
**
0.23
*
0.32
**
0.29
** 0.15 0.36
**
0.29
** 0.17 0.16 0.26
*
0.29
**
0.23
* 0.18 0.22
*
0.25
* 0.10 0.14 0.11 1.00
Q30 -0.17 0.02 0.00 -0.07 0.06 0.00 -0.07 -0.09 -0.02 0.06 0.13 0.05 0.00 -0.16 0.11 0.11 0.09 -0.02 0.06 0.19 0.12 0.22
*
0.27
** 0.19 0.20 0.10 0.21
*
0.29
**
0.39
** 1.00
Q31 0.12 -0.02 -0.08 -0.08 0.05 0.03 0.10 0.13 0.00 0.21
* -0.01 0.09 0.14 0.02 -0.05 0.03 -0.02 0.19 0.15 0.22
* 0.07 0.10 0.04 0.14 0.14 -0.06 -0.13 -0.12 0.06 -0.15 1.00
Q32 0.04 -0.01 0.04 -0.05 -0.07 -0.04 0.16 0.19 0.02 0.17 -0.05 -0.02 0.21
* 0.10 0.06 0.09 -0.05 0.13 0.11 0.10 0.13 0.07 0.04 -0.06 0.07 0.00 0.02 -0.03 0.12 -0.10 0.43
** 1.00
Q33 -0.08 -0.12 -0.19 -0.13 -0.03 0.01 -0.05 -0.04 -0.05 0.03 -0.11 -0.14 -0.09 -0.22
* 0.09 0.04 0.02 -0.06 -0.06 0.02 0.07 0.12 0.09 0.24
* 0.02 0.02 0.02 0.37
**
0.22
*
0.52
** -0.11 -0.02 1.00
Q34 0.08 0.14 0.24
* 0.06 0.09 -0.01 -0.13 0.11 0.02 0.02 0.08 0.02 0.15 0.04 0.07 0.15 0.07 0.04 0.03 -0.08 -0.06 -0.03 0.04 -0.07 -0.14 0.03 0.13 0.00 0.24
* 0.01 -0.10 -0.06 0.03 1.00
Q35 0.12 0.24
*
0.25
*
0.27
**
0.31
** 0.18 0.19 0.17 0.21
* 0.15 0.17 0.16 0.22
*
0.31
** 0.20 0.23
* 0.18 0.09 0.11 0.09 0.07 0.18 0.28
**
0.22
* 0.07 0.18 0.24
* 0.18 0.60
**
0.24
* -0.08 0.15 0.11 0.41
** 1.00
Q36 0.01 0.06 0.07 0.05 0.11 0.06 0.14 0.14 0.11 -0.01 0.14 0.14 0.13 0.06 0.25
*
0.22
* 0.13 -0.13 -0.01 0.03 0.14 0.29
** 0.18 0.20 0.14 0.19 0.00 0.15 0.36
**
0.24
*
-0.24
* -0.04 0.24
* 0.19 0.45
** 1.00
Q37 0.21
*
0.24
* 0.18 0.28
**
0.39
**
0.44
**
0.24
*
0.32
**
0.22
*
0.21
*
0.27
** 0.16 0.08 0.22
* 0.14 0.25
* 0.18 0.06 0.09 0.33
**
0.48
**
0.49
** 0.18 0.13 0.33
**
0.25
* 0.20 -0.05 0.40
** 0.20 0.06 0.07 0.13 0.04 0.35
** 0.19 1.00
Q38 0.17 0.19 0.13 0.13 0.24
*
0.24
*
0.25
*
0.24
*
0.25
* 0.07 0.00 0.00 0.16 0.27
** 0.12 0.25
*
0.25
* 0.17 0.15 0.24
*
0.23
*
0.25
* 0.10 0.11 0.13 0.07 0.10 0.18 0.40
** 0.04 0.23
*
0.33
**
0.23
* 0.07 0.42
** 0.13 0.54
** 1.00
Q39 -0.12 -0.03 -0.02 -0.08 0.03 0.05 0.09 0.13 0.18 -0.13 0.04 0.09 -0.08 -0.06 0.32
**
0.23
* 0.17 -0.06 0.05 -0.03 -0.01 0.13 -0.06 -0.16 0.08 0.07 0.07 0.06 -0.01 -0.12 -0.19 -0.03 -0.05 0.13 -0.03 0.28
** -0.14 -0.21
* 1.00
** Correlation is significant at the 0.01 level (2-tailed). * Correlation is significant at the 0.05 level (2-tailed). 434
Appendix 12: Item-item correlation for the 39-item OIQoL.
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Appendix 13 
Version 3.  OIQoL 
 
Being safe and careful 
 
Q1.  In the last week did someone give you extra help to     
keep you safe? 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q2.  In the last week did you keep away from busy areas to 
keep safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q3.  In the last week did you keep away from crowds to keep 
safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q4.  In the last week did you try to keep safe to stop you 
breaking a bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q5.  In the last week did you keep away from some activities 
to stop you having a broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q6.  In the last week did you think before playing sports to 
avoid having a broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
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Fatigue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q7.  In the last week have you felt tired in the day? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q8.  In the last week have you felt tired by the end of the 
day? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q9.  In the last week did you have to take rests in the day? 
 
 
Always Most of the time Sometimes       Not much Never 
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Reduced Function 
 
Q10.  In the last week has having OI stopped you doing 
things? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q11.  In the last week has it been more difficult to move 
around? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q12.  In the last week have you had to do things differently 
because of a OI? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q13.  In the last week did you use equipment to help you to 
move around? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q14.  In the last week did you have to use equipment to help 
at school or home? 
 
 
Always Most of the time Sometimes       Not much Never 
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Pain 
 
 
 
 
 
 
 
 
 
 
 
 
Q15.  In the last week have you had pain in your back? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q16.  In the last week have you had pain in your legs or 
arms? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q17.  In the last week have you had to take medicine for 
pain? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q19.  In the last week did you have pain because you had a 
OI? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q20.  In the last week have you missed meeting up with your 
friends? 
 
 
Always Most of the time Sometimes       Not much Never 
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Fear 
 
 
 
 
 
 
 
Q21.  In the last week have you been worried about breaking 
a bone?                  
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q22.  In the last week did you get scared about doing 
something that might make you break a bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q23.  In the last week did you worry about coming into 
hospital? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q24.  In the last week did you get scared about needles? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q25.  In the last week did you worry that someone might 
move you wrong and cause a broken bone? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q26.  In the last week have you worried about new people 
handling you? 
 
 
Always Most of the time Sometimes       Not much Never 
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Life Skills 
 
Q29.  In the last week did you have as much freedom as your 
friends? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q30.  In the last week did your family let you make your own 
decision about what is safe? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q33.  In the last week did your family let you choose your own 
activities? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q34.  In the last week did you see your friends outside of school? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q35.  In the last week were you able to do everything your 
friends do? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q36.  In the last week did you get to do lots of different activities? 
 
 
Always Most of the time Sometimes       Not much Never 
 
 
Q37.  In the last week did you feel different because you have to 
be more careful than your friends? 
 
 
Always Most of the time Sometimes       Not much Never 
 
Q38.  In the last week have people treated you differently     
because you have brittle bones? 
 
Always Most of the time Sometimes       Not much Never 
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